{
  "QualityAttribute:CGT:0:CMC team Assignments - confirm SIs  6 months prior to NME declaration": "ex:QualityAttribute_cmc_team_assignments_766340b8",
  "QualityAttribute:CGT:0:Critical Questions exercise to be initiated (CMC Team to lead with attendees from Discovery) and documented in the Risk Register.": "ex:QualityAttribute_critical_questions_e_5c908ef5",
  "QualityAttribute:CGT:0:Donor material - alignment to US/EU donor testing requirements  need to have discussion whether its autologous or allogenic": "ex:QualityAttribute_donor_material_align_b35ece11",
  "QualityAttribute:CGT:0:EHS Requirement: Determine DG classification & packaging reqs.": "ex:QualityAttribute_ehs_requirement_dete_b54d6509",
  "QualityAttribute:CGT:0:Full plasmid sequencing and legal identification/freedom to operate before sending to CMO to start MCB activities": "ex:QualityAttribute_full_plasmid_sequenc_4f1fad9c",
  "QualityAttribute:CGT:0:IPSC Meetings completed  for  knowledge transfer from Discovery.": "ex:QualityAttribute_ipsc_meetings_comple_d806e14c",
  "QualityAttribute:CGT:0:Identify new de novo methods to support new modalities.": "ex:QualityAttribute_identify_new_de_novo_51603e39",
  "QualityAttribute:CGT:0:Identify the needs of critical reagents of new process impurities and plan for manufacturing.": "ex:QualityAttribute_identify_the_needs_o_df16bb13",
  "QualityAttribute:CGT:0:In collaboration\u00a0with TD, CLD, API, DPD and EQ complete material and supplier selection on new raw materials and\u00a0ensure representative raw materials\u00a0are used in early development and leading into Early Look Material (ELM), non-GLP and GLP tox batches.": "ex:QualityAttribute_in_collaboration_wit_eb40ccb4",
  "QualityAttribute:CGT:0:Knowledge transfer from the above IPSC (Discovery to BTDS).": "ex:QualityAttribute_knowledge_transfer_f_2000cce0",
  "QualityAttribute:CGT:0:Recommend adding SG 0 for CMCRA - Defining the CGT Raw Material and Starting Material Sourcing Strategy (e.g. Plasmids & Vectors, Cell line, Excipients, IP/licensing considerations e.g. Japan)": "ex:QualityAttribute_recommend_adding_sg_2c7f6853",
  "QualityAttribute:CGT:0:Review available data from Therapeutics Discovery (TD) on the program": "ex:QualityAttribute_review_available_dat_4971f712",
  "QualityAttribute:CGT:0:Review of plasmid construct details with TD- sequence, maps, element tables in source document": "ex:QualityAttribute_review_of_plasmid_co_4fdf3509",
  "QualityAttribute:CGT:0:Risk assessment initiated using the Risk Registers.": "ex:QualityAttribute_risk_assessment_init_f5ec52a3",
  "QualityAttribute:CGT:0:Sourcing committee review of plasmid supplier": "ex:QualityAttribute_sourcing_committee_r_a0befa2a",
  "QualityAttribute:CGT:0:Start collaboration with Cell Enginering (CE) and Therapeutics Discovery (TD) to start knowledge transfer and align on methods used  for early development": "ex:QualityAttribute_start_collaboration_dd143bf8",
  "QualityAttribute:CGT:0:Target Molecule Profile developed": "ex:QualityAttribute_target_molecule_prof_272cfb74",
  "QualityAttribute:CGT:10:API sections of Marketing Application reviewed and approved.": "ex:QualityAttribute_api_sections_of_mark_ab9b3b04",
  "QualityAttribute:CGT:10:All formulation and process robustness source documents completed.": "ex:QualityAttribute_all_formulation_and_15353d47",
  "QualityAttribute:CGT:10:All source documents completed and approved.": "ex:QualityAttribute_all_source_documents_ca540088",
  "QualityAttribute:CGT:10:Analytical sections of Marketing Application reviewed and approved.": "ex:QualityAttribute_analytical_sections_0496dac8",
  "QualityAttribute:CGT:10:CPDP Commercialization Stage Initiated": "ex:QualityAttribute_cpdp_commercializati_5e2a1b37",
  "QualityAttribute:CGT:10:Commercial Container Closure System Summary Report completed.": "ex:QualityAttribute_commercial_container_ce8d9447",
  "QualityAttribute:CGT:10:Commercial Secondary/Tertiary Packaging Design locked.": "ex:QualityAttribute_commercial_secondary_40f7d746",
  "QualityAttribute:CGT:10:Commercial pharmacy manual supportive studies completed & documented (if required).": "ex:QualityAttribute_commercial_pharmacy_0e8a8a9d",
  "QualityAttribute:CGT:10:Commercially acceptable stability achieved at real-time storage conditions according to regulatory submission strategy.": "ex:QualityAttribute_commercially_accepta_7168b2b8",
  "QualityAttribute:CGT:10:Complete CMC Strategic Plan covering Stages 10-12 (includes life cycle management strategy). -": "ex:QualityAttribute_complete_cmc_strateg_0fb0322a",
  "QualityAttribute:CGT:10:Complete Customer Value deliverables for this stage (if applicable).": "ex:QualityAttribute_complete_customer_va_48cf7932",
  "QualityAttribute:CGT:10:Complete PAI readiness activities for raw materials for DS and DP including technical/scientific documentation and compliance.": "ex:QualityAttribute_complete_pai_readine_102984d8",
  "QualityAttribute:CGT:10:Confirm commercial sourcing strategy with CMC team e.g. Raw Materials, Vector, Cell Bank": "ex:QualityAttribute_confirm_commercial_s_0badd70f",
  "QualityAttribute:CGT:10:Confirm that commercial DS/DP processes for launch materials match the validated processes. Communicate any differences.": "ex:QualityAttribute_confirm_that_commerc_2aa74d13",
  "QualityAttribute:CGT:10:Continuous Process verification (CPV) approved and ready for implementation": "ex:QualityAttribute_continuous_process_v_a87fc543",
  "QualityAttribute:CGT:10:Continuous Process verification (CPV) protocol approved and ready for implementation (applicable to LV)": "ex:QualityAttribute_continuous_process_v_93ada7bc",
  "QualityAttribute:CGT:10:Continuous Process verification (CPV) strategy approved": "ex:QualityAttribute_continuous_process_v_8de7ded5",
  "QualityAttribute:CGT:10:Continuous Process verification (CPV) strategy defined (linked to stabilization metrics) and implementation started.": "ex:QualityAttribute_continuous_process_v_7fdb738e",
  "QualityAttribute:CGT:10:Continuous Process verification (CPV) strategy defined (linked to stabilization metrics) and implementation started.--> SG 9: CPV strategy defined; SG 10: CPV strategy approved": "ex:QualityAttribute_continuous_process_v_518aebe2",
  "QualityAttribute:CGT:10:Continuous Process verification (CPV) strategy defined and implementation started.": "ex:QualityAttribute_continuous_process_v_f651d5e4",
  "QualityAttribute:CGT:10:Coordinate aggregated clinical/non-clinical demand in support of commercial/Ph3 mfg. to the JSC organization": "ex:QualityAttribute_coordinate_aggregate_ce01b373",
  "QualityAttribute:CGT:10:Create use-related risk analysis (URRA), if needed.": "ex:QualityAttribute_create_use_related_r_649b4bb9",
  "QualityAttribute:CGT:10:DP sections of Marketing Application reviewed and approved.": "ex:QualityAttribute_dp_sections_of_marke_57ad7999",
  "QualityAttribute:CGT:10:DP: at risk launch inventory build approved and production initiated (if needed).": "ex:QualityAttribute_dp_at_risk_launch_in_3fd5619d",
  "QualityAttribute:CGT:10:Data for 6-12 months long term leachable data completed and ready for Marketing Application": "ex:QualityAttribute_data_for_6_12_months_556e1067",
  "QualityAttribute:CGT:10:Decision on rapid launch strategy made with commercial affiliates.": "ex:QualityAttribute_decision_on_rapid_la_2560f9be",
  "QualityAttribute:CGT:10:Design Control": "ex:QualityAttribute_design_control_86e14105",
  "QualityAttribute:CGT:10:Design History File (Update)": "ex:QualityAttribute_design_history_file_b83c30ae",
  "QualityAttribute:CGT:10:Design and Development Plan  (Update)": "ex:QualityAttribute_design_and_developme_c0f7aa31",
  "QualityAttribute:CGT:10:Develop scenarios in support of strategic planning (as required).": "ex:QualityAttribute_develop_scenarios_in_ab4ddcdd",
  "QualityAttribute:CGT:10:Device Master Record (DMR) (Update)": "ex:QualityAttribute_device_master_record_d1565dd3",
  "QualityAttribute:CGT:10:Device Risk Management  (Update) - CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_8306c10f",
  "QualityAttribute:CGT:10:Device Risk Management  (Update) - Device Control Strategy (Review and Update)": "ex:QualityAttribute_device_risk_manageme_089ac13f",
  "QualityAttribute:CGT:10:Device Risk Management  (Update) - Product Risk Assessment/Hazard ID (Update)": "ex:QualityAttribute_device_risk_manageme_3e48b235",
  "QualityAttribute:CGT:10:Device Risk Management  (Update) - Risk Management Report (Update)": "ex:QualityAttribute_device_risk_manageme_2cd3f53f",
  "QualityAttribute:CGT:10:Device Risk Management  (Update) - dFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_520d73d1",
  "QualityAttribute:CGT:10:Device Risk Management  (Update) - pFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_bcb68880",
  "QualityAttribute:CGT:10:Device Risk Management  (Update) - uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_b7d5ddf8",
  "QualityAttribute:CGT:10:Document list(s) (including process characterization reports, robustness study reports, process validation protocol and reports, or process development history report) completed.": "ex:QualityAttribute_document_list_s_incl_555953d0",
  "QualityAttribute:CGT:10:E2E Value Chain Risk Management started.": "ex:QualityAttribute_e2e_value_chain_risk_9f488fd2",
  "QualityAttribute:CGT:10:EHS Requirement: compliance assessment for DP manufacturing completed.": "ex:QualityAttribute_ehs_requirement_comp_d7c57ce1",
  "QualityAttribute:CGT:10:EHS Requirement: compliance assessment for DS manufacturing completed, environmental risk assessment completed and filed": "ex:QualityAttribute_ehs_requirement_comp_1b9733cc",
  "QualityAttribute:CGT:10:Finalize JJ Packaging Design protocol.": "ex:QualityAttribute_finalize_jj_packagin_13b927d4",
  "QualityAttribute:CGT:10:Finalize raw material control strategy for DS and DP including risk assessments (supplier and CA) and control including monitoring and trending.": "ex:QualityAttribute_finalize_raw_materia_46009df5",
  "QualityAttribute:CGT:10:Initial commercial launch quantities defined.": "ex:QualityAttribute_initial_commercial_l_e81f30e7",
  "QualityAttribute:CGT:10:Initiate discussions with VCL/JSC to have plan in place to support Medical Affairs and any other ongoing studies from commercial supplies.": "ex:QualityAttribute_initiate_discussions_9b84e606",
  "QualityAttribute:CGT:10:Maintain sample archive/permanent retention program for all Clinical and ProVal batches.": "ex:QualityAttribute_maintain_sample_arch_4547db97",
  "QualityAttribute:CGT:10:Marketing Application internally reviewed and approved, and derivative dossiers completed according to project timelines.": "ex:QualityAttribute_marketing_applicatio_512b5d6a",
  "QualityAttribute:CGT:10:Marketing Application internally reviewed and approved.": "ex:QualityAttribute_marketing_applicatio_07680d23",
  "QualityAttribute:CGT:10:Marketing Application reviewed and approved including JSC sections (i.e. Facilities).": "ex:QualityAttribute_marketing_applicatio_a38b6d29",
  "QualityAttribute:CGT:10:Marketing Application reviewed and approved.": "ex:QualityAttribute_marketing_applicatio_050450d3",
  "QualityAttribute:CGT:10:Marketing Application submitted to primary markets according to project timelines.": "ex:QualityAttribute_marketing_applicatio_c917361a",
  "QualityAttribute:CGT:10:Overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_overall_csc_fte_and_9c643420",
  "QualityAttribute:CGT:10:PAI readiness achieved at DS/DP manufacturing and testing sites": "ex:QualityAttribute_pai_readiness_achiev_985e597a",
  "QualityAttribute:CGT:10:PSR refreshed & JSC Presentation (if needed)": "ex:QualityAttribute_psr_refreshed_jsc_pr_e4c7dc23",
  "QualityAttribute:CGT:10:PVMP Summary Report(s) approved.": "ex:QualityAttribute_pvmp_summary_report_ea01fd20",
  "QualityAttribute:CGT:10:Passive shipping systems qualified, if applicable.": "ex:QualityAttribute_passive_shipping_sys_1e49f0ed",
  "QualityAttribute:CGT:10:Patent and Publication Strategy:  summarize potential unique aspects of the process that could lead to publications and/or patents.": "ex:QualityAttribute_patent_and_publicati_9a72dd75",
  "QualityAttribute:CGT:10:Ph3 and ProVal DS & DP stability data trending completed by JSC QC (if at External then BTDS AD)": "ex:QualityAttribute_ph3_and_proval_ds_dp_defa95ce",
  "QualityAttribute:CGT:10:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_d7a9b7b9",
  "QualityAttribute:CGT:10:Post PPQ Criticality Report Reviewed": "ex:QualityAttribute_post_ppq_criticality_be5eaca1",
  "QualityAttribute:CGT:10:Pre-Approval Inspection Readiness - Checklist execution Summary/Remediation Report": "ex:QualityAttribute_pre_approval_inspect_1bb35615",
  "QualityAttribute:CGT:10:Pre-Approval Inspection Readiness - Mock PAI Inspection of Compliance": "ex:QualityAttribute_pre_approval_inspect_a2b6687f",
  "QualityAttribute:CGT:10:Pre-Approval Inspection Readiness - PAI Readiness Checklist (Device/Combo)": "ex:QualityAttribute_pre_approval_inspect_79fb4b6a",
  "QualityAttribute:CGT:10:Prepare for potential high risk HA questions during dossier review and PAI readiness.": "ex:QualityAttribute_prepare_for_potentia_83366f47",
  "QualityAttribute:CGT:10:ProVal DS & DP stability data trending completed by JSC QC.": "ex:QualityAttribute_proval_ds_dp_stabili_7dbe0c79",
  "QualityAttribute:CGT:10:Process characterization report(s) approved.": "ex:QualityAttribute_process_characteriza_484c3445",
  "QualityAttribute:CGT:10:Process validation report(s) approved.": "ex:QualityAttribute_process_validation_r_8f3bfa62",
  "QualityAttribute:CGT:10:Product-specific Extractable Risk Assessments and Summary Report completed as dossier drop-in reports.": "ex:QualityAttribute_product_specific_ext_532b9f90",
  "QualityAttribute:CGT:10:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_3b6ccdba",
  "QualityAttribute:CGT:10:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_f5fb711d",
  "QualityAttribute:CGT:10:Raw Material sections of Marketing Application authored, reviewed and approved.": "ex:QualityAttribute_raw_material_section_299fc6d1",
  "QualityAttribute:CGT:10:Review Marketing Application data and conduct lessons learned (if applicable).": "ex:QualityAttribute_review_marketing_app_2be4933d",
  "QualityAttribute:CGT:10:Review and approve process validation reports.": "ex:QualityAttribute_review_and_approve_p_e03512cb",
  "QualityAttribute:CGT:10:Review and endorsement of proposed commercial label completed.": "ex:QualityAttribute_review_and_endorseme_7b40253b",
  "QualityAttribute:CGT:10:Review process characterization reports.": "ex:QualityAttribute_review_process_chara_e56f2d02",
  "QualityAttribute:CGT:10:Risk Management Plan (Update)": "ex:QualityAttribute_risk_management_plan_5d948eeb",
  "QualityAttribute:CGT:10:Risk Register completed for major predictable CMC filing issues (RA/CMCL).": "ex:QualityAttribute_risk_register_comple_25397fc9",
  "QualityAttribute:CGT:10:Secure funding for any post launch optimization projects (JSC & R&D)": "ex:QualityAttribute_secure_funding_for_a_37858a8e",
  "QualityAttribute:CGT:10:Site compliance, PAI readiness evaluated and PAI observations addressed.": "ex:QualityAttribute_site_compliance_pai_627775a8",
  "QualityAttribute:CGT:10:Stage 10 CMC Council presentation completed.": "ex:QualityAttribute_stage_10_cmc_council_2c0afe0e",
  "QualityAttribute:CGT:10:Submit Product Quality Complaint New Product Set Up Form for commercial product": "ex:QualityAttribute_submit_product_quali_6e4c0ee4",
  "QualityAttribute:CGT:10:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_7ee2642e",
  "QualityAttribute:CGT:10:Transportation/Distribution strategy defined. Transportation channel and shipping protection selected (Distribution Risk Assessment completed).": "ex:QualityAttribute_transportation_distr_2fc99f00",
  "QualityAttribute:CGT:10:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_957a559c",
  "QualityAttribute:CGT:10:Update Criticality Analysis (if applicable).": "ex:QualityAttribute_update_criticality_a_2a13efb5",
  "QualityAttribute:CGT:10:Update FMEAs (u, d, p) (including verification and effectiveness (COMBO Product Requirement)": "ex:QualityAttribute_update_fmeas_u_d_p_i_b59994a2",
  "QualityAttribute:CGT:10:Update PMR Plan/Report (including Product Risk Benefit Analysis)": "ex:QualityAttribute_update_pmr_plan_repo_c2ee633b",
  "QualityAttribute:CGT:10:Update PRA (including verification and effectiveness)": "ex:QualityAttribute_update_pra_including_99168828",
  "QualityAttribute:CGT:10:Update strategic forecast and capacity planning for DS and DP via NPS/FIS.": "ex:QualityAttribute_update_strategic_for_166b2317",
  "QualityAttribute:CGT:10:Update to Regulated Substances Plan, Supplier Regulated Substances Declarations and Regulated Substances Report (if applicable)": "ex:QualityAttribute_update_to_regulated_740f7ccf",
  "QualityAttribute:CGT:10:Updated Cost of Goods Sold (COGS) and Gross Profit (GP) for launch and steady state.": "ex:QualityAttribute_updated_cost_of_good_e2434d94",
  "QualityAttribute:CGT:11:A summary of all At-Risk Inventories approved prior to launch should be presented.": "ex:QualityAttribute_a_summary_of_all_at_6a27e0bd",
  "QualityAttribute:CGT:11:Adjust commercial specifications following health authority approval (if applicable).": "ex:QualityAttribute_adjust_commercial_sp_ecf50b67",
  "QualityAttribute:CGT:11:Agreements regarding safety stock at the DS level, WIP level and Finished Good level should be defined and agreements reached on launch quantities and strategy.": "ex:QualityAttribute_agreements_regarding_617e9abc",
  "QualityAttribute:CGT:11:Approval timing, pricing and launch timings and quantities should be defined and presented. Launch Plan including Rapid Launch Plan (if applicable) should be presented.": "ex:QualityAttribute_approval_timing_pric_979fa7fc",
  "QualityAttribute:CGT:11:Approvals obtained from primary markets.": "ex:QualityAttribute_approvals_obtained_f_799b0374",
  "QualityAttribute:CGT:11:CMC responses to HAs completed and commitments initiated (if applicable).": "ex:QualityAttribute_cmc_responses_to_has_8bed5a07",
  "QualityAttribute:CGT:11:COGS and COGS improvement plan should be updated and presented.": "ex:QualityAttribute_cogs_and_cogs_improv_44791337",
  "QualityAttribute:CGT:11:CPDP Commercialization Stage": "ex:QualityAttribute_cpdp_commercializati_2c81b89a",
  "QualityAttribute:CGT:11:Commercial DS & DP release & shelf-life specification document approved.": "ex:QualityAttribute_commercial_ds_dp_rel_b5f64f9e",
  "QualityAttribute:CGT:11:Complete Commercial Patient Safety and Compliance (PSCI) Document": "ex:QualityAttribute_complete_commercial_a4a66050",
  "QualityAttribute:CGT:11:Conduct lessons learned if any significant issues occurred during HA review.": "ex:QualityAttribute_conduct_lessons_lear_4a20faba",
  "QualityAttribute:CGT:11:Confirm completion of all process validations and associated reports, and packaging line qualifications/validations.": "ex:QualityAttribute_confirm_completion_o_988e9af3",
  "QualityAttribute:CGT:11:Confirm completion of shipping qualifications or validations (associated with cold chain).": "ex:QualityAttribute_confirm_completion_o_1bb813c2",
  "QualityAttribute:CGT:11:Container Closure Integrity Testing post shipping - (PPQ material)": "ex:QualityAttribute_container_closure_in_9c182f1f",
  "QualityAttribute:CGT:11:Coordinate aggregated clinical/non-clinical demand (including Medical affairs) in support of commercial/Ph3 mfg. to the JSC organization": "ex:QualityAttribute_coordinate_aggregate_f9f0c24e",
  "QualityAttribute:CGT:11:DP life cycle management development work initiated (if applicable).": "ex:QualityAttribute_dp_life_cycle_manage_8edad200",
  "QualityAttribute:CGT:11:Define raw material supply chain reliability strategy for DS and DP (media, buffers, resins, chemicals, excipients, and polymeric product contact materials).": "ex:QualityAttribute_define_raw_material_d8eb5b48",
  "QualityAttribute:CGT:11:Design Control": "ex:QualityAttribute_design_control_df67765d",
  "QualityAttribute:CGT:11:Design History File (Update)": "ex:QualityAttribute_design_history_file_58b08b0a",
  "QualityAttribute:CGT:11:Design and Development Plan  (Update)": "ex:QualityAttribute_design_and_developme_dc14907f",
  "QualityAttribute:CGT:11:Developed scenarios in support of strategic planning (as required).": "ex:QualityAttribute_developed_scenarios_ed07fd8b",
  "QualityAttribute:CGT:11:Device Master Record (DMR) (Update)": "ex:QualityAttribute_device_master_record_0dfe9e1d",
  "QualityAttribute:CGT:11:Device Risk Management  (Update) - CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_cc4d7d3f",
  "QualityAttribute:CGT:11:Device Risk Management  (Update) - Device Control Strategy (Review and Update)": "ex:QualityAttribute_device_risk_manageme_5858039e",
  "QualityAttribute:CGT:11:Device Risk Management  (Update) - Product Risk Assessment/Hazard ID (Update)": "ex:QualityAttribute_device_risk_manageme_d673ccef",
  "QualityAttribute:CGT:11:Device Risk Management  (Update) - Risk Management Plan (Update)": "ex:QualityAttribute_device_risk_manageme_4c3cbfec",
  "QualityAttribute:CGT:11:Device Risk Management  (Update) - Risk Management Report (Update)": "ex:QualityAttribute_device_risk_manageme_b2dfe401",
  "QualityAttribute:CGT:11:Device Risk Management  (Update) - dFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_19ca5c57",
  "QualityAttribute:CGT:11:Device Risk Management  (Update) - pFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_3c1f8e12",
  "QualityAttribute:CGT:11:Device Risk Management  (Update) - uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_db5c48e4",
  "QualityAttribute:CGT:11:Distribution requirements strategy identified from Hub DC to First Line Customer": "ex:QualityAttribute_distribution_require_55ed1d75",
  "QualityAttribute:CGT:11:Distribution requirements strategy identified to point of HUB DC. Global product distribution chain set up and implemented.": "ex:QualityAttribute_distribution_require_d0086e7f",
  "QualityAttribute:CGT:11:EHS Requirement: update SDS and label for DP": "ex:QualityAttribute_ehs_requirement_upda_bc246735",
  "QualityAttribute:CGT:11:EHS Requirement: update SDS and label for DS.": "ex:QualityAttribute_ehs_requirement_upda_cbd24273",
  "QualityAttribute:CGT:11:HA inspections successfully completed.": "ex:QualityAttribute_ha_inspections_succe_721dcf0b",
  "QualityAttribute:CGT:11:Importation activities/licenses planned (e.g., controlled substances \u2192 DEA, pre-importations).": "ex:QualityAttribute_importation_activiti_aec8eab4",
  "QualityAttribute:CGT:11:JSC relevant Marketing Application regulatory responses reviewed & approved (as applicable).": "ex:QualityAttribute_jsc_relevant_marketi_2b923440",
  "QualityAttribute:CGT:11:Knowledge Management Database updated with Product Fact Book": "ex:QualityAttribute_knowledge_management_df6ad59e",
  "QualityAttribute:CGT:11:LCM upstream & downstream work initiated (if applicable).": "ex:QualityAttribute_lcm_upstream_downstr_586ada58",
  "QualityAttribute:CGT:11:Launch readiness confirmed at all involved commercial manufacturing & packaging sites.  Assess the impact of a rapid launch, if requested by commercial. This includes an assessment of the capabilities of the launch sites involved.": "ex:QualityAttribute_launch_readiness_con_33444f38",
  "QualityAttribute:CGT:11:Overall CSC FTE and OOP budget compound and study level": "ex:QualityAttribute_overall_csc_fte_and_a682b130",
  "QualityAttribute:CGT:11:PSR refreshed and JSC Presentation (if needed)": "ex:QualityAttribute_psr_refreshed_and_js_ce07926a",
  "QualityAttribute:CGT:11:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_845cd368",
  "QualityAttribute:CGT:11:Pre-Launch Importation Request (PLAIR) submitted and approved (as applicable).": "ex:QualityAttribute_pre_launch_importati_baa66972",
  "QualityAttribute:CGT:11:Preliminary artwork will have been filed with the Marketing Applications and Marketing should be preparing final commercial artwork, with trademark, if one has been determined.": "ex:QualityAttribute_preliminary_artwork_9bde3c17",
  "QualityAttribute:CGT:11:Prepare responses to HA questions": "ex:QualityAttribute_prepare_responses_to_04a13682",
  "QualityAttribute:CGT:11:Product Financial flows should be determined.": "ex:QualityAttribute_product_financial_fl_df1c89b4",
  "QualityAttribute:CGT:11:Product Launch supplies manufactured and released. \"And released\" added by Portfolio Mgmt.": "ex:QualityAttribute_product_launch_suppl_8d94fceb",
  "QualityAttribute:CGT:11:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_1011caa3",
  "QualityAttribute:CGT:11:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_6f68e33e",
  "QualityAttribute:CGT:11:Quality agreement for commercial completed/revised for all mfg. sites/testing labs (external and internal) (if applicable)": "ex:QualityAttribute_quality_agreement_fo_ccc5e03b",
  "QualityAttribute:CGT:11:Raw material life cycle management development work initiated (if applicable).": "ex:QualityAttribute_raw_material_life_cy_1ab40606",
  "QualityAttribute:CGT:11:Regional operational forecasts available and translated into manufacturing forecasts (for markets preparing to launch).": "ex:QualityAttribute_regional_operational_8fd6e421",
  "QualityAttribute:CGT:11:Regulatory commitments entered into appropriate GRA system(s).": "ex:QualityAttribute_regulatory_commitmen_5d64496b",
  "QualityAttribute:CGT:11:Review FMEAs (u, p, d), update if additions/changes risk management activities (COMBO Product) Requirement)": "ex:QualityAttribute_review_fmeas_u_p_d_u_96b9078d",
  "QualityAttribute:CGT:11:Review PRA, update if additional/changed risk management activities": "ex:QualityAttribute_review_pra_update_if_dc156f24",
  "QualityAttribute:CGT:11:Review PRM Plan/Report, update if additional/changed risk management activities": "ex:QualityAttribute_review_prm_plan_repo_1f4cd3f2",
  "QualityAttribute:CGT:11:Risk Analysis & Mitigation plans from Stage Gate Review 10 should be updated and presented.": "ex:QualityAttribute_risk_analysis_mitiga_a5373d5a",
  "QualityAttribute:CGT:11:Shipping Methods & allowable Temperature Excursions documented.": "ex:QualityAttribute_shipping_methods_all_4e7e41de",
  "QualityAttribute:CGT:11:Site business systems set-up finished (SAP etc.).": "ex:QualityAttribute_site_business_system_80b6ab7a",
  "QualityAttribute:CGT:11:Stability data updates provided to health authority (if applicable).": "ex:QualityAttribute_stability_data_updat_5acc9ae4",
  "QualityAttribute:CGT:11:Stability review (post-submission data) & marketed stability plan reviewed and assessed for completeness and potential risks.": "ex:QualityAttribute_stability_review_pos_a1c1deb6",
  "QualityAttribute:CGT:11:Stage 11 CMC Council presentation review completed.": "ex:QualityAttribute_stage_11_cmc_council_cd51ed01",
  "QualityAttribute:CGT:11:Strategic forecast should be updated and long term strategic capacity analysis updated via NPS/FIS.": "ex:QualityAttribute_strategic_forecast_s_c347cc48",
  "QualityAttribute:CGT:11:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_73a7235b",
  "QualityAttribute:CGT:11:Support PAI at manufacturing sites.": "ex:QualityAttribute_support_pai_at_manuf_74032860",
  "QualityAttribute:CGT:11:Support PAI inspection of manufacturing sites": "ex:QualityAttribute_support_pai_inspecti_da64f508",
  "QualityAttribute:CGT:11:Support PAI inspection of manufacturing sites (DS and DP).": "ex:QualityAttribute_support_pai_inspecti_047f3493",
  "QualityAttribute:CGT:11:Support PAI inspection of manufacturing sites.": "ex:QualityAttribute_support_pai_inspecti_2956adc1",
  "QualityAttribute:CGT:11:Support Post Approval Tech transfer alignment": "ex:QualityAttribute_support_post_approva_99e95e0c",
  "QualityAttribute:CGT:11:Update CMC Risk Register": "ex:QualityAttribute_update_cmc_risk_regi_97ba4b95",
  "QualityAttribute:CGT:11:Update Criticality Analysis and integrated Control Strategy (if applicable due to HA feedback).": "ex:QualityAttribute_update_criticality_a_9c4e0289",
  "QualityAttribute:CGT:11:Updated Cost of Goods Sold (COGS) and Gross Profit (GP) for launch and steady state.": "ex:QualityAttribute_updated_cost_of_good_6b748552",
  "QualityAttribute:CGT:12:Accept ownership CPV program for DS and DP, whether in stage 3a or 3b": "ex:QualityAttribute_accept_ownership_cpv_1142ac70",
  "QualityAttribute:CGT:12:Align with CMCRA for ownership of project specific deliverables per DDO/CMCRA Best Practice \"DDO Post-Approval Responsibility\"\nhttps://jnj.sharepoint.com/:w:/r/teams/DDOPortal/_layouts/15/Doc.aspx?sourcedoc=%7BB46278C1-AD7A-47CE-84E2-BD2F26ADB084%7D&file=Best%20Practice%20DDO%20Deliverable%20Decision%20Tree.docx": "ex:QualityAttribute_align_with_cmcra_for_203453d2",
  "QualityAttribute:CGT:12:Approved LCM (Lifecycle Management) work initiated/supported including post-approval commitments (if applicable).": "ex:QualityAttribute_approved_lcm_lifecyc_8dc58992",
  "QualityAttribute:CGT:12:Approved LCM upstream & downstream work initiated/supported including post-approval commitments (if applicable).": "ex:QualityAttribute_approved_lcm_upstrea_e465533e",
  "QualityAttribute:CGT:12:Approved LCM work initiated/supported including post-approval commitments (if applicable).": "ex:QualityAttribute_approved_lcm_work_in_4d306550",
  "QualityAttribute:CGT:12:CMC responses to HAs completed": "ex:QualityAttribute_cmc_responses_to_has_91c4664c",
  "QualityAttribute:CGT:12:CPDP Commercialization Stage Complete": "ex:QualityAttribute_cpdp_commercializati_def60572",
  "QualityAttribute:CGT:12:Collect Annual Review Product Data (test Results, IPC, OOS, deviations, complaints etc.).": "ex:QualityAttribute_collect_annual_revie_0cf61a5d",
  "QualityAttribute:CGT:12:Commercialization Stage Design Review": "ex:QualityAttribute_commercialization_st_4a65d6d4",
  "QualityAttribute:CGT:12:Complete Proactive Product Quality Scan (PPQS).": "ex:QualityAttribute_complete_proactive_p_9999c51b",
  "QualityAttribute:CGT:12:Complete plans to address all DP process post-approval commitments.": "ex:QualityAttribute_complete_plans_to_ad_36bf2440",
  "QualityAttribute:CGT:12:Complete raw material reliability assessment and trending recommendations.": "ex:QualityAttribute_complete_raw_materia_27094d98",
  "QualityAttribute:CGT:12:Consolidated (JSC & BioTD) lessons learned. \"JSC & BTDS\" text added by Portfolio Management.": "ex:QualityAttribute_consolidated_jsc_bio_43a56e78",
  "QualityAttribute:CGT:12:Consolidated lessons learned completed (BTDS & JSC).": "ex:QualityAttribute_consolidated_lessons_11011128",
  "QualityAttribute:CGT:12:Continue LCM activities to support process requirements, as needed": "ex:QualityAttribute_continue_lcm_activit_bd7cf29f",
  "QualityAttribute:CGT:12:Continuous Process verification (CPV) Stage 3a final report approved, CPV program  ownership transfer to TLI completed": "ex:QualityAttribute_continuous_process_v_7b99748d",
  "QualityAttribute:CGT:12:Coordinate aggregated clinical/non-clinical demand in support of commercial/Ph3 mfg. to the JSC organization.": "ex:QualityAttribute_coordinate_aggregate_d2443975",
  "QualityAttribute:CGT:12:DP process robustness and supply chain review completed.": "ex:QualityAttribute_dp_process_robustnes_3495d920",
  "QualityAttribute:CGT:12:Define and initiate Product Dashboard.": "ex:QualityAttribute_define_and_initiate_537f683e",
  "QualityAttribute:CGT:12:Design Control": "ex:QualityAttribute_design_control_39917f86",
  "QualityAttribute:CGT:12:Design History File (Update)": "ex:QualityAttribute_design_history_file_3a1df9dd",
  "QualityAttribute:CGT:12:Design and Development Plan  (Update)": "ex:QualityAttribute_design_and_developme_e1e8ad35",
  "QualityAttribute:CGT:12:Device Master Record (DMR) (Update)": "ex:QualityAttribute_device_master_record_59239323",
  "QualityAttribute:CGT:12:Device Risk Management  (Update) - CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_ec808939",
  "QualityAttribute:CGT:12:Device Risk Management  (Update) - Device Control Strategy (Review and Update)": "ex:QualityAttribute_device_risk_manageme_0347e11a",
  "QualityAttribute:CGT:12:Device Risk Management  (Update) - Product Risk Assessment/Hazard ID (Update)": "ex:QualityAttribute_device_risk_manageme_f5e58ca4",
  "QualityAttribute:CGT:12:Device Risk Management  (Update) - Risk Management Plan (Update)": "ex:QualityAttribute_device_risk_manageme_482f24e4",
  "QualityAttribute:CGT:12:Device Risk Management  (Update) - Risk Management Report (Update)": "ex:QualityAttribute_device_risk_manageme_2f906131",
  "QualityAttribute:CGT:12:Device Risk Management  (Update) - dFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_390ad5a0",
  "QualityAttribute:CGT:12:Device Risk Management  (Update) - pFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_f134ca85",
  "QualityAttribute:CGT:12:Device Risk Management  (Update) - uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_478390af",
  "QualityAttribute:CGT:12:Knowledge Management Database updated.": "ex:QualityAttribute_knowledge_management_af0a23f4",
  "QualityAttribute:CGT:12:Launches executed/launch metrics met.": "ex:QualityAttribute_launches_executed_la_ae7a2cf8",
  "QualityAttribute:CGT:12:Lessons learned completed": "ex:QualityAttribute_lessons_learned_comp_2b047c47",
  "QualityAttribute:CGT:12:OOT (Out of Trend) and OOS (Out of Specifications) results reviewed.": "ex:QualityAttribute_oot_out_of_trend_and_d26eb7c9",
  "QualityAttribute:CGT:12:Overall CSC FTE and OOP budget compound and study level": "ex:QualityAttribute_overall_csc_fte_and_dccffd64",
  "QualityAttribute:CGT:12:Ownership for base business and Product Strategy Roadmap transferred to Supply Chain Product Owner and manufacturing sites": "ex:QualityAttribute_ownership_for_base_b_84adb618",
  "QualityAttribute:CGT:12:Ownership for base business and Product Strategy Roadmap transferred to Value Stream Team and manufacturing sites including existing Change Controls and Post-Marketing Commitments.": "ex:QualityAttribute_ownership_for_base_b_bc2224ea",
  "QualityAttribute:CGT:12:PSR refreshed; JSC Product Council endorsement (if needed)": "ex:QualityAttribute_psr_refreshed_jsc_pr_d888e987",
  "QualityAttribute:CGT:12:Patent Strategy: summarize potential unique aspects of the process that could lead to patent applications": "ex:QualityAttribute_patent_strategy_summ_1e3be0e5",
  "QualityAttribute:CGT:12:Patent and Publication Strategy:  summarize potential unique aspects of the process that could lead to publications and/or patents.": "ex:QualityAttribute_patent_and_publicati_b711593d",
  "QualityAttribute:CGT:12:Product Risk Register transferred to JSC": "ex:QualityAttribute_product_risk_registe_02e744ec",
  "QualityAttribute:CGT:12:Review & Update Traceability Matrix (If applicable)": "ex:QualityAttribute_review_update_tracea_5326b80f",
  "QualityAttribute:CGT:12:Risk register transferred to Life Cycle Management Team": "ex:QualityAttribute_risk_register_transf_ccc41c6a",
  "QualityAttribute:CGT:12:Risk register transferred to Value Stream Team.": "ex:QualityAttribute_risk_register_transf_a4ddb245",
  "QualityAttribute:CGT:12:Stage 12 CMC Council presentation completed": "ex:QualityAttribute_stage_12_cmc_council_bac18cbb",
  "QualityAttribute:CGT:12:Stage 12 CMC Council presentation review completed.": "ex:QualityAttribute_stage_12_cmc_council_27ac4f09",
  "QualityAttribute:CGT:12:Stage Gate Approval Form": "ex:QualityAttribute_stage_gate_approval_e09b8940",
  "QualityAttribute:CGT:12:Strategy for future production scale-up/capacity/utilization (DS and DP) in place.": "ex:QualityAttribute_strategy_for_future_d564e5de",
  "QualityAttribute:CGT:12:Support CPV program in support of transfer of CPV ownership to TO.": "ex:QualityAttribute_support_cpv_program_29ae2909",
  "QualityAttribute:CGT:12:Support Regulatory Plan for prioritization of GFLS and post-approval supplements": "ex:QualityAttribute_support_regulatory_p_ad0af3c9",
  "QualityAttribute:CGT:12:Team agreement (JSC & BTDS) that product is stable and to transfer ownership for product. \"JSC & BioTD\" text added by Portfolio Management.": "ex:QualityAttribute_team_agreement_jsc_b_0dc16f66",
  "QualityAttribute:CGT:12:Update Cost of Goods Sold (COGS) and Gross Profit (GP) for steady state.  Summarize COGS progression and opportunities.": "ex:QualityAttribute_update_cost_of_goods_0cf55141",
  "QualityAttribute:CGT:12:Update dosage forms, marketed SKU\u2019s, supply chain flow.": "ex:QualityAttribute_update_dosage_forms_235bde8a",
  "QualityAttribute:CGT:12:Update forecasts, sales performance, inventories at transfer point, capacity review, and market intelligence.": "ex:QualityAttribute_update_forecasts_sal_2f6fcf5d",
  "QualityAttribute:CGT:12:Update new risks identified for business, regulatory, and Business Continuity Plans. Prepare summary, discussion and mitigation plan for any Yellow/Red items, and identify owners. (Can these be collectively called VCRM Risks?)": "ex:QualityAttribute_update_new_risks_ide_7457d9f3",
  "QualityAttribute:CGT:12:Update to Regulated Substances Plan, Supplier Regulated Substances Declarations and Regulated Substances Report (if applicable)": "ex:QualityAttribute_update_to_regulated_6f5fde4f",
  "QualityAttribute:CGT:12:When CPV reaches stage 3, support CPV  protocols, if non-routine testing needed, in support of transfer of CPV ownership to TO": "ex:QualityAttribute_when_cpv_reaches_sta_529c3b6e",
  "QualityAttribute:CGT:1:CAR-T IP platform: Assessment completed on CAR-T IP Vein to vein  specific requirements - Logistic, CPCC, COC/COI, Systems and identification of long lead times risking readiness for Stage 2.": "ex:QualityAttribute_car_t_ip_platform_as_fd08e602",
  "QualityAttribute:CGT:1:CMO Tech Transfer / Internal site engagement and on-boarding  for introduction of Ph1/2a raw material requirements controls (selection, qualification, release testing specifications and analytical methods) as soon as able based on site selection decision and legal/business requirements (as applicable) and include in business contracts (SOWs). Critical review of CMO material qualification, methods, specifications and change management practices for raw materials.  Alignment of CMO to Janssen standards and expectations for overall material qualification and controls.": "ex:QualityAttribute_cmo_tech_transfer_in_74a7aa29",
  "QualityAttribute:CGT:1:CPDP Portfolio Management & Concept Feasibility Stage (Concludes concurrently with End of Stage 4 CMC)": "ex:QualityAttribute_cpdp_portfolio_manag_1b10579b",
  "QualityAttribute:CGT:1:Clinical Container Closure System Suitability Assessment initiated.": "ex:QualityAttribute_clinical_container_c_1269c9c3",
  "QualityAttribute:CGT:1:Clinical Primary Component Specifications initiated.": "ex:QualityAttribute_clinical_primary_com_58296c55",
  "QualityAttribute:CGT:1:Complete early characterization data review from DAS Committee  (or L&A external partner) and ensure risks are identified and mitigation plans developed.": "ex:QualityAttribute_complete_early_chara_7f9a38fa",
  "QualityAttribute:CGT:1:Confirm early phase manufacturing process is equivalent to the Discovery Mfg. process (CAR-T & other Gene Therapies)": "ex:QualityAttribute_confirm_early_phase_96384403",
  "QualityAttribute:CGT:1:Confirm that a Formulation lock is in place before GLP-Tox / Phase 1 batches are produced (to enable appropriate Early Reference Material coverage, enable Analytical Method Development and enable Cleaning Validation).": "ex:QualityAttribute_confirm_that_a_formu_aba9029c",
  "QualityAttribute:CGT:1:Confirm that sampling plans have been set up such that (non-clinical) needs and  BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_fb2750e3",
  "QualityAttribute:CGT:1:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_a2dce65f",
  "QualityAttribute:CGT:1:DAS Committee  has \u00a0reported knowledge of Mechanism of Action at time of NME designation.\u00a0 Gaps are acceptable when documented in the risk register and accompanied by commitment (Therapeutics  Discovery (TD), TA) to fill them by SG 4. Level 1 Governance and BCC will work with CMC Team to monitor progress on closing MoA gaps at SG discussions between SG 1 \u2013 SG 4. (work in progress)": "ex:QualityAttribute_das_committee_has_re_37e98d7b",
  "QualityAttribute:CGT:1:Define CRITICAL QUESTIONS based on information available in the initial TPP, criticality analysis and molecule properties from Discovery, DAS Committee  or external partner (L&A). Gaps in knowledge of mechanism of action or mechanism of toxicity could be considered for critical questions. Note when CQAs are linked to gaps in knowledge of Mechanism of Action or Mechanism of Toxicity; as gaps are closed by TA and/or Biotech CoE, method development can begin.": "ex:QualityAttribute_define_critical_ques_8aec7fef",
  "QualityAttribute:CGT:1:Define CRITICAL QUESTIONS in Risk Register based on information available in the initial TPP, criticality analysis and molecule properties from Discovery, DAS Committee  or external partner (L&A). Gaps in knowledge of mechanism of action or mechanism of toxicity could be considered for critical questions. Note when CQAs are linked to gaps in knowledge of Mechanism of Action or Mechanism of Toxicity; as gaps are closed by TA and/or Biotech CoE, method development can begin.": "ex:QualityAttribute_define_critical_ques_f3a57182",
  "QualityAttribute:CGT:1:Define Tox supply strategy and DPDS R&R (as some times DPDS does not supply) including comparability strategy to Phase 1 GMP (if required).": "ex:QualityAttribute_define_tox_supply_st_5de8230c",
  "QualityAttribute:CGT:1:Define clinical starting dose (MABEL or other).": "ex:QualityAttribute_define_clinical_star_206566b7",
  "QualityAttribute:CGT:1:Define route of administration.": "ex:QualityAttribute_define_route_of_admi_83971dfd",
  "QualityAttribute:CGT:1:Define the need for  placebo, define the  strategy for placebo production (e.g., product-specific?). Define which  attributes need to be blinded.": "ex:QualityAttribute_define_the_need_for_1e36b2f2",
  "QualityAttribute:CGT:1:Define the strategy for placebo production (e.g., product-specific?). Define which attributes need to be blinded.": "ex:QualityAttribute_define_the_strategy_1fb407e2",
  "QualityAttribute:CGT:1:Develop CMC Risk Register.": "ex:QualityAttribute_develop_cmc_risk_reg_6719e948",
  "QualityAttribute:CGT:1:Developability assessment report reviewed (if applicable).": "ex:QualityAttribute_developability_asses_240d5f9b",
  "QualityAttribute:CGT:1:Device options for tox, phase1/2a, if applicable [Pack & Dev]": "ex:QualityAttribute_device_options_for_t_bca2c105",
  "QualityAttribute:CGT:1:EHS Requirement:  Develop default SDS, Confirm default API PBOEL HHC Category Determine the Risk Group (RG) and appropriate Biosafety Level (BSL); Initiate regulated substances impact - as applicable (see EHS tab for contacts); ERA categorical exclusion  (USA IND)": "ex:QualityAttribute_ehs_requirement_deve_fd2747c9",
  "QualityAttribute:CGT:1:EHS Requirement: Supplier & Contractor assessment (evaluate if needed)": "ex:QualityAttribute_ehs_requirement_supp_d1b7bad0",
  "QualityAttribute:CGT:1:Early Phase Plasmid/Master Virus Bank has been identified (if applicable)": "ex:QualityAttribute_early_phase_plasmid_5d8aaa95",
  "QualityAttribute:CGT:1:Endorse plan for DP manufacturing process & formulation in support of initial clinical": "ex:QualityAttribute_endorse_plan_for_dp_04514cc8",
  "QualityAttribute:CGT:1:Engage Material Sciences (MS) on any potential off-platform materials and selecting raw material suppliers, as needed.": "ex:QualityAttribute_engage_material_scie_596ed6dc",
  "QualityAttribute:CGT:1:Engage with API/DPD&D/Cell Banking/CMO to support material selection strategy for the build of Ph1/2a Bill of Materials (BOM). Define raw material control strategy for new and new use raw materials used in API (cell banking, upstream, downstream) and DP processes.": "ex:QualityAttribute_engage_with_api_dpd_9251d417",
  "QualityAttribute:CGT:1:Ensure Integrated Strategic Plan is prepared (EtoE DPDS focus).": "ex:QualityAttribute_ensure_integrated_st_b23b5051",
  "QualityAttribute:CGT:1:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_0f219699",
  "QualityAttribute:CGT:1:Ensure raw material compendial compliance (e.g., USP-NF, Ph. Eur., JP, ChP) as applicable to meet IND/IMPD control of raw materials.": "ex:QualityAttribute_ensure_raw_material_cc5db0ad",
  "QualityAttribute:CGT:1:Establish preliminary CMC TPP which then populates the QTPP worksheet.  Ensure that initial/Early development CMC-TPP created & approved by CMC Council, GSM, TA. Completing the TPP fields populates the QTPP.": "ex:QualityAttribute_establish_preliminar_93b0d790",
  "QualityAttribute:CGT:1:Evaluate program fit to platform methods with PAS input, identify non-platform needs and add to risk register.": "ex:QualityAttribute_evaluate_program_fit_9800a5c6",
  "QualityAttribute:CGT:1:Evaluate stability and dosage prep/compatibility requirements versus the early development TPP and identify risks and mitigations.": "ex:QualityAttribute_evaluate_stability_a_60ccd8f6",
  "QualityAttribute:CGT:1:Evaluation of platform approach for early phase container closure selection per TV-TRG-08576": "ex:QualityAttribute_evaluation_of_platfo_b5f50a78",
  "QualityAttribute:CGT:1:IND ready/Full GMP plasmids and/or pre-MVB released (if applicable)": "ex:QualityAttribute_ind_ready_full_gmp_p_02ef563d",
  "QualityAttribute:CGT:1:IPSC (Intrinsic Properties & Structural Characterization) report from J-Bio reviewed.": "ex:QualityAttribute_ipsc_intrinsic_prope_e801b8f9",
  "QualityAttribute:CGT:1:Identification of regulatory risks and mitigations": "ex:QualityAttribute_identification_of_re_15347211",
  "QualityAttribute:CGT:1:Initial/Early development TPP-CMC created & approved by CMC Council, GSM, TA.": "ex:QualityAttribute_initial_early_develo_f38e8541",
  "QualityAttribute:CGT:1:Initiate Criticality Analysis.": "ex:QualityAttribute_initiate_criticality_d4407126",
  "QualityAttribute:CGT:1:Initiate Criticality Analysis. Delete as Stage 2 captures the deliverable.": "ex:QualityAttribute_initiate_criticality_4b2763b1",
  "QualityAttribute:CGT:1:Patent and Publication Strategy:  Summarize potential unique aspects of the process that could lead to publications and/or patents.": "ex:QualityAttribute_patent_and_publicati_eb1811b1",
  "QualityAttribute:CGT:1:Perform formulation screening of pre-NME candidates for the vector and Cell therapy candidate & review the data package for NME declaration": "ex:QualityAttribute_perform_formulation_25b854a1",
  "QualityAttribute:CGT:1:Ph1 CMC project team kick-off.": "ex:QualityAttribute_ph1_cmc_project_team_3c7f146a",
  "QualityAttribute:CGT:1:Ph1 TT project team kick-off.": "ex:QualityAttribute_ph1_tt_project_team_7f6d0248",
  "QualityAttribute:CGT:1:Ph2b/Ph3/commercial manufacturing cell line available (applicable for Lenti Vector & other Gene Therapies)": "ex:QualityAttribute_ph2b_ph3_commercial_59e3d325",
  "QualityAttribute:CGT:1:Provide early supply chain input as needed (COGS estimates - based on Pharmaceutical Valuation Guideline (PVG), capacity analysis, sourcing options).": "ex:QualityAttribute_provide_early_supply_9028e338",
  "QualityAttribute:CGT:1:Quality agreement at all sites (external & internal) initiated (if applicable).": "ex:QualityAttribute_quality_agreement_at_7ba2e77c",
  "QualityAttribute:CGT:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls)-  Device Quality Agreement (Device component, device itself and Purchasing Control/ for Combo    Products)": "ex:QualityAttribute_readiness_for_the_co_12bdc5c2",
  "QualityAttribute:CGT:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls)-  Device Testing Quality Agreement (Lab to Lab)": "ex:QualityAttribute_readiness_for_the_co_715326ca",
  "QualityAttribute:CGT:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls)-  Spec for Immediate(Primary) Container Packaging Materials (i.e. Syringe, and Vial w/stopper)": "ex:QualityAttribute_readiness_for_the_co_b6276346",
  "QualityAttribute:CGT:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls)-  Third Party  (Design Partner) Design Control Audit Report (If Applicable)": "ex:QualityAttribute_readiness_for_the_co_b43639ae",
  "QualityAttribute:CGT:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls)- Device Quality Agreement (Supplier/Manufacturer) [If applicable]": "ex:QualityAttribute_readiness_for_the_co_caa0a8f9",
  "QualityAttribute:CGT:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls)- Supplier and Contractor Audit [If applicable]": "ex:QualityAttribute_readiness_for_the_co_ff4fa82b",
  "QualityAttribute:CGT:1:Regulatory Implementation Strategy defined based on global development strategy": "ex:QualityAttribute_regulatory_implement_b1984ee6",
  "QualityAttribute:CGT:1:Review Global Import/Export Strategy (e.g. Autologous CAR-T and LV)": "ex:QualityAttribute_review_global_import_500ff66e",
  "QualityAttribute:CGT:1:Review and support Global GMO Strategy initiated by GMO group": "ex:QualityAttribute_review_and_support_g_32748d8e",
  "QualityAttribute:CGT:1:Secure early development sourcing decision from sourcing committee.": "ex:QualityAttribute_secure_early_develop_4d36160d",
  "QualityAttribute:CGT:1:Set up End-to-end planning and meeting, including sourcing/capacity assessment and risks": "ex:QualityAttribute_set_up_end_to_end_pl_4120a719",
  "QualityAttribute:CGT:1:Site Readiness and GMP status confirmed (as applicable).": "ex:QualityAttribute_site_readiness_and_g_c1550f1c",
  "QualityAttribute:CGT:1:Sourcing of reference materials aligned across Functional lines": "ex:QualityAttribute_sourcing_of_referenc_653096a9",
  "QualityAttribute:CGT:1:Sourcing options identified for ENG/Ph1 from sourcing committee (incl vector and plasmid.)": "ex:QualityAttribute_sourcing_options_ide_d367cd0f",
  "QualityAttribute:CGT:1:Stage 1 CMC Council presentation completed.": "ex:QualityAttribute_stage_1_cmc_council_6ad9cbe8",
  "QualityAttribute:CGT:1:Supplier/external lab qualification initiated.": "ex:QualityAttribute_supplier_external_la_dc009304",
  "QualityAttribute:CGT:1:Support proposals for Health Authority engagement (e.g. Scientific Advice, FDA pre IND meetings, INTERACT)": "ex:QualityAttribute_support_proposals_fo_f4e319db",
  "QualityAttribute:CGT:2:API & DP: Ph1-2a  manufacturing sites sourced/locked": "ex:QualityAttribute_api_dp_ph1_2a_manufa_e390a510",
  "QualityAttribute:CGT:2:API (inc. Vectors & Plasmids) : Assessment of (a) long term raw materials, (b) equipment & facility requirements completed (identify long-lead items that could affect sourcing decisions in SG 5)": "ex:QualityAttribute_api_inc_vectors_plas_ba7b89e8",
  "QualityAttribute:CGT:2:Add comparability risk to risk register (if applicable).": "ex:QualityAttribute_add_comparability_ri_6b0bd2b3",
  "QualityAttribute:CGT:2:Approve Criticality Assessment prior to release of clinical supplies.": "ex:QualityAttribute_approve_criticality_cfe729b7",
  "QualityAttribute:CGT:2:Assess the need to kick off VCT in SG 2 or SG 3 for Fast to Market / Accelerated programs (ATV, Breakthrough, In-License)": "ex:QualityAttribute_assess_the_need_to_k_632c5f42",
  "QualityAttribute:CGT:2:Assessment of \"Platformability\" and validation of Platform IPC, DS, DP Analytical Methods for clinical release (includes bioactivity) completed or added to the risk register to mitigate.": "ex:QualityAttribute_assessment_of_platfo_d8e9d77d",
  "QualityAttribute:CGT:2:CAR-T IP platform: CAR-T IP Vein to vein ready for Ph1/2 - Logistic, CPCC, COC/COI, Systems. If pending topics, stage gate 3 risk assessment readiness completed.": "ex:QualityAttribute_car_t_ip_platform_ca_fb72717c",
  "QualityAttribute:CGT:2:CPDP Portfolio Management & Concept Feasibility Stage": "ex:QualityAttribute_cpdp_portfolio_manag_952976b7",
  "QualityAttribute:CGT:2:Cell Bank history source documents approved.": "ex:QualityAttribute_cell_bank_history_so_2e75c91d",
  "QualityAttribute:CGT:2:Cell line history source documents approved.": "ex:QualityAttribute_cell_line_history_so_d0ea76af",
  "QualityAttribute:CGT:2:Clinical Design History File (per DS-SOP-16241) for the investigation combination product being used in Phase 0/1/2 if applicable.": "ex:QualityAttribute_clinical_design_hist_f2a355c8",
  "QualityAttribute:CGT:2:Clinical filings IND, IMPD": "ex:QualityAttribute_clinical_filings_ind_9773f87c",
  "QualityAttribute:CGT:2:Communicate Tox/Ph1 formulation to API / AD.": "ex:QualityAttribute_communicate_tox_ph1_ed6ecd7a",
  "QualityAttribute:CGT:2:Complete Complexity Assessment Form with team. Complete Complexity Assessment Decision": "ex:QualityAttribute_complete_complexity_20b58716",
  "QualityAttribute:CGT:2:Complete a raw materials and polymeric product contact materials selection, qualification and release testing gap assessment and mitigation plan per the site BOM": "ex:QualityAttribute_complete_a_raw_mater_01a7553e",
  "QualityAttribute:CGT:2:Complete \u00a0Probability of Delamination Occurrence for glass components (PDO) assessment": "ex:QualityAttribute_complete_probability_37895eb6",
  "QualityAttribute:CGT:2:Confirm that analyses and small-scale study results are available and align with scale-up plans (related to sourcing decisions / volume of future demand) with BTDS API (Inc. Vector & Plasmid) team.": "ex:QualityAttribute_confirm_that_analyse_579c850a",
  "QualityAttribute:CGT:2:Confirm that analyses and small-scale study results are available and align with scale-up plans (related to sourcing decisions / volume of future demand).": "ex:QualityAttribute_confirm_that_analyse_c55e92b2",
  "QualityAttribute:CGT:2:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_99be981f",
  "QualityAttribute:CGT:2:Criticality assessment of impurity levels versus acceptable toxicological thresholds completed prior to release of first clinical batch.": "ex:QualityAttribute_criticality_assessme_b23b4754",
  "QualityAttribute:CGT:2:DPD PF2P activities completed at Ph 1 DP manufacturing sites - as applicable": "ex:QualityAttribute_dpd_pf2p_activities_36fab316",
  "QualityAttribute:CGT:2:Define sample retention strategy for in-process intermediates, DS and DP, for clinical and late-stage production campaigns.": "ex:QualityAttribute_define_sample_retent_a4f20db8",
  "QualityAttribute:CGT:2:Develop Pharmacy Manual Plan (including diluent for Gene Therapy as needed)": "ex:QualityAttribute_develop_pharmacy_man_fb9fb842",
  "QualityAttribute:CGT:2:Developed scenarios in support of strategic planning (as required)": "ex:QualityAttribute_developed_scenarios_fd8db2e2",
  "QualityAttribute:CGT:2:Developmental Assay Controls (i.e. early research reference material) filled and qualified for use (if needed).": "ex:QualityAttribute_developmental_assay_7105ba55",
  "QualityAttribute:CGT:2:Draft IPPI, compatibility study and dose verification study plans reviewed by line functions, CMC teams, and DPAT. Evaluate stability and dosage prep/compatibility results versus the early development TPP prescribed formulation and identify risks and mitigations.": "ex:QualityAttribute_draft_ippi_compatibi_b431b611",
  "QualityAttribute:CGT:2:EHS Requirement: Ensure CMC information is provided to Environmental Risk Assessment (ERA) on Genetically Modified Organisms (ERA GMO Clinical).": "ex:QualityAttribute_ehs_requirement_ensu_bc034ef7",
  "QualityAttribute:CGT:2:EHS Requirement: Integrate DGTC reqs. Into Ph1 1st, 2nd, 3rd packaging solution": "ex:QualityAttribute_ehs_requirement_inte_71cb2e19",
  "QualityAttribute:CGT:2:EHS requirement: Prepare Bio-safety classification memo (BSL/RG)": "ex:QualityAttribute_ehs_requirement_prep_11c9d0d3",
  "QualityAttribute:CGT:2:EHS requirements: Create SDS for API, Confirm PBOEL HHC 2, if required": "ex:QualityAttribute_ehs_requirements_cre_c1d70fa3",
  "QualityAttribute:CGT:2:Evaluate and identify risks regarding the ability to meet commercial TPP requirements.": "ex:QualityAttribute_evaluate_and_identif_a97cca19",
  "QualityAttribute:CGT:2:Execute selection, qualification and release testing gap mitigation for DS (including MCB, WCB) and DP Raw Materials and Product Contact Polymeric Materials for Phase 1 manufacture including specifications and analytical methods.": "ex:QualityAttribute_execute_selection_qu_099d0fe1",
  "QualityAttribute:CGT:2:External lab / supplier qualification performed (if applicable)": "ex:QualityAttribute_external_lab_supplie_3ce2b897",
  "QualityAttribute:CGT:2:GLP Tox \"Conditions of Use\" supportive studies completed.": "ex:QualityAttribute_glp_tox_conditions_o_16e07273",
  "QualityAttribute:CGT:2:In-process methods development & qualification report for Tox/Ph1 DS & DP sites completed": "ex:QualityAttribute_in_process_methods_d_0fdea759",
  "QualityAttribute:CGT:2:Kick off Drug Product Preparation and Administration Team (DPAT).": "ex:QualityAttribute_kick_off_drug_produc_a7e85243",
  "QualityAttribute:CGT:2:Link defined CQA's to control strategy.": "ex:QualityAttribute_link_defined_cqa_s_t_35fedc1b",
  "QualityAttribute:CGT:2:MCB and WCB CoAs generated (as applicable)": "ex:QualityAttribute_mcb_and_wcb_coas_gen_cffd384f",
  "QualityAttribute:CGT:2:Make and release plasmids/virus": "ex:QualityAttribute_make_and_release_pla_574aca60",
  "QualityAttribute:CGT:2:Mycoplasma and AVA testing completed for Tox/Ph1 intermediate, if applicable.": "ex:QualityAttribute_mycoplasma_and_ava_t_91f729df",
  "QualityAttribute:CGT:2:Overall  CSC TA FTE and OOP budget compound and study level": "ex:QualityAttribute_overall_csc_ta_fte_a_9ec41b08",
  "QualityAttribute:CGT:2:Perform Critical Quality Attribute analysis.": "ex:QualityAttribute_perform_critical_qua_6d2e02f9",
  "QualityAttribute:CGT:2:Ph1 intermediate, DS and DP Stability Protocols completed.": "ex:QualityAttribute_ph1_intermediate_ds_2955c6e0",
  "QualityAttribute:CGT:2:Ph1 mfg. lots scheduled": "ex:QualityAttribute_ph1_mfg_lots_schedul_0eae1af7",
  "QualityAttribute:CGT:2:Ph1 specification for release and stability (including justification) approved for MVB/MVSS intermediate (if applicable), drug substance and drug product.": "ex:QualityAttribute_ph1_specification_fo_8890617f",
  "QualityAttribute:CGT:2:Ph1-2a DS&DP mfg. equipment qualified and site(s) ready.": "ex:QualityAttribute_ph1_2a_ds_dp_mfg_equ_7e715e81",
  "QualityAttribute:CGT:2:Ph1/2 FTE and OOP demand estimates completed and updated in V6": "ex:QualityAttribute_ph1_2_fte_and_oop_de_b5720e27",
  "QualityAttribute:CGT:2:Plasmid Characterization and incoming receipt testing plans in place and reviewed by Level 1 governance": "ex:QualityAttribute_plasmid_characteriza_44527875",
  "QualityAttribute:CGT:2:Plasmid bank /MVB history source documents approved.": "ex:QualityAttribute_plasmid_bank_mvb_his_57867f52",
  "QualityAttribute:CGT:2:Plasmid/MVB history source documents approved.": "ex:QualityAttribute_plasmid_mvb_history_354ec4e2",
  "QualityAttribute:CGT:2:Preliminary Ph2b/Ph3/commercial manufacturing technology fit and manufacturing network assessment completed (API & DP, internal vs. external manufacturing)\n*Is technology in accordance to preferred processes (e.g., platforms) for API (inc. Vectors & Plasmids)  and DP?\n*Identify gaps in site fit or in available capacity early to take necessary remedial action (e.g., capital investment).\n*Evaluation of advanced manufacturing options.  Include in development plan with link to sourcing and network strategy.": "ex:QualityAttribute_preliminary_ph2b_ph3_85e63fd2",
  "QualityAttribute:CGT:2:Process Fit to Plant (PF2P) activities completed at Tox/Ph 1 manufacturing site. Risks/mitigation plans identified. (as applicable)": "ex:QualityAttribute_process_fit_to_plant_e35fe70d",
  "QualityAttribute:CGT:2:Process flow for reference material approved": "ex:QualityAttribute_process_flow_for_ref_2834f497",
  "QualityAttribute:CGT:2:Provide \"release\" documentation for non-GLP Tox lab-scale development batch (endotoxin, BB).": "ex:QualityAttribute_provide_release_docu_a52f38e0",
  "QualityAttribute:CGT:2:Purchasing Control - Device Quality Agreement (Device component, device itself and Purchasing Control/ for Combo Products)": "ex:QualityAttribute_purchasing_control_d_b7b97ac3",
  "QualityAttribute:CGT:2:Purchasing Control - Device Quality Agreement (Manufacturing)": "ex:QualityAttribute_purchasing_control_d_c862800d",
  "QualityAttribute:CGT:2:Purchasing Control - Device Testing Quality Agreement (Lab to Lab)": "ex:QualityAttribute_purchasing_control_d_199a94f8",
  "QualityAttribute:CGT:2:Purchasing Control - Spec for Immediate(Primary) Container Packaging Materials (i.e. Syringe, and Vial w/stopper)": "ex:QualityAttribute_purchasing_control_s_310ea460",
  "QualityAttribute:CGT:2:Purchasing Control - Supplier and Contractor Audit": "ex:QualityAttribute_purchasing_control_s_cf2275db",
  "QualityAttribute:CGT:2:Purchasing Control - Third Party Design Control Audit Report (If Applicable)": "ex:QualityAttribute_purchasing_control_t_402795a5",
  "QualityAttribute:CGT:2:Quality agreement (External & Internal) approved (if required)": "ex:QualityAttribute_quality_agreement_ex_9bc856c4",
  "QualityAttribute:CGT:2:Raw Materials inventory assessed and procurement risk mitigated for  Ph1-2a DS&DP manufacturing": "ex:QualityAttribute_raw_materials_invent_dcac01a0",
  "QualityAttribute:CGT:2:Receive and review PF2P result and assessment on Ph1 manufacturing facility.": "ex:QualityAttribute_receive_and_review_p_a2725cdb",
  "QualityAttribute:CGT:2:Receive estimated productivity and yield info from API (inc. Vectors & Plasmids)  (From Stage Gate 1)": "ex:QualityAttribute_receive_estimated_pr_84f845a5",
  "QualityAttribute:CGT:2:Review and revise the CGT Raw Material and Starting Material Sourcing Strategy (e.g. Plasmids & Vectors, Cell line, Excipients, IP/licensing considerations) as needed": "ex:QualityAttribute_review_and_revise_th_decaa9e8",
  "QualityAttribute:CGT:2:Review current plans and data to determine if development buy-ups are needed.": "ex:QualityAttribute_review_current_plans_5c923a70",
  "QualityAttribute:CGT:2:Review of Global GMO Strategy and impact on clinical filings and GCDO": "ex:QualityAttribute_review_of_global_gmo_b72442c4",
  "QualityAttribute:CGT:2:Review of regulatory risks and mitigations": "ex:QualityAttribute_review_of_regulatory_0d970335",
  "QualityAttribute:CGT:2:Review testing protocol and execute \"Conditions of Use\" study (protocol from DPD) to support GLP Tox study.": "ex:QualityAttribute_review_testing_proto_3250cd3c",
  "QualityAttribute:CGT:2:Review/Approve DPFD and/or site BOM.": "ex:QualityAttribute_review_approve_dpfd_8ab5d432",
  "QualityAttribute:CGT:2:Secure material for method development, preparation of Research Reference Material (RRM) and early development controls, and initiate temperature cycling studies, as applicable.": "ex:QualityAttribute_secure_material_for_8b04bf60",
  "QualityAttribute:CGT:2:Select Devices (Prototype Delivery System to Support Phase 0/1/2a - TV-SOP-21504) if applicable.": "ex:QualityAttribute_select_devices_proto_9cd70aa5",
  "QualityAttribute:CGT:2:Site readiness and GMP status confirmed; including equipment being qualified": "ex:QualityAttribute_site_readiness_and_g_7047a3e5",
  "QualityAttribute:CGT:2:Stability plans in place for the MCB/plasmid/virus": "ex:QualityAttribute_stability_plans_in_p_a323cc23",
  "QualityAttribute:CGT:2:Stability protocol approved and study initiated (ensure that sample test requirements are communicated to Analytical)": "ex:QualityAttribute_stability_protocol_a_e6afd590",
  "QualityAttribute:CGT:2:Stage 2 CMC Council presentation completed.": "ex:QualityAttribute_stage_2_cmc_council_dfd66bfc",
  "QualityAttribute:CGT:2:Submit Product Quality Complaint New Product Set Up Form for clinical trials": "ex:QualityAttribute_submit_product_quali_2cb2db13",
  "QualityAttribute:CGT:2:Support CMC TL and CMC team to meet all deliverables through planning coordination": "ex:QualityAttribute_support_cmc_tl_and_c_7269f8b2",
  "QualityAttribute:CGT:2:Tox shipping/storage memos approved - moved from CSC": "ex:QualityAttribute_tox_shipping_storage_2a72abb3",
  "QualityAttribute:CGT:2:Tox/Ph1 DP TT memo (or DPFD) for DP mfg. site approved.": "ex:QualityAttribute_tox_ph1_dp_tt_memo_o_330fafb4",
  "QualityAttribute:CGT:2:Tox/Ph1 TT to DS mfg. site documents approved (e.g., DPFD).": "ex:QualityAttribute_tox_ph1_tt_to_ds_mfg_09621f72",
  "QualityAttribute:CGT:2:Tox/Ph1 formulation composition and DP presentation defined along with accompanying raw materials and primary packaging.": "ex:QualityAttribute_tox_ph1_formulation_57c77ae5",
  "QualityAttribute:CGT:2:Tox/Ph1/2 Clinical supply plan prepared and aligned with clinical demand forecast and enrollment projection": "ex:QualityAttribute_tox_ph1_2_clinical_s_1a0e42f5",
  "QualityAttribute:CGT:2:Tox/Ph1/MVB/MVSS/DS/DP methods transfer completed (CRS or applicable testing labs ready).": "ex:QualityAttribute_tox_ph1_mvb_mvss_ds_17a4dca0",
  "QualityAttribute:CGT:2:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_e206de74",
  "QualityAttribute:CGT:2:Update CRITICAL QUESTIONS, if necessary, based on information available in the initial TPP, criticality analysis and molecule properties from Discovery, DAS Committee or external partner (L&A). Gaps in knowledge of mechanism of action or mechanism of toxicity could be considered for critical questions. Note when CQAs are linked to gaps in knowledge of Mechanism of Action or Mechanism of Toxicity; as gaps are closed by TA and/or Biotech CoE, method development can begin.": "ex:QualityAttribute_update_critical_ques_edbfae9b",
  "QualityAttribute:CGT:3:Alignment of IPPI with supportive change controls to ensure updates are captured": "ex:QualityAttribute_alignment_of_ippi_wi_131360a8",
  "QualityAttribute:CGT:3:Analytical CMC sections of IND/IMPD submission are verified and completed.": "ex:QualityAttribute_analytical_cmc_secti_5786d5b1",
  "QualityAttribute:CGT:3:Approve Phase 1 criticality analysis report for releasing first lot of DP for human use.": "ex:QualityAttribute_approve_phase_1_crit_7401c2dc",
  "QualityAttribute:CGT:3:Author/Review IND/IMPD Control of Materials": "ex:QualityAttribute_author_review_ind_im_d2cee065",
  "QualityAttribute:CGT:3:CMC Module 3 completed for IND/IMPD Submission.": "ex:QualityAttribute_cmc_module_3_complet_fa7330f8",
  "QualityAttribute:CGT:3:CMC sections of IND/IMPD submission are verified and approved by the functional area owners.": "ex:QualityAttribute_cmc_sections_of_ind_a6d83e34",
  "QualityAttribute:CGT:3:CPDP Portfolio Management & Concept Feasibility Stage": "ex:QualityAttribute_cpdp_portfolio_manag_97d11f9e",
  "QualityAttribute:CGT:3:Clinical Container Closure System Suitability Assessment (Ph1)": "ex:QualityAttribute_clinical_container_c_7a13572f",
  "QualityAttribute:CGT:3:Clinical primary Component Specifications (Ph1)": "ex:QualityAttribute_clinical_primary_com_405a802d",
  "QualityAttribute:CGT:3:Complete initial Product Risk Assessment (PRA) (Only sections related to hazard analysis, and initial risk evaluation are required)": "ex:QualityAttribute_complete_initial_pro_47e70f01",
  "QualityAttribute:CGT:3:Complete initial Product Risk Management Plan/Report (PRM) (including risk plan and PRA summary)": "ex:QualityAttribute_complete_initial_pro_e8a53333",
  "QualityAttribute:CGT:3:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create uFMEA for clinical product, if needed.": "ex:QualityAttribute_complete_or_revisit_9f963125",
  "QualityAttribute:CGT:3:Completion of Clinical Design History File (TV-SOP-21504) for the investigation combination product being used in Phase 0/1/2 if applicable.": "ex:QualityAttribute_completion_of_clinic_79f5e2f3",
  "QualityAttribute:CGT:3:Confirm CoC and CoI for autologous programs": "ex:QualityAttribute_confirm_coc_and_coi_b6a9996e",
  "QualityAttribute:CGT:3:Country Specific Requirements confirmed for CTA filing readiness (this should be CMCRA responsibility)": "ex:QualityAttribute_country_specific_req_c3d673b3",
  "QualityAttribute:CGT:3:DPD CMC sections of IND/IMPD submission are verified and completed - or drafted as applicable": "ex:QualityAttribute_dpd_cmc_sections_of_7d4fce04",
  "QualityAttribute:CGT:3:Developed scenarios in support of strategic planning (as required)": "ex:QualityAttribute_developed_scenarios_62357d26",
  "QualityAttribute:CGT:3:Device Regulatory Strategy": "ex:QualityAttribute_device_regulatory_st_b2a501db",
  "QualityAttribute:CGT:3:Devices (Prototype Delivery System to Support Phase 0/1/2a - DS-SOP-16241 TV-SOP-21504) if applicable ready for clinical use.": "ex:QualityAttribute_devices_prototype_de_2603af62",
  "QualityAttribute:CGT:3:EHS Requirement: Develop MSDS for drug product  (see EHS tab for contacts)": "ex:QualityAttribute_ehs_requirement_deve_d84df4e7",
  "QualityAttribute:CGT:3:Engineering assessment for all manufacturing sites approved (with approved CAPA plan if required)": "ex:QualityAttribute_engineering_assessme_c32997ca",
  "QualityAttribute:CGT:3:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_32189950",
  "QualityAttribute:CGT:3:Ensure plan is in place to capture process efficiency data (to inform later stage activities)": "ex:QualityAttribute_ensure_plan_is_in_pl_fac79011",
  "QualityAttribute:CGT:3:Evaluate at scale (GLP-Tox and Phase 1 GMP) process efficiency data and communicated to JSC VCL (to update COGS, sourcing assumptions).": "ex:QualityAttribute_evaluate_at_scale_gl_3c713350",
  "QualityAttribute:CGT:3:Evaluate whether Tox/Ph1 comparability study is required.": "ex:QualityAttribute_evaluate_whether_tox_dee8cdc9",
  "QualityAttribute:CGT:3:FIH committee meeting minutes (digitally signed) for QP release of clinical supplies.": "ex:QualityAttribute_fih_committee_meetin_f0a980e7",
  "QualityAttribute:CGT:3:Full E2E supply plan in place in alignment with clinical development plan & enrollment projections, as well as non-clinical demand including tox.": "ex:QualityAttribute_full_e2e_supply_plan_e5aea3b8",
  "QualityAttribute:CGT:3:IND/IMPD review (Manufacturing and Packaging locations, stability plan) and delivery of submission labels as needed.": "ex:QualityAttribute_ind_impd_review_manu_8de2e400",
  "QualityAttribute:CGT:3:Kick-Off Customer Value Process with Combo Device Team. Align on the Compound Overview & Timeline and  prioritize deliverables.": "ex:QualityAttribute_kick_off_customer_va_16cc802b",
  "QualityAttribute:CGT:3:Obtain large-scale (GLP-TOX and Phase 1 GMP). Process efficiency data must be evaluated with earlier data from BTDS API (inc. Vectors & Plasmids) .": "ex:QualityAttribute_obtain_large_scale_g_2bb1b824",
  "QualityAttribute:CGT:3:Overall CSC FTE and OOP budget compound and study level": "ex:QualityAttribute_overall_csc_fte_and_ae9762b9",
  "QualityAttribute:CGT:3:Ph 1/2 plan updated and reviewed with CMC Team": "ex:QualityAttribute_ph_1_2_plan_updated_048d6e17",
  "QualityAttribute:CGT:3:Ph1 & 2a DS and DP supply manufactured": "ex:QualityAttribute_ph1_2a_ds_and_dp_sup_3faab529",
  "QualityAttribute:CGT:3:Ph1 API & DP Storage/Shipping Memo approved - move from CSC": "ex:QualityAttribute_ph1_api_dp_storage_s_2d6ff579",
  "QualityAttribute:CGT:3:Ph1 API released": "ex:QualityAttribute_ph1_api_released_ce951326",
  "QualityAttribute:CGT:3:Ph1 CMC dossier submitted or scheduled to be submitted to HA for FIH (Comment: SG#3 often occur BEFORE the first filing, the Phase 1 CMC dossier may still in progress at the time of SG#3 review)": "ex:QualityAttribute_ph1_cmc_dossier_subm_882fb5ef",
  "QualityAttribute:CGT:3:Ph1 CTA approval achieved (Not applicable if SG# occurs prior to CTA submission or approval) (this should be CMCRA responsibility)": "ex:QualityAttribute_ph1_cta_approval_ach_13a36862",
  "QualityAttribute:CGT:3:Ph1 DP released": "ex:QualityAttribute_ph1_dp_released_b33f2cf5",
  "QualityAttribute:CGT:3:Ph1 P&L'd drug product released": "ex:QualityAttribute_ph1_p_l_d_drug_produ_1ec3189b",
  "QualityAttribute:CGT:3:Ph1 intermediate (if applicable), DS (if applicable) and DP expiry memos approved (temperature excursion guideline included, as applicable).": "ex:QualityAttribute_ph1_intermediate_if_25ae3c74",
  "QualityAttribute:CGT:3:Ph1 or IND Supporting Mfg. complete & early-stage product quality attributes and yield targets achieved.": "ex:QualityAttribute_ph1_or_ind_supportin_cfff27a4",
  "QualityAttribute:CGT:3:Ph1 pharmacy manual reports approved, supportive studies and risk assessments completed (if applicable). Evaluate stability and dosage prep/compatibility requirements versus the early development TPP prescribed formulation and identify risks and mitigations.": "ex:QualityAttribute_ph1_pharmacy_manual_9d19cfd3",
  "QualityAttribute:CGT:3:Ph1 representative DP mfg. complete & early-stage product quality attributes and yield targets achieved.": "ex:QualityAttribute_ph1_representative_d_59526d01",
  "QualityAttribute:CGT:3:Ph1 supply delivered to clinical sites.": "ex:QualityAttribute_ph1_supply_delivered_48a4cc1a",
  "QualityAttribute:CGT:3:Ph1 vs. Ph2 comparability plan approved by BCC (if required)": "ex:QualityAttribute_ph1_vs_ph2_comparabi_e58f00ed",
  "QualityAttribute:CGT:3:Ph1/2 FTE and OOP demand estimates completed and updated in V6": "ex:QualityAttribute_ph1_2_fte_and_oop_de_19d6b817",
  "QualityAttribute:CGT:3:Ph2 formulation/drug product optimization studies initiated (if required).": "ex:QualityAttribute_ph2_formulation_drug_06e6fa91",
  "QualityAttribute:CGT:3:Ph2 process optimization studies initiated (if required).": "ex:QualityAttribute_ph2_process_optimiza_66cf9339",
  "QualityAttribute:CGT:3:Phase 1 Pharmacy manual testing completed (compatibility, in-use stability, & accuracy if needed)": "ex:QualityAttribute_phase_1_pharmacy_man_fa6190ee",
  "QualityAttribute:CGT:3:Pre-IND/CTA package prepared/briefing book completed": "ex:QualityAttribute_pre_ind_cta_package_3cd2b1f9",
  "QualityAttribute:CGT:3:Preliminary commercial early estimate COGs assessment complete": "ex:QualityAttribute_preliminary_commerci_6bc85bac",
  "QualityAttribute:CGT:3:QA review of Ph1 CMC dossier completed": "ex:QualityAttribute_qa_review_of_ph1_cmc_22898795",
  "QualityAttribute:CGT:3:QP approval of Ph1 supplies achieved": "ex:QualityAttribute_qp_approval_of_ph1_s_b825284e",
  "QualityAttribute:CGT:3:Receive DPD PF2P results and assessment.": "ex:QualityAttribute_receive_dpd_pf2p_res_cf8d1541",
  "QualityAttribute:CGT:3:Review critical questions and mitigation plans. Identify new critical questions based on emerging data.": "ex:QualityAttribute_review_critical_ques_5ed287e1",
  "QualityAttribute:CGT:3:Review current plans and data to determine if buy-ups are needed.": "ex:QualityAttribute_review_current_plans_06ad96b9",
  "QualityAttribute:CGT:3:Review of regulatory risks and mitigations": "ex:QualityAttribute_review_of_regulatory_4a492087",
  "QualityAttribute:CGT:3:Secure DPAT approval of IPPI for Ph1 study.": "ex:QualityAttribute_secure_dpat_approval_88dee159",
  "QualityAttribute:CGT:3:Stage 3 CMC Team presentation review completed": "ex:QualityAttribute_stage_3_cmc_team_pre_d6666ac4",
  "QualityAttribute:CGT:3:Support CMC TL and CMC team to meet all deliverables through planning coordination": "ex:QualityAttribute_support_cmc_tl_and_c_9239d685",
  "QualityAttribute:CGT:3:Support of Health Authority Meetings (US FDA and/or EU National/Scientific Advice) (if needed/applicable)": "ex:QualityAttribute_support_of_health_au_fc51c0ac",
  "QualityAttribute:CGT:3:TPP-CMC updated and aligned with customers & approved by CMC Council, GSM, TA (if applicable)": "ex:QualityAttribute_tpp_cmc_updated_and_68f0bf4c",
  "QualityAttribute:CGT:3:Tox/Ph1 formulation history report initiated.": "ex:QualityAttribute_tox_ph1_formulation_a62832cf",
  "QualityAttribute:CGT:3:Update CMC Risk Register": "ex:QualityAttribute_update_cmc_risk_regi_cda92291",
  "QualityAttribute:CGT:3:Viral clearance studies and reports approved (if applicable)": "ex:QualityAttribute_viral_clearance_stud_1120b072",
  "QualityAttribute:CGT:4:Amendments to IND/IMPDs prepared and approved": "ex:QualityAttribute_amendments_to_ind_im_c58e5044",
  "QualityAttribute:CGT:4:As needed, Ph2 MVB/MVSS, DS, DP specification documents (including justification) completed.": "ex:QualityAttribute_as_needed_ph2_mvb_mv_c939dcfb",
  "QualityAttribute:CGT:4:Assess the need to accelerate Stage 5 deliverables to meet pivotal clinical trial milestones (Ph2b/Ph3 FPI).": "ex:QualityAttribute_assess_the_need_to_a_f1dec37a",
  "QualityAttribute:CGT:4:CMO Tech Transfer / Internal site engagement and on-boarding  for introduction of raw material controls (selection, qualification, release testing specifications and analytical methods) as soon as able based on site selection decision and legal/business requirements (as applicable) and include in business contracts (SOWs). Critical review of CMO material qualification, methods, specifications and change management practices for raw materials. Alignment of CMO to Janssen standards and expectations for overall material qualification and controls.": "ex:QualityAttribute_cmo_tech_transfer_in_30d17be6",
  "QualityAttribute:CGT:4:CPDP Portfolio Management & Concept Feasibility Stage": "ex:QualityAttribute_cpdp_portfolio_manag_256df081",
  "QualityAttribute:CGT:4:Co-lead DPAT review/approval of all changes to clinical protocol that lead to a change to the IPPI/PM study.": "ex:QualityAttribute_co_lead_dpat_review_7543b3b7",
  "QualityAttribute:CGT:4:Combination Product Feasibility Report": "ex:QualityAttribute_combination_product_b599abc0",
  "QualityAttribute:CGT:4:Complete CMC Strategic Plan, covering Stages 4-9 including assessment of gaps in structure/function knowledge. Ensure that gaps and mechanism of action/toxicity are closed or identify risks/mitigation plans.": "ex:QualityAttribute_complete_cmc_strateg_a656a6f6",
  "QualityAttribute:CGT:4:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for clinical product, as needed.": "ex:QualityAttribute_complete_or_revisit_3f5fef11",
  "QualityAttribute:CGT:4:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_1f4cea42",
  "QualityAttribute:CGT:4:Confirm that the right analyses and study results are available to align with DP manufacturing equipment (related to sourcing decisions / volume of future demand)": "ex:QualityAttribute_confirm_that_the_rig_f5485c6a",
  "QualityAttribute:CGT:4:Customer Centered Design Assessment Document if applicable.": "ex:QualityAttribute_customer_centered_de_000b08e9",
  "QualityAttribute:CGT:4:DP pCPP/pCMA review completed.": "ex:QualityAttribute_dp_pcpp_pcma_review_f02910c2",
  "QualityAttribute:CGT:4:DPD PF2P activities completed at Ph2 DP manufacturing sites (if required).": "ex:QualityAttribute_dpd_pf2p_activities_0dc26d34",
  "QualityAttribute:CGT:4:Define and review integrated control strategy with the appropriate governance. Initiate assay development for any new attributes identified.": "ex:QualityAttribute_define_and_review_in_86db2669",
  "QualityAttribute:CGT:4:Define the approach and review all available  information from temperature cycling stability studies (program specific approach presented to governance if TV-SOP-33790 doesn't apply), including trending results, at appropriate governance. Items to consider include prior and platform knowledge, risk assessment, process DOE, hold time studies, process relevant degradation, and modeling data": "ex:QualityAttribute_define_the_approach_e4ba661d",
  "QualityAttribute:CGT:4:Define the approach for acquiring S-F knowledge and review at appropriate governance.\u00a0The MoA/MoT gap list must be closed or the risks identified.": "ex:QualityAttribute_define_the_approach_4a3248ca",
  "QualityAttribute:CGT:4:Develop CMC Regulatory Strategy for Phase 2/Pivotal filing": "ex:QualityAttribute_develop_cmc_regulato_0510069f",
  "QualityAttribute:CGT:4:Developed scenarios in support of strategic planning (as required).": "ex:QualityAttribute_developed_scenarios_6fe9ad78",
  "QualityAttribute:CGT:4:EHS Requirement: Integrate DGTC reqs. Into Ph2 1st, 2nd, 3rd packaging solution": "ex:QualityAttribute_ehs_requirement_inte_4902aabd",
  "QualityAttribute:CGT:4:EHS Requirement: Provide CMC-RA input to GMO dossiers to enable clinical trials, update CMC information (if applicable)": "ex:QualityAttribute_ehs_requirement_prov_970e7c5f",
  "QualityAttribute:CGT:4:Engage with API/DPD&D/Cell Banking/CMO to support material selection strategy for the build of Ph2b/3 Bill of Materials (BOM).": "ex:QualityAttribute_engage_with_api_dpd_bd554a75",
  "QualityAttribute:CGT:4:Engage with Material Sciences (MS) on selecting raw material suppliers, as needed.": "ex:QualityAttribute_engage_with_material_80dc2506",
  "QualityAttribute:CGT:4:Ensure Customer Value deliverables completed for this stage.": "ex:QualityAttribute_ensure_customer_valu_926c1da5",
  "QualityAttribute:CGT:4:Ensure overall CSC FTE and OOP budget compound and study level": "ex:QualityAttribute_ensure_overall_csc_f_bc08103f",
  "QualityAttribute:CGT:4:Ensure raw material compendial compliance (e.g., USP-NF, Ph. Eur., JP, ChP) as applicable to meet IND/IMPD control of raw materials.": "ex:QualityAttribute_ensure_raw_material_21bc06cc",
  "QualityAttribute:CGT:4:Full E2E supply plan in place in alignment with clinical development plan and enrollment projections as well as non-clinical demand up to Ph2a and including tox": "ex:QualityAttribute_full_e2e_supply_plan_fdcbdf40",
  "QualityAttribute:CGT:4:Identify and flag possible causes that could present a Bioavailability issue such as administration routes (IV, SC, etc.).": "ex:QualityAttribute_identify_and_flag_po_620497bb",
  "QualityAttribute:CGT:4:PF2P activities completed at Ph2 DS manufacturing sites (if required).": "ex:QualityAttribute_pf2p_activities_comp_a4f4e7b5",
  "QualityAttribute:CGT:4:Passive shipping systems qualified, if applicable. (Ph2 B or later)": "ex:QualityAttribute_passive_shipping_sys_28f7fe87",
  "QualityAttribute:CGT:4:Pediatric CMC Assessment (assess potential for pediatric formulation development) completed.": "ex:QualityAttribute_pediatric_cmc_assess_903ad0d9",
  "QualityAttribute:CGT:4:Perform pCMA analysis in collaboration with API and DPD": "ex:QualityAttribute_perform_pcma_analysi_38c47eef",
  "QualityAttribute:CGT:4:Ph 2 Pharmacy Manual testing for DPD, if required.": "ex:QualityAttribute_ph_2_pharmacy_manual_138d5d8a",
  "QualityAttribute:CGT:4:Ph1 & 2 resupply manufactured according to supply plan": "ex:QualityAttribute_ph1_2_resupply_manuf_50950556",
  "QualityAttribute:CGT:4:Ph1 DP re-supply lots and/or Ph2 DP released.": "ex:QualityAttribute_ph1_dp_re_supply_lot_231ff8d9",
  "QualityAttribute:CGT:4:Ph1 DS re-supply lots and/or Ph2 DS released.": "ex:QualityAttribute_ph1_ds_re_supply_lot_df2d1c2f",
  "QualityAttribute:CGT:4:Ph1 vs Ph2 comparability plan review with CGTV and BCC completed (if required).": "ex:QualityAttribute_ph1_vs_ph2_comparabi_03600919",
  "QualityAttribute:CGT:4:Ph2 Container Closure System Clinical Suitability Assessment.": "ex:QualityAttribute_ph2_container_closur_1e381570",
  "QualityAttribute:CGT:4:Ph2 Primary Component Specifications prepared.": "ex:QualityAttribute_ph2_primary_componen_1352a933",
  "QualityAttribute:CGT:4:Ph2 TT to Site completed, TTM approved (if required).": "ex:QualityAttribute_ph2_tt_to_site_compl_c819d7fb",
  "QualityAttribute:CGT:4:Ph2 drug product TT to DP site completed (if required) - TTM approved.": "ex:QualityAttribute_ph2_drug_product_tt_4f6d1b41",
  "QualityAttribute:CGT:4:Ph2 drug product development stability (if required).": "ex:QualityAttribute_ph2_drug_product_dev_1f935045",
  "QualityAttribute:CGT:4:Ph2 pharmacy manual studies completed and approved (if required).": "ex:QualityAttribute_ph2_pharmacy_manual_c0009e7e",
  "QualityAttribute:CGT:4:Ph2b/3 drug product development strategy (i.e. formulation, dosage form, & stability study) initiated.": "ex:QualityAttribute_ph2b_3_drug_product_e17034f2",
  "QualityAttribute:CGT:4:Ph2b/Ph3 development plan defined (API-LM late phase module deliverable)": "ex:QualityAttribute_ph2b_ph3_development_598c9172",
  "QualityAttribute:CGT:4:Ph3 cell culture media TT strategy defined (confirm with Material Sciences and NPT) if required.": "ex:QualityAttribute_ph3_cell_culture_med_887acee1",
  "QualityAttribute:CGT:4:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_59c14e32",
  "QualityAttribute:CGT:4:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_e3bf53e2",
  "QualityAttribute:CGT:4:QP approval of Ph1 supplies and Ph2 supplies obtained (if required).": "ex:QualityAttribute_qp_approval_of_ph1_s_587f60a7",
  "QualityAttribute:CGT:4:Raw materials specified for Ph2b/3, and reviewed by Material Sciences.": "ex:QualityAttribute_raw_materials_specif_2a272482",
  "QualityAttribute:CGT:4:Review PRA, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_pra_update_if_8762b7b0",
  "QualityAttribute:CGT:4:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_2c3ff34a",
  "QualityAttribute:CGT:4:Review Ph2b/Ph3 devt plan (API (inc. Vectors & Plasmids) -LM late phase module deliverable).": "ex:QualityAttribute_review_ph2b_ph3_devt_4cb872f0",
  "QualityAttribute:CGT:4:Review and assess impact of Ph3 cell culture media TT strategy (defined by BTDS API and MS).": "ex:QualityAttribute_review_and_assess_im_0ae32475",
  "QualityAttribute:CGT:4:Review of plasmid WCB needs": "ex:QualityAttribute_review_of_plasmid_wc_ac6c116f",
  "QualityAttribute:CGT:4:Review of plasmid/MCB construct (if needed, especially for in licensed projects)": "ex:QualityAttribute_review_of_plasmid_mc_ec7e512d",
  "QualityAttribute:CGT:4:Review/Update Criticality Assessment as needed. Verify that the identified CQA's and their established ranges are supportive of the desired in-vivo situation.": "ex:QualityAttribute_review_update_critic_61a0fe93",
  "QualityAttribute:CGT:4:Samples and information will be collected for the sample archive permanent retention program during all stages following NME, for all Clinical lots, all\u00a0ProVal lots, and for any representative lot(s) manufactured after a significant process change.": "ex:QualityAttribute_samples_and_informat_764a99a2",
  "QualityAttribute:CGT:4:Sourcing and capacity review for plasmid/virus manufacture(r)": "ex:QualityAttribute_sourcing_and_capacit_406cd2d2",
  "QualityAttribute:CGT:4:Stage 4 CMC Team and appropriate focus group presentation reviews completed.": "ex:QualityAttribute_stage_4_cmc_team_and_40a6a4b3",
  "QualityAttribute:CGT:4:Support API (inc. Vectors & Plasmids)  and DPD&D on selecting raw material suppliers and initiate SWOT Assessment.": "ex:QualityAttribute_support_api_inc_vect_b4e30c71",
  "QualityAttribute:CGT:4:Support CMC Scientific Advice Strategy to support Breakthrough Therapy & PRIME": "ex:QualityAttribute_support_cmc_scientif_593f7382",
  "QualityAttribute:CGT:4:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_0cd87c1f",
  "QualityAttribute:CGT:4:Support High level commercial strategy for BLA/MAA, including GFLS landscape": "ex:QualityAttribute_support_high_level_c_38851ae1",
  "QualityAttribute:CGT:4:TPP-CMC updated and aligned with customers & approved by CMC Council, GSM, TA (if applicable).": "ex:QualityAttribute_tpp_cmc_updated_and_786b2a97",
  "QualityAttribute:CGT:4:Tox/Ph1/Ph2 comparability data reviewed to confirm comparability (if applicable).": "ex:QualityAttribute_tox_ph1_ph2_comparab_da5a09ff",
  "QualityAttribute:CGT:4:Tox/Ph1/Ph2 comparability plan reviewed with BCC (if applicable).": "ex:QualityAttribute_tox_ph1_ph2_comparab_3b9e2c7e",
  "QualityAttribute:CGT:4:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_854c9589",
  "QualityAttribute:CGT:4:Update Criticality Analysis with presumptive CPPs/CMAs for development strategy.  pCMA analysis needs to be performed in collaboration with Material Sciences.": "ex:QualityAttribute_update_criticality_a_2a719268",
  "QualityAttribute:CGT:4:Verify and confirm a clear link between relevant CQA's and the Justification of Specifications.": "ex:QualityAttribute_verify_and_confirm_a_9b332ca1",
  "QualityAttribute:CGT:5:API (inc. Vectors & Plasmids) & DP: Ph3 & Commercial manufacturing sites locked.": "ex:QualityAttribute_api_inc_vectors_plas_add80ec9",
  "QualityAttribute:CGT:5:Additional Supplier/ External lab qualified (if applicable)": "ex:QualityAttribute_additional_supplier_b5ff89e9",
  "QualityAttribute:CGT:5:Allocate material to support generation of Primary Reference material.": "ex:QualityAttribute_allocate_material_to_3719b996",
  "QualityAttribute:CGT:5:Approve Brand Protection Product Risk Assessment.": "ex:QualityAttribute_approve_brand_protec_38ca87fd",
  "QualityAttribute:CGT:5:As per CPDP Definition & Planning Stage (TV-SOP-28491)": "ex:QualityAttribute_as_per_cpdp_definiti_7bc451a8",
  "QualityAttribute:CGT:5:Assign Commercial SI and TO to participate in the analytical subteam": "ex:QualityAttribute_assign_commercial_si_9038ae2f",
  "QualityAttribute:CGT:5:CPDP Definition & Planning Stage Design Review": "ex:QualityAttribute_cpdp_definition_plan_2202a4b3",
  "QualityAttribute:CGT:5:Cell-based Bioassay development initiated including strategy for cell-line licensing if needed.": "ex:QualityAttribute_cell_based_bioassay_aaac82f0",
  "QualityAttribute:CGT:5:Co-lead DPAT review/approval of all changes to clinical protocol that lead to a change to the IPPI/PM study.": "ex:QualityAttribute_co_lead_dpat_review_1bcb3981",
  "QualityAttribute:CGT:5:Combination Product Designation Form": "ex:QualityAttribute_combination_product_92416166",
  "QualityAttribute:CGT:5:Commercial Concept Development Summary": "ex:QualityAttribute_commercial_concept_d_864a2e8f",
  "QualityAttribute:CGT:5:Complete a raw materials and polymeric product contact materials selection, qualification and release testing gap assessment and mitigation plan per the site BOM.": "ex:QualityAttribute_complete_a_raw_mater_d8e011bd",
  "QualityAttribute:CGT:5:Complete assessment of endotoxin recovery.": "ex:QualityAttribute_complete_assessment_f0eb3d8a",
  "QualityAttribute:CGT:5:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create uFMEA for commercial product, if needed.": "ex:QualityAttribute_complete_or_revisit_41219346",
  "QualityAttribute:CGT:5:Conduct gap analysis of early development methods and establish strategy for method transfer or co-validation": "ex:QualityAttribute_conduct_gap_analysis_22a6fba0",
  "QualityAttribute:CGT:5:Conduct stability data review and identify risk mitigation strategy as needed.": "ex:QualityAttribute_conduct_stability_da_bcecd99f",
  "QualityAttribute:CGT:5:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_3f2a9f71",
  "QualityAttribute:CGT:5:Confirm the submission plan endorsed by CDT, including GFLS country list and timeline.": "ex:QualityAttribute_confirm_the_submissi_104dffa6",
  "QualityAttribute:CGT:5:Consult with JSC regarding Speed to Optimization initiative.": "ex:QualityAttribute_consult_with_jsc_reg_46acaa2c",
  "QualityAttribute:CGT:5:Coordinate aggregated clinical/non-clinical demand in support of Ph3 mfg. and provide to the JSC organization for final commercial sourcing decision": "ex:QualityAttribute_coordinate_aggregate_050cf0b8",
  "QualityAttribute:CGT:5:Critical Raw Materials have been sourced and utilized in Phase-3 Formulation Development  to represent potential  variability in the Phase 3 clinical production process.": "ex:QualityAttribute_critical_raw_materia_f20608ee",
  "QualityAttribute:CGT:5:Critical reagents program for late phase development established.": "ex:QualityAttribute_critical_reagents_pr_3beda2e3",
  "QualityAttribute:CGT:5:DPD PF2P Stage 1 activities completed (First Process Walk-through).": "ex:QualityAttribute_dpd_pf2p_stage_1_act_a6b5e718",
  "QualityAttribute:CGT:5:DPD Raw materials specified for Ph2b/3.": "ex:QualityAttribute_dpd_raw_materials_sp_4110046f",
  "QualityAttribute:CGT:5:DS/DP Matrices defined and material received for validating stability, IPC, release, and process characterization methods.": "ex:QualityAttribute_ds_dp_matrices_defin_3a80ff24",
  "QualityAttribute:CGT:5:Define Variability Strategy, i.e., the intention to generate variability in Phase 3 DS and DP manufacturing by controlled introduction of Raw Material variability and/or parameter variability (at end of ranges).": "ex:QualityAttribute_define_variability_s_ff4a59b0",
  "QualityAttribute:CGT:5:Define manufacturing strategy (routine sources of variability), see Portfolio Management deliverable.": "ex:QualityAttribute_define_manufacturing_8cfa10fe",
  "QualityAttribute:CGT:5:Deliver Labels (as needed) - Devices may input but should be under Clinical Supply Unit???": "ex:QualityAttribute_deliver_labels_as_ne_2b88812d",
  "QualityAttribute:CGT:5:Demonstrate sufficient shelf life stability": "ex:QualityAttribute_demonstrate_sufficie_0e07763a",
  "QualityAttribute:CGT:5:Design History File (Initiate)": "ex:QualityAttribute_design_history_file_dd66d882",
  "QualityAttribute:CGT:5:Design and Development Plan (Initiate) - Clinical & Regulatory Strategy Plan (Initiate) [Can be included in the Design & Development Plan]": "ex:QualityAttribute_design_and_developme_a9b3892b",
  "QualityAttribute:CGT:5:Design and Development Plan (Initiate) - Stability Plan": "ex:QualityAttribute_design_and_developme_dfeaf957",
  "QualityAttribute:CGT:5:Develop and execute a\u00a0strategy around continuous analytical monitoring\u00a0of media and critical raw materials.": "ex:QualityAttribute_develop_and_execute_5e5d0fc7",
  "QualityAttribute:CGT:5:Developed scenarios in support of strategic planning (as required).": "ex:QualityAttribute_developed_scenarios_0f6ee27f",
  "QualityAttribute:CGT:5:Device Design Verification Plan  (Initiate)": "ex:QualityAttribute_device_design_verifi_b81df33a",
  "QualityAttribute:CGT:5:Device Risk Management (Initiate) - CTQ Flow Down(Initiate)": "ex:QualityAttribute_device_risk_manageme_f4b2118e",
  "QualityAttribute:CGT:5:Device Risk Management (Initiate) - Product Risk Assessment (Initiate)": "ex:QualityAttribute_device_risk_manageme_8494a08f",
  "QualityAttribute:CGT:5:Device Risk Management (Initiate) - Risk Management Plan (Initiate)": "ex:QualityAttribute_device_risk_manageme_55f68871",
  "QualityAttribute:CGT:5:Device Risk Management (Initiate) - uFMEA (Initiate)": "ex:QualityAttribute_device_risk_manageme_2079df4c",
  "QualityAttribute:CGT:5:EHS Requirement: Evaluate unique waste disposal requirements; risk evaluation of unique chemicals, Update SDS for API, Initiate environmental risk assessment, Conduct process risk assessment, supplier risk assessment (evaluate if needed); include EHS items in CAR. Provide CMC-RA input to GMO dossiers to enable clinical trials, update CMC information ( if applicable)": "ex:QualityAttribute_ehs_requirement_eval_de844008",
  "QualityAttribute:CGT:5:Ensure Customer Value deliverables completed for this stage (combo products).": "ex:QualityAttribute_ensure_customer_valu_42792b4b",
  "QualityAttribute:CGT:5:Ensure overall CSC FTE and OOP budget compound and study level": "ex:QualityAttribute_ensure_overall_csc_f_e4d2f1ea",
  "QualityAttribute:CGT:5:Execute selection, qualification and release testing specifications/methods gap mitigation for DS (including MCB, WCB, MVSS, plasmid, apheresis, AAV/LV drug substance, as applicable) and DP Raw Materials and Product Contact Polymeric Materials for Phase 2b/3 manufacture including specifications and analytical methods.": "ex:QualityAttribute_execute_selection_qu_2b97781a",
  "QualityAttribute:CGT:5:First Product Strategy Roadmap (PSR) workshop completed; JSC Product Council endorsement": "ex:QualityAttribute_first_product_strate_efc9ee16",
  "QualityAttribute:CGT:5:First strategic forecast and capacity planning for API (inc. Vectors & Plasmids) and DP via initial New Product Segmentation (NPS) and Forecast Integration Session (FIS) - Socialization.": "ex:QualityAttribute_first_strategic_fore_2aa06d6b",
  "QualityAttribute:CGT:5:High level Ph3 drug product development & TT strategy prepared.": "ex:QualityAttribute_high_level_ph3_drug_faef1399",
  "QualityAttribute:CGT:5:Human Factors Study Plan  (Initiate)": "ex:QualityAttribute_human_factors_study_1c85b27d",
  "QualityAttribute:CGT:5:IND/IMPD review (Manufacturing & Packaging locations, Stability plan, as needed) and delivery of submission labels": "ex:QualityAttribute_ind_impd_review_manu_14f1aaa3",
  "QualityAttribute:CGT:5:Initiate Device-PFS interaction risk assessment and plan to evaluate completed, if applicable (study specifics to be captured in action plan, expectation is demonstrated biochemical and functional stability over 12-18m storage at real-time conditions).": "ex:QualityAttribute_initiate_device_pfs_b6183910",
  "QualityAttribute:CGT:5:Initiate Extractables studies on new CCS components, as needed. For new SUS introduction, follow TV-SOP-36880.": "ex:QualityAttribute_initiate_extractable_96b22103",
  "QualityAttribute:CGT:5:Initiate General Safety and Performance Requirements (GSPR) Checklist": "ex:QualityAttribute_initiate_general_saf_1aceb482",
  "QualityAttribute:CGT:5:Initiate Pediatric CMC Strategy Review.": "ex:QualityAttribute_initiate_pediatric_c_a4a0bff1",
  "QualityAttribute:CGT:5:Initiate Phase 3 development studies (DOE's).": "ex:QualityAttribute_initiate_phase_3_dev_6ddfcf70",
  "QualityAttribute:CGT:5:Initiate preparation of preliminary Life Cycle Management Plan.": "ex:QualityAttribute_initiate_preparation_f7233dde",
  "QualityAttribute:CGT:5:Investigation Product Preparation Instructions (as needed) (Should move to DP section???)": "ex:QualityAttribute_investigation_produc_2ef6a0c0",
  "QualityAttribute:CGT:5:JJ Packaging Design Protocol": "ex:QualityAttribute_jj_packaging_design_41d22d6c",
  "QualityAttribute:CGT:5:JSC FTE & Capital TT costs established for CAR (API/DP/Device); CAR approved.": "ex:QualityAttribute_jsc_fte_capital_tt_c_84a7a31a",
  "QualityAttribute:CGT:5:JSC VCT kicked off (may have been kicked off in a previous Stage (refer to SG 2).": "ex:QualityAttribute_jsc_vct_kicked_off_m_2b0accae",
  "QualityAttribute:CGT:5:JSC review and approval of Full Development Strategy and CMC-TPP.": "ex:QualityAttribute_jsc_review_and_appro_236c0122",
  "QualityAttribute:CGT:5:Manufacturing Strategy and Design Transfer Plan": "ex:QualityAttribute_manufacturing_strate_0cb76c3f",
  "QualityAttribute:CGT:5:Patent and Publication Strategy:  Summarize potential unique aspects of the process that could lead to publications and/or patents.": "ex:QualityAttribute_patent_and_publicati_2ae3d84d",
  "QualityAttribute:CGT:5:Ph 2 CMC dossier submitted to HAs and approved (if applicable). IB update if needed": "ex:QualityAttribute_ph_2_cmc_dossier_sub_5fcd4bd2",
  "QualityAttribute:CGT:5:Ph2/3 pharmacy manual studies completed and approved (if required).": "ex:QualityAttribute_ph2_3_pharmacy_manua_f06ae99f",
  "QualityAttribute:CGT:5:Ph2b/Ph3 target process and scale-up parameters (if applicable) identified.": "ex:QualityAttribute_ph2b_ph3_target_proc_c0403e49",
  "QualityAttribute:CGT:5:Ph3 Stability Protocol drafted.": "ex:QualityAttribute_ph3_stability_protoc_294794bf",
  "QualityAttribute:CGT:5:Ph3 cleaning validation methods qualification completed (if applicable as mostly disposable)": "ex:QualityAttribute_ph3_cleaning_validat_d6d45494",
  "QualityAttribute:CGT:5:Ph3 device test method development initiated if required (change in presentation or formulation), if applicable.": "ex:QualityAttribute_ph3_device_test_meth_3445c7b6",
  "QualityAttribute:CGT:5:Ph3/commercial TPP-CMC lock achieved.": "ex:QualityAttribute_ph3_commercial_tpp_c_4e22dcdc",
  "QualityAttribute:CGT:5:Polymeric risk assessment\u00a0strategy/memo developed for new platforms (as needed).": "ex:QualityAttribute_polymeric_risk_asses_3a7626ea",
  "QualityAttribute:CGT:5:Prepare temperature cycled materials and develop plans to close structure - function knowledge gaps.": "ex:QualityAttribute_prepare_temperature_2e0737a6",
  "QualityAttribute:CGT:5:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_6bdf8a62",
  "QualityAttribute:CGT:5:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_fa032652",
  "QualityAttribute:CGT:5:Proval / Commercial analytical testing sites confirmed.": "ex:QualityAttribute_proval_commercial_an_39c85c40",
  "QualityAttribute:CGT:5:Quality agreement completed/revised for all mfg. sites / testing labs (External & Internal) (if applicable).": "ex:QualityAttribute_quality_agreement_co_4137a91c",
  "QualityAttribute:CGT:5:Raw materials specified for Ph2b/3 (DS inc Vector and DP).  Identify alternative materials if needed.  Assess impact on Phase 3/Commercial production.": "ex:QualityAttribute_raw_materials_specif_d76ebf5a",
  "QualityAttribute:CGT:5:Reduced and/or full scale robustness and characterization studies initiated in accordance with Ph2b/Ph3 devt plan.": "ex:QualityAttribute_reduced_and_or_full_6d42a98c",
  "QualityAttribute:CGT:5:Regulated Substances Plan": "ex:QualityAttribute_regulated_substances_5ec76e32",
  "QualityAttribute:CGT:5:Review PRA, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_pra_update_if_7dc7e761",
  "QualityAttribute:CGT:5:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_511256cc",
  "QualityAttribute:CGT:5:Review critical questions and mitigation plans. Identify new critical questions based on emerging data.": "ex:QualityAttribute_review_critical_ques_10ac0e96",
  "QualityAttribute:CGT:5:Review/Approve DPFD or site BOM.": "ex:QualityAttribute_review_approve_dpfd_df681ec0",
  "QualityAttribute:CGT:5:Review/Update Criticality Assessment.": "ex:QualityAttribute_review_update_critic_e0a4281e",
  "QualityAttribute:CGT:5:Stage 5 CMC Council presentation and appropriate focus group presentation reviews completed.": "ex:QualityAttribute_stage_5_cmc_council_b8255291",
  "QualityAttribute:CGT:5:Stage Gate Approval Form": "ex:QualityAttribute_stage_gate_approval_4e40b28e",
  "QualityAttribute:CGT:5:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_2c3758f6",
  "QualityAttribute:CGT:5:Support of Pivotal CMC dossier to HAs.": "ex:QualityAttribute_support_of_pivotal_c_fbe9cd8e",
  "QualityAttribute:CGT:5:Tech Transfer Plan and Ph2b/3 development strategy sections are updated, if necessary.": "ex:QualityAttribute_tech_transfer_plan_a_000c6f4d",
  "QualityAttribute:CGT:5:Technical Design Requirements  (Initiate)": "ex:QualityAttribute_technical_design_req_9ec44952",
  "QualityAttribute:CGT:5:Third Party Supplier Design Control Audit Report (If applicable)": "ex:QualityAttribute_third_party_supplier_1e56c850",
  "QualityAttribute:CGT:5:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_b5ab2294",
  "QualityAttribute:CGT:5:Update Cost of Goods Sold (COGS) and Gross Profit (GP) for launch and steady state (prior to Mfg. Investment Decision & Source Lock).": "ex:QualityAttribute_update_cost_of_goods_ecc073c8",
  "QualityAttribute:CGT:5:User Requirements (Initiate)": "ex:QualityAttribute_user_requirements_in_ae0f9c85",
  "QualityAttribute:CGT:5:WCB CoAs generated (as applicable)": "ex:QualityAttribute_wcb_coas_generated_a_a662655a",
  "QualityAttribute:CGT:5:WVB CoAs generated (as applicable)": "ex:QualityAttribute_wvb_coas_generated_a_f10d0806",
  "QualityAttribute:CGT:6:API (inc. Vectors & Plasmids) & DP Key Deliverable: Establish data plan and structure to drive DOEs for important variables to enable predictive control and real time release.": "ex:QualityAttribute_api_inc_vectors_plas_0a14be5a",
  "QualityAttribute:CGT:6:Allocate material to support generation of Primary Reference Material and plan preparation from the first Phase 3  batch manufactured with the representative commercial process.": "ex:QualityAttribute_allocate_material_to_b0382d88",
  "QualityAttribute:CGT:6:Author/Review IND/IMPD Control of Materials": "ex:QualityAttribute_author_review_ind_im_a2a01ecd",
  "QualityAttribute:CGT:6:CAR-T IP platform: CAR-T IP  Vein to vein ready for Ph3/Commercial - Logistic, CPCC, COC/COI, Systems (if applicable)": "ex:QualityAttribute_car_t_ip_platform_ca_2b1bd518",
  "QualityAttribute:CGT:6:CMC RA will bridge between GRT and CMC team": "ex:QualityAttribute_cmc_ra_will_bridge_b_8c2e38a9",
  "QualityAttribute:CGT:6:Clinical IFU - Development & IFU Draft (as needed) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_clinical_ifu_develop_8ae50686",
  "QualityAttribute:CGT:6:Co-lead DPAT review/approval of all changes to clinical protocol that lead to a change in the IPPI/PM study.": "ex:QualityAttribute_co_lead_dpat_review_4b3a8986",
  "QualityAttribute:CGT:6:Complete Ph3 device test method development and validation report (if device used at this stage - 6B).": "ex:QualityAttribute_complete_ph3_device_00ba70d6",
  "QualityAttribute:CGT:6:Complete Request Intake Form for Product Quality Complaint New Product Introduction for Clinical per TV-WI-33240 as part of the general Product Quality Complaint Process, outlined in TV-SOP-35428.": "ex:QualityAttribute_complete_request_int_8da3ccb3",
  "QualityAttribute:CGT:6:Complete initial design FMEA (combo product requirement)": "ex:QualityAttribute_complete_initial_des_ec101387",
  "QualityAttribute:CGT:6:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.": "ex:QualityAttribute_complete_or_revisit_ec41fc29",
  "QualityAttribute:CGT:6:Complete selection, qualification and release testing specifications/methods gap mitigations for raw materials for API and DP for Phase 2b/3 manufacture.": "ex:QualityAttribute_complete_selection_q_ec23b157",
  "QualityAttribute:CGT:6:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_b098e8ae",
  "QualityAttribute:CGT:6:Control Strategy initiated As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_control_strategy_ini_3eb3b124",
  "QualityAttribute:CGT:6:Coordinate aggregated clinical/non-clinical demand in support of Ph3 mfg. and provide to the JSC organization": "ex:QualityAttribute_coordinate_aggregate_ce6b373f",
  "QualityAttribute:CGT:6:DP Ph3(Pivotal)  SOPs & batch records approved.": "ex:QualityAttribute_dp_ph3_pivotal_sops_409cc12a",
  "QualityAttribute:CGT:6:DP formulation robustness DOE study initiated.": "ex:QualityAttribute_dp_formulation_robus_9903a3de",
  "QualityAttribute:CGT:6:DPD PF2P Stage 1-3 activities completed (if applicable)": "ex:QualityAttribute_dpd_pf2p_stage_1_3_a_6910f00e",
  "QualityAttribute:CGT:6:DS & DP temperature cycling study completed (if applicable) and report approved. Close structure - function knowledge gaps and update control strategy as necessary.": "ex:QualityAttribute_ds_dp_temperature_cy_a8fad8ac",
  "QualityAttribute:CGT:6:DS (inc.Vectors/plasmids) & DP: cleaning validation strategy implemented.": "ex:QualityAttribute_ds_inc_vectors_plasm_308248d6",
  "QualityAttribute:CGT:6:DS (inc.Vectors/plasmids) Ph3 SOPs & batch records approved.": "ex:QualityAttribute_ds_inc_vectors_plasm_1dff2018",
  "QualityAttribute:CGT:6:Define Process Validation Strategy for DS and DP raw materials": "ex:QualityAttribute_define_process_valid_8cb7be76",
  "QualityAttribute:CGT:6:Design Output Specifications (as appropriate) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_design_output_specif_e2936415",
  "QualityAttribute:CGT:6:Design Validation Plan As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_design_validation_pl_05d13150",
  "QualityAttribute:CGT:6:Design Verification Protocols  As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_design_verification_e5cc8fc8",
  "QualityAttribute:CGT:6:Design-FMEA As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_design_fmea_as_per_c_79637783",
  "QualityAttribute:CGT:6:Detailed strategy for Ph3 analytical method optimization and qualification completed (includes robustness studies) for DS/DP.": "ex:QualityAttribute_detailed_strategy_fo_dc61d4f8",
  "QualityAttribute:CGT:6:Develop co-validation strategy for the identified QC testing sites.": "ex:QualityAttribute_develop_co_validatio_a1b23ced",
  "QualityAttribute:CGT:6:Developed scenarios in support of strategic planning (as required).": "ex:QualityAttribute_developed_scenarios_2acc0d81",
  "QualityAttribute:CGT:6:Development and Verification Stage Design Review As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_development_and_veri_562c8a92",
  "QualityAttribute:CGT:6:Device Master Record (DMR) - Note: A Master Batch Record showing device traceability can be used in place of DMR at this stage of development As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_device_master_record_94c9b50d",
  "QualityAttribute:CGT:6:Device method validation reports approved (6B) (If devices used)": "ex:QualityAttribute_device_method_valida_8254e44c",
  "QualityAttribute:CGT:6:Distribution Testing Procedure -Technical Report Adoption or Develop Test Protocol (as needed) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_distribution_testing_bd5e5382",
  "QualityAttribute:CGT:6:Draft IPPI, Pharm Manual and dose verification study plans to be reviewed by line function, CMC team, and DPAT as needed.": "ex:QualityAttribute_draft_ippi_pharm_man_10a07d17",
  "QualityAttribute:CGT:6:EHS requirements: Provide CMC-RA input to GMO dossiers to enable clinical trials, update CMC information (if applicable)": "ex:QualityAttribute_ehs_requirements_pro_6b3babde",
  "QualityAttribute:CGT:6:EOPCB Strategy defined (if applicable for gene therapy), cell bank (for Lentiviral vector) control strategy defined.": "ex:QualityAttribute_eopcb_strategy_defin_7050604a",
  "QualityAttribute:CGT:6:Ensure CMC team review of the following draft Key Dossier Centric Reports: DS & DP specification and JOS; DS and DP Criticality Analysis (CQA, CPP, CMA); DP Tech Transfer Plan.": "ex:QualityAttribute_ensure_cmc_team_revi_fdf98d20",
  "QualityAttribute:CGT:6:Ensure Criticality assessment (CQA) is updated.": "ex:QualityAttribute_ensure_criticality_a_e48a2cbe",
  "QualityAttribute:CGT:6:Ensure Customer Value deliverables are completed for this stage, if applicable.": "ex:QualityAttribute_ensure_customer_valu_9dac4f33",
  "QualityAttribute:CGT:6:Formulation and primary packaging lock achieved based on risk-based successful container/closure integrity study and sufficient stability data (DP manf'd and tested) at real-time storage conditions for 1 or 2 mfg. dev lots made available (6B).": "ex:QualityAttribute_formulation_and_prim_8245ef14",
  "QualityAttribute:CGT:6:Identify and allocate Ph3 material needs for developmental activities to support tech transfer\\.": "ex:QualityAttribute_identify_and_allocat_4c6f7cf4",
  "QualityAttribute:CGT:6:Implement manufacturing variability strategy into the clinical trials.": "ex:QualityAttribute_implement_manufactur_a1d2e2bc",
  "QualityAttribute:CGT:6:Initiate planning for End of Pivotal trial HA meeting. (CMC RA will bridge between GRT and CMC team).": "ex:QualityAttribute_initiate_planning_fo_67d7b700",
  "QualityAttribute:CGT:6:Initiate the Extractables risk assessment (and testing if needed) of New Category I materials if Ph3 and PPQ are in at the same site. Develop mitigation plans for high risk materials. \u00a0Identify alternative materials if needed.": "ex:QualityAttribute_initiate_the_extract_e1908d00",
  "QualityAttribute:CGT:6:JJ packaging design protocol (review and update as needed)": "ex:QualityAttribute_jj_packaging_design_bf7ccf1c",
  "QualityAttribute:CGT:6:Labeling - Design & Content Development (as needed) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_labeling_design_cont_4653e41c",
  "QualityAttribute:CGT:6:Manufacturing and Design Transfer Plan As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_manufacturing_and_de_c9066f31",
  "QualityAttribute:CGT:6:Manufacturing strategy to introduce routine process variability developed.": "ex:QualityAttribute_manufacturing_strate_0f00eff9",
  "QualityAttribute:CGT:6:Overall CSC FTE and OOP budget compound and study level": "ex:QualityAttribute_overall_csc_fte_and_7ef680ac",
  "QualityAttribute:CGT:6:PF2P activities (DS including Vector/Plasmids etc., DP) initiated at Ph3(Pivotal)  Commercial manufacturing sites.": "ex:QualityAttribute_pf2p_activities_ds_i_6b6c57e3",
  "QualityAttribute:CGT:6:PF2P activities completed at Ph2b/Ph 3 manufacturing site.": "ex:QualityAttribute_pf2p_activities_comp_daacdb75",
  "QualityAttribute:CGT:6:Passive shipping systems qualified, if applicable.": "ex:QualityAttribute_passive_shipping_sys_52b848d6",
  "QualityAttribute:CGT:6:Ph1/2 Comparability to Ph2b/Ph3 process": "ex:QualityAttribute_ph1_2_comparability_606967b7",
  "QualityAttribute:CGT:6:Ph2b/Ph3 DPFDs approved.": "ex:QualityAttribute_ph2b_ph3_dpfds_appro_87d25df8",
  "QualityAttribute:CGT:6:Ph2b/Ph3 process characterization, and sampling plan protocol approved.": "ex:QualityAttribute_ph2b_ph3_process_cha_31b263c4",
  "QualityAttribute:CGT:6:Ph3 Container Closure System Clinical Suitability Assessment": "ex:QualityAttribute_ph3_container_closur_96cbd860",
  "QualityAttribute:CGT:6:Ph3 DP manufacturing FMEA (engineering run) completed, if applicable (6B).": "ex:QualityAttribute_ph3_dp_manufacturing_7c42088f",
  "QualityAttribute:CGT:6:Ph3 DP mfg. process (including process characterization and enhanced sampling plans) TTP approved.": "ex:QualityAttribute_ph3_dp_mfg_process_i_f3fdbdff",
  "QualityAttribute:CGT:6:Ph3 Eng run executed (DP process and DP characterization), if applicable": "ex:QualityAttribute_ph3_eng_run_executed_a36c82bc",
  "QualityAttribute:CGT:6:Ph3 Intermediate (if applicable), DS and DP JOS approved (6A/6B).": "ex:QualityAttribute_ph3_intermediate_if_bc24da75",
  "QualityAttribute:CGT:6:Ph3 JoS approved (IPC)": "ex:QualityAttribute_ph3_jos_approved_ipc_0e5ee643",
  "QualityAttribute:CGT:6:Ph3 Primary Component Specifications completed.": "ex:QualityAttribute_ph3_primary_componen_6271f075",
  "QualityAttribute:CGT:6:Ph3 QC Master Virus cell Banks produced": "ex:QualityAttribute_ph3_qc_master_virus_f29c45d1",
  "QualityAttribute:CGT:6:Ph3 non-compendial raw material methods developed and qualified  with approved reports. (N/A for BCMA but maybe for other programs)": "ex:QualityAttribute_ph3_non_compendial_r_dfba1f9f",
  "QualityAttribute:CGT:6:Ph3(Pivotal)  DP mfg. equipment qualified (IOQ) & ready.": "ex:QualityAttribute_ph3_pivotal_dp_mfg_e_bff1fd12",
  "QualityAttribute:CGT:6:Ph3(Pivotal)  DS (inc. Vectors/Plasmids) mfg. equipment qualified (IOQ) & ready.": "ex:QualityAttribute_ph3_pivotal_ds_inc_v_3eb415d8",
  "QualityAttribute:CGT:6:Ph3(Pivotal) Shipping routes verified/mock shipments complete for DS (Inc. Vectors/Plasmids etc.), DP, and samples.": "ex:QualityAttribute_ph3_pivotal_shipping_0a7b1378",
  "QualityAttribute:CGT:6:Phase 3 DP material commercial specifications (excipients, primary packaging, etc.) completed.": "ex:QualityAttribute_phase_3_dp_material_77d22c1f",
  "QualityAttribute:CGT:6:Placebo & active comparator blinding assessment with Clinical team documented completed (if applicable).": "ex:QualityAttribute_placebo_active_compa_edfc2881",
  "QualityAttribute:CGT:6:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_9614a6b5",
  "QualityAttribute:CGT:6:Primary Container (Package) \u2013 CCS Development Report As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_primary_container_pa_27109363",
  "QualityAttribute:CGT:6:Product Design Rationale Report (if applicable) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_product_design_ratio_82c4ac16",
  "QualityAttribute:CGT:6:Product characterization method development and qualification reports approved (6A/6B).": "ex:QualityAttribute_product_characteriza_19274f69",
  "QualityAttribute:CGT:6:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_f4cf7033",
  "QualityAttribute:CGT:6:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_925070c7",
  "QualityAttribute:CGT:6:Refresh forecast and capacity planning for API and DP via initial New Product Segmentation (NPS) and Forecast Integration Session (FIS) - Socialization, if needed": "ex:QualityAttribute_refresh_forecast_and_8361ed6c",
  "QualityAttribute:CGT:6:Regulated Substances Report and Supplier Regulated Substances Declarations As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_regulated_substances_ccaaf170",
  "QualityAttribute:CGT:6:Reports approved for robustness studies (as defined in Stage Gate 4 Ph2b/Ph3 devt plan), if applicable": "ex:QualityAttribute_reports_approved_for_1c4bb46e",
  "QualityAttribute:CGT:6:Review DS & DP shipment (simulated transportation supportive) study report (on Primary Containers inc. Plasmids).": "ex:QualityAttribute_review_ds_dp_shipmen_1f761428",
  "QualityAttribute:CGT:6:Review DS (inc.Vectors/plasmids) and DP documents, including robustness study report, process characterization plan/protocols/reports, sampling plan, DPFD, small-scale model, SAFT report, EEPCB protocol, process variability plan.": "ex:QualityAttribute_review_ds_inc_vector_766cb5fd",
  "QualityAttribute:CGT:6:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_a6ed08ee",
  "QualityAttribute:CGT:6:Review/Update Criticality Analysis as needed.": "ex:QualityAttribute_review_update_critic_09eb4785",
  "QualityAttribute:CGT:6:SMQ process complete and DS/DP raw materials Late Development Qualified/Commercial Qualified prior to Ph3 DS/DP release.": "ex:QualityAttribute_smq_process_complete_ca0969bf",
  "QualityAttribute:CGT:6:Secondary Package \u2013 Process Design (as needed) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_secondary_package_pr_8465479d",
  "QualityAttribute:CGT:6:Secure CMC Council Decision on engineering run(s) prior to first Ph3 GMP batch (if required).": "ex:QualityAttribute_secure_cmc_council_d_6ae649e4",
  "QualityAttribute:CGT:6:Site(s) Integrated project plans prepared (DS including Vector/Plasmids etc., DP) - Project specific integrated KEM.": "ex:QualityAttribute_site_s_integrated_pr_4ae0b0f1",
  "QualityAttribute:CGT:6:Small scale process model protocols drafted (if required) for process characterization": "ex:QualityAttribute_small_scale_process_9e2e7a8a",
  "QualityAttribute:CGT:6:Stability Plan As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_stability_plan_as_pe_8f4b80cc",
  "QualityAttribute:CGT:6:Stability strategy finalized for intermediate, DS, DP and earlier stage data reviewed and verified.": "ex:QualityAttribute_stability_strategy_f_49ee2269",
  "QualityAttribute:CGT:6:Stage 6A/6B CMC Team presentation completed.": "ex:QualityAttribute_stage_6a_6b_cmc_team_a1f47050",
  "QualityAttribute:CGT:6:Stage Gate Approval Form As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_stage_gate_approval_35c016bd",
  "QualityAttribute:CGT:6:Summary of Human Factors Activities As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_summary_of_human_fac_9d8ee53a",
  "QualityAttribute:CGT:6:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_c3d41cac",
  "QualityAttribute:CGT:6:Update  Critical Quality Attributes (CQA).": "ex:QualityAttribute_update_critical_qual_e291d927",
  "QualityAttribute:CGT:6:Update  Criticality assessment (CQA, CPPs, CMAs).": "ex:QualityAttribute_update_criticality_a_95e265e9",
  "QualityAttribute:CGT:6:Update CMC Risk register including risk of manufacturing ProVal batches at risk before POC data is known.": "ex:QualityAttribute_update_cmc_risk_regi_5f67fe81",
  "QualityAttribute:CGT:6:Update Clinical and Regulatory Plans (can be included within the D&D Plan) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_clinical_and_e80c684c",
  "QualityAttribute:CGT:6:Update Criticality Analysis (CQA, CPPS and CMAs).": "ex:QualityAttribute_update_criticality_a_491435bb",
  "QualityAttribute:CGT:6:Update Criticality assessment (CQA, CPPs, CMAs).": "ex:QualityAttribute_update_criticality_a_c1fe2fbb",
  "QualityAttribute:CGT:6:Update D&D Plan As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_d_d_plan_as_p_c946b2cb",
  "QualityAttribute:CGT:6:Update DHF As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_dhf_as_per_cp_e0b889b2",
  "QualityAttribute:CGT:6:Update General Safety and Performance Requirements (GSPR) Checklist As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_general_safet_443ec09d",
  "QualityAttribute:CGT:6:Update PRA, complete all sections": "ex:QualityAttribute_update_pra_complete_d13170b8",
  "QualityAttribute:CGT:6:Update Product Risk Assessment (PRA) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_product_risk_a7bbcd3e",
  "QualityAttribute:CGT:6:Update Risk Management Plan (Update section 6 of TV-TMP-01715) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_risk_manageme_692b531a",
  "QualityAttribute:CGT:6:Update drug product expiry memo to support temperature excursions.": "ex:QualityAttribute_update_drug_product_515d1ac8",
  "QualityAttribute:CGT:6:Update of Regulated Substances Plan As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_of_regulated_ce12dc90",
  "QualityAttribute:CGT:6:Verify and confirm a clear link between established CQAs and the Justification of Specifications.": "ex:QualityAttribute_verify_and_confirm_a_dc6adef9",
  "QualityAttribute:CGT:6:Verify no change in analytical methods between Phase 3 and Process Validation (PPQ).": "ex:QualityAttribute_verify_no_change_in_650275c3",
  "QualityAttribute:CGT:7:Additional process robustness studies initiated (if required).": "ex:QualityAttribute_additional_process_r_edecf351",
  "QualityAttribute:CGT:7:Alignment with Medical Affairs on potential demands": "ex:QualityAttribute_alignment_with_medic_4753aeed",
  "QualityAttribute:CGT:7:Any new DS and DP analytical method development and co-qualification/transfer completed.": "ex:QualityAttribute_any_new_ds_and_dp_an_94bd23b4",
  "QualityAttribute:CGT:7:As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_as_per_cpdp_developm_f78c273c",
  "QualityAttribute:CGT:7:Clinical IFU - Development & IFU Draft (as needed) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_clinical_ifu_develop_25280c01",
  "QualityAttribute:CGT:7:Co-lead DPAT review/approval of all changes to clinical protocol that lead to a change to the IPPI/PM study.": "ex:QualityAttribute_co_lead_dpat_review_f500f137",
  "QualityAttribute:CGT:7:Complete Customer Value deliverables for this stage, if applicable.": "ex:QualityAttribute_complete_customer_va_e5363350",
  "QualityAttribute:CGT:7:Complete Request Intake Form for Product Quality Complaint New Product Introduction for Clinical per TV-WI-33240 as part of the general Product Quality Complaint Process, outlined in TV-SOP-35428. As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_complete_request_int_07a641f1",
  "QualityAttribute:CGT:7:Complete assessment of Device Abuse/Misuse and mitigation, if applicable.": "ex:QualityAttribute_complete_assessment_f9abe6b2",
  "QualityAttribute:CGT:7:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.  Complete HF studies, if needed.": "ex:QualityAttribute_complete_or_revisit_7f448d16",
  "QualityAttribute:CGT:7:Confirm filing strategy for Phase 3 e.g. Saudi Arabia, Russia, Asia Pacific": "ex:QualityAttribute_confirm_filing_strat_05da7168",
  "QualityAttribute:CGT:7:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_7fdbafa9",
  "QualityAttribute:CGT:7:Confirm vector souring strategy with CMC and CDT": "ex:QualityAttribute_confirm_vector_souri_a58d0d11",
  "QualityAttribute:CGT:7:Control Strategy initiated As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_control_strategy_ini_350a487b",
  "QualityAttribute:CGT:7:Coordinate aggregated clinical/non-clinical demand in support of Ph3 mfg. and provide to the JSC organization.": "ex:QualityAttribute_coordinate_aggregate_6118cf20",
  "QualityAttribute:CGT:7:DP ProVal master plan drafted": "ex:QualityAttribute_dp_proval_master_pla_b1b1ae15",
  "QualityAttribute:CGT:7:DPD PF2P Stage 4 activities completed.": "ex:QualityAttribute_dpd_pf2p_stage_4_act_704b7284",
  "QualityAttribute:CGT:7:DS PF2P Stage 4 activities completed (person in plant).": "ex:QualityAttribute_ds_pf2p_stage_4_acti_701354d4",
  "QualityAttribute:CGT:7:DS and DP release testing and COA completed by release lab.": "ex:QualityAttribute_ds_and_dp_release_te_8671c581",
  "QualityAttribute:CGT:7:DS virus and microbiology methods approved at QC and/or contract test sites.": "ex:QualityAttribute_ds_virus_and_microbi_d542a742",
  "QualityAttribute:CGT:7:Deliver Ph3 packaged kits to clinical sites to meet FPI": "ex:QualityAttribute_deliver_ph3_packaged_59a8884e",
  "QualityAttribute:CGT:7:Design Output Specifications (as appropriate) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_design_output_specif_2518d18b",
  "QualityAttribute:CGT:7:Design Validation Plan As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_design_validation_pl_34068fa7",
  "QualityAttribute:CGT:7:Design Verification Report Complete As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_design_verification_0e4b7a2d",
  "QualityAttribute:CGT:7:Design-FMEA As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_design_fmea_as_per_c_ff397e6e",
  "QualityAttribute:CGT:7:Developed scenarios in support of strategic planning (as required).": "ex:QualityAttribute_developed_scenarios_d0425974",
  "QualityAttribute:CGT:7:Development and Verification Stage Design Review As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_development_and_veri_e5c16dd7",
  "QualityAttribute:CGT:7:Device Master Record (DMR) - Note: A Master Batch Record showing device traceability can be used in place of DMR at this stage of development As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_device_master_record_4e1579ad",
  "QualityAttribute:CGT:7:Distribution Testing Procedure -Technical Report Adoption or Develop Test Protocol (as needed) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_distribution_testing_61d7d2f5",
  "QualityAttribute:CGT:7:EHS Requirement: initiate environmental toxicity studies. Provide CMC-RA input to GMO dossiers to enable clinical trials, update CMC information (if applicable)": "ex:QualityAttribute_ehs_requirement_init_e67c9f6d",
  "QualityAttribute:CGT:7:End of Phase 2/Pre-Phase 3/Scientific Advice meeting package completed": "ex:QualityAttribute_end_of_phase_2_pre_p_ad523c8a",
  "QualityAttribute:CGT:7:End of Phase 2/Pre-Phase 3/Scientific Advice meeting package completed & submitted to HA.": "ex:QualityAttribute_end_of_phase_2_pre_p_41e267c0",
  "QualityAttribute:CGT:7:Ensure Completion of  IPC, release and stability method co-validations or transfers prior to PPQ": "ex:QualityAttribute_ensure_completion_of_2071e634",
  "QualityAttribute:CGT:7:Execute selection, qualification and release testing specifications/methods gap mitigation for DS (including MCB, WCB, MVSS, plasmid, apheresis, AAV/LV drug substance, as applicable) and DP Raw Materials and Product Contact Polymeric Materials for PPQ manufacture including specifications and analytical methods.": "ex:QualityAttribute_execute_selection_qu_6cc523c6",
  "QualityAttribute:CGT:7:First Ph3 clinical DS and DP release (CoA, CoC & QP).": "ex:QualityAttribute_first_ph3_clinical_d_2af91012",
  "QualityAttribute:CGT:7:IND/IMPD review (Manufacturing & Packaging locations, Stability plan, as needed) and delivery of submission labels": "ex:QualityAttribute_ind_impd_review_manu_b9c617d6",
  "QualityAttribute:CGT:7:Initiate co-validation plans in JSC labs, or designated labs.": "ex:QualityAttribute_initiate_co_validati_ff60c60c",
  "QualityAttribute:CGT:7:JJ packaging design protocol (review and update as needed)": "ex:QualityAttribute_jj_packaging_design_f580dadc",
  "QualityAttribute:CGT:7:Labeling - Design & Content Development (as needed) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_labeling_design_cont_aeadc638",
  "QualityAttribute:CGT:7:Manufacturing and Design Transfer Plan As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_manufacturing_and_de_a26a57f6",
  "QualityAttribute:CGT:7:Overall CSC FTE and OOP budget compound and study level": "ex:QualityAttribute_overall_csc_fte_and_1c301961",
  "QualityAttribute:CGT:7:PF2P activities completed.": "ex:QualityAttribute_pf2p_activities_comp_0d6dc266",
  "QualityAttribute:CGT:7:Participate in Criticality Analysis (CQA)  and add product specific information as available.   Increased  (p)CMA  identification, increased (p)CPP knowledge.": "ex:QualityAttribute_participate_in_criti_3f240de6",
  "QualityAttribute:CGT:7:Ph2/3 comparability study strategy reviewed at BCC.": "ex:QualityAttribute_ph2_3_comparability_e253fa6c",
  "QualityAttribute:CGT:7:Ph2b/Ph3  batches released & process characterization reports approved. (if required)": "ex:QualityAttribute_ph2b_ph3_batches_rel_0b2de00b",
  "QualityAttribute:CGT:7:Ph2b/Ph3 CMC sections of IND/IMPD submission completed.": "ex:QualityAttribute_ph2b_ph3_cmc_section_f1ba1612",
  "QualityAttribute:CGT:7:Ph2b/Ph3 TTR approved (if required)": "ex:QualityAttribute_ph2b_ph3_ttr_approve_e7426512",
  "QualityAttribute:CGT:7:Ph3 Analytical sections of IND/IMPD submission completed.": "ex:QualityAttribute_ph3_analytical_secti_dbf7decb",
  "QualityAttribute:CGT:7:Ph3 CMC dossier prepared & management approval completed and amendments to clinical applications as needed.": "ex:QualityAttribute_ph3_cmc_dossier_prep_7f9fb170",
  "QualityAttribute:CGT:7:Ph3 CMC dossier prepared & management approval completed/published.": "ex:QualityAttribute_ph3_cmc_dossier_prep_179c4757",
  "QualityAttribute:CGT:7:Ph3 DP CMC sections of IND/IMPD submission completed.": "ex:QualityAttribute_ph3_dp_cmc_sections_3c0721f3",
  "QualityAttribute:CGT:7:Ph3 DP mfg. process TTR & CSRs approved (including device mfg. process, if applicable).": "ex:QualityAttribute_ph3_dp_mfg_process_t_7e1e0548",
  "QualityAttribute:CGT:7:Ph3 DS and DP formulation robustness interim study initiated if applicable.": "ex:QualityAttribute_ph3_ds_and_dp_formul_46b2d533",
  "QualityAttribute:CGT:7:Ph3 DS and DP temperature cycling completed and stability statement approved.": "ex:QualityAttribute_ph3_ds_and_dp_temper_4ffd5135",
  "QualityAttribute:CGT:7:Ph3 Device JoS approved (includes LIMS configuration info) (If applicable).": "ex:QualityAttribute_ph3_device_jos_appro_69ac80f7",
  "QualityAttribute:CGT:7:Ph3 Eng run DP mfg. process TTR approved (if required).": "ex:QualityAttribute_ph3_eng_run_dp_mfg_p_f6e6cd80",
  "QualityAttribute:CGT:7:Ph3 pharmacy manual studies completed & documented.": "ex:QualityAttribute_ph3_pharmacy_manual_dcc46fd3",
  "QualityAttribute:CGT:7:Ph3(Pivotal)  Mfg. CMC sections of IND/IMPD submission reviewed and approved within JSC.": "ex:QualityAttribute_ph3_pivotal_mfg_cmc_6f2d394d",
  "QualityAttribute:CGT:7:Ph3(Pivotal)  clinical DS and DP batch(es) manufacturing successfully executed (at least 1 batch).": "ex:QualityAttribute_ph3_pivotal_clinical_ec9d552d",
  "QualityAttribute:CGT:7:Ph3(Pivotal)  clinical device mfg. & assembly successfully executed (if applicable).": "ex:QualityAttribute_ph3_pivotal_clinical_675d3324",
  "QualityAttribute:CGT:7:Ph3(Pivotal)  upstream, downstream and DP process samples shipped to test sites.": "ex:QualityAttribute_ph3_pivotal_upstream_c49d0b34",
  "QualityAttribute:CGT:7:Phase 3 pharmacy manual testing completed.": "ex:QualityAttribute_phase_3_pharmacy_man_2a64f409",
  "QualityAttribute:CGT:7:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_bba9253e",
  "QualityAttribute:CGT:7:Primary Container (Package) \u2013 CCS Development Report As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_primary_container_pa_8f36ae1d",
  "QualityAttribute:CGT:7:Primary Reference standard JoS drafted.": "ex:QualityAttribute_primary_reference_st_3730a228",
  "QualityAttribute:CGT:7:ProVal master plan(s) and subordinate plans approved.": "ex:QualityAttribute_proval_master_plan_s_bbf20918",
  "QualityAttribute:CGT:7:Process Validation FPO's, key deliverables, and timing established.": "ex:QualityAttribute_process_validation_f_3f97353c",
  "QualityAttribute:CGT:7:Process characterization testing of Ph3 DS and DP batches completed & data made available to study director.": "ex:QualityAttribute_process_characteriza_a352d0f2",
  "QualityAttribute:CGT:7:Product Design Rationale Report (if applicable) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_product_design_ratio_4faf0f07",
  "QualityAttribute:CGT:7:Product Strategy Roadmap (PSR) refreshed.": "ex:QualityAttribute_product_strategy_roa_bedee620",
  "QualityAttribute:CGT:7:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_97890d8e",
  "QualityAttribute:CGT:7:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_4b1786ed",
  "QualityAttribute:CGT:7:Protocol for generation of EOPCB executed (included in sampling plan), EOPCB shipped to Cell Banking, Cell and Developability Sciences notified to enable Ph2b/Ph3 (pivotal) genetic characterization stability testing; genetic characterization completed and reports generated (if applicable for gene therapy)": "ex:QualityAttribute_protocol_for_generat_660c418b",
  "QualityAttribute:CGT:7:QA review of Ph3 CMC dossier.": "ex:QualityAttribute_qa_review_of_ph3_cmc_bb48829f",
  "QualityAttribute:CGT:7:Refresh forecast and capacity planning for API and DP via initial New Product Segmentation (NPS) and Forecast Integration Session (FIS) - Socialization, if needed": "ex:QualityAttribute_refresh_forecast_and_5dd5a814",
  "QualityAttribute:CGT:7:Regulated Substances Report and Supplier Regulated Substances Declarations As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_regulated_substances_d1d20b00",
  "QualityAttribute:CGT:7:Review PRA, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_pra_update_if_8bda58cd",
  "QualityAttribute:CGT:7:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_013b39ab",
  "QualityAttribute:CGT:7:Review critical questions and mitigation plans. Identify new critical questions based on emerging data. Review process to date and conduct lesson learn review.": "ex:QualityAttribute_review_critical_ques_2d833881",
  "QualityAttribute:CGT:7:Review process characterization report, small-scale model qualification report, process robustness study plan, TTR & CSRs, ProVal master plan (for both upstream and downstream).": "ex:QualityAttribute_review_process_chara_c074712d",
  "QualityAttribute:CGT:7:Review/Update Criticality Assessment as needed.": "ex:QualityAttribute_review_update_critic_9da05307",
  "QualityAttribute:CGT:7:Secondary Package \u2013 Process Design (as needed) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_secondary_package_pr_3505a5bf",
  "QualityAttribute:CGT:7:Small-scale model qualification report approved (if applicable)": "ex:QualityAttribute_small_scale_model_qu_51fe6f45",
  "QualityAttribute:CGT:7:Stability Plan As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_stability_plan_as_pe_61ff561a",
  "QualityAttribute:CGT:7:Stage 7 CMC Council presentation review completed.": "ex:QualityAttribute_stage_7_cmc_council_35475a89",
  "QualityAttribute:CGT:7:Stage Gate Approval Form As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_stage_gate_approval_1d8f4a39",
  "QualityAttribute:CGT:7:Summary of Human Factors Activities as per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_summary_of_human_fac_fdcbf1c8",
  "QualityAttribute:CGT:7:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_483b388e",
  "QualityAttribute:CGT:7:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_84473a45",
  "QualityAttribute:CGT:7:Update Clinical and Regulatory Plans (can be included within the D&D Plan) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_clinical_and_ec0d9baf",
  "QualityAttribute:CGT:7:Update Criticality Analysis (CQA, CPPs, CMAs) as applicable.": "ex:QualityAttribute_update_criticality_a_f7c86746",
  "QualityAttribute:CGT:7:Update Criticality Analysis (CQA, CPPs, CMAs), as applicable": "ex:QualityAttribute_update_criticality_a_9744e683",
  "QualityAttribute:CGT:7:Update D&D Plan As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_d_d_plan_as_p_87614cf2",
  "QualityAttribute:CGT:7:Update DHF As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_dhf_as_per_cp_86647729",
  "QualityAttribute:CGT:7:Update General Safety and Performance Requirements (GSPR) Checklist As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_general_safet_9660c7db",
  "QualityAttribute:CGT:7:Update Product Risk Assessment (PRA) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_product_risk_1467214d",
  "QualityAttribute:CGT:7:Update Risk Management Plan (Update section 6 of TV-TMP-01715) As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_risk_manageme_2422e670",
  "QualityAttribute:CGT:7:Update of Regulated Substances Plan As per CPDP Development and Verification Stage in DS-SOP-16238": "ex:QualityAttribute_update_of_regulated_f8fe966a",
  "QualityAttribute:CGT:7:Update strategic forecast and capacity planning for API and DP via NPS/FIS.": "ex:QualityAttribute_update_strategic_for_f9ea69df",
  "QualityAttribute:CGT:7:Updated COGS and GP for launch and steady state (Prior to Full Development Decision).": "ex:QualityAttribute_updated_cogs_and_gp_020e0675",
  "QualityAttribute:CGT:8:Additional process robustness studies report approved (if required).": "ex:QualityAttribute_additional_process_r_72fe6c80",
  "QualityAttribute:CGT:8:Alignment with Medical Affairs on potential demands": "ex:QualityAttribute_alignment_with_medic_a58194a8",
  "QualityAttribute:CGT:8:All DS and DP in-process, release/stability test methods approved for commercial use  (8A/8B).": "ex:QualityAttribute_all_ds_and_dp_in_pro_36e318d7",
  "QualityAttribute:CGT:8:All PF2P activities completed for commercial process(es).": "ex:QualityAttribute_all_pf2p_activities_ed4df1e2",
  "QualityAttribute:CGT:8:All PF2P activities completed for commercial process.": "ex:QualityAttribute_all_pf2p_activities_1af672e5",
  "QualityAttribute:CGT:8:All polymeric risk scoring initiated and completed by end of PPQ. Initiate  Extractables study if required.": "ex:QualityAttribute_all_polymeric_risk_s_259e132e",
  "QualityAttribute:CGT:8:Allocate material to support generation of working reference material; if applicable.": "ex:QualityAttribute_allocate_material_to_51dfda70",
  "QualityAttribute:CGT:8:Apply previous lessons learned to the ProVal Strategy if applicable.": "ex:QualityAttribute_apply_previous_lesso_8618f5d2",
  "QualityAttribute:CGT:8:Approve Criticality Analysis.": "ex:QualityAttribute_approve_criticality_be051628",
  "QualityAttribute:CGT:8:As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_as_per_cpdp_design_p_14c7cb7e",
  "QualityAttribute:CGT:8:CMC team review of the following draft Key Dossier Centric Reports if applicable (DS Process Validation Plan; DP Process Validation Plan; DS/DP updated Criticality Analysis; DS & DP Comparability Report(s); Pharmaceutical Development Report(s).": "ex:QualityAttribute_cmc_team_review_of_t_4b138a5f",
  "QualityAttribute:CGT:8:Calculate Thermal Density of Temperature Shipping Systems (as needed)": "ex:QualityAttribute_calculate_thermal_de_47327847",
  "QualityAttribute:CGT:8:Characterization of excipients, heavy metals and silicones (process/product impurities) for clinical batches completed (if applicable - depends on primary container, administration delivery procedure & mfg. process)": "ex:QualityAttribute_characterization_of_d8500ee8",
  "QualityAttribute:CGT:8:Clinical Batch data reviewed, ProVal specification documents (including justification) approved for intermediate, drug substance and drug product.": "ex:QualityAttribute_clinical_batch_data_42c4d0b1",
  "QualityAttribute:CGT:8:Clinical Submission": "ex:QualityAttribute_clinical_submission_4a766aab",
  "QualityAttribute:CGT:8:Co-lead DPAT review/approval of all changes to clinical protocol that lead to a change to the IPPI/PM study.": "ex:QualityAttribute_co_lead_dpat_review_9a6b480d",
  "QualityAttribute:CGT:8:Co-validations / method transfers completed with JSC or External Partner.": "ex:QualityAttribute_co_validations_metho_452d8c41",
  "QualityAttribute:CGT:8:Commercial Container Closure System": "ex:QualityAttribute_commercial_container_abee3f18",
  "QualityAttribute:CGT:8:Commercial Primary Component Specifications updated as needed.": "ex:QualityAttribute_commercial_primary_c_93e282c3",
  "QualityAttribute:CGT:8:Commercial financial product flow system set-up.": "ex:QualityAttribute_commercial_financial_2e16dae9",
  "QualityAttribute:CGT:8:Commercial secondary packaging strategy initiated.": "ex:QualityAttribute_commercial_secondary_aa469cf5",
  "QualityAttribute:CGT:8:Commercial shipping routes identified for DS, DP & Finished Product (for DPD shipper validation).": "ex:QualityAttribute_commercial_shipping_531cedb3",
  "QualityAttribute:CGT:8:Commercialization readiness checklist": "ex:QualityAttribute_commercialization_re_ff3d089d",
  "QualityAttribute:CGT:8:Complaint Handling Plan (Initiate)": "ex:QualityAttribute_complaint_handling_p_7efdaf9f",
  "QualityAttribute:CGT:8:Complete Request Intake Form for Product Quality Complaint New Product Introduction for Clinical as part of the general Product Quality Complaint Process": "ex:QualityAttribute_complete_request_int_a20c45c4",
  "QualityAttribute:CGT:8:Complete Request Intake Form for Product Quality Complaint New Product Introduction for Commercial Products per TV-WI-33240 as part of the general Product Quality Complaint Process, outlined in TV-SOP-35428.": "ex:QualityAttribute_complete_request_int_665adc89",
  "QualityAttribute:CGT:8:Complete characterization studies.": "ex:QualityAttribute_complete_characteriz_b0f006af",
  "QualityAttribute:CGT:8:Complete initial process FMEA (combo product requirement)": "ex:QualityAttribute_complete_initial_pro_beb4298e",
  "QualityAttribute:CGT:8:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.  Complete HF studies, if needed.": "ex:QualityAttribute_complete_or_revisit_8526cb78",
  "QualityAttribute:CGT:8:Complete protocols/documentation supporting inclusion of raw materials variation and characterization in DS and DP Process Validation Strategy (media, buffers, resins, chemicals, excipients and polymeric product contact materials).": "ex:QualityAttribute_complete_protocols_d_f815c8be",
  "QualityAttribute:CGT:8:Complete selection, qualification and release testing specifications/methods gap mitigations for raw materials for DS and DP for PPQ manufacture.": "ex:QualityAttribute_complete_selection_q_45fff991",
  "QualityAttribute:CGT:8:Confirm Customer Value deliverables completed for this stage, if applicable": "ex:QualityAttribute_confirm_customer_val_6ad0f826",
  "QualityAttribute:CGT:8:Confirm that the ProVal Strategy is \"current\", i.e.,  up-to-date with recent HA guidance/feedback and/or changes in Industry Standards.": "ex:QualityAttribute_confirm_that_the_pro_25abe0cc",
  "QualityAttribute:CGT:8:Confirm validation strategy for CoC and CoI (autologous programs only)": "ex:QualityAttribute_confirm_validation_s_d6ac6adc",
  "QualityAttribute:CGT:8:Control Plan": "ex:QualityAttribute_control_plan_e9b5d5c3",
  "QualityAttribute:CGT:8:Control Strategy": "ex:QualityAttribute_control_strategy_d516a09a",
  "QualityAttribute:CGT:8:Coordinate aggregated clinical/non-clinical demand in support of Ph3 mfg. and provide to the JSC organization .": "ex:QualityAttribute_coordinate_aggregate_728dd3b6",
  "QualityAttribute:CGT:8:Criticality Analysis updated as necessary.": "ex:QualityAttribute_criticality_analysis_24528b89",
  "QualityAttribute:CGT:8:DP process development and robustness studies data reviewed at level 1 governance.": "ex:QualityAttribute_dp_process_developme_8a99c5e9",
  "QualityAttribute:CGT:8:DP process master plan & validation protocol approved (8B).": "ex:QualityAttribute_dp_process_master_pl_ac330f39",
  "QualityAttribute:CGT:8:DS & DP expiry extension completed (if required).": "ex:QualityAttribute_ds_dp_expiry_extensi_c69880d6",
  "QualityAttribute:CGT:8:DS and DP Process Validation Batch Records and SOP's approved.": "ex:QualityAttribute_ds_and_dp_process_va_aa1d48ab",
  "QualityAttribute:CGT:8:DS and DP commercial min & max batch sizes determined.": "ex:QualityAttribute_ds_and_dp_commercial_8c8d1b12",
  "QualityAttribute:CGT:8:Design Control - Design Validation  (CPDP Deliverable)": "ex:QualityAttribute_design_control_desig_384a1507",
  "QualityAttribute:CGT:8:Design Control - Design Validation Protocol": "ex:QualityAttribute_design_control_desig_d28bb8dc",
  "QualityAttribute:CGT:8:Design Control - Design Validation Protocol/Execution": "ex:QualityAttribute_design_control_desig_c1175a76",
  "QualityAttribute:CGT:8:Design Control - Design Validation Report": "ex:QualityAttribute_design_control_desig_0e9b4765",
  "QualityAttribute:CGT:8:Design Control - Design Validation Summary Report": "ex:QualityAttribute_design_control_desig_a4a243df",
  "QualityAttribute:CGT:8:Design Control - Software Validation Report (If Applicable)": "ex:QualityAttribute_design_control_softw_81844bed",
  "QualityAttribute:CGT:8:Design Output  (CPDP Deliverable) - DHF  (Update if required)": "ex:QualityAttribute_design_output_cpdp_d_4ec056d1",
  "QualityAttribute:CGT:8:Design Output  (CPDP Deliverable) - DMR  (Update if required)": "ex:QualityAttribute_design_output_cpdp_d_32b5bc5e",
  "QualityAttribute:CGT:8:Design Transfer: Traceability Matrix (Update)": "ex:QualityAttribute_design_transfer_trac_1f9ff28e",
  "QualityAttribute:CGT:8:Design Validation Protocols, Reports and Summary Report": "ex:QualityAttribute_design_validation_pr_0ea04f5b",
  "QualityAttribute:CGT:8:Design Validation and Process Validation Stage Design Review": "ex:QualityAttribute_design_validation_an_694eeca3",
  "QualityAttribute:CGT:8:Developed scenarios in support of strategic planning (as required), strategic impact analysis (critical path, risk, budget variances).": "ex:QualityAttribute_developed_scenarios_24431735",
  "QualityAttribute:CGT:8:Device Risk Management  (Update) - CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_27f6d0c5",
  "QualityAttribute:CGT:8:Device Risk Management  (Update) - Device Control Strategy (Review and Update)": "ex:QualityAttribute_device_risk_manageme_86b24a0c",
  "QualityAttribute:CGT:8:Device Risk Management  (Update) - Product Risk Assessment/Hazard ID (Update)": "ex:QualityAttribute_device_risk_manageme_27df5084",
  "QualityAttribute:CGT:8:Device Risk Management  (Update) - Risk Management Plan (Update)": "ex:QualityAttribute_device_risk_manageme_15cfe329",
  "QualityAttribute:CGT:8:Device Risk Management  (Update) - Risk Management Report (Update)": "ex:QualityAttribute_device_risk_manageme_f35c3f53",
  "QualityAttribute:CGT:8:Device Risk Management  (Update) - dFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_4c8f3428",
  "QualityAttribute:CGT:8:Device Risk Management  (Update) - pFMEA (Initiate)": "ex:QualityAttribute_device_risk_manageme_b601991d",
  "QualityAttribute:CGT:8:Device Risk Management  (Update) - uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_ce93d818",
  "QualityAttribute:CGT:8:Device in-process and release/stability test methods approved for commercial use (8B). (as applicable)": "ex:QualityAttribute_device_in_process_an_fe29c59b",
  "QualityAttribute:CGT:8:Distribution Assessment team created after sourcing decision (is this applicable given sourcing dec. in SG 5?)": "ex:QualityAttribute_distribution_assessm_1f7b65fe",
  "QualityAttribute:CGT:8:Distribution Testing Procedure \u2013 Approve Test Protocol & Distribution Test Results (as needed)": "ex:QualityAttribute_distribution_testing_5d157691",
  "QualityAttribute:CGT:8:Document list (including process characterization reports, robustness study reports, process validation protocol and reports) compiled for process development section of BLA and PAI readiness.": "ex:QualityAttribute_document_list_includ_3235969a",
  "QualityAttribute:CGT:8:EHS Requirement: complete design for sustainability document, develop label for DP, update Drug Product SDS.": "ex:QualityAttribute_ehs_requirement_comp_28a750b1",
  "QualityAttribute:CGT:8:EHS Requirement: determine if OEL for DS is needed, Complete environmental fate and effect studies and complete environmental risk assessment, update API SDS, develop label for drug substance, REACH notification approved.": "ex:QualityAttribute_ehs_requirement_dete_e0fba71e",
  "QualityAttribute:CGT:8:Executed In-Use Reliability Testing Report": "ex:QualityAttribute_executed_in_use_reli_35d8519d",
  "QualityAttribute:CGT:8:Facilitate After Action Review and PF2P sessions.": "ex:QualityAttribute_facilitate_after_act_a7e38e36",
  "QualityAttribute:CGT:8:Final Design Verification and Summary Reports": "ex:QualityAttribute_final_design_verific_9392e497",
  "QualityAttribute:CGT:8:Final Labeling - approved IFU and device/packaging labels (as needed)": "ex:QualityAttribute_final_labeling_appro_75ab9a2c",
  "QualityAttribute:CGT:8:Final equipment and process changes implemented (based on After Action Review from clinical production).": "ex:QualityAttribute_final_equipment_and_ca81d45d",
  "QualityAttribute:CGT:8:Finalize Criticality Analysis (CQA and control strategy).": "ex:QualityAttribute_finalize_criticality_f926e0c1",
  "QualityAttribute:CGT:8:Finalize Criticality Analysis (CQA, CPP's, CMA's and control strategy) for all applicable processes.": "ex:QualityAttribute_finalize_criticality_b4dfcc90",
  "QualityAttribute:CGT:8:Finalize Criticality Analysis (CQA, CPP's, CMAs and control strategy).": "ex:QualityAttribute_finalize_criticality_0acbcfea",
  "QualityAttribute:CGT:8:Finalize Traceability Matrix": "ex:QualityAttribute_finalize_traceabilit_a0a8ad55",
  "QualityAttribute:CGT:8:Functional area review of DS and DP process control, pooling, hold-time, and characterization.": "ex:QualityAttribute_functional_area_revi_ef6bb867",
  "QualityAttribute:CGT:8:Human Factors Summary Report": "ex:QualityAttribute_human_factors_summar_1d5afa99",
  "QualityAttribute:CGT:8:IFU - DDO Submission & HA Approval (as needed)": "ex:QualityAttribute_ifu_ddo_submission_h_ec41584b",
  "QualityAttribute:CGT:8:JJ Packaging Design protocol (review and update if needed)": "ex:QualityAttribute_jj_packaging_design_c526a274",
  "QualityAttribute:CGT:8:Marketing Application dossier strategy and development timeline completed.  Review the current MAA/BLA review process (BLA/MAA kick off meeting, extended team review, functional area review, and BLA/MAA endorsement) with other functions.": "ex:QualityAttribute_marketing_applicatio_668c8f86",
  "QualityAttribute:CGT:8:Overall CSC FTE and OOP budget compound and study level": "ex:QualityAttribute_overall_csc_fte_and_fe705e67",
  "QualityAttribute:CGT:8:Participate in After Action Review from Ph3 batches and document in risk register.": "ex:QualityAttribute_participate_in_after_d822c399",
  "QualityAttribute:CGT:8:Participate in Criticality Analysis (CQA, CPPs, CMA's, control strategy, CPV 3a plan/protocol).": "ex:QualityAttribute_participate_in_criti_1ebe951e",
  "QualityAttribute:CGT:8:Passive shipping systems qualified, if applicable.": "ex:QualityAttribute_passive_shipping_sys_3df142bb",
  "QualityAttribute:CGT:8:Pediatric CMC assessment (assess potential for pediatric formulation development) completed.": "ex:QualityAttribute_pediatric_cmc_assess_f8e08c39",
  "QualityAttribute:CGT:8:Ph3 DS / DP product characterization & process impurity testing completed.": "ex:QualityAttribute_ph3_ds_dp_product_ch_7cb3ede6",
  "QualityAttribute:CGT:8:Place Stability study units on aging": "ex:QualityAttribute_place_stability_stud_2bf99106",
  "QualityAttribute:CGT:8:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_305d1318",
  "QualityAttribute:CGT:8:Post-Market Product Management Plan (if applicable) - Note: This could include planned design changes, enhancements, process changes, site transfers, etc.": "ex:QualityAttribute_post_market_product_0f29863e",
  "QualityAttribute:CGT:8:Preparation for PPQ/stability \"small scale model\" review meetings and Scientific Advice": "ex:QualityAttribute_preparation_for_ppq_b3f252d3",
  "QualityAttribute:CGT:8:Primary Container (Package) \u2013 CCS Summary Report": "ex:QualityAttribute_primary_container_pa_82e0f366",
  "QualityAttribute:CGT:8:Primary and working reference material specification approved; if applicable.": "ex:QualityAttribute_primary_and_working_995d9311",
  "QualityAttribute:CGT:8:Process Validation Protocols and Reports": "ex:QualityAttribute_process_validation_p_16d8863e",
  "QualityAttribute:CGT:8:Process control, pooling, hold-time, and characterization functional area review completed.": "ex:QualityAttribute_process_control_pool_435218f2",
  "QualityAttribute:CGT:8:Process validation protocol(s) approved.": "ex:QualityAttribute_process_validation_p_68226e38",
  "QualityAttribute:CGT:8:Process-FMEA": "ex:QualityAttribute_process_fmea_18d9053a",
  "QualityAttribute:CGT:8:Product specific DS and DP method validation protocols and reports approved for commercial use (8A/8B).": "ex:QualityAttribute_product_specific_ds_8690aff4",
  "QualityAttribute:CGT:8:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_72d13ef1",
  "QualityAttribute:CGT:8:Project plan updated and reviewed with CMC Team: prioritize, track team milestones & deliverables, proactive management of KEM aligned to CMC SG\u2019s.": "ex:QualityAttribute_project_plan_updated_b9f739e9",
  "QualityAttribute:CGT:8:Protocol approved for generation of EOEPCB, and Cell and Developability Sciences notified to enable ProVal genetic characterization testing - if applicable.  Initiate importation code generation for cell bank shipment into United States, if applicable for gene therapy.": "ex:QualityAttribute_protocol_approved_fo_bc7fc083",
  "QualityAttribute:CGT:8:Qualification Report of Insulated Shipping Container for Temperature Sensitive Products (as needed)": "ex:QualityAttribute_qualification_report_a0f0b941",
  "QualityAttribute:CGT:8:Qualify primary reference material; if applicable.": "ex:QualityAttribute_qualify_primary_refe_607d26fe",
  "QualityAttribute:CGT:8:Regulatory Submission": "ex:QualityAttribute_regulatory_submissio_82f40b5a",
  "QualityAttribute:CGT:8:Review DP  formulation robustness DOE study (available data on range finding).": "ex:QualityAttribute_review_dp_formulatio_79fdcc21",
  "QualityAttribute:CGT:8:Review DS and DP documents, including process robustness study report, small-scale model dev report, process validation protocol, genetic stability validation protocol, small scale model data functional and tech review, CQA and CPP report/memos, process validation strategy.": "ex:QualityAttribute_review_ds_and_dp_doc_35a7e8a7",
  "QualityAttribute:CGT:8:Review PRA, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_pra_update_if_9581e6e2",
  "QualityAttribute:CGT:8:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_55e91da3",
  "QualityAttribute:CGT:8:Review critical questions and mitigation plans. Identify new critical questions based on emerging data.": "ex:QualityAttribute_review_critical_ques_94421982",
  "QualityAttribute:CGT:8:Risk Management Report": "ex:QualityAttribute_risk_management_repo_722a5e75",
  "QualityAttribute:CGT:8:Risk register review e.g. Impurity clearance & assessment, characterization/analytical strategy, release/stability and overall control strategy, DPD strategies": "ex:QualityAttribute_risk_register_review_870882a8",
  "QualityAttribute:CGT:8:Sampling plan reviewed for DS/DP process validation characterization.": "ex:QualityAttribute_sampling_plan_review_46ee9899",
  "QualityAttribute:CGT:8:Secondary Package \u2013 Process Qualification (as needed)": "ex:QualityAttribute_secondary_package_pr_850d1e5c",
  "QualityAttribute:CGT:8:Shipping Process Validation Report \u2013 Cold Chain (as needed)": "ex:QualityAttribute_shipping_process_val_7a57a84a",
  "QualityAttribute:CGT:8:Small scale model data reviewed at Functional Level 1 governance (if applicable)": "ex:QualityAttribute_small_scale_model_da_4e319d0d",
  "QualityAttribute:CGT:8:Software Validation (if applicable)": "ex:QualityAttribute_software_validation_42af1123",
  "QualityAttribute:CGT:8:Stage 8A/8B CMC Team presentation review completed.": "ex:QualityAttribute_stage_8a_8b_cmc_team_03d2acfd",
  "QualityAttribute:CGT:8:Stage Gate Approval Form": "ex:QualityAttribute_stage_gate_approval_63518654",
  "QualityAttribute:CGT:8:Support  the current MAA/BLA review process (BLA/MAA kick off meeting, extended team review, functional area review, and BLA/MAA endorsement) with other functions.": "ex:QualityAttribute_support_the_current_a84ada56",
  "QualityAttribute:CGT:8:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_6b6f7061",
  "QualityAttribute:CGT:8:Support JSC in scenarios commercial sourcing strategic planning  (as required), strategic impact analysis (critical path, risk, budget variances).": "ex:QualityAttribute_support_jsc_in_scena_e41df0c3",
  "QualityAttribute:CGT:8:Support risk management activities: includes risk identification, mitigation, monitor & control; risk register utilization.": "ex:QualityAttribute_support_risk_managem_22f34799",
  "QualityAttribute:CGT:8:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_d132b8c3",
  "QualityAttribute:CGT:8:Update DHF": "ex:QualityAttribute_update_dhf_10d9a33c",
  "QualityAttribute:CGT:8:Update DMR": "ex:QualityAttribute_update_dmr_1275a689",
  "QualityAttribute:CGT:8:Update Design and Development Plan": "ex:QualityAttribute_update_design_and_de_41cd09c1",
  "QualityAttribute:CGT:8:Update General Performance and Safety (GSPR) Checklist": "ex:QualityAttribute_update_general_perfo_5c5cab83",
  "QualityAttribute:CGT:8:Update General Safety and Performance Requirements (GSPR) Checklist (if required)": "ex:QualityAttribute_update_general_safet_495d4878",
  "QualityAttribute:CGT:8:Update Human Factors Plan": "ex:QualityAttribute_update_human_factors_0bcb7191",
  "QualityAttribute:CGT:8:Update Product Risk Assessment (PRA)": "ex:QualityAttribute_update_product_risk_0269ec3c",
  "QualityAttribute:CGT:8:Update Regulated Substances Plan (if required)": "ex:QualityAttribute_update_regulated_sub_49f43733",
  "QualityAttribute:CGT:8:Update Regulatory Plan": "ex:QualityAttribute_update_regulatory_pl_d396bd9f",
  "QualityAttribute:CGT:8:Update of Regulated Substances Plan (if required)": "ex:QualityAttribute_update_of_regulated_ddbca0fa",
  "QualityAttribute:CGT:8:Update of Regulated Substances Report and Supplier Regulated Substances Declarations (if required)": "ex:QualityAttribute_update_of_regulated_ad9d12eb",
  "QualityAttribute:CGT:8:Update to Manufacturing and Design Transfer Plan and Report": "ex:QualityAttribute_update_to_manufactur_41c5dabc",
  "QualityAttribute:CGT:9:Alignment with Medical Affairs on potential demands": "ex:QualityAttribute_alignment_with_medic_a84fac2e",
  "QualityAttribute:CGT:9:All Critical Questions answered.": "ex:QualityAttribute_all_critical_questio_e92ea1de",
  "QualityAttribute:CGT:9:Analytical pre-BLA meeting content & management review completed (if applicable).": "ex:QualityAttribute_analytical_pre_bla_m_066e007e",
  "QualityAttribute:CGT:9:CTD (Common Technical Document) (ECTD template for BLA in RimDocs) draft analytical sections started.": "ex:QualityAttribute_ctd_common_technical_9e38f3f0",
  "QualityAttribute:CGT:9:CTD draft sections started for all applicable processes.": "ex:QualityAttribute_ctd_draft_sections_s_fb8ebee8",
  "QualityAttribute:CGT:9:Calculate Thermal Density of Temperature Shipping Systems (as needed) As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_calculate_thermal_de_abc2ebfc",
  "QualityAttribute:CGT:9:Cleaning validation completed.": "ex:QualityAttribute_cleaning_validation_d67c32ee",
  "QualityAttribute:CGT:9:Clinical Submission As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_clinical_submission_963aeadb",
  "QualityAttribute:CGT:9:Commercial Secondary Packaging Source locked.": "ex:QualityAttribute_commercial_secondary_f958ecd3",
  "QualityAttribute:CGT:9:Commercialization readiness checklist As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_commercialization_re_858b0f29",
  "QualityAttribute:CGT:9:Complete EU Excipient Risk Assessment (DP-independent by end of PPQ and DP-dependent as part of BLA preparation).": "ex:QualityAttribute_complete_eu_excipien_b57fd6bf",
  "QualityAttribute:CGT:9:Complete ICH Q3D Elemental Impurities Risk Assessment on DP": "ex:QualityAttribute_complete_ich_q3d_ele_8aac7ca4",
  "QualityAttribute:CGT:9:Complete Request Intake Form for Product Quality Complaint New Product Introduction for Commercial Products per TV-WI-33240 as part of the general Product Quality Complaint Process, outlined in TV-SOP-35428. As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_complete_request_int_ab571b78",
  "QualityAttribute:CGT:9:Complete analysis and documentation of raw material-related elements of Process Validation (media, buffers, resins, chemicals, excipients and polymeric product contact materials).": "ex:QualityAttribute_complete_analysis_an_d9b1bea8",
  "QualityAttribute:CGT:9:Complete container closure integrity study for DP": "ex:QualityAttribute_complete_container_c_4876d4a8",
  "QualityAttribute:CGT:9:Complete in vivo studies, if applicable - Team to comment if N/A": "ex:QualityAttribute_complete_in_vivo_stu_1bfb9883",
  "QualityAttribute:CGT:9:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.  Complete HF studies, if needed.": "ex:QualityAttribute_complete_or_revisit_f9640305",
  "QualityAttribute:CGT:9:Complete raw material-related source documents for CTD for media, buffers, resins, excipients and polymeric product contact materials.": "ex:QualityAttribute_complete_raw_materia_e74ab48c",
  "QualityAttribute:CGT:9:Confirm Global commercial device strategy": "ex:QualityAttribute_confirm_global_comme_37bc8bd6",
  "QualityAttribute:CGT:9:Continue preparation of S.3.1 Elucidation of Structure.": "ex:QualityAttribute_continue_preparation_9f1eacc3",
  "QualityAttribute:CGT:9:Continued Process verification (CPV) strategy drafted and review completed": "ex:QualityAttribute_continued_process_ve_79081a56",
  "QualityAttribute:CGT:9:Control Plan As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_control_plan_as_per_952373eb",
  "QualityAttribute:CGT:9:Control Strategy As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_control_strategy_as_83127079",
  "QualityAttribute:CGT:9:Coordinate aggregated clinical/non-clinical demand in support of Ph3 mfg. and provide to the JSC organization": "ex:QualityAttribute_coordinate_aggregate_718389bd",
  "QualityAttribute:CGT:9:Create and complete the device technical dossier for review and opinion by NB, if applicable": "ex:QualityAttribute_create_and_complete_e096ba4a",
  "QualityAttribute:CGT:9:DP & Device criticality analysis and control strategy review by level 1 governance completed (9B).": "ex:QualityAttribute_dp_device_criticalit_11284cd1",
  "QualityAttribute:CGT:9:DP and Device pre-BLA meeting content & management review completed (if applicable).": "ex:QualityAttribute_dp_and_device_pre_bl_1a248999",
  "QualityAttribute:CGT:9:DP development history and other CTD source documents completed.": "ex:QualityAttribute_dp_development_histo_99ada262",
  "QualityAttribute:CGT:9:DP process validation data level 1 governance review completed (9B).": "ex:QualityAttribute_dp_process_validatio_70fa15c1",
  "QualityAttribute:CGT:9:DS & DP shipment (simulated transportation supportive) study report approved.": "ex:QualityAttribute_ds_dp_shipment_simul_e88502eb",
  "QualityAttribute:CGT:9:DS and DP ProVal batches released.": "ex:QualityAttribute_ds_and_dp_proval_bat_491e1b98",
  "QualityAttribute:CGT:9:DS intermediate, DS (9A) and DP (9B) comprehensive analytical data review by functional area completed including stability data.": "ex:QualityAttribute_ds_intermediate_ds_9_461ab457",
  "QualityAttribute:CGT:9:DS: at-risk launch inventory build approved and production initiated (if needed).": "ex:QualityAttribute_ds_at_risk_launch_in_287970a9",
  "QualityAttribute:CGT:9:Design Validation Protocols, Reports and Summary Report As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_design_validation_pr_3e283202",
  "QualityAttribute:CGT:9:Design Validation and Process Validation Stage Design Review As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_design_validation_an_ccea9291",
  "QualityAttribute:CGT:9:Developed scenarios in support of strategic planning (as required), strategic impact analysis (critical path, risk, budget variances).": "ex:QualityAttribute_developed_scenarios_302492e4",
  "QualityAttribute:CGT:9:Development history & other CTD source documents completed for all applicable processes.": "ex:QualityAttribute_development_history_7bd2d16a",
  "QualityAttribute:CGT:9:Distribution Testing Procedure \u2013 Approve Test Protocol & Distribution Test Results (as needed)  As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_distribution_testing_dd9a0f9b",
  "QualityAttribute:CGT:9:Draft / Approve CPP / Criticality reports for all applicable processes": "ex:QualityAttribute_draft_approve_cpp_cr_1bdfc367",
  "QualityAttribute:CGT:9:Draft and obtain AD endorsement of initial commercial specifications for intermediate, DS, DP (9C). Final proposal will come following availability of 3-6 mo stability data on Proval batches (evaluate deliverable for accelerated programs).": "ex:QualityAttribute_draft_and_obtain_ad_1ed26d36",
  "QualityAttribute:CGT:9:E2E Value Chain Risk Management started if feasible.": "ex:QualityAttribute_e2e_value_chain_risk_ba406127",
  "QualityAttribute:CGT:9:EHS Requirement: REACH registration approved, develop IH sampling and method if appropriate.": "ex:QualityAttribute_ehs_requirement_reac_a6742085",
  "QualityAttribute:CGT:9:EHS Requirement: Update DP SDS to align with approved IFU/product label; Marketing Application preparation.": "ex:QualityAttribute_ehs_requirement_upda_69fcda2a",
  "QualityAttribute:CGT:9:EOPCB generation executed; genetic characterization completed by Cell and Developability Sciences and reports approved (if applicable for gene therapy)": "ex:QualityAttribute_eopcb_generation_exe_87d450f1",
  "QualityAttribute:CGT:9:Ensure CMC team review of the following draft Key Dossier Centric Reports: DS & DP specification and JOS; DS & DP Criticality Reports.": "ex:QualityAttribute_ensure_cmc_team_revi_e4c51fdb",
  "QualityAttribute:CGT:9:Ensure Customer Value deliverables are completed for this stage, as applicable.": "ex:QualityAttribute_ensure_customer_valu_f3b10db9",
  "QualityAttribute:CGT:9:Executed In-Use Reliability Testing Report As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_executed_in_use_reli_89fe3cd5",
  "QualityAttribute:CGT:9:Facilitate After Action Review and PF2P sessions.": "ex:QualityAttribute_facilitate_after_act_030f1811",
  "QualityAttribute:CGT:9:Final Design Verification and Summary Reports. As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_final_design_verific_b664c5a0",
  "QualityAttribute:CGT:9:Final Labeling - approved IFU and device/packaging labels (as needed) As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_final_labeling_appro_c040e702",
  "QualityAttribute:CGT:9:Finalize Traceability Matrix As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_finalize_traceabilit_6bc876f4",
  "QualityAttribute:CGT:9:Functional area review of DS and DP reports, including process validation data and small-scale model validation, criticality analysis, and development history.": "ex:QualityAttribute_functional_area_revi_44ab3014",
  "QualityAttribute:CGT:9:High level Commercial Launch Strategy initiated.": "ex:QualityAttribute_high_level_commercia_5e53b52c",
  "QualityAttribute:CGT:9:Human Factors Summary Report  As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_human_factors_summar_0344245c",
  "QualityAttribute:CGT:9:IFU - DDO Submission & HA Approval (as needed) As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_ifu_ddo_submission_h_f2e4abaf",
  "QualityAttribute:CGT:9:Initiate leachable study to support BLA/Marketing Application using Process validation batches.": "ex:QualityAttribute_initiate_leachable_s_18d471b0",
  "QualityAttribute:CGT:9:Internal pre-BLA meeting CMC content & management review completed (if applicable).": "ex:QualityAttribute_internal_pre_bla_mee_b1712b8a",
  "QualityAttribute:CGT:9:JJ Packaging Design Protocol (review and updated when needed)": "ex:QualityAttribute_jj_packaging_design_c50c977c",
  "QualityAttribute:CGT:9:Maintain sample archive/permanent retention program for all Clinical and ProVal batches.": "ex:QualityAttribute_maintain_sample_arch_057f74a9",
  "QualityAttribute:CGT:9:Marketing Application development in progress and complete dossier strategy for derivative dossiers": "ex:QualityAttribute_marketing_applicatio_a86c3183",
  "QualityAttribute:CGT:9:Overall CSC FTE and OOP budget compound and study level": "ex:QualityAttribute_overall_csc_fte_and_6d7d8286",
  "QualityAttribute:CGT:9:PAI readiness plans established.": "ex:QualityAttribute_pai_readiness_plans_5b7495b8",
  "QualityAttribute:CGT:9:Place Stability study units on aging As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_place_stability_stud_6b8d3796",
  "QualityAttribute:CGT:9:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_140be289",
  "QualityAttribute:CGT:9:Post-Market Product Management Plan (if applicable) - Note: This could include planned design changes, enhancements, process changes, site transfers, etc. As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_post_market_product_0a7749ff",
  "QualityAttribute:CGT:9:Pre-Submission meeting package completed (if applicable).": "ex:QualityAttribute_pre_submission_meeti_236bece0",
  "QualityAttribute:CGT:9:Pre-Submission meeting package submitted to HA's/meetings completed (if applicable).": "ex:QualityAttribute_pre_submission_meeti_c3729a3e",
  "QualityAttribute:CGT:9:Preliminary Life Cycle management plans identified.": "ex:QualityAttribute_preliminary_life_cyc_0bf24087",
  "QualityAttribute:CGT:9:Primary Container (Package) \u2013 CCS Summery Report As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_primary_container_pa_0142ed95",
  "QualityAttribute:CGT:9:Primary and Working reference standard characterization completed and COA issued, if applicable.": "ex:QualityAttribute_primary_and_working_aef124dd",
  "QualityAttribute:CGT:9:ProVal DS and DP batches manufactured.": "ex:QualityAttribute_proval_ds_and_dp_bat_45f96ef6",
  "QualityAttribute:CGT:9:ProVal characterization samples (upstream, downstream & DP) data provided to study director.": "ex:QualityAttribute_proval_characterizat_3c2a96b6",
  "QualityAttribute:CGT:9:ProVal characterization, release and stability samples sent to testing labs (as required).": "ex:QualityAttribute_proval_characterizat_77c4158d",
  "QualityAttribute:CGT:9:ProVal device batches manufactured (if applicable)": "ex:QualityAttribute_proval_device_batche_b99816de",
  "QualityAttribute:CGT:9:Process Validation Protocols and Reports As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_process_validation_p_1cc9ee5f",
  "QualityAttribute:CGT:9:Process validation data & small-scale model module(s) validation review by Level 1 governance completed.": "ex:QualityAttribute_process_validation_d_e6a54f5e",
  "QualityAttribute:CGT:9:Process-FMEA As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_process_fmea_as_per_f82afe52",
  "QualityAttribute:CGT:9:Product Strategy Roadmap (PSR) refreshed.": "ex:QualityAttribute_product_strategy_roa_eb80ad3e",
  "QualityAttribute:CGT:9:Product characterization studies (degradation pathways etc.) and report completed.": "ex:QualityAttribute_product_characteriza_8fcb2c94",
  "QualityAttribute:CGT:9:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_3509ba26",
  "QualityAttribute:CGT:9:Project plan updated and reviewed with CMC Team: prioritize, track team milestones & deliverables, proactive management of KEM aligned to CMC SG\u2019s.": "ex:QualityAttribute_project_plan_updated_ca131552",
  "QualityAttribute:CGT:9:Qualification Report of Insulated Shipping Container for Temperature Sensitive Products (as needed)  As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_qualification_report_5e4fb72d",
  "QualityAttribute:CGT:9:Regulatory Submission As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_regulatory_submissio_9ecf0640",
  "QualityAttribute:CGT:9:Review PRA, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_pra_update_if_f45dce80",
  "QualityAttribute:CGT:9:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_3a9539e1",
  "QualityAttribute:CGT:9:Review cold-chain and DS/DP shipping strategy (for primary containers).": "ex:QualityAttribute_review_cold_chain_an_208b69bd",
  "QualityAttribute:CGT:9:Review the current MAA/BLA review process (BLA/MAA kick off meeting, extended team review, functional area review, and BLA/MAA endorsement) with other functions (if not done yet in Stage Gate 8).": "ex:QualityAttribute_review_the_current_m_2d93a04c",
  "QualityAttribute:CGT:9:Reviewing BLA enabling studies e.g. CPV, PVMPs, MVPR, specs, stability plans, shipping plans etc.": "ex:QualityAttribute_reviewing_bla_enabli_f2ca5b81",
  "QualityAttribute:CGT:9:Risk Management Report As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_risk_management_repo_36090fb9",
  "QualityAttribute:CGT:9:Secondary Package \u2013 Process Qualification (as needed) As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_secondary_package_pr_94151735",
  "QualityAttribute:CGT:9:Shipping Process Validation Report \u2013 Cold Chain (as needed) As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_shipping_process_val_befe74a6",
  "QualityAttribute:CGT:9:Software Validation (if applicable) As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_software_validation_09d4c843",
  "QualityAttribute:CGT:9:Stage 9A/9B/9C Council presentation review completed.": "ex:QualityAttribute_stage_9a_9b_9c_counc_52e2fbbb",
  "QualityAttribute:CGT:9:Stage Gate Approval Form As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_stage_gate_approval_ab93cf15",
  "QualityAttribute:CGT:9:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_64152ab7",
  "QualityAttribute:CGT:9:Support Marketing Application development in progress (including Post Approvals Comparability Protocols)": "ex:QualityAttribute_support_marketing_ap_ea31189d",
  "QualityAttribute:CGT:9:Support risk management activities: includes risk identification, mitigation, monitor & control; risk register utilization.": "ex:QualityAttribute_support_risk_managem_92a7d4b8",
  "QualityAttribute:CGT:9:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_91380450",
  "QualityAttribute:CGT:9:Update Criticality Analysis(if applicable).": "ex:QualityAttribute_update_criticality_a_3af60c44",
  "QualityAttribute:CGT:9:Update DHF As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_update_dhf_as_per_cp_e7faf7bd",
  "QualityAttribute:CGT:9:Update DMR As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_update_dmr_as_per_cp_049e40d9",
  "QualityAttribute:CGT:9:Update Design and Development Plan  As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_update_design_and_de_cfc5e8d7",
  "QualityAttribute:CGT:9:Update General Safety and Performance Requirements (GSPR) Checklist (if required) As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_update_general_safet_5407180a",
  "QualityAttribute:CGT:9:Update Human Factors Plan As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_update_human_factors_f8b3b4e7",
  "QualityAttribute:CGT:9:Update Product Risk Assessment (PRA) As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_update_product_risk_47cdc515",
  "QualityAttribute:CGT:9:Update Regulatory Plan As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_update_regulatory_pl_4d4cc65b",
  "QualityAttribute:CGT:9:Update SWOT Assessment (if needed).": "ex:QualityAttribute_update_swot_assessme_8d3bd0b5",
  "QualityAttribute:CGT:9:Update criticality analysis and control strategy review for all applicable processes": "ex:QualityAttribute_update_criticality_a_ff164cce",
  "QualityAttribute:CGT:9:Update of Regulated Substances Plan (if required) As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_update_of_regulated_2fb4f2a8",
  "QualityAttribute:CGT:9:Update of Regulated Substances Report and Supplier Regulated Substances Declarations (if required) As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_update_of_regulated_b2fd164f",
  "QualityAttribute:CGT:9:Update to Manufacturing and Design Transfer Plan and Report As per CPDP Design & Process Validation Stage in DS-SOP-16238": "ex:QualityAttribute_update_to_manufactur_32ace9fc",
  "QualityAttribute:CGT:9:Updated strategic forecast and capacity planning for API and DP via NPS/FIS.": "ex:QualityAttribute_updated_strategic_fo_69da02d5",
  "QualityAttribute:CGT:9:Validation Execution Plan Completed": "ex:QualityAttribute_validation_execution_5c8feefe",
  "QualityAttribute:Protein:0:Assign AD-SI upon request for portfolio Mgt (approx.: one month prior to cell line selection)": "ex:QualityAttribute_assign_ad_si_upon_re_0b72c506",
  "QualityAttribute:Protein:0:Assign a CSI and MSI to CMC team pre NME declaration (prior Cell line selection)": "ex:QualityAttribute_assign_a_csi_and_msi_f467bc19",
  "QualityAttribute:Protein:0:Biologics Discovery Biophysics group is responsible for ensuring IPSC is available. CMCL to ensure CMC team has received critical information about administration route, dosing, and physical properties/liabilities from discovery/CDT.  Identification of pre-NME batch materials used for studies that will enable FIH clinical trials": "ex:QualityAttribute_biologics_discovery_beb61950",
  "QualityAttribute:Protein:0:CMC Criitcal Questions initiated and Risk assessment in line with Joint development risk assessment developed": "ex:QualityAttribute_cmc_criitcal_questio_abe1db10",
  "QualityAttribute:Protein:0:CMC Team assigned (CMC Leader and SIs) and initial workplan with budget developed.": "ex:QualityAttribute_cmc_team_assigned_cm_419eb472",
  "QualityAttribute:Protein:0:Confirm any pre-NME batch data & material retains used for studies that support FIH clinical trials are in place": "ex:QualityAttribute_confirm_any_pre_nme_0a88075e",
  "QualityAttribute:Protein:0:Connect with CEAS for material and initiate stability studies.": "ex:QualityAttribute_connect_with_ceas_fo_61292e67",
  "QualityAttribute:Protein:0:Determine DG classification & packaging reqs.": "ex:QualityAttribute_determine_dg_classif_08191330",
  "QualityAttribute:Protein:0:Ensure ELM generation and hand-off for AD and DPD activities": "ex:QualityAttribute_ensure_elm_generatio_9b60930b",
  "QualityAttribute:Protein:0:Ensure Integrated Strategic Plan is prepared (EtoE DPDS focus).  Alignment on progression of lead and backup molecule (if required)": "ex:QualityAttribute_ensure_integrated_st_4f40dc14",
  "QualityAttribute:Protein:0:Ensure any batch material requests (ELM, Non-glp material) are clearly indentified to API and CMC leader.": "ex:QualityAttribute_ensure_any_batch_mat_57c24b7b",
  "QualityAttribute:Protein:0:IPSC  package is completed  and joint development risk assesment complete & communicated": "ex:QualityAttribute_ipsc_package_is_comp_74aabfca",
  "QualityAttribute:Protein:0:Identify critical reagents needs & new process/product impurities and plan for method development": "ex:QualityAttribute_identify_critical_re_ff10be81",
  "QualityAttribute:Protein:0:Identify new de novo methods to support new protein modalities.": "ex:QualityAttribute_identify_new_de_novo_4c8c1eb6",
  "QualityAttribute:Protein:0:In collaboration\u00a0with TD, CEAS, API, DPD and EQ complete material and supplier selection on new raw materials and\u00a0ensure representative raw materials\u00a0are used in early development and leading into Early Look Material (ELM), non-GLP and GLP tox batches.": "ex:QualityAttribute_in_collaboration_wit_28f76507",
  "QualityAttribute:Protein:0:Initiate Molecular modeling for formulation and stability assessment.": "ex:QualityAttribute_initiate_molecular_m_14c663ac",
  "QualityAttribute:Protein:0:LSAM (Lead Selection Alignment Meeting) that includes IPSC package info is complete for knowledge transfer from Therapeutics Discovery (TD) to BTDS.": "ex:QualityAttribute_lsam_lead_selection_417695f3",
  "QualityAttribute:Protein:0:Mfg plasmids ordered and released.  For Tri-specifc ensure ratio scouting is complete.  Obtain ~10 mg of reference std from TD and any Octet titering detection reagents or purification methods if needed.": "ex:QualityAttribute_mfg_plasmids_ordered_a96b74d3",
  "QualityAttribute:Protein:0:Mfg plasmids ordered released and provided API (Cell Engineering & Analytical Sciences)": "ex:QualityAttribute_mfg_plasmids_ordered_1fcfd1d0",
  "QualityAttribute:Protein:0:Review IPSC package for risks to formulation and stability with respect to TCP/TPP.\u00a0 Attend LSAM": "ex:QualityAttribute_review_ipsc_package_8a3577e7",
  "QualityAttribute:Protein:0:Review of IPSC data & Joint development risk assesment through LSAM": "ex:QualityAttribute_review_of_ipsc_data_2acfe21e",
  "QualityAttribute:Protein:0:Review open materials requests from TD.": "ex:QualityAttribute_review_open_material_19054faa",
  "QualityAttribute:Protein:0:Start knowledge transfer from TD/CEAS (including MOA) and align on methods used for early development": "ex:QualityAttribute_start_knowledge_tran_5cbc406b",
  "QualityAttribute:Protein:10:Alignment with Medical Affairs on potential demands": "ex:QualityAttribute_alignment_with_medic_c2530f04",
  "QualityAttribute:Protein:10:All formulation and process dev history / robustness source documents completed.": "ex:QualityAttribute_all_formulation_and_7e0df881",
  "QualityAttribute:Protein:10:All source documents completed and approved.": "ex:QualityAttribute_all_source_documents_31d70abd",
  "QualityAttribute:Protein:10:Analytical sections of Marketing Application reviewed and approved.": "ex:QualityAttribute_analytical_sections_9352b032",
  "QualityAttribute:Protein:10:Approval of proposed commercial label completed.": "ex:QualityAttribute_approval_of_proposed_b5e7ffa5",
  "QualityAttribute:Protein:10:CPDP Commercialization Stage": "ex:QualityAttribute_cpdp_commercializati_2d978f0a",
  "QualityAttribute:Protein:10:Commercial Container Closure System Summary Report completed.": "ex:QualityAttribute_commercial_container_6fd167c4",
  "QualityAttribute:Protein:10:Commercial Secondary/Tertiary Packaging Design locked.": "ex:QualityAttribute_commercial_secondary_a4f8aa45",
  "QualityAttribute:Protein:10:Commercial pharmacy manual supportive studies completed & documented (if required).": "ex:QualityAttribute_commercial_pharmacy_5eefcedb",
  "QualityAttribute:Protein:10:Commercially acceptable stability achieved at real-time storage conditions according to regulatory submission strategy.": "ex:QualityAttribute_commercially_accepta_6f853256",
  "QualityAttribute:Protein:10:Complete PAI readiness activities for raw materials for DS and DP including technical/scientific documentation and compliance.": "ex:QualityAttribute_complete_pai_readine_2e4111ba",
  "QualityAttribute:Protein:10:Complete PRM and WRM qualification reports and  issue COA for BLA/MAA": "ex:QualityAttribute_complete_prm_and_wrm_b3bd65ec",
  "QualityAttribute:Protein:10:Complete product characterization method qualification reports  for BLA/MAA.": "ex:QualityAttribute_complete_product_cha_edfa5980",
  "QualityAttribute:Protein:10:Confirm that commercial DS/DP processes for launch materials match the validated processes. Communicate any differences.": "ex:QualityAttribute_confirm_that_commerc_9d77b402",
  "QualityAttribute:Protein:10:Continue discussions on Patent and Publication Strategy with team and legal. Summarize potential unique aspects of the process, product formulations and devices that could lead to publications and/or patents.": "ex:QualityAttribute_continue_discussions_f8f5fe12",
  "QualityAttribute:Protein:10:Continuous Process verification (CPV) strategy defined (linked to stabilization metrics) and implementation started.": "ex:QualityAttribute_continuous_process_v_eebd11ae",
  "QualityAttribute:Protein:10:Continuous Process verification (CPV) strategy defined and implementation started.": "ex:QualityAttribute_continuous_process_v_efc41f64",
  "QualityAttribute:Protein:10:Coordinate aggregated clinical/non-clinical demand in support of commercial/Ph3 mfg. and provide to the JSC organization": "ex:QualityAttribute_coordinate_aggregate_c00cdf88",
  "QualityAttribute:Protein:10:DP sections of Marketing Application reviewed and approved.": "ex:QualityAttribute_dp_sections_of_marke_aa1636e2",
  "QualityAttribute:Protein:10:DP: at risk launch inventory build approved and production initiated (if needed).": "ex:QualityAttribute_dp_at_risk_launch_in_df332764",
  "QualityAttribute:Protein:10:DS sections of Marketing Application reviewed and approved.": "ex:QualityAttribute_ds_sections_of_marke_41526257",
  "QualityAttribute:Protein:10:DS upstream and downstream process characterization report approved.": "ex:QualityAttribute_ds_upstream_and_down_0af8b765",
  "QualityAttribute:Protein:10:DS upstream and downstream process validation report approved.": "ex:QualityAttribute_ds_upstream_and_down_22af3f34",
  "QualityAttribute:Protein:10:Data for 6-12 months long term leachable data completed and ready for Marketing Application.": "ex:QualityAttribute_data_for_6_12_months_4db95b73",
  "QualityAttribute:Protein:10:Decision on rapid launch strategy made with commercial affiliates.": "ex:QualityAttribute_decision_on_rapid_la_1a8d1bd7",
  "QualityAttribute:Protein:10:Design Control": "ex:QualityAttribute_design_control_853fbb26",
  "QualityAttribute:Protein:10:Design History File (Update)": "ex:QualityAttribute_design_history_file_f304e014",
  "QualityAttribute:Protein:10:Design and Development Plan  (Update)": "ex:QualityAttribute_design_and_developme_966c278c",
  "QualityAttribute:Protein:10:Develop scenarios in support of strategic planning (as required).": "ex:QualityAttribute_develop_scenarios_in_1e4baccf",
  "QualityAttribute:Protein:10:Device Master Record (DMR) (Update)": "ex:QualityAttribute_device_master_record_6ddd9085",
  "QualityAttribute:Protein:10:Device Risk Management  (Update) - CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_d3ebb8a8",
  "QualityAttribute:Protein:10:Device Risk Management  (Update) - Device Control Strategy (Review and Update)": "ex:QualityAttribute_device_risk_manageme_58d48c15",
  "QualityAttribute:Protein:10:Device Risk Management  (Update) - Product Risk Assessment (Update)": "ex:QualityAttribute_device_risk_manageme_c9a65fd8",
  "QualityAttribute:Protein:10:Device Risk Management  (Update) - Risk Management Plan/Report (Update)": "ex:QualityAttribute_device_risk_manageme_93831a59",
  "QualityAttribute:Protein:10:Device Risk Management  (Update) - dFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_27ed1bef",
  "QualityAttribute:Protein:10:Device Risk Management  (Update) - pFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_b23c4348",
  "QualityAttribute:Protein:10:Device Risk Management  (Update) - uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_2b7c2065",
  "QualityAttribute:Protein:10:Document list (including process characterization reports, robustness study reports, process validation protocol and reports, or process development history report) completed.": "ex:QualityAttribute_document_list_includ_7eaa0847",
  "QualityAttribute:Protein:10:E2E Value Chain Risk Management started.": "ex:QualityAttribute_e2e_value_chain_risk_ab24fe3c",
  "QualityAttribute:Protein:10:EHS Requirement: compliance assessment for DP manufacturing completed.": "ex:QualityAttribute_ehs_requirement_comp_fa9b720d",
  "QualityAttribute:Protein:10:EHS Requirement: compliance assessment for DS manufacturing completed. Complete and file ERA (RIMdocs)": "ex:QualityAttribute_ehs_requirement_comp_7c18d145",
  "QualityAttribute:Protein:10:Ensure Customer Centered Design deliverables are completed for this stage (combo products), inclusive of Customer Centered Design Workshop as needed.": "ex:QualityAttribute_ensure_customer_cent_d013f812",
  "QualityAttribute:Protein:10:Ensure Customer Centered Design deliverables are completed for this stage. (CMCL Co-owner)": "ex:QualityAttribute_ensure_customer_cent_a45419ad",
  "QualityAttribute:Protein:10:Ensure LD Criticality Report is updated (if applicable).": "ex:QualityAttribute_ensure_ld_criticalit_79ace095",
  "QualityAttribute:Protein:10:Ensure comprehensive justification for human factors study plans has been documented.  (For non-combination products, consult with CMCRA whether URRA should be included in NDA/BLA (not applicable to MAA).\u00a0 Roles and responsibilities for URRA may be DPD&D as appropriate)": "ex:QualityAttribute_ensure_comprehensive_04dd1bbc",
  "QualityAttribute:Protein:10:Ensure initial worldwide filing strategy has been defined.": "ex:QualityAttribute_ensure_initial_world_ae7ffeef",
  "QualityAttribute:Protein:10:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_041a4b4b",
  "QualityAttribute:Protein:10:Finalize JJ Packaging Design protocol": "ex:QualityAttribute_finalize_jj_packagin_17bb1642",
  "QualityAttribute:Protein:10:Finalize raw material control strategy for DS and DP including risk assessments (supplier and CA) and control including monitoring and trending.": "ex:QualityAttribute_finalize_raw_materia_fff5e1b9",
  "QualityAttribute:Protein:10:Initial commercial launch quantities defined.": "ex:QualityAttribute_initial_commercial_l_709edff6",
  "QualityAttribute:Protein:10:Initiate discussions with VCL/JSC to have plan in place to support Medical Affairs and any other ongoing studies from commercial supplies.": "ex:QualityAttribute_initiate_discussions_9f26454f",
  "QualityAttribute:Protein:10:MAM/CMO \u2013 Packaging equipment qualification (IQOQPQ) completed\nTO/Pack TLI \u2013 Packaging process validation (PPQ) completed\nSCDL/PA CoE \u2013 Packaging mock-ups filed": "ex:QualityAttribute_mam_cmo_packaging_eq_9a12ff6d",
  "QualityAttribute:Protein:10:Maintain sample archive/permanent retention program for all Clinical and ProVal batches.": "ex:QualityAttribute_maintain_sample_arch_1a0207e7",
  "QualityAttribute:Protein:10:Marketing Application internally reviewed and approved, and derivative dossiers completed.": "ex:QualityAttribute_marketing_applicatio_f22833bc",
  "QualityAttribute:Protein:10:Marketing Application reviewed and approved including JSC sections (i.e. Facilities).": "ex:QualityAttribute_marketing_applicatio_b2b79d40",
  "QualityAttribute:Protein:10:Marketing Application reviewed and approved.": "ex:QualityAttribute_marketing_applicatio_9c18a7b8",
  "QualityAttribute:Protein:10:Marketing Application reviewed and approved. Conduct lessons learned if applicable.": "ex:QualityAttribute_marketing_applicatio_cf3dce1b",
  "QualityAttribute:Protein:10:Marketing Application submitted to primary markets according to project timelines.": "ex:QualityAttribute_marketing_applicatio_e7283f03",
  "QualityAttribute:Protein:10:PAI readiness achieved at DS and DP mfg. & test sites.": "ex:QualityAttribute_pai_readiness_achiev_8b571d72",
  "QualityAttribute:Protein:10:PSR refreshed & JSC Presentation (if needed)": "ex:QualityAttribute_psr_refreshed_jsc_pr_e40f362f",
  "QualityAttribute:Protein:10:PVMP Summary Report approved.": "ex:QualityAttribute_pvmp_summary_report_92d4ea66",
  "QualityAttribute:Protein:10:Passive shipping systems qualified, if applicable.": "ex:QualityAttribute_passive_shipping_sys_2e742c61",
  "QualityAttribute:Protein:10:Ph3 and ProVal DS & DP stability data completed by AD Cork and  JSC QC, respectively and trending completed by AD Cork.": "ex:QualityAttribute_ph3_and_proval_ds_dp_8701baef",
  "QualityAttribute:Protein:10:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_25f4540a",
  "QualityAttribute:Protein:10:Pre-Approval Inspection Readiness - Checklist execution Summary/Remediation Report": "ex:QualityAttribute_pre_approval_inspect_83022bdb",
  "QualityAttribute:Protein:10:Pre-Approval Inspection Readiness - Mock PAI Inspection of Compliance": "ex:QualityAttribute_pre_approval_inspect_cbc8994c",
  "QualityAttribute:Protein:10:Pre-Approval Inspection Readiness - PAI Readiness Checklist (Device/Combo)": "ex:QualityAttribute_pre_approval_inspect_b4fd7987",
  "QualityAttribute:Protein:10:ProVal DS & DP stability data trending completed by JSC QC.": "ex:QualityAttribute_proval_ds_dp_stabili_8b9bb6fc",
  "QualityAttribute:Protein:10:Product-specific Extractable Risk Assessments and Summary Report completed as dossier drop-in reports.": "ex:QualityAttribute_product_specific_ext_c718109f",
  "QualityAttribute:Protein:10:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_89a210b5",
  "QualityAttribute:Protein:10:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_e0efb856",
  "QualityAttribute:Protein:10:Provide a detailed  summary of  any late phase development IP discussions. Discuss any novel original ideas and innovations and progress made toward completing a patent application": "ex:QualityAttribute_provide_a_detailed_s_0ad03d5b",
  "QualityAttribute:Protein:10:Provide a detailed  summary of any late development IP discussions. Discuss any novel original ideas and innovations and progress made toward completing a patent application.": "ex:QualityAttribute_provide_a_detailed_s_addf830a",
  "QualityAttribute:Protein:10:RRM and any critical controls, standards  data  trending  completed by AD Cork.": "ex:QualityAttribute_rrm_and_any_critical_573d6c1c",
  "QualityAttribute:Protein:10:Raw Material sections of Marketing Application authored, reviewed and approved.": "ex:QualityAttribute_raw_material_section_37dc1951",
  "QualityAttribute:Protein:10:Regulatory filing strategy defined": "ex:QualityAttribute_regulatory_filing_st_a1211910",
  "QualityAttribute:Protein:10:Review and approve process validation reports.": "ex:QualityAttribute_review_and_approve_p_c4ee93ed",
  "QualityAttribute:Protein:10:Review process characterization reports.": "ex:QualityAttribute_review_process_chara_27a82be1",
  "QualityAttribute:Protein:10:Risk Register completed for major predictable CMC filing issues (RA/DDO/CMCL).": "ex:QualityAttribute_risk_register_comple_557b728f",
  "QualityAttribute:Protein:10:Secure funding for any post launch optimization projects (JSC & R&D)": "ex:QualityAttribute_secure_funding_for_a_14d96c82",
  "QualityAttribute:Protein:10:Site compliance, PAI readiness evaluated and PAI observations addressed.": "ex:QualityAttribute_site_compliance_pai_3dc7b5d7",
  "QualityAttribute:Protein:10:Stage 10 CMC Council presentation completed.": "ex:QualityAttribute_stage_10_cmc_council_02d97b49",
  "QualityAttribute:Protein:10:Submit Product Quality Complaint New Product Set Up Form for commercial product": "ex:QualityAttribute_submit_product_quali_230390cd",
  "QualityAttribute:Protein:10:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_633504af",
  "QualityAttribute:Protein:10:Transportation/Distribution strategy defined. Transportation channel and shipping protection selected (Distribution Risk Assessment completed).": "ex:QualityAttribute_transportation_distr_4020ebe8",
  "QualityAttribute:Protein:10:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_78a2b578",
  "QualityAttribute:Protein:10:Update FMEAs (u, d, p) (including verification and effectiveness (COMBO Product Requirement)": "ex:QualityAttribute_update_fmeas_u_d_p_i_97d993c0",
  "QualityAttribute:Protein:10:Update PMR Plan/Report (including Product Risk Benefit Analysis)": "ex:QualityAttribute_update_pmr_plan_repo_96760f69",
  "QualityAttribute:Protein:10:Update PRA (including verification and effectiveness)": "ex:QualityAttribute_update_pra_including_80b3c442",
  "QualityAttribute:Protein:10:Update strategic forecast and capacity planning for DS and DP via NPS/FIS.": "ex:QualityAttribute_update_strategic_for_c1c3048a",
  "QualityAttribute:Protein:10:Update to Regulated Substances Plan, Supplier Regulated Substances Declarations and Regulated Substances Report (if applicable)": "ex:QualityAttribute_update_to_regulated_d304b655",
  "QualityAttribute:Protein:10:Updated Cost of Goods Sold (COGS) and Gross Profit (GP) for launch and steady state.": "ex:QualityAttribute_updated_cost_of_good_2b141f22",
  "QualityAttribute:Protein:11:A summary of all At-Risk Inventories approved prior to launch should be presented.": "ex:QualityAttribute_a_summary_of_all_at_b424d787",
  "QualityAttribute:Protein:11:Adjust commercial specifications following health authority approval (if applicable).": "ex:QualityAttribute_adjust_commercial_sp_6740b149",
  "QualityAttribute:Protein:11:Agreements regarding safety stock at the DS level, WIP level and Finished Good level should be defined and agreements reached on launch quantities and strategy.": "ex:QualityAttribute_agreements_regarding_e37abd18",
  "QualityAttribute:Protein:11:Alignment with Medical Affairs on potential demands": "ex:QualityAttribute_alignment_with_medic_22620deb",
  "QualityAttribute:Protein:11:Approval timing, pricing and launch timings and quantities should be defined and presented. Launch Plan including Rapid Launch Plan (if applicable) should be presented.": "ex:QualityAttribute_approval_timing_pric_002da38c",
  "QualityAttribute:Protein:11:Approvals obtained from primary markets.": "ex:QualityAttribute_approvals_obtained_f_f7334685",
  "QualityAttribute:Protein:11:CMC responses to HAs completed and commitments initiated (if applicable).": "ex:QualityAttribute_cmc_responses_to_has_bc487ea9",
  "QualityAttribute:Protein:11:COGS and COGS improvement plan should be updated and presented.": "ex:QualityAttribute_cogs_and_cogs_improv_9cdcffe6",
  "QualityAttribute:Protein:11:CPDP Commercialization Stage": "ex:QualityAttribute_cpdp_commercializati_bb65c8c8",
  "QualityAttribute:Protein:11:Commercial DS & DP release & shelf-life specification document approved.": "ex:QualityAttribute_commercial_ds_dp_rel_8cb23d43",
  "QualityAttribute:Protein:11:Complete Commercial Patient Safety and Compliance (PSCI) Document": "ex:QualityAttribute_complete_commercial_c093a086",
  "QualityAttribute:Protein:11:Conduct lessons learned if any significant issues occurred during HA review.": "ex:QualityAttribute_conduct_lessons_lear_45f90e2a",
  "QualityAttribute:Protein:11:Confirm completion of all process validations and associated reports, and packaging line qualifications/validations.": "ex:QualityAttribute_confirm_completion_o_817c107a",
  "QualityAttribute:Protein:11:Confirm completion of shipping qualifications or validations (associated with cold chain).": "ex:QualityAttribute_confirm_completion_o_f69a74d9",
  "QualityAttribute:Protein:11:Continue discussion with team and legal on Patent and Publication Strategy.  Summarize potential unique aspects of the process that could lead to publications and/or patents in core team meeting minutes.": "ex:QualityAttribute_continue_discussion_136bb05d",
  "QualityAttribute:Protein:11:Coordinate aggregated clinical/non-clinical demand in support of commercial/Ph3 mfg. and provide to the JSC organization": "ex:QualityAttribute_coordinate_aggregate_86529b38",
  "QualityAttribute:Protein:11:DP life cycle management development work initiated (if applicable).": "ex:QualityAttribute_dp_life_cycle_manage_21edffa6",
  "QualityAttribute:Protein:11:Define raw material supply chain reliability strategy for DS and DP (media, buffers, resins, chemicals, excipients, and polymeric product contact materials).": "ex:QualityAttribute_define_raw_material_77155c45",
  "QualityAttribute:Protein:11:Design Control": "ex:QualityAttribute_design_control_9c8a7c0f",
  "QualityAttribute:Protein:11:Design History File (Update)": "ex:QualityAttribute_design_history_file_1c6b8653",
  "QualityAttribute:Protein:11:Design Transfer  (CPDP Deliverables) - Design Review": "ex:QualityAttribute_design_transfer_cpdp_0f2204b0",
  "QualityAttribute:Protein:11:Design Transfer  (CPDP Deliverables) - Post Market Human Factor Activities": "ex:QualityAttribute_design_transfer_cpdp_49221496",
  "QualityAttribute:Protein:11:Design Transfer  (CPDP Deliverables) - Traceability Matrix (Update if Required)": "ex:QualityAttribute_design_transfer_cpdp_f948f925",
  "QualityAttribute:Protein:11:Design and Development Plan  (Update)": "ex:QualityAttribute_design_and_developme_d87934c9",
  "QualityAttribute:Protein:11:Developed scenarios in support of strategic planning (as required).": "ex:QualityAttribute_developed_scenarios_ef1c96dc",
  "QualityAttribute:Protein:11:Device Master Record (DMR) (Update)": "ex:QualityAttribute_device_master_record_8dd18798",
  "QualityAttribute:Protein:11:Device Risk Management  (Update) - CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_c2af499d",
  "QualityAttribute:Protein:11:Device Risk Management  (Update) - Device Control Strategy (Review and Update)": "ex:QualityAttribute_device_risk_manageme_b7541495",
  "QualityAttribute:Protein:11:Device Risk Management  (Update) - Product Risk Assessment/Hazard ID (Update)": "ex:QualityAttribute_device_risk_manageme_7c7f7ab1",
  "QualityAttribute:Protein:11:Device Risk Management  (Update) - Risk Management Plan/Report (Update)": "ex:QualityAttribute_device_risk_manageme_09b55ceb",
  "QualityAttribute:Protein:11:Device Risk Management  (Update) - dFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_ec87dfa0",
  "QualityAttribute:Protein:11:Device Risk Management  (Update) - pFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_b29f7014",
  "QualityAttribute:Protein:11:Device Risk Management  (Update) - uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_ab04e49c",
  "QualityAttribute:Protein:11:Distribution requirements strategy identified from Hub DC to First Line Customer": "ex:QualityAttribute_distribution_require_86e0767a",
  "QualityAttribute:Protein:11:Distribution requirements strategy identified to point of HUB DC. Global product distribution chain set up and implemented.": "ex:QualityAttribute_distribution_require_12c75361",
  "QualityAttribute:Protein:11:Ensure LD Criticality Report and integrated Control Strategy are updated (if applicable due to HA feedback).": "ex:QualityAttribute_ensure_ld_criticalit_8de01576",
  "QualityAttribute:Protein:11:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_94a78be5",
  "QualityAttribute:Protein:11:Final packaging QC, operations and IPC procedures approved and staff trained": "ex:QualityAttribute_final_packaging_qc_o_93091bf2",
  "QualityAttribute:Protein:11:HA inspections successfully completed.": "ex:QualityAttribute_ha_inspections_succe_5aa91062",
  "QualityAttribute:Protein:11:Importation activities/licenses planned (e.g., controlled substances \u2192 DEA, pre-importations).": "ex:QualityAttribute_importation_activiti_b0bef398",
  "QualityAttribute:Protein:11:JSC relevant Marketing Application regulatory responses reviewed & approved (as applicable).": "ex:QualityAttribute_jsc_relevant_marketi_abbbf046",
  "QualityAttribute:Protein:11:Knowledge Management Database updated with Product Fact Book": "ex:QualityAttribute_knowledge_management_85e9a277",
  "QualityAttribute:Protein:11:Launch readiness confirmed at all involved commercial manufacturing & packaging sites.  Assess the impact of a rapid launch, if requested by commercial. This includes an assessment of the capabilities of the launch sites involved.": "ex:QualityAttribute_launch_readiness_con_71b8c4e1",
  "QualityAttribute:Protein:11:PSR refreshed and JSC Presentation (if needed)": "ex:QualityAttribute_psr_refreshed_and_js_a64226d5",
  "QualityAttribute:Protein:11:Packaging site systems ready for launch": "ex:QualityAttribute_packaging_site_syste_20f9d103",
  "QualityAttribute:Protein:11:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_8791a2d3",
  "QualityAttribute:Protein:11:Pre-Launch Importation Request (PLAIR) submitted and approved (as applicable).": "ex:QualityAttribute_pre_launch_importati_8f464407",
  "QualityAttribute:Protein:11:Preliminary artwork will have been filed with the Marketing Applications and Marketing should be preparing final commercial artwork, with trademark, if one has been determined.": "ex:QualityAttribute_preliminary_artwork_04cd06fb",
  "QualityAttribute:Protein:11:Prepare and complete responses to HA questions": "ex:QualityAttribute_prepare_and_complete_d59356d5",
  "QualityAttribute:Protein:11:Product Financial flows should be determined.": "ex:QualityAttribute_product_financial_fl_faecedcc",
  "QualityAttribute:Protein:11:Product Launch supplies manufactured and released. \"And released\" added by Portfolio Management.": "ex:QualityAttribute_product_launch_suppl_c81dce16",
  "QualityAttribute:Protein:11:Product Strategy Roadmap upstream & downstream work initiated (if applicable).": "ex:QualityAttribute_product_strategy_roa_1ed218e9",
  "QualityAttribute:Protein:11:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_486afd27",
  "QualityAttribute:Protein:11:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_51553d56",
  "QualityAttribute:Protein:11:Quality agreement for commercial completed/revised for all mfg. sites/testing labs (external and internal) (if applicable)": "ex:QualityAttribute_quality_agreement_fo_cccb641c",
  "QualityAttribute:Protein:11:Raw material life cycle management development work initiated (if applicable).": "ex:QualityAttribute_raw_material_life_cy_7e49ea98",
  "QualityAttribute:Protein:11:Re-evaluate and update characterization tests in commercial lab specs, based on a review of available data & HA feedback.": "ex:QualityAttribute_re_evaluate_and_upda_f3e4c04c",
  "QualityAttribute:Protein:11:Regional operational forecasts available and translated into manufacturing forecasts (for markets preparing to launch).": "ex:QualityAttribute_regional_operational_410a6332",
  "QualityAttribute:Protein:11:Regulatory Submission Documentation Review (Update)": "ex:QualityAttribute_regulatory_submissio_0fc9100c",
  "QualityAttribute:Protein:11:Regulatory commitments entered into ETS and GRA Commitments database.": "ex:QualityAttribute_regulatory_commitmen_ce0d5b71",
  "QualityAttribute:Protein:11:Review FMEAs (u, p, d), update if additions/changes risk management activities (COMBO Product) Requirement)": "ex:QualityAttribute_review_fmeas_u_p_d_u_21f3d3c3",
  "QualityAttribute:Protein:11:Review PRA, update if additional/changed risk management activities": "ex:QualityAttribute_review_pra_update_if_c490f8cc",
  "QualityAttribute:Protein:11:Review PRM Plan/Report, update if additional/changed risk management activities": "ex:QualityAttribute_review_prm_plan_repo_6d74cfa9",
  "QualityAttribute:Protein:11:Review current plans and data to determine if development buy-ups are needed.": "ex:QualityAttribute_review_current_plans_7b630e5c",
  "QualityAttribute:Protein:11:Review/update worldwide filing strategy if applicable.": "ex:QualityAttribute_review_update_worldw_eae8b92e",
  "QualityAttribute:Protein:11:Risk Analysis & Mitigation plans from Stage Gate Review 10 should be updated and presented.": "ex:QualityAttribute_risk_analysis_mitiga_2f2fcfa5",
  "QualityAttribute:Protein:11:Site business systems set-up finished (SAP etc.).": "ex:QualityAttribute_site_business_system_cdb07214",
  "QualityAttribute:Protein:11:Stability data updates provided to health authority (if applicable).": "ex:QualityAttribute_stability_data_updat_4b11b5c2",
  "QualityAttribute:Protein:11:Stability review (post-submission data) & marketed stability plan reviewed and assessed for completeness and potential risks.": "ex:QualityAttribute_stability_review_pos_f7bf0a08",
  "QualityAttribute:Protein:11:Stage 11 CMC Council presentation review completed.": "ex:QualityAttribute_stage_11_cmc_council_27dd926d",
  "QualityAttribute:Protein:11:Startup packaging materials setup & ordered": "ex:QualityAttribute_startup_packaging_ma_bbc0bef4",
  "QualityAttribute:Protein:11:Strategic forecast should be updated and long term strategic capacity analysis updated via NPS/FIS.": "ex:QualityAttribute_strategic_forecast_s_2bef3c69",
  "QualityAttribute:Protein:11:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_ae943a37",
  "QualityAttribute:Protein:11:Support PAI at manufacturing sites.": "ex:QualityAttribute_support_pai_at_manuf_220a1f58",
  "QualityAttribute:Protein:11:Support PAI inspection of manufacturing and testing  sites (DS and DP).": "ex:QualityAttribute_support_pai_inspecti_243208e7",
  "QualityAttribute:Protein:11:Support PAI inspection of manufacturing sites": "ex:QualityAttribute_support_pai_inspecti_87935b9e",
  "QualityAttribute:Protein:11:Support PAI inspection of manufacturing sites.": "ex:QualityAttribute_support_pai_inspecti_315f6205",
  "QualityAttribute:Protein:11:Update CMC Risk Register": "ex:QualityAttribute_update_cmc_risk_regi_121a7250",
  "QualityAttribute:Protein:11:Update to Regulated Substances Plan, Supplier Regulated Substances Declarations and Regulated Substances Report (if applicable)": "ex:QualityAttribute_update_to_regulated_bd588e9d",
  "QualityAttribute:Protein:11:Updated Cost of Goods Sold (COGS) and Gross Profit (GP) for launch and steady state.": "ex:QualityAttribute_updated_cost_of_good_e103bb6c",
  "QualityAttribute:Protein:12:Approved Product Strategy Roadmap upstream & downstream work initiated/supported including post-approval commitments (if applicable).": "ex:QualityAttribute_approved_product_str_ce82da62",
  "QualityAttribute:Protein:12:Approved Product Strategy Roadmap work initiated/supported including post-approval commitments (if applicable).": "ex:QualityAttribute_approved_product_str_93346a8f",
  "QualityAttribute:Protein:12:CMC responses to HAs completed": "ex:QualityAttribute_cmc_responses_to_has_325fed96",
  "QualityAttribute:Protein:12:CPDP Commercialization Stage": "ex:QualityAttribute_cpdp_commercializati_5a549d1f",
  "QualityAttribute:Protein:12:Collect Annual Review Product Data (test Results, IPC, OOS, OOT, deviations, complaints etc.).": "ex:QualityAttribute_collect_annual_revie_0cc71982",
  "QualityAttribute:Protein:12:Commercialization Stage Design Review": "ex:QualityAttribute_commercialization_st_77332a99",
  "QualityAttribute:Protein:12:Complete Proactive Product Quality Scan (PPQS).": "ex:QualityAttribute_complete_proactive_p_6928df7e",
  "QualityAttribute:Protein:12:Complete plans to address all DP process post-approval commitments.": "ex:QualityAttribute_complete_plans_to_ad_c789e8b1",
  "QualityAttribute:Protein:12:Complete raw material reliability assessment and trending recommendations.": "ex:QualityAttribute_complete_raw_materia_374c25d7",
  "QualityAttribute:Protein:12:Consolidated (JSC & BTDS) lessons learned. \"JSC & BTDS\" text added by Portfolio Management.": "ex:QualityAttribute_consolidated_jsc_btd_28d313bc",
  "QualityAttribute:Protein:12:Consolidated lessons learned completed (BTDS & JSC).": "ex:QualityAttribute_consolidated_lessons_7bda3fb5",
  "QualityAttribute:Protein:12:Continue Product Strategy Roadmap activities to support process requirements, as needed": "ex:QualityAttribute_continue_product_str_5ee01e04",
  "QualityAttribute:Protein:12:Coordinate aggregated clinical/non-clinical demand in support of commercial/Ph3 mfg. and provide to the JSC organization.": "ex:QualityAttribute_coordinate_aggregate_0b751ba0",
  "QualityAttribute:Protein:12:DP process robustness and supply chain review completed.": "ex:QualityAttribute_dp_process_robustnes_c02fa391",
  "QualityAttribute:Protein:12:DS upstream and downstream process robustness review completed, including Continued Process Verification (CPV) Stage 3a results to date and process capability assessments  (i.e., Ppk), where applicable": "ex:QualityAttribute_ds_upstream_and_down_4a5f460d",
  "QualityAttribute:Protein:12:Define and initiate Product Dashboard.": "ex:QualityAttribute_define_and_initiate_5edbcc7e",
  "QualityAttribute:Protein:12:Design Control": "ex:QualityAttribute_design_control_36a54f19",
  "QualityAttribute:Protein:12:Design History File (Update)": "ex:QualityAttribute_design_history_file_2f4da5af",
  "QualityAttribute:Protein:12:Design and Development Plan  (Update)": "ex:QualityAttribute_design_and_developme_72d0715b",
  "QualityAttribute:Protein:12:Device Master Record (DMR) (Update)": "ex:QualityAttribute_device_master_record_dbef0245",
  "QualityAttribute:Protein:12:Device Risk Management  (Update) - CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_6362c16a",
  "QualityAttribute:Protein:12:Device Risk Management  (Update) - Device Control Strategy (Review and Update)": "ex:QualityAttribute_device_risk_manageme_cf37367f",
  "QualityAttribute:Protein:12:Device Risk Management  (Update) - Product Risk Assessment/Hazard ID (Update)": "ex:QualityAttribute_device_risk_manageme_8aa792d5",
  "QualityAttribute:Protein:12:Device Risk Management  (Update) - Risk Management Plan/Report (Update)": "ex:QualityAttribute_device_risk_manageme_446b3242",
  "QualityAttribute:Protein:12:Device Risk Management  (Update) - dFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_cc61afff",
  "QualityAttribute:Protein:12:Device Risk Management  (Update) - pFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_41729347",
  "QualityAttribute:Protein:12:Device Risk Management  (Update) - uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_86df5097",
  "QualityAttribute:Protein:12:Ensure completion of raw material reliability assessment and trending recommendations.": "ex:QualityAttribute_ensure_completion_of_214eca37",
  "QualityAttribute:Protein:12:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_0afc3a0b",
  "QualityAttribute:Protein:12:Finalize any open discussions with team and legal on Patent and Publication Strategy.  Summarize potential unique aspects of the process that could lead to publications and/or patents in core team meeting minutes.": "ex:QualityAttribute_finalize_any_open_di_50433130",
  "QualityAttribute:Protein:12:Knowledge Management Database updated.": "ex:QualityAttribute_knowledge_management_aa44fc48",
  "QualityAttribute:Protein:12:Launches executed/launch metrics met.": "ex:QualityAttribute_launches_executed_la_b2d5c651",
  "QualityAttribute:Protein:12:Medical Affairs supply plan updated and aligned with clinical demand/enrollment projection.": "ex:QualityAttribute_medical_affairs_supp_fc85e87b",
  "QualityAttribute:Protein:12:Ownership for base business and Product Strategy Roadmap transferred to Value Chain Team and manufacturing sites including existing Change Controls and Post-Marketing Commitments.": "ex:QualityAttribute_ownership_for_base_b_ef11628b",
  "QualityAttribute:Protein:12:PSR refreshed; JSC Product Council endorsement (if needed)": "ex:QualityAttribute_psr_refreshed_jsc_pr_fea7baaa",
  "QualityAttribute:Protein:12:Pack TLI - Packaging lessons learned review completed, feedback to standards and procedures shared\nPack TLI \u2013 Packaging post-launch support provided and transfer to LCM completed (~1 year post-launch first major market)": "ex:QualityAttribute_pack_tli_packaging_l_fa6588de",
  "QualityAttribute:Protein:12:Product Risk Register transferred to JSC": "ex:QualityAttribute_product_risk_registe_185755bc",
  "QualityAttribute:Protein:12:Provide a high level summary of any late development IP discussions. Discuss any novel original ideas and innovations and progress made toward completing a patent application.": "ex:QualityAttribute_provide_a_high_level_69d9af15",
  "QualityAttribute:Protein:12:Regulatory Plan for process changes (post-approval supplements) completed if applicable.": "ex:QualityAttribute_regulatory_plan_for_977733c6",
  "QualityAttribute:Protein:12:Regulatory strategy developed regarding outstanding countries to be filed.": "ex:QualityAttribute_regulatory_strategy_1addecf6",
  "QualityAttribute:Protein:12:Remove remaining characterization tests from the commercial specs": "ex:QualityAttribute_remove_remaining_cha_84ccf68d",
  "QualityAttribute:Protein:12:Review & Update Traceability Matrix (If applicable)": "ex:QualityAttribute_review_update_tracea_ca8baf14",
  "QualityAttribute:Protein:12:Review Control charts from network QC labs and ensure standardized format from all labs.  Assay issues identified.": "ex:QualityAttribute_review_control_chart_662dd99d",
  "QualityAttribute:Protein:12:Review summary of OOT (Out of Trend) and OOS (Out of Specifications) results provided by JSC QC": "ex:QualityAttribute_review_summary_of_oo_c1bbadcf",
  "QualityAttribute:Protein:12:Risk register transferred to Value Chain Team.": "ex:QualityAttribute_risk_register_transf_8bfe8f88",
  "QualityAttribute:Protein:12:Stage 12 CMC Council presentation review completed.": "ex:QualityAttribute_stage_12_cmc_council_cd6653d4",
  "QualityAttribute:Protein:12:Strategy for future production scale-up/capacity/utilization (DS and DP) in place.": "ex:QualityAttribute_strategy_for_future_0510d178",
  "QualityAttribute:Protein:12:Support CPV program for DS and DP, whether in stage 3a or 3b, transfer to TLIs.": "ex:QualityAttribute_support_cpv_program_c7f79e7a",
  "QualityAttribute:Protein:12:Support CPV program in support of transfer of CPV ownership to TLI.": "ex:QualityAttribute_support_cpv_program_04725953",
  "QualityAttribute:Protein:12:Support CPV protocols if non-routine testing needed.": "ex:QualityAttribute_support_cpv_protocol_d48f9035",
  "QualityAttribute:Protein:12:Team agreement (JSC & BTDS) that product is stable and to transfer ownership for product. \"JSC & BTDS\" text added by Portfolio Management.": "ex:QualityAttribute_team_agreement_jsc_b_3bd5dabd",
  "QualityAttribute:Protein:12:Update Cost of Goods Sold (COGS) and Gross Profit (GP) for steady state.  Summarize COGS progression and opportunities.": "ex:QualityAttribute_update_cost_of_goods_eb232335",
  "QualityAttribute:Protein:12:Update dosage forms, marketed SKU\u2019s, supply chain flow.": "ex:QualityAttribute_update_dosage_forms_a045264b",
  "QualityAttribute:Protein:12:Update forecasts, sales performance, inventories at transfer point, capacity review, and market intelligence.": "ex:QualityAttribute_update_forecasts_sal_593def6a",
  "QualityAttribute:Protein:12:Update new risks identified for business, regulatory, and Business Continuity Plans. Prepare summary, discussion and mitigation plan for any Yellow/Red items, and identify owners.": "ex:QualityAttribute_update_new_risks_ide_0f56bf3f",
  "QualityAttribute:Protein:12:Update to Regulated Substances Plan, Supplier Regulated Substances Declarations and Regulated Substances Report (if applicable)": "ex:QualityAttribute_update_to_regulated_43278dcd",
  "QualityAttribute:Protein:1:CMC Leader responsible to obtain  MABEL or clinical starting dose from CDT.": "ex:QualityAttribute_cmc_leader_responsib_48eef6f5",
  "QualityAttribute:Protein:1:CMO Tech Transfer / Internal site engagement and on-boarding  for introduction of Ph1/2a raw material requirements controls (selection, qualification, release testing specifications and analytical methods) as soon as able based on site selection decision and legal/business requirements (as applicable) and include in business contracts (SOWs). Critical review of CMO material qualification, methods, specifications and change management practices for raw materials.  Alignment of CMO to Janssen standards and expectations for overall material qualification and controls.": "ex:QualityAttribute_cmo_tech_transfer_in_5773b106",
  "QualityAttribute:Protein:1:CPDP Portfolio Management & Concept Feasibility Stage (Concludes concurrently with End of Stage 4 CMC)": "ex:QualityAttribute_cpdp_portfolio_manag_079ad452",
  "QualityAttribute:Protein:1:Clinical Container Closure System Suitability Assessment initiated.": "ex:QualityAttribute_clinical_container_c_322fb143",
  "QualityAttribute:Protein:1:Clinical Primary Component Specifications initiated.": "ex:QualityAttribute_clinical_primary_com_828f51bd",
  "QualityAttribute:Protein:1:Complete Complexity Assessment Form with team.  Complete complexity assessment decision. (For non-combination products.\u00a0 HF SME owns Complexity Assessment Form and will walk team through the form to assess early the complexity of a clinical product presentation.\u00a0 Complexity assessment decision will be based on reviewing results of Complexity Assessment Form with cross-functional team, including CMCRA.\u00a0 This deliverable is applicable to drug-only products and those drug products intended to be delivered in clinical studies using device components, regardless of whether those components will eventually be commercialized.\u00a0 This form will be revisited at later Stage Gates to assess any changes to clinical presentation or to commercial product presentation)": "ex:QualityAttribute_complete_complexity_856a7035",
  "QualityAttribute:Protein:1:Complete review of IPSC (or external partner) data from the molecule ensure risks are identified and mitigation plans developed": "ex:QualityAttribute_complete_review_of_i_22bd8cdb",
  "QualityAttribute:Protein:1:Confirm that a Formulation lock and presentation/fill volume is in place before the GLP-Tox / Phase 1 batches are produced (to enable appropriate Early Reference Material coverage, enable Analytical Method Development and enable Cleaning Validation).": "ex:QualityAttribute_confirm_that_a_formu_d2463976",
  "QualityAttribute:Protein:1:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_053120d7",
  "QualityAttribute:Protein:1:Define CRITICAL QUESTIONS in Risk Register based on information available in the initial TPP, criticality analysis and molecule properties from Discovery, Lead Selection Alignment Meeting (LSAM) or external partner (L&A). Gaps in knowledge of mechanism of action or mechanism of toxicity could be considered for critical questions. Note when CQAs are linked to gaps in knowledge of Mechanism of Action or Mechanism of Toxicity; as gaps are closed by TA and/or Biotech CoE, method development can begin.": "ex:QualityAttribute_define_critical_ques_77911354",
  "QualityAttribute:Protein:1:Define Tox and clinical supply strategy and DPDS R&R (as some times DPDS does not supply) including comparability strategy to Phase 1 GMP (if required). Ensure supply plan is developed to meet tox. and P1 needs in E2E meeting.": "ex:QualityAttribute_define_tox_and_clini_6b8d2c7e",
  "QualityAttribute:Protein:1:Define the strategy for placebo production (e.g., product-specific?). Define which attributes need to be blinded.": "ex:QualityAttribute_define_the_strategy_79fa283b",
  "QualityAttribute:Protein:1:Develop CMC Risk Register.": "ex:QualityAttribute_develop_cmc_risk_reg_b2c11b37",
  "QualityAttribute:Protein:1:Device options for tox, phase1/2a, if applicable [Pack & Dev]": "ex:QualityAttribute_device_options_for_t_24555ab2",
  "QualityAttribute:Protein:1:EHS Requirement:  Develop default SDS, Determine the Risk Group (RG) and appropriate Biosafety Level (BSL) category for upstream and downstream process": "ex:QualityAttribute_ehs_requirement_deve_36857de9",
  "QualityAttribute:Protein:1:EHS Requirement: Supplier & Contractor assessment (evaluate if needed)": "ex:QualityAttribute_ehs_requirement_supp_8964c6b1",
  "QualityAttribute:Protein:1:Engage with API/DPD&D/Cell Banking/CMO to support material selection strategy for the build of Ph1/2a Bill of Materials (BOM). Define raw material control strategy for new and new use raw materials used in API (cell banking, upstream, downstream) and DP processes.": "ex:QualityAttribute_engage_with_api_dpd_c1837ea9",
  "QualityAttribute:Protein:1:Ensure Tox & Ph1 mfg. lots that have been scheduled with supplies allocated continue to meet projected Tox & Ph1 CDT approved demand in E2E meeting.": "ex:QualityAttribute_ensure_tox_ph1_mfg_l_b4362bf7",
  "QualityAttribute:Protein:1:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_e0b2ac30",
  "QualityAttribute:Protein:1:Ensure raw material compendial compliance (e.g., USP-NF, Ph. Eur., JP, ChP) as applicable to meet IND/IMPD control of raw materials.": "ex:QualityAttribute_ensure_raw_material_712dbd32",
  "QualityAttribute:Protein:1:Ensure that theoretical Absorptivity Constant Calculation Report is completed (including outsourced programs), and its value has been communicated to other functions.": "ex:QualityAttribute_ensure_that_theoreti_c9068897",
  "QualityAttribute:Protein:1:Ensure that theoretical Absorptivity Constant Calculation Report is completed by CEAS Analytical (including outsourced program), and its value has been communicated to other functions.": "ex:QualityAttribute_ensure_that_theoreti_5d0b6c92",
  "QualityAttribute:Protein:1:Establish preliminary CMC TPP which then populates the QTPP worksheet.  Ensure that initial/Early development CMC-TPP created & approved by CMC Council, GSM, TA. Completing the TPP fields populates the QTPP.": "ex:QualityAttribute_establish_preliminar_8eee79d1",
  "QualityAttribute:Protein:1:Evaluate and identify risks regarding the ability to meet commercial TPP requirements.": "ex:QualityAttribute_evaluate_and_identif_b1da7c56",
  "QualityAttribute:Protein:1:Evaluate molecule fit to AD platform methods, identify non-platform needs and add to risk register. Request information on new excipients from DPD&D to start method development": "ex:QualityAttribute_evaluate_molecule_fi_0394d848",
  "QualityAttribute:Protein:1:Evaluate stability and dosage prep/compatibility requirements versus the early development TPP and identify risks and mitigations. Ensure AD stability strategy aligns with recommendations": "ex:QualityAttribute_evaluate_stability_a_d93b9f8d",
  "QualityAttribute:Protein:1:Evaluation of platform approach for early phase container closure selection per TV-TRG-08576_x000D__x000D_": "ex:QualityAttribute_evaluation_of_platfo_893bcd41",
  "QualityAttribute:Protein:1:IDP number for project created and V6 profile activated.": "ex:QualityAttribute_idp_number_for_proje_4272ba95",
  "QualityAttribute:Protein:1:IPSC (Intrinsic Properties & Structural Characterization) report/slide deck from J-Bio reviewed.": "ex:QualityAttribute_ipsc_intrinsic_prope_40112aee",
  "QualityAttribute:Protein:1:Passive shipping systems qualified, if applicable.": "ex:QualityAttribute_passive_shipping_sys_c658c0d1",
  "QualityAttribute:Protein:1:Patent and Publication Strategy:  Summarize potential unique aspects of the process that could lead to publications and/or patents.": "ex:QualityAttribute_patent_and_publicati_7a9f6928",
  "QualityAttribute:Protein:1:Perform formulation screening of final NME candidate to identify risks and mitigations.": "ex:QualityAttribute_perform_formulation_85b6622f",
  "QualityAttribute:Protein:1:Ph1 CMC project team kick-off.": "ex:QualityAttribute_ph1_cmc_project_team_ca4ec2fe",
  "QualityAttribute:Protein:1:Ph3 manufacturing/commercial cell line selected.  If no, then document in Risk Register that switch may be required": "ex:QualityAttribute_ph3_manufacturing_co_6955acc8",
  "QualityAttribute:Protein:1:Project plan/KEM created in Planning System.": "ex:QualityAttribute_project_plan_kem_cre_23e7d7aa",
  "QualityAttribute:Protein:1:Provide early supply chain input as needed (Early COGS estimates - based on Pharmaceutical Valuation Guideline (PVG), capacity analysis, sourcing options).": "ex:QualityAttribute_provide_early_supply_a543a342",
  "QualityAttribute:Protein:1:Quality agreement at all sites (external and internal) initiated (if applicable).": "ex:QualityAttribute_quality_agreement_at_f4317fd1",
  "QualityAttribute:Protein:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) -  Device Quality Agreement (Supplier/Manufacturer) [If applicable]": "ex:QualityAttribute_readiness_for_the_co_634f1805",
  "QualityAttribute:Protein:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) - Device Quality Agreement (Device component, device itself and Purchasing Control/ for Combo    Products)": "ex:QualityAttribute_readiness_for_the_co_3f76095a",
  "QualityAttribute:Protein:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) - Device Testing Quality Agreement (Lab to Lab)": "ex:QualityAttribute_readiness_for_the_co_3ace43f9",
  "QualityAttribute:Protein:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) - Spec for Immediate(Primary) Container Packaging Materials (i.e. Syringe, and Vial w/stopper)": "ex:QualityAttribute_readiness_for_the_co_5a6dd563",
  "QualityAttribute:Protein:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) - Supplier and Contractor Audit [If applicable]": "ex:QualityAttribute_readiness_for_the_co_45b16461",
  "QualityAttribute:Protein:1:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) - Third Party  (Design Partner) Design Control Audit Report (If Applicable)": "ex:QualityAttribute_readiness_for_the_co_86c846fe",
  "QualityAttribute:Protein:1:Review SG1 CMC-TPP, identify gaps and risks for analytical control strategy": "ex:QualityAttribute_review_sg1_cmc_tpp_i_d0ea7e49",
  "QualityAttribute:Protein:1:Review the polysorbate control strategy  critical questions and identify any risks for FIH  and mitigation plans.": "ex:QualityAttribute_review_the_polysorba_1e549ce5",
  "QualityAttribute:Protein:1:Review the polysorbate control strategy critical questions and identify any risks for FIH and mitigation plans.": "ex:QualityAttribute_review_the_polysorba_33f85b1a",
  "QualityAttribute:Protein:1:Secure Phase 1 GMP sourcing decision for API and DP from sourcing committee": "ex:QualityAttribute_secure_phase_1_gmp_s_d6de0260",
  "QualityAttribute:Protein:1:Set up End-to-end planning and meeting, including sourcing/capacity assessment and risks": "ex:QualityAttribute_set_up_end_to_end_pl_d4f1fbd9",
  "QualityAttribute:Protein:1:Site Readiness and GMP status confirmed (as applicable).": "ex:QualityAttribute_site_readiness_and_g_96412689",
  "QualityAttribute:Protein:1:Stage 1  Level 1 and CMC team presentations completed/reviewed.": "ex:QualityAttribute_stage_1_level_1_and_aef05583",
  "QualityAttribute:Protein:1:Supplier Audits performed (if applicable).": "ex:QualityAttribute_supplier_audits_perf_96940b31",
  "QualityAttribute:Protein:1:Supplier/external lab qualification initiated (if applicable)": "ex:QualityAttribute_supplier_external_la_a9cf58fb",
  "QualityAttribute:Protein:2:(Joint with JSC VCM) Initiate conversations and paper assessment of what process intensification technologies may be appropriate to meet commercial , Cost of Goods ( COGS) and Manufacturing Capacity needs of the product for inclusion in Ph2b/3 plans": "ex:QualityAttribute_joint_with_jsc_vcm_i_0b162618",
  "QualityAttribute:Protein:2:(Joint with JSC VCT) Best Process at Launch (BPAL) assessment initiated for commercial process.  Apply BPAL worksheet to initiate conversations and paper assessment of what process intensification technologies may be appropriate to meet commercial, JSC VCT estimated Cost of Goods (COGS) and Manufacturing Capacity needs of the product for inclusion in Ph2b/Ph3 development plans (preference is to include technology as standard, and justify removal as needed)": "ex:QualityAttribute_joint_with_jsc_vct_b_f571b16f",
  "QualityAttribute:Protein:2:API & DP: Ph1-2a  manufacturing sites sourced/locked": "ex:QualityAttribute_api_dp_ph1_2a_manufa_f67b02a9",
  "QualityAttribute:Protein:2:API -  Assessment of (a) long term raw materials, (b) equipment & facility requirements completed (identify long-lead items that could affect sourcing decisions in SG 5)": "ex:QualityAttribute_api_assessment_of_a_0b8e6f20",
  "QualityAttribute:Protein:2:Approve lead stability batch specifications.": "ex:QualityAttribute_approve_lead_stabili_915cf4ca",
  "QualityAttribute:Protein:2:Assay Control filled and qualified for use.": "ex:QualityAttribute_assay_control_filled_6202c6c8",
  "QualityAttribute:Protein:2:Assess the need to kick off VCT in SG 2 or SG 3 for Fast to Market / Accelerated programs (ATV, Breakthrough, In-License)": "ex:QualityAttribute_assess_the_need_to_k_f0f90757",
  "QualityAttribute:Protein:2:Assessment of assay qualification strategy (New method qualification or limited qualification for platforms methods).": "ex:QualityAttribute_assessment_of_assay_74931c11",
  "QualityAttribute:Protein:2:CPDP Portfolio Management & Concept Feasibility Stage": "ex:QualityAttribute_cpdp_portfolio_manag_bd5dd329",
  "QualityAttribute:Protein:2:Cell Bank history source documents approved (Cell Banking group)": "ex:QualityAttribute_cell_bank_history_so_5d3ce099",
  "QualityAttribute:Protein:2:Cell line history source documents approved (CDS group)": "ex:QualityAttribute_cell_line_history_so_151d683d",
  "QualityAttribute:Protein:2:Clinical Design History File (per TV-SOP-21504) for the investigation combination product being used in Phase 0/1/2 if applicable.": "ex:QualityAttribute_clinical_design_hist_4fc0fd66",
  "QualityAttribute:Protein:2:Complete Complexity Assessment Form with team.  Complete complexity assessment decision. (See Stage 1 comment regarding Complexity Assessment Form)": "ex:QualityAttribute_complete_complexity_a5cc3f83",
  "QualityAttribute:Protein:2:Complete a raw materials and polymeric product contact materials selection, qualification and release testing gap assessment and mitigation plan per the site BOM": "ex:QualityAttribute_complete_a_raw_mater_56201f5f",
  "QualityAttribute:Protein:2:Complete qualification and/or method transfer for IPC, clinical release & clinical Stability (AD Cork or applicable JSC labs).": "ex:QualityAttribute_complete_qualificati_65b764a4",
  "QualityAttribute:Protein:2:Complete \u00a0Probability of Delamination Occurrence (PDO) assessment": "ex:QualityAttribute_complete_probability_6728e186",
  "QualityAttribute:Protein:2:Confirm sufficient DS and DP supply for clinical (tox and Ph1/2) and non-clinical demands and scheduling as part of the E2E meeting including sourcing/capacity assessment and risks.": "ex:QualityAttribute_confirm_sufficient_d_5f169f80",
  "QualityAttribute:Protein:2:Confirm that analyses and small-scale process study results are available and align with scale-up plans (related to sourcing decisions / volume of future demand).": "ex:QualityAttribute_confirm_that_analyse_9c5cd38c",
  "QualityAttribute:Protein:2:Confirm that analyses and small-scale study results are available and align with scale-up plans (related to sourcing decisions / volume of future demand) with API team.": "ex:QualityAttribute_confirm_that_analyse_d07fe215",
  "QualityAttribute:Protein:2:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_957a4a96",
  "QualityAttribute:Protein:2:DPD PF2P activities completed at Ph 1 DP manufacturing sites - as applicable": "ex:QualityAttribute_dpd_pf2p_activities_6c61ac7e",
  "QualityAttribute:Protein:2:Define sample retention strategy for in-process intermediates, DS and DP, for clinical campaigns.": "ex:QualityAttribute_define_sample_retent_e808fc8f",
  "QualityAttribute:Protein:2:Developed scenarios in support of strategic planning (as required)": "ex:QualityAttribute_developed_scenarios_14ce975c",
  "QualityAttribute:Protein:2:Development Batch stability protocol approved and study initiated (ensure that sample test requirements are communicated to Analytical)": "ex:QualityAttribute_development_batch_st_61088e63",
  "QualityAttribute:Protein:2:Diluent compatibility completed and GLP Tox \"Conditions of Use\" supportive studies completed and communicated to NCS.": "ex:QualityAttribute_diluent_compatibilit_e5a6bd50",
  "QualityAttribute:Protein:2:Downstream PF2P activities completed at Tox/Ph1 manufacturing site. Risks/mitigation plans identified.": "ex:QualityAttribute_downstream_pf2p_acti_6e8c453d",
  "QualityAttribute:Protein:2:Draft IPPI, compatibility study and dose verification study plans reviewed by line functions, CMC teams, and DPAT. Evaluate stability and dosage prep/compatibility results versus the early development TPP prescribed formulation and identify risks and mitigations.": "ex:QualityAttribute_draft_ippi_compatibi_8ff21c76",
  "QualityAttribute:Protein:2:EHS Requirement: Determine the biosafety risk group for upstream process (Occupational Toxicology); Determine API PBOEL HHC for downstream process (Occupational Toxicology); ERA categorical exclusion  (USA IND)": "ex:QualityAttribute_ehs_requirement_dete_9ecae1af",
  "QualityAttribute:Protein:2:EHS Requirement: Integrate DGTC reqs. Into Ph1 1st, 2nd, 3rd packaging solution": "ex:QualityAttribute_ehs_requirement_inte_5b692de9",
  "QualityAttribute:Protein:2:EHS requirements: Create SDS for API, Confirm PBOEL HHC 2": "ex:QualityAttribute_ehs_requirements_cre_d6a761e1",
  "QualityAttribute:Protein:2:Ensure ED Criticality Report is approved prior to release of clinical supplies.": "ex:QualityAttribute_ensure_ed_criticalit_a186b26a",
  "QualityAttribute:Protein:2:Ensure methods are qualified for Tox CoT (ID & A280, SEC methods).  Complete transfer of protein content method to Tox sites (CRO) for dose verification (If applicable).": "ex:QualityAttribute_ensure_methods_are_q_a5e73c7e",
  "QualityAttribute:Protein:2:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_d3e8b5c9",
  "QualityAttribute:Protein:2:Execute selection, qualification and release testing gap mitigation for DS (including MCB, WCB) and DP Raw Materials and Product Contact Polymeric Materials for Phase 1 manufacture including specifications and analytical methods.": "ex:QualityAttribute_execute_selection_qu_ff01759f",
  "QualityAttribute:Protein:2:Experimental absorptivity constant determination completed for all non-platform proteins or products acquired by L&A.": "ex:QualityAttribute_experimental_absorpt_284855bf",
  "QualityAttribute:Protein:2:Generate & Approve Interim DP Shelf-life memo": "ex:QualityAttribute_generate_approve_int_a26bb538",
  "QualityAttribute:Protein:2:IDE Stand-Alone Devices (Prototype Delivery System to Support Phase 0/1/2a - TV-SOP-21504) if applicable.": "ex:QualityAttribute_ide_stand_alone_devi_6ace61a5",
  "QualityAttribute:Protein:2:Identify/Assign TLIs to the program": "ex:QualityAttribute_identify_assign_tlis_3f86de87",
  "QualityAttribute:Protein:2:In collaboration with DPD&D, GLP Tox Certificate of Testing (CoT) approved for release and end of use.": "ex:QualityAttribute_in_collaboration_wit_51596092",
  "QualityAttribute:Protein:2:In-process & cleaning methods development & qualification report for Ph1 DS & DP sites completed": "ex:QualityAttribute_in_process_cleaning_8154c618",
  "QualityAttribute:Protein:2:Kick off Drug Product Preparation and Administration Team (DPAT).": "ex:QualityAttribute_kick_off_drug_produc_54d2415c",
  "QualityAttribute:Protein:2:MCB and two WCB CoAs generated (Cell Banking group)": "ex:QualityAttribute_mcb_and_two_wcb_coas_2e5bc252",
  "QualityAttribute:Protein:2:Mycoplasma and AVA qualification completed for Tox & Ph1 Bioreactor harvest material": "ex:QualityAttribute_mycoplasma_and_ava_q_b3f9f54d",
  "QualityAttribute:Protein:2:Ph1 Container Closure System Development Checklist completed.": "ex:QualityAttribute_ph1_container_closur_50994967",
  "QualityAttribute:Protein:2:Ph1 DP TT memo (or DPFD) for DP mfg. site approved.": "ex:QualityAttribute_ph1_dp_tt_memo_or_dp_9e1f9dcd",
  "QualityAttribute:Protein:2:Ph1 Primary Component Specifications defined.": "ex:QualityAttribute_ph1_primary_componen_d345fc3b",
  "QualityAttribute:Protein:2:Ph1 VIN intermediate, DS (JOS), DP (JOS), RM specification documents approved.": "ex:QualityAttribute_ph1_vin_intermediate_80012b8c",
  "QualityAttribute:Protein:2:Ph1 intermediate, VIN (if frozen intermediate), DS and DP Stability Protocols completed.": "ex:QualityAttribute_ph1_intermediate_vin_2f1a6c5f",
  "QualityAttribute:Protein:2:Ph1 mfg. lots scheduled": "ex:QualityAttribute_ph1_mfg_lots_schedul_af05087c",
  "QualityAttribute:Protein:2:Ph1-2a DS&DP mfg. equipment qualified and site(s) ready.": "ex:QualityAttribute_ph1_2a_ds_dp_mfg_equ_6a0e010f",
  "QualityAttribute:Protein:2:Ph1/2 FTE and OOP demand estimates completed and updated in V6": "ex:QualityAttribute_ph1_2_fte_and_oop_de_2ab4207f",
  "QualityAttribute:Protein:2:Preliminary Ph2b/Ph3/commercial manufacturing technology fit and manufacturing network assessment completed (API & DP, internal vs. external manufacturing)\n * Is technology in accordance to preferred processes (e.g., platforms) for API and DP?\n * Identify gaps in site fit or in available capacity early to take necessary remedial action (e.g., capital investment).\n * Evaluation of advanced manufacturing options.  Include in development plan with link to sourcing and network strategy.": "ex:QualityAttribute_preliminary_ph2b_ph3_6018e43a",
  "QualityAttribute:Protein:2:Purchasing Control - Device Quality Agreement (Device component, device itself and Purchasing Control/ for Combo    Products)": "ex:QualityAttribute_purchasing_control_d_b1c09b55",
  "QualityAttribute:Protein:2:Purchasing Control - Device Quality Agreement (Manufacturing)": "ex:QualityAttribute_purchasing_control_d_c83f0c8a",
  "QualityAttribute:Protein:2:Purchasing Control - Device Testing Quality Agreement (Lab to Lab)": "ex:QualityAttribute_purchasing_control_d_b2e780d8",
  "QualityAttribute:Protein:2:Purchasing Control - Spec for Immediate(Primary) Container Packaging Materials (i.e. Syringe, and Vial w/stopper)": "ex:QualityAttribute_purchasing_control_s_8f16cf37",
  "QualityAttribute:Protein:2:Purchasing Control - Supplier and Contractor Audit": "ex:QualityAttribute_purchasing_control_s_2004947b",
  "QualityAttribute:Protein:2:Purchasing Control - Third Party Design Control Audit Report (If Applicable)": "ex:QualityAttribute_purchasing_control_t_99462ac2",
  "QualityAttribute:Protein:2:Quality agreement (external and internal )approved (if required)": "ex:QualityAttribute_quality_agreement_ex_adecef05",
  "QualityAttribute:Protein:2:Raw Materials inventory assessed and procurement risk mitigated for  Ph1-2a DS&DP manufacturing": "ex:QualityAttribute_raw_materials_invent_707b0f86",
  "QualityAttribute:Protein:2:Receive and review PF2P result and assessment on Ph1 manufacturing facility.": "ex:QualityAttribute_receive_and_review_p_ddbea0a7",
  "QualityAttribute:Protein:2:Receive estimated productivity and yield info from API (From Stage Gate 1)": "ex:QualityAttribute_receive_estimated_pr_45bf3c8a",
  "QualityAttribute:Protein:2:Request Risk assessment of process-related impurity levels versus acceptable toxicological thresholds from API etc (include nitrosamines as applicable).": "ex:QualityAttribute_request_risk_assessm_4af42a1b",
  "QualityAttribute:Protein:2:Review current plans and data to determine if development buy-ups are needed.": "ex:QualityAttribute_review_current_plans_c9d24b4d",
  "QualityAttribute:Protein:2:Review testing protocol and execute \"Conditions of Use\" study (protocol from DPD&D) to support GLP Tox study.": "ex:QualityAttribute_review_testing_proto_5dcaab53",
  "QualityAttribute:Protein:2:Review/Approve DPFD and/or site BOM.": "ex:QualityAttribute_review_approve_dpfd_16ec2f32",
  "QualityAttribute:Protein:2:Risk assessment of process-related impurity levels versus acceptable toxicological thresholds completed prior to release of first clinical batch and shared with AD": "ex:QualityAttribute_risk_assessment_of_p_8e7f3489",
  "QualityAttribute:Protein:2:Stage 2 Level 1 and CMC team presentations completed/reviewed.": "ex:QualityAttribute_stage_2_level_1_and_2cbe8b52",
  "QualityAttribute:Protein:2:Submit Product Quality Complaint New Product Set Up Form for clinical trials": "ex:QualityAttribute_submit_product_quali_db14a16e",
  "QualityAttribute:Protein:2:Summarize at high level any early development IP discussions. Discuss any novel original ideas and innovations and progress made toward completing a patent application.": "ex:QualityAttribute_summarize_at_high_le_ef8073ba",
  "QualityAttribute:Protein:2:Suppler/external lab qualification performed (if applicable)": "ex:QualityAttribute_suppler_external_lab_f680f2ce",
  "QualityAttribute:Protein:2:Support CMC TL and CMC team to meet all deliverables through planning coordination": "ex:QualityAttribute_support_cmc_tl_and_c_622257fc",
  "QualityAttribute:Protein:2:Tox and Lead stability fills planned/executed in DPD&D.": "ex:QualityAttribute_tox_and_lead_stabili_8e555e2c",
  "QualityAttribute:Protein:2:Tox/Ph1 Upstream TT to DS mfg. site documents approved (e.g., DPFD).": "ex:QualityAttribute_tox_ph1_upstream_tt_7a624eba",
  "QualityAttribute:Protein:2:Tox/Ph1 formulation composition and DP presentation defined along with accompanying raw materials and primary packaging.": "ex:QualityAttribute_tox_ph1_formulation_5566036c",
  "QualityAttribute:Protein:2:Tox/Ph1/2 Clinical supply plan prepared and aligned with clinical demand forecast and enrollment projection": "ex:QualityAttribute_tox_ph1_2_clinical_s_b5ff0cf2",
  "QualityAttribute:Protein:2:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_09781785",
  "QualityAttribute:Protein:2:Upstream Process Fit to Plant (PF2P) activities completed at Tox/Ph 1 manufacturing site. Risks/mitigation plans identified.": "ex:QualityAttribute_upstream_process_fit_dc04ed78",
  "QualityAttribute:Protein:3:Analytical CMC sections of IND/IMPD submission are verified and completed.": "ex:QualityAttribute_analytical_cmc_secti_3c709067",
  "QualityAttribute:Protein:3:Author/Review IND/IMPD Control of Materials": "ex:QualityAttribute_author_review_ind_im_b8712508",
  "QualityAttribute:Protein:3:CMC Module 3 completed for IND/IMPD Submission.": "ex:QualityAttribute_cmc_module_3_complet_fb2e42c9",
  "QualityAttribute:Protein:3:CMC RA input provided to GRT and incorporated in FIH Submission plan.": "ex:QualityAttribute_cmc_ra_input_provide_ba650ff8",
  "QualityAttribute:Protein:3:CPDP Portfolio Management & Concept Feasibility Stage": "ex:QualityAttribute_cpdp_portfolio_manag_526204c8",
  "QualityAttribute:Protein:3:Clinical Design History File (per TV-SOP-21504) for the investigation combination product being used in Phase 0/1/2 if applicable.": "ex:QualityAttribute_clinical_design_hist_0fc78c6d",
  "QualityAttribute:Protein:3:Complete initial Product Risk Assessment (PRA) (Only sections related to hazard analysis, and initial risk evaluation are required)": "ex:QualityAttribute_complete_initial_pro_8be4a814",
  "QualityAttribute:Protein:3:Complete initial Product Risk Management Plan/Report (PRM) (including risk plan and PRA summary)": "ex:QualityAttribute_complete_initial_pro_34435c36",
  "QualityAttribute:Protein:3:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create uFMEA for clinical product, if needed. (For non-combination products.\u00a0 See Stage 1 comment regarding Complexity Assessment Form.\u00a0 Roles and responsibilities for uFMEA of drug-only product may be DPD&D as appropriate)": "ex:QualityAttribute_complete_or_revisit_77b4d22a",
  "QualityAttribute:Protein:3:Complete selection, qualification and release testing specifications/methods gap mitigations for raw materials for API and DP for Phase 1/2a manufacture.": "ex:QualityAttribute_complete_selection_q_57db1abc",
  "QualityAttribute:Protein:3:Country Specific Requirements confirmed for CTA filing readiness": "ex:QualityAttribute_country_specific_req_4f02bf43",
  "QualityAttribute:Protein:3:DPD CMC sections of IND/IMPD submission are verified and completed.": "ex:QualityAttribute_dpd_cmc_sections_of_b2277fa9",
  "QualityAttribute:Protein:3:EHS requirements: Develop product specific SDS for DP": "ex:QualityAttribute_ehs_requirements_dev_7d4deabe",
  "QualityAttribute:Protein:3:Engineering assessment for all manufacturing sites approved (with approved CAPA plan if required)": "ex:QualityAttribute_engineering_assessme_93fad33f",
  "QualityAttribute:Protein:3:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_02b671e8",
  "QualityAttribute:Protein:3:Evaluate large-scale (lead stability batch and Phase 1 GMP) process efficiency data and communicated to JSC VCL (to update COGS, sourcing assumptions).": "ex:QualityAttribute_evaluate_large_scale_0e8435aa",
  "QualityAttribute:Protein:3:FIH committee meeting minutes (digitally signed) for QP release of clinical supplies.": "ex:QualityAttribute_fih_committee_meetin_f88f18ad",
  "QualityAttribute:Protein:3:Full E2E supply plan in place in alignment with clinical development plan & enrollment projections, as well as non-clinical demand including tox.": "ex:QualityAttribute_full_e2e_supply_plan_2ada33d4",
  "QualityAttribute:Protein:3:IDE Stand-Alone Devices (Prototype Delivery System to Support Phase 0/1/2a TV-SOP-21504) if applicable.": "ex:QualityAttribute_ide_stand_alone_devi_b50ec7b3",
  "QualityAttribute:Protein:3:IND/IMPD review (Manufacturing and Packaging locations, stability plan) and delivery of submission labels as needed.": "ex:QualityAttribute_ind_impd_review_manu_7538052a",
  "QualityAttribute:Protein:3:If HF assessment form completed at SG2 concludes HF studies may be needed, complete uFMEA for clinical product and preliminary usability assessments.": "ex:QualityAttribute_if_hf_assessment_for_2ee91c1d",
  "QualityAttribute:Protein:3:Initiate discussion with team on Patent and Publication Strategy.  Summarize potential unique aspects of the process that could lead to publications and/or patents in core team meeting minutes.": "ex:QualityAttribute_initiate_discussion_3c019174",
  "QualityAttribute:Protein:3:Issue DS and DP Laboratory CoA": "ex:QualityAttribute_issue_ds_and_dp_labo_e8d987df",
  "QualityAttribute:Protein:3:Kick-Off Customer Centered Design Process with the Customer Centered Design Integrator and Combo Device Team, inclusive of Customer Centered Design Workshop as needed.  Align on the Compound Overview & Timeline and prioritize deliverables. If this item remains, add to the JSC/VSL deliverables as well (co-ownership with JSC/VCL).": "ex:QualityAttribute_kick_off_customer_ce_ce0d427a",
  "QualityAttribute:Protein:3:Lead DPAT process to deliver an approved IPPI and training materials for Ph1 study.": "ex:QualityAttribute_lead_dpat_process_to_3b25661e",
  "QualityAttribute:Protein:3:Obtain large-scale (GLP-TOX and Phase 1 GMP). Process efficiency data must be evaluated with earlier data from API.": "ex:QualityAttribute_obtain_large_scale_g_9aa34112",
  "QualityAttribute:Protein:3:Participate in determining the strategy for Health Authority Meetings (US FDA and/or EU National/Scientific Advice) (if needed/applicable)": "ex:QualityAttribute_participate_in_deter_ae482018",
  "QualityAttribute:Protein:3:Ph 1/2 plan updated and reviewed with CMC Team": "ex:QualityAttribute_ph_1_2_plan_updated_afa912c1",
  "QualityAttribute:Protein:3:Ph1 & 2a DS and DP supply manufactured": "ex:QualityAttribute_ph1_2a_ds_and_dp_sup_46675368",
  "QualityAttribute:Protein:3:Ph1 API released": "ex:QualityAttribute_ph1_api_released_45cc7ec4",
  "QualityAttribute:Protein:3:Ph1 CMC dossier approved for submission to HA for FIH (Comment: SG#3 often occur BEFORE the first filing, the Phase 1 CMC dossier may still in progress at the time of SG#3 review)": "ex:QualityAttribute_ph1_cmc_dossier_appr_3abfaf2b",
  "QualityAttribute:Protein:3:Ph1 CTA submission to HA (Not applicable if SG# occurs prior to CTA submission or approval)": "ex:QualityAttribute_ph1_cta_submission_t_0a771b66",
  "QualityAttribute:Protein:3:Ph1 DP mfg. complete & early-stage product quality attributes and yield targets achieved.": "ex:QualityAttribute_ph1_dp_mfg_complete_96a54599",
  "QualityAttribute:Protein:3:Ph1 P&L'd drug product released": "ex:QualityAttribute_ph1_p_l_d_drug_produ_bff89867",
  "QualityAttribute:Protein:3:Ph1 Upstream and Downstream mfg. complete & early-stage product quality attributes and yield targets achieved.": "ex:QualityAttribute_ph1_upstream_and_dow_bff6bf83",
  "QualityAttribute:Protein:3:Ph1 intermediate (if applicable), DS (if applicable) and DP shelf life memos approved (temperature excursion guideline included, as applicable).": "ex:QualityAttribute_ph1_intermediate_if_c264471c",
  "QualityAttribute:Protein:3:Ph1 pharmacy manual reports approved, supportive studies and risk assessments completed (if applicable). Evaluate stability and dosage prep/compatibility requirements versus the early development TPP prescribed formulation and identify risks and mitigations.": "ex:QualityAttribute_ph1_pharmacy_manual_2e28ebd2",
  "QualityAttribute:Protein:3:Ph1 supply delivered to clinical sites.": "ex:QualityAttribute_ph1_supply_delivered_b13e8f86",
  "QualityAttribute:Protein:3:Ph1 vs. Ph2 comparability plan approved by BCC (if required)": "ex:QualityAttribute_ph1_vs_ph2_comparabi_94181e5b",
  "QualityAttribute:Protein:3:Ph1/2 FTE and OOP demand estimates completed and updated in V6": "ex:QualityAttribute_ph1_2_fte_and_oop_de_9f1ec49f",
  "QualityAttribute:Protein:3:Ph2 Upstream and Downstream process optimization studies initiated (if required).": "ex:QualityAttribute_ph2_upstream_and_dow_06b7541d",
  "QualityAttribute:Protein:3:Ph2 mfg. lots scheduled and supply allocated to meet projected Ph2 CDT approved clinical & tox demand (for accelerated programs).": "ex:QualityAttribute_ph2_mfg_lots_schedul_4ce5ef5f",
  "QualityAttribute:Protein:3:Phase 1 Pharmacy manual testing completed (compatibility, in-use stability, & accuracy if needed).": "ex:QualityAttribute_phase_1_pharmacy_man_9cbe0c99",
  "QualityAttribute:Protein:3:Phase 1 packaged supplies available to ship to clinical trials.": "ex:QualityAttribute_phase_1_packaged_sup_7b980668",
  "QualityAttribute:Protein:3:Pre-IND/CTA Briefing book package prepared": "ex:QualityAttribute_pre_ind_cta_briefing_4f080204",
  "QualityAttribute:Protein:3:Preliminary commercial COGs assessment complete and to update sourcing assumptions": "ex:QualityAttribute_preliminary_commerci_ca73821d",
  "QualityAttribute:Protein:3:Provide a high level summary of any early development IP discussions. Discuss any novel original ideas and innovations and progress made toward completing a patent application.": "ex:QualityAttribute_provide_a_high_level_705972a9",
  "QualityAttribute:Protein:3:Purchasing Control (CPDP RACI)": "ex:QualityAttribute_purchasing_control_c_dfb0f7fb",
  "QualityAttribute:Protein:3:QA review of Ph1 CMC dossier completed": "ex:QualityAttribute_qa_review_of_ph1_cmc_57a0ca19",
  "QualityAttribute:Protein:3:QP approval of Ph1 supplies achieved": "ex:QualityAttribute_qp_approval_of_ph1_s_09efba2f",
  "QualityAttribute:Protein:3:Receive DPD PF2P results and assessment.": "ex:QualityAttribute_receive_dpd_pf2p_res_cdf3a3a8",
  "QualityAttribute:Protein:3:Review current plans and data to determine if development buy-ups are needed.": "ex:QualityAttribute_review_current_plans_8fcf5bd3",
  "QualityAttribute:Protein:3:Stage 3 Level 1 and CMC team presentations completed/reviewed.": "ex:QualityAttribute_stage_3_level_1_and_71e7c894",
  "QualityAttribute:Protein:3:Subsequent Ph 1 DP (i.e. dose escalation) and Ph2 formulation/drug product optimization studies initiated (if required).": "ex:QualityAttribute_subsequent_ph_1_dp_i_c3d6c117",
  "QualityAttribute:Protein:3:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_a9593e1e",
  "QualityAttribute:Protein:3:Tox/Ph1 comparability study report completed (if needed).": "ex:QualityAttribute_tox_ph1_comparabilit_db02c4d7",
  "QualityAttribute:Protein:3:Tox/Ph1 formulation history report drafted.": "ex:QualityAttribute_tox_ph1_formulation_58adeefb",
  "QualityAttribute:Protein:3:Update CMC Risk Register": "ex:QualityAttribute_update_cmc_risk_regi_7aab8a1a",
  "QualityAttribute:Protein:3:Update the polysorbate control strategy critical questions and identify additional risks (if applicable).": "ex:QualityAttribute_update_the_polysorba_7f45d19e",
  "QualityAttribute:Protein:3:Upstream and Downstream CMC sections of IND/IMPD submission are verified and approved by the functional area owners.": "ex:QualityAttribute_upstream_and_downstr_135a6978",
  "QualityAttribute:Protein:3:Viral clearance studies are complete and reports approved.": "ex:QualityAttribute_viral_clearance_stud_7583d4bb",
  "QualityAttribute:Protein:4:(Joint with JSC VCT and CMC team) complete the Best Process at Launch (BPAL) assessment of what process intensification or other technologies are appropriate to meet commercial, Cost of Goods (COGS) and Manufacturing Capacity needs of the product  and include associated Ph2b/Ph3 development and sourcing plans (preference is to include technology as standard, and justify removal as needed).  The assessment and agreed strategy must be documented in the Level 1 slide deck.": "ex:QualityAttribute_joint_with_jsc_vct_a_8bf13a40",
  "QualityAttribute:Protein:4:(Joint with JSC VCT and CMC team) complete the Best Process at Launch (BPAL) assessment of what process technologies are appropriate to meet commercial, Cost of Goods (COGS) and Manufacturing Capacity needs of the product  and include associated Ph2b/Ph3 development and sourcing plans (preference is to include technology as standard, and justify removal as needed).  The assessment and agreed strategy must be documented in the Level 1 slide deck.": "ex:QualityAttribute_joint_with_jsc_vct_a_da1a9ed2",
  "QualityAttribute:Protein:4:Assess if nitrosamine risk factors are present in DP formulation and process (with Material Sciences and PC&D)": "ex:QualityAttribute_assess_if_nitrosamin_752838cf",
  "QualityAttribute:Protein:4:Assess the need to accelerate Stage 5 deliverables to meet pivotal clinical trial milestones (Ph2b/Ph3 FPI).": "ex:QualityAttribute_assess_the_need_to_a_e37988bc",
  "QualityAttribute:Protein:4:CMO Tech Transfer / Internal site engagement and on-boarding  for introduction of raw material controls (selection, qualification, release testing specifications and analytical methods) as soon as able based on site selection decision and legal/business requirements (as applicable) and include in business contracts (SOWs). Critical review of CMO material qualification, methods, specifications and change management practices for raw materials. Alignment of CMO to Janssen standards and expectations for overall material qualification and controls.": "ex:QualityAttribute_cmo_tech_transfer_in_7a039589",
  "QualityAttribute:Protein:4:CPDP Portfolio Management & Concept Feasibility Stage": "ex:QualityAttribute_cpdp_portfolio_manag_3bac436e",
  "QualityAttribute:Protein:4:Combination Product Feasibility Report": "ex:QualityAttribute_combination_product_18c76200",
  "QualityAttribute:Protein:4:Complete CMC development strategy/KEM, covering Stages 4-9 including assessment of gaps in structure/function knowledge. Ensure that gaps and mechanism of action/toxicity are closed or identify risks/mitigation plans.": "ex:QualityAttribute_complete_cmc_develop_a316724d",
  "QualityAttribute:Protein:4:Complete ED CQA Report": "ex:QualityAttribute_complete_ed_cqa_repo_cb08691e",
  "QualityAttribute:Protein:4:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for clinical product, as needed. (For non-combination products.\u00a0 See Comment in Stage 3)": "ex:QualityAttribute_complete_or_revisit_8a05184a",
  "QualityAttribute:Protein:4:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_6421bc60",
  "QualityAttribute:Protein:4:Continue discussion with team and legal on Patent and Publication Strategy.  Summarize potential unique aspects of the process that could lead to publications and/or patents in core team meeting minutes.": "ex:QualityAttribute_continue_discussion_b6800efd",
  "QualityAttribute:Protein:4:Customer Centered Design Assessment Document if applicable.": "ex:QualityAttribute_customer_centered_de_790c0500",
  "QualityAttribute:Protein:4:DPD PF2P activities completed at Ph2 DP manufacturing sites (if required).": "ex:QualityAttribute_dpd_pf2p_activities_6778da75",
  "QualityAttribute:Protein:4:Define and review integrated control strategy with the appropriate governance. Initiate assay development for any new attributes identified.": "ex:QualityAttribute_define_and_review_in_52e305e4",
  "QualityAttribute:Protein:4:Define the approach and review all available  information from forced-degradation / stability studies, including trending results, at appropriate governance. Items to consider include prior and platform knowledge, risk assessment, process DOE, hold time studies, process relevant degradation, and modeling data/ID of PTM \u201chot spots\u201d.": "ex:QualityAttribute_define_the_approach_504aa160",
  "QualityAttribute:Protein:4:Define the approach for acquiring S-F knowledge and review at appropriate governance.\u00a0The MoA/MoT gap list must be closed or the risks identified.": "ex:QualityAttribute_define_the_approach_d7d802b0",
  "QualityAttribute:Protein:4:Define the need and strategy for complex clinical study design projections (ie - comparators, placebo, double dummy, over encapsulation, etc.) if needed.  Define which attributes need to be blinded.": "ex:QualityAttribute_define_the_need_and_90f708e8",
  "QualityAttribute:Protein:4:Develop strategy for Phase 2 filing.": "ex:QualityAttribute_develop_strategy_for_7d4fa44c",
  "QualityAttribute:Protein:4:Downstream PF2P activities completed at Ph2 DS manufacturing sites (if required).": "ex:QualityAttribute_downstream_pf2p_acti_11a272af",
  "QualityAttribute:Protein:4:EHS Requirement: Integrate DGTC reqs. Into Ph2 1st, 2nd, 3rd packaging solution": "ex:QualityAttribute_ehs_requirement_inte_a9a87919",
  "QualityAttribute:Protein:4:Engage with API/DPD/Cell Banking/CMO to support material selection strategy for the build of Ph2b/3 Bill of Materials (BOM).": "ex:QualityAttribute_engage_with_api_dpd_dcf15e86",
  "QualityAttribute:Protein:4:Engage with Material Sciences (MS) on any potential off platform materials and selecting raw material suppliers, as needed.": "ex:QualityAttribute_engage_with_material_cb16ffc7",
  "QualityAttribute:Protein:4:Ensure Best Process at Launch (BPAL) meetings across functions/JSC to complete definition of Phase 3/commercial manufacturing strategy for all functions (preference is to include technology as standard, and justify removal as needed).": "ex:QualityAttribute_ensure_best_process_a3907635",
  "QualityAttribute:Protein:4:Ensure Customer Centered Design deliverables are completed for this stage. (CMCL Co-owner)": "ex:QualityAttribute_ensure_customer_cent_18cc6026",
  "QualityAttribute:Protein:4:Ensure Customer Centered Design deliverables are completed for this stage. (VCL co-owns this deliverable)": "ex:QualityAttribute_ensure_customer_cent_46368d4a",
  "QualityAttribute:Protein:4:Ensure Ph1 & 2 resupply batches manufactured and allocated to meet projected Ph1 & 2 CDT approved clinical demand (as required).": "ex:QualityAttribute_ensure_ph1_2_resuppl_b39c0540",
  "QualityAttribute:Protein:4:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_0cc763f6",
  "QualityAttribute:Protein:4:Ensure raw material compendial compliance (e.g., USP-NF, Ph. Eur., JP, ChP) as applicable to meet IND/IMPD control of raw materials.": "ex:QualityAttribute_ensure_raw_material_0d3bd8a5",
  "QualityAttribute:Protein:4:Evaluate current DP compared to RP2D to determine development strategy for Ph 2b/3": "ex:QualityAttribute_evaluate_current_dp_87c16ebf",
  "QualityAttribute:Protein:4:Full E2E supply plan in place in alignment with clinical development plan and enrollment projections as well as non-clinical demand up to Ph2a and including tox": "ex:QualityAttribute_full_e2e_supply_plan_4dd6b151",
  "QualityAttribute:Protein:4:In preparation for Phase 3,  initiate alignment on future file content and regulatory strategy.": "ex:QualityAttribute_in_preparation_for_p_2898bceb",
  "QualityAttribute:Protein:4:Initiate Ph2 drug product stability (if required).": "ex:QualityAttribute_initiate_ph2_drug_pr_370b1cde",
  "QualityAttribute:Protein:4:Lead team Review/Update Criticality Assessment as needed. Verify that the identified CQA's and their established ranges are supportive of the desired in-vivo situation.": "ex:QualityAttribute_lead_team_review_upd_fbb90a31",
  "QualityAttribute:Protein:4:Passive shipping systems qualified, if applicable.": "ex:QualityAttribute_passive_shipping_sys_756962cb",
  "QualityAttribute:Protein:4:Pediatric CMC Assessment (assess potential for pediatric formulation development) completed.": "ex:QualityAttribute_pediatric_cmc_assess_2808d0d9",
  "QualityAttribute:Protein:4:Perform pCMA analysis in collaboration with API and DPD": "ex:QualityAttribute_perform_pcma_analysi_4bc523b3",
  "QualityAttribute:Protein:4:Ph 2 Pharmacy Manual testing for DPD&D, if required.": "ex:QualityAttribute_ph_2_pharmacy_manual_e4f43b8d",
  "QualityAttribute:Protein:4:Ph1 & 2a DS and DP resupply manufactured according to the supply plan": "ex:QualityAttribute_ph1_2a_ds_and_dp_res_bd1722da",
  "QualityAttribute:Protein:4:Ph1 DP re-supply lots and/or Ph2 DP released.": "ex:QualityAttribute_ph1_dp_re_supply_lot_e950cccc",
  "QualityAttribute:Protein:4:Ph1 DS re-supply lots and/or Ph2 DS released.": "ex:QualityAttribute_ph1_ds_re_supply_lot_9a341c3a",
  "QualityAttribute:Protein:4:Ph2 Container Closure System Development Checklist initiated.": "ex:QualityAttribute_ph2_container_closur_f6d26b48",
  "QualityAttribute:Protein:4:Ph2 Formulated Bulk TT memo for DS site approved (if required).": "ex:QualityAttribute_ph2_formulated_bulk_5a1e4751",
  "QualityAttribute:Protein:4:Ph2 Primary Component Specifications prepared.": "ex:QualityAttribute_ph2_primary_componen_efe922a6",
  "QualityAttribute:Protein:4:Ph2 Upstream TT to API site completed, TTM approved (if required).": "ex:QualityAttribute_ph2_upstream_tt_to_a_d79727df",
  "QualityAttribute:Protein:4:Ph2 downstream TT to DS site completed, TTM approved (if required).": "ex:QualityAttribute_ph2_downstream_tt_to_5223b1c0",
  "QualityAttribute:Protein:4:Ph2 drug product TT to DP site completed(if required) - TTM approved.": "ex:QualityAttribute_ph2_drug_product_tt_05866ef4",
  "QualityAttribute:Protein:4:Ph2 intermediate, DS (JOS), DP (JOS) , RM specification documents updated ( if needed).": "ex:QualityAttribute_ph2_intermediate_ds_9822e542",
  "QualityAttribute:Protein:4:Ph2 pharmacy manual studies completed and approved (if required).": "ex:QualityAttribute_ph2_pharmacy_manual_ba3044f0",
  "QualityAttribute:Protein:4:Ph2b/Ph3 devt plan defined (API-LM late phase module deliverable)": "ex:QualityAttribute_ph2b_ph3_devt_plan_d_605a2668",
  "QualityAttribute:Protein:4:Ph3 cell culture media TT strategy defined (confirm with Material Sciences and VCT).": "ex:QualityAttribute_ph3_cell_culture_med_44a4a37f",
  "QualityAttribute:Protein:4:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_e3acb0d5",
  "QualityAttribute:Protein:4:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_1ab08e61",
  "QualityAttribute:Protein:4:Provide aggregated clinical/non-clinical demand in support of Ph2b/3 mfg. (pivotal material) to the JSC organization for final commercial sourcing decision (for accelerated programs)": "ex:QualityAttribute_provide_aggregated_c_b82f3ca7",
  "QualityAttribute:Protein:4:QP approval of Ph1 supplies and Ph2 supplies obtained (if required).": "ex:QualityAttribute_qp_approval_of_ph1_s_7d0afd61",
  "QualityAttribute:Protein:4:Review PRA, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_pra_update_if_83ec7a5c",
  "QualityAttribute:Protein:4:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_523078a2",
  "QualityAttribute:Protein:4:Review Ph2b/Ph3 devt plan (API-LM late phase module deliverable).": "ex:QualityAttribute_review_ph2b_ph3_devt_59982c03",
  "QualityAttribute:Protein:4:Review and assess impact of Ph3 cell culture media TT strategy (defined by API and MS).": "ex:QualityAttribute_review_and_assess_im_972f9e80",
  "QualityAttribute:Protein:4:Review current plans and data to determine if development buy-ups are needed.": "ex:QualityAttribute_review_current_plans_6f0b5d9a",
  "QualityAttribute:Protein:4:Review the polysorbate control strategy critical questions and identify any risks for Ph 2b/3 development  and mitigation plans.": "ex:QualityAttribute_review_the_polysorba_78995d38",
  "QualityAttribute:Protein:4:Stage 4 CMC Team and appropriate focus group presentation reviews completed.": "ex:QualityAttribute_stage_4_cmc_team_and_38e0234c",
  "QualityAttribute:Protein:4:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_68363e42",
  "QualityAttribute:Protein:4:Support Mat. Sci. on selecting raw material suppliers and initiate SWOT Assessment.": "ex:QualityAttribute_support_mat_sci_on_s_fe106f70",
  "QualityAttribute:Protein:4:TPP-CMC Late Development updated finalized and aligned with customers & approved by CMC Council (ad hoc meeting), GSM, TA (if applicable).": "ex:QualityAttribute_tpp_cmc_late_develop_3acb1ac5",
  "QualityAttribute:Protein:4:Tox/Ph1/Ph2 comparability data reviewed to confirm comparability (if applicable).": "ex:QualityAttribute_tox_ph1_ph2_comparab_1ac8ea0f",
  "QualityAttribute:Protein:4:Update Criticality Analysis report with presumptive CPPs/CMAs for development strategy. \u00a0pCMA analysis needs to be performed in collaboration with Material Sciences (includes process/product sensitivity risk assessment for metals in cell culture media).": "ex:QualityAttribute_update_criticality_a_713bd822",
  "QualityAttribute:Protein:4:Updated criticality report, including DP pCPP/pCMA review completed.": "ex:QualityAttribute_updated_criticality_fe156ae6",
  "QualityAttribute:Protein:4:Upstream PF2P activities completed at Ph2 DS manufacturing sites (if required).": "ex:QualityAttribute_upstream_pf2p_activi_9b30d466",
  "QualityAttribute:Protein:5:API & DP: Ph3 & Commercial manufacturing sites locked": "ex:QualityAttribute_api_dp_ph3_commercia_ff0cfbe4",
  "QualityAttribute:Protein:5:Additional supplier/external lab qualified (if applicable)": "ex:QualityAttribute_additional_supplier_bcb1a1cb",
  "QualityAttribute:Protein:5:Approve Brand Protection Product Risk Assessment for Brand Protection.": "ex:QualityAttribute_approve_brand_protec_7a3a9901",
  "QualityAttribute:Protein:5:CMC and Regulatory Strategic Planning Document completed (High level Ph3/Marketing Application RA strategy: Key regulatory risks, key milestones, presentations to be filed, mfg. sites, comparability plan, device, etc.).": "ex:QualityAttribute_cmc_and_regulatory_s_682ac7be",
  "QualityAttribute:Protein:5:CPDP Definition & Planning Stage": "ex:QualityAttribute_cpdp_definition_plan_cd3943bf",
  "QualityAttribute:Protein:5:CPDP Definition & Planning Stage Design Review": "ex:QualityAttribute_cpdp_definition_plan_bf6fc225",
  "QualityAttribute:Protein:5:Cell & Developability Sciences notified by API SI to begin genetic characterization assay development (using MCB and WCB)": "ex:QualityAttribute_cell_developability_0f188592",
  "QualityAttribute:Protein:5:Cell-based Bioassay development initiated including strategy for cell-line licensing if needed if not initiated at an earlier stage gate.": "ex:QualityAttribute_cell_based_bioassay_e13bd528",
  "QualityAttribute:Protein:5:Combination Product Designation Form": "ex:QualityAttribute_combination_product_a215ad01",
  "QualityAttribute:Protein:5:Commercial Concept Development Summary": "ex:QualityAttribute_commercial_concept_d_8ce59b2b",
  "QualityAttribute:Protein:5:Commercial secondary packaging requirements defined & agreed across functions (regulatory, commercial, SCDL, PA CoE, GBP, PCD, VCL, HFS)": "ex:QualityAttribute_commercial_secondary_8a8468c1",
  "QualityAttribute:Protein:5:Complete a raw materials and polymeric product contact materials selection, qualification and release testing gap assessment and mitigation plan per the site BOM.": "ex:QualityAttribute_complete_a_raw_mater_937e95ec",
  "QualityAttribute:Protein:5:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for clinical product, as needed. (For non-combination products.\u00a0 See Comment in Stage 3)": "ex:QualityAttribute_complete_or_revisit_715ab3ea",
  "QualityAttribute:Protein:5:Complete the experimental verification of absorptivity constant if it has not been performed in previous stages.": "ex:QualityAttribute_complete_the_experim_94dc59b6",
  "QualityAttribute:Protein:5:Conduct Ph 1-2 DP stability data review and identify risk mitigation strategy as needed.": "ex:QualityAttribute_conduct_ph_1_2_dp_st_e73f30c2",
  "QualityAttribute:Protein:5:Conduct gap analysis of early development methods and establish strategy for method transfer or co-validation": "ex:QualityAttribute_conduct_gap_analysis_25f6b075",
  "QualityAttribute:Protein:5:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_9ff88af1",
  "QualityAttribute:Protein:5:Continue discussion with team on Patent and Publication Strategy.  Summarize potential unique aspects of the process that could lead to publications and/or patents in core team meeting minutes.": "ex:QualityAttribute_continue_discussion_15752237",
  "QualityAttribute:Protein:5:Coordinate aggregated clinical/non-clinical demand in support of Ph3 mfg. and provide to the JSC organization for final commercial sourcing decision": "ex:QualityAttribute_coordinate_aggregate_b1204a99",
  "QualityAttribute:Protein:5:Critical Raw Materials have been sourced and utilized in Phase-3 Formulation Development  to represent potential  variability in the Phase 3 clinical production process.": "ex:QualityAttribute_critical_raw_materia_33f880c0",
  "QualityAttribute:Protein:5:Critical reagents program for late phase development established if not done in earlier stage gates.": "ex:QualityAttribute_critical_reagents_pr_e9535ac8",
  "QualityAttribute:Protein:5:DP Mfg. Strategy and PF2P Stage 1 activities completed (First Process Walk-through).": "ex:QualityAttribute_dp_mfg_strategy_and_741d0ed1",
  "QualityAttribute:Protein:5:DS/DP Matrices defined and material received for validating stability, IPC, release, and process characterization methods.": "ex:QualityAttribute_ds_dp_matrices_defin_8b86326b",
  "QualityAttribute:Protein:5:Deliver Labels (as needed)": "ex:QualityAttribute_deliver_labels_as_ne_b843848b",
  "QualityAttribute:Protein:5:Design History File (Initiate)": "ex:QualityAttribute_design_history_file_75a13bec",
  "QualityAttribute:Protein:5:Design and Development Plan  (Initiate) - Clinical and Regulatory Strategy Plan (Initiate) [Can be included in the Design & Development Plan]": "ex:QualityAttribute_design_and_developme_02d46fd7",
  "QualityAttribute:Protein:5:Determine assay panel and allocate  bioassay/separation support for forced degradation/mild stress study (save all the retains).": "ex:QualityAttribute_determine_assay_pane_1ab2badf",
  "QualityAttribute:Protein:5:Develop and execute a\u00a0strategy around continuous analytical monitoring\u00a0of media and critical raw materials.": "ex:QualityAttribute_develop_and_execute_32f1ab87",
  "QualityAttribute:Protein:5:Develop in vivo (or ex vivo) strategy for glycoform clearance and degradation studies.": "ex:QualityAttribute_develop_in_vivo_or_e_37d2088b",
  "QualityAttribute:Protein:5:Developed scenarios in support of strategic planning (as required).": "ex:QualityAttribute_developed_scenarios_fb9c2b39",
  "QualityAttribute:Protein:5:Device Design Verification Plan  (Initiate)": "ex:QualityAttribute_device_design_verifi_63630216",
  "QualityAttribute:Protein:5:Device Risk Management (Initiate) - CTQ Flow Down(Initiate)": "ex:QualityAttribute_device_risk_manageme_a73427ac",
  "QualityAttribute:Protein:5:Device Risk Management (Initiate) - Product Risk Assessment (Initiate)": "ex:QualityAttribute_device_risk_manageme_f418347a",
  "QualityAttribute:Protein:5:Device Risk Management (Initiate) - Risk Management Plan (Initiate)": "ex:QualityAttribute_device_risk_manageme_2e8b47f6",
  "QualityAttribute:Protein:5:Device Risk Management (Initiate) - uFMEA (Initiate)": "ex:QualityAttribute_device_risk_manageme_fe4fa15e",
  "QualityAttribute:Protein:5:Device Stability Plan (Initiate)": "ex:QualityAttribute_device_stability_pla_dbc307a9",
  "QualityAttribute:Protein:5:Downstream Tech Transfer Plan and Ph2b/3 development strategy sections are updated, if necessary.": "ex:QualityAttribute_downstream_tech_tran_0029421a",
  "QualityAttribute:Protein:5:Drug Product Administration Team and Procedures for Creating and Maintaining Investigation Product Preparation Instructions (as needed)": "ex:QualityAttribute_drug_product_adminis_30384c47",
  "QualityAttribute:Protein:5:EHS Requirement: Evaluate unique waste disposal requirements; Update SDS for API; risk evaluation of unique chemicals, Initiate environmental risk assessment, Conduct process risk assessment, supplier risk assessment (evaluate if needed); include EHS items in CAR - as applicable\u00a0 (see EHS tab for contacts).": "ex:QualityAttribute_ehs_requirement_eval_9201fe47",
  "QualityAttribute:Protein:5:Ensure Customer Centered Design deliverables are completed for this stage (combo products), inclusive of Customer Centered Design Workshop as needed.": "ex:QualityAttribute_ensure_customer_cent_df261dda",
  "QualityAttribute:Protein:5:Ensure Customer Centered Design deliverables are completed for this stage. (CMCL Co-owner)": "ex:QualityAttribute_ensure_customer_cent_ec02e6de",
  "QualityAttribute:Protein:5:Ensure DPAT review/approval of all changes to clinical protocol that lead to a change to the IPPI/PM study.": "ex:QualityAttribute_ensure_dpat_review_a_f6d1e1d1",
  "QualityAttribute:Protein:5:Ensure ED Criticality Report is updated if necessary.": "ex:QualityAttribute_ensure_ed_criticalit_928d791a",
  "QualityAttribute:Protein:5:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_6ae65c0b",
  "QualityAttribute:Protein:5:Ensure variability Strategy, i.e., the intention to generate variability in Phase 3 DS and DP manufacturing by controlled introduction of Raw Material variability and/or parameter variability (at end of ranges).": "ex:QualityAttribute_ensure_variability_s_1591367c",
  "QualityAttribute:Protein:5:Evaluation of platform approach for vials and/or syringe selection per TV-TEC-157617 and TV-TEC-158580, respectively.": "ex:QualityAttribute_evaluation_of_platfo_d01133b9",
  "QualityAttribute:Protein:5:Execute selection, qualification and release testing specifications/methods gap mitigation for DS (including MCB, WCB) and DP Raw Materials and Product Contact Polymeric Materials for Phase 2b/3 manufacture including specifications and analytical methods.": "ex:QualityAttribute_execute_selection_qu_7e3f0224",
  "QualityAttribute:Protein:5:Execute technology transfer plan for raw materials for DS and DP for Phase 2b/3 manufacture (internal and CMO).": "ex:QualityAttribute_execute_technology_t_a9e62663",
  "QualityAttribute:Protein:5:First Product Strategy Roadmap (PSR) workshop completed; JSC Product Council endorsement": "ex:QualityAttribute_first_product_strate_3232625b",
  "QualityAttribute:Protein:5:First strategic forecast and capacity planning for API and DP via initial New Product Segmentation (NPS) and Forecast Integration Session (FIS) - Socialization.": "ex:QualityAttribute_first_strategic_fore_0f29ad65",
  "QualityAttribute:Protein:5:Human Factors Study Plan  (Initiate)": "ex:QualityAttribute_human_factors_study_30dbfcf1",
  "QualityAttribute:Protein:5:IND/IMPD review (Manufacturing & Packaging locations, Stability plan, as needed) and delivery of submission labels": "ex:QualityAttribute_ind_impd_review_manu_96c3e4da",
  "QualityAttribute:Protein:5:Initiate Device-PFS interaction risk assessment and evaluation plan, if applicable (study specifics to be captured in action plan, expectation is demonstrated biochemical and functional stability over 12-18m storage at real-time conditions).": "ex:QualityAttribute_initiate_device_pfs_47585053",
  "QualityAttribute:Protein:5:Initiate Extractables studies on new CCS components, as needed. For new SUS introduction, follow TV-SOP-36880.": "ex:QualityAttribute_initiate_extractable_1c691e49",
  "QualityAttribute:Protein:5:Initiate General Safety and Performance Requirements (GSPR) Checklist": "ex:QualityAttribute_initiate_general_saf_906010f9",
  "QualityAttribute:Protein:5:Initiate Pediatric CMC Strategy Review.": "ex:QualityAttribute_initiate_pediatric_c_357b4bb5",
  "QualityAttribute:Protein:5:Initiate Phase 3 development studies (DOE's).": "ex:QualityAttribute_initiate_phase_3_dev_b7c76c41",
  "QualityAttribute:Protein:5:Isolate Product Variants for Structure / Function studies.": "ex:QualityAttribute_isolate_product_vari_100817b3",
  "QualityAttribute:Protein:5:JJ Packaging Design Protocol": "ex:QualityAttribute_jj_packaging_design_83ee13ad",
  "QualityAttribute:Protein:5:JSC VCT kicked off (may have been kicked off in a previous Stage (refer to SG 2).": "ex:QualityAttribute_jsc_vct_kicked_off_m_de383bb4",
  "QualityAttribute:Protein:5:JSC review and approval of Full Development Strategy and CMC-TPP.": "ex:QualityAttribute_jsc_review_and_appro_90f0576f",
  "QualityAttribute:Protein:5:Manufacturing Strategy and Design Transfer Plan": "ex:QualityAttribute_manufacturing_strate_68af8711",
  "QualityAttribute:Protein:5:Ph3 Downstream target process and scale-up parameters identified.": "ex:QualityAttribute_ph3_downstream_targe_11b05180",
  "QualityAttribute:Protein:5:Ph3 Stability Protocol drafted.": "ex:QualityAttribute_ph3_stability_protoc_41d5edab",
  "QualityAttribute:Protein:5:Ph3 Upstream target process and scale-up parameters identified.": "ex:QualityAttribute_ph3_upstream_target_79fd9908",
  "QualityAttribute:Protein:5:Ph3 cleaning validation methods qualification completed.": "ex:QualityAttribute_ph3_cleaning_validat_ad1f89c2",
  "QualityAttribute:Protein:5:Ph3 device test method development initiated if required (change in presentation or formulation),  if not started earlier.": "ex:QualityAttribute_ph3_device_test_meth_ff61cacb",
  "QualityAttribute:Protein:5:Ph3 drug product development (i.e. formulation, dosage form, & stability) strategy & TT strategy prepared based on TPP product design inputs (e.g. CCD).": "ex:QualityAttribute_ph3_drug_product_dev_0080b92d",
  "QualityAttribute:Protein:5:Phase 2 CTA dossier submitted to HAs and approved (if applicable). IB update if needed": "ex:QualityAttribute_phase_2_cta_dossier_0f784483",
  "QualityAttribute:Protein:5:Polymeric risk assessment\u00a0strategy/memo developed for new platforms (as needed).": "ex:QualityAttribute_polymeric_risk_asses_de3d9967",
  "QualityAttribute:Protein:5:Process-related impurity risk assessment initiated": "ex:QualityAttribute_process_related_impu_5e86de68",
  "QualityAttribute:Protein:5:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_5c91b5cd",
  "QualityAttribute:Protein:5:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_6ab6d670",
  "QualityAttribute:Protein:5:Proval / Commercial analytical testing sites confirmed": "ex:QualityAttribute_proval_commercial_an_4ee1d3cc",
  "QualityAttribute:Protein:5:Provide a detailed description of the completed IP review of novel ideas and innovations during early phase development.  Request approval of patent and publication strategy.": "ex:QualityAttribute_provide_a_detailed_d_12c9e867",
  "QualityAttribute:Protein:5:Quality agreement completed/revised for all mfg. sites/testing labs (external and internal) (if applicable).": "ex:QualityAttribute_quality_agreement_co_fd776834",
  "QualityAttribute:Protein:5:Raw materials specified for Ph2b/3 (downstream),  and reviewed by Material Sciences.": "ex:QualityAttribute_raw_materials_specif_83b1a510",
  "QualityAttribute:Protein:5:Raw materials specified for Ph2b/3 (upstream & downstream).  Identify alternative materials if needed.  Assess impact on Phase 3/Commercial production.": "ex:QualityAttribute_raw_materials_specif_f1580373",
  "QualityAttribute:Protein:5:Raw materials specified for Ph2b/3 (upstream), and reviewed by Material Sciences.": "ex:QualityAttribute_raw_materials_specif_7158cd39",
  "QualityAttribute:Protein:5:Reduced-scale robustness and characterization studies initiated in accordance with Ph3 devt plan (downstream).": "ex:QualityAttribute_reduced_scale_robust_fb953d3a",
  "QualityAttribute:Protein:5:Reduced-scale robustness and characterization studies initiated in accordance with Ph3 devt plan (upstream).": "ex:QualityAttribute_reduced_scale_robust_07c24926",
  "QualityAttribute:Protein:5:Regulated Substances Plan": "ex:QualityAttribute_regulated_substances_702e4233",
  "QualityAttribute:Protein:5:Request Process Impurity Risk Assessment from API LM to establish  methods needed for testing and demonstrating clearance (include nitrosamines as applicable).": "ex:QualityAttribute_request_process_impu_52544d0c",
  "QualityAttribute:Protein:5:Review CMC requirements, including manufacturing sites for stability batches and temperature zone, DP configurations for stability and pharmacy manual studies, of the relevant EMAX countries and incorporate the requirements in the late stage CMC strategy definition and Phase 3 manufacturing resource plan.******": "ex:QualityAttribute_review_cmc_requireme_7c6f8f20",
  "QualityAttribute:Protein:5:Review PRA, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_pra_update_if_bcfa08e5",
  "QualityAttribute:Protein:5:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_aebdc63f",
  "QualityAttribute:Protein:5:Review current plans and data to determine if development buy-ups are needed.": "ex:QualityAttribute_review_current_plans_7c531de4",
  "QualityAttribute:Protein:5:Review the submission plan endorsed by CDT, including EMAX country list and timeline.": "ex:QualityAttribute_review_the_submissio_e277125e",
  "QualityAttribute:Protein:5:Review/Approve DPFD or site BOM.": "ex:QualityAttribute_review_approve_dpfd_b308b57b",
  "QualityAttribute:Protein:5:Stability protocol drafted to support room temperature storage for patient use (if required in the TPP)": "ex:QualityAttribute_stability_protocol_d_fe09413b",
  "QualityAttribute:Protein:5:Stage 5 CMC Council presentation and appropriate focus group presentation reviews completed.": "ex:QualityAttribute_stage_5_cmc_council_289fc16e",
  "QualityAttribute:Protein:5:Start assessment of endotoxin recovery.": "ex:QualityAttribute_start_assessment_of_5793df72",
  "QualityAttribute:Protein:5:Start to prepare forced-degraded materials and develop plans to close structure - function knowledge gaps.": "ex:QualityAttribute_start_to_prepare_for_576b5a11",
  "QualityAttribute:Protein:5:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_8c2bd0ac",
  "QualityAttribute:Protein:5:Technical Design Requirements  (Initiate)": "ex:QualityAttribute_technical_design_req_e753e046",
  "QualityAttribute:Protein:5:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_4b771e37",
  "QualityAttribute:Protein:5:Update Cost of Goods Sold (COGS) and Gross Profit (GP) for launch and steady state (prior to Mfg Investment Decision & Source Lock).": "ex:QualityAttribute_update_cost_of_goods_4015a7d8",
  "QualityAttribute:Protein:5:Upstream Tech Transfer Plan and Ph2b/3 development strategy sections are updated, if necessary.": "ex:QualityAttribute_upstream_tech_transf_4f2db674",
  "QualityAttribute:Protein:5:User Requirements (Initiate)": "ex:QualityAttribute_user_requirements_in_391d7ca2",
  "QualityAttribute:Protein:5:Verify Best Process at Launch (BPAL) strategy being executed by functional teams is current and aligned with JSC VCL, and documented in CMC SG5 presentation for each function (preference is to include technology as standard, and justify removal as needed).": "ex:QualityAttribute_verify_best_process_703db169",
  "QualityAttribute:Protein:6:API & DP Key Deliverable: Establish data plan and structure to drive DOEs for important variables to enable predictive control and real time release.": "ex:QualityAttribute_api_dp_key_deliverab_f7a25f95",
  "QualityAttribute:Protein:6:Allocate material to support generation of Primary Reference material and plan preparation from the  selected Phase 3  batch manufactured with the representative commercial process.": "ex:QualityAttribute_allocate_material_to_5e6e2bad",
  "QualityAttribute:Protein:6:Author/Review IND/IMPD Control of Materials": "ex:QualityAttribute_author_review_ind_im_c21dc966",
  "QualityAttribute:Protein:6:CPDP Development and Verification Stage": "ex:QualityAttribute_cpdp_development_and_b80f8075",
  "QualityAttribute:Protein:6:Complete Ph3 device test method development and validation report (if device used at this stage).": "ex:QualityAttribute_complete_ph3_device_e641085a",
  "QualityAttribute:Protein:6:Complete assessment of endotoxin recovery.": "ex:QualityAttribute_complete_assessment_301a7d66",
  "QualityAttribute:Protein:6:Complete initial Design FMEA (COMBO Product Requirement)": "ex:QualityAttribute_complete_initial_des_50d89bcd",
  "QualityAttribute:Protein:6:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for clinical product, as needed. (For non-combination products.\u00a0 See Comment in Stage 3)": "ex:QualityAttribute_complete_or_revisit_bce573d4",
  "QualityAttribute:Protein:6:Complete selection, qualification and release testing specifications/methods gap mitigations for raw materials for DS and DP for Phase 2b/3 manufacture": "ex:QualityAttribute_complete_selection_q_04924379",
  "QualityAttribute:Protein:6:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_2b1cea40",
  "QualityAttribute:Protein:6:Continue discussion with team on Patent and Publication Strategy with team and legal.  Summarize potential unique aspects of the process that could lead to publications and/or patents in core team meeting minutes.": "ex:QualityAttribute_continue_discussion_40eef3da",
  "QualityAttribute:Protein:6:Coordinate aggregated clinical/non-clinical demand in support of Ph3 mfg. and provide to the JSC organization": "ex:QualityAttribute_coordinate_aggregate_f681c0c8",
  "QualityAttribute:Protein:6:DP Ph3 SOPs & batch records approved.": "ex:QualityAttribute_dp_ph3_sops_batch_re_1c3c5cf1",
  "QualityAttribute:Protein:6:DPD PF2P Stage 2-3 activities completed, including DP mfg. FMEA": "ex:QualityAttribute_dpd_pf2p_stage_2_3_a_4d8fe15f",
  "QualityAttribute:Protein:6:DS & DP: cleaning validation strategy implemented.": "ex:QualityAttribute_ds_dp_cleaning_valid_64869f21",
  "QualityAttribute:Protein:6:DS downstream Ph3 SOPs & batch records approved.": "ex:QualityAttribute_ds_downstream_ph3_so_003422e3",
  "QualityAttribute:Protein:6:DS upstream Ph3 SOPs & batch records approved.": "ex:QualityAttribute_ds_upstream_ph3_sops_64cac951",
  "QualityAttribute:Protein:6:Define Process Validation Strategy for DS and DP raw materials": "ex:QualityAttribute_define_process_valid_97608b6d",
  "QualityAttribute:Protein:6:Design Output Specification (Initiate)": "ex:QualityAttribute_design_output_specif_95da2f87",
  "QualityAttribute:Protein:6:Detailed strategy for Ph3 analytical method\u00a0optimization and qualification completed (includes robustness studies) for DS/DP.": "ex:QualityAttribute_detailed_strategy_fo_84e12cc6",
  "QualityAttribute:Protein:6:Develop Ph3 supply and sampling plans (including any engineering batches) to account for all material needs for developmental activities, testing needs, and clinical needs in E2E": "ex:QualityAttribute_develop_ph3_supply_a_d4c1b7b2",
  "QualityAttribute:Protein:6:Develop co-validation/transfer  strategy for the identified QC testing sites.": "ex:QualityAttribute_develop_co_validatio_fbd0849a",
  "QualityAttribute:Protein:6:Developed scenarios in support of strategic planning (as required).": "ex:QualityAttribute_developed_scenarios_a10ada42",
  "QualityAttribute:Protein:6:Device Risk Management  (Update) -  CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_214c0dd4",
  "QualityAttribute:Protein:6:Device Risk Management  (Update) -  uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_99d930dc",
  "QualityAttribute:Protein:6:Device Risk Management  (Update) - Control Strategy (Initiate)": "ex:QualityAttribute_device_risk_manageme_20fdc013",
  "QualityAttribute:Protein:6:Device Risk Management  (Update) - Product Risk Assessment/Hazard ID (Update)": "ex:QualityAttribute_device_risk_manageme_5474cc74",
  "QualityAttribute:Protein:6:Device Risk Management  (Update) - Risk Management Plan (Update)": "ex:QualityAttribute_device_risk_manageme_889494dd",
  "QualityAttribute:Protein:6:Device Risk Management  (Update) - dFMEA (Initiate)": "ex:QualityAttribute_device_risk_manageme_ec0b1433",
  "QualityAttribute:Protein:6:Downstream PF2P activities completed at Ph 3 manufacturing site.": "ex:QualityAttribute_downstream_pf2p_acti_b4644d0b",
  "QualityAttribute:Protein:6:Downstream reports approved for robustness studies (as defined in Stage gate 4's Ph2b/Ph3 devt plan).": "ex:QualityAttribute_downstream_reports_a_aca463fe",
  "QualityAttribute:Protein:6:Draft IPPI, Pharm Manual and dose verification study plans to be reviewed by line function, CMC team, and DPAT as needed.": "ex:QualityAttribute_draft_ippi_pharm_man_9d069cfc",
  "QualityAttribute:Protein:6:Ensure CMC team members identified in functional review matrices review the following draft Reports: DS & DP specification and JOS; DS and DP Criticality Analysis (CQA, CPP, CMA); DP Tech Transfer Plan). Needs further discussion within Portfolio Management": "ex:QualityAttribute_ensure_cmc_team_memb_bcc3b348",
  "QualityAttribute:Protein:6:Ensure Customer Centered Design deliverables are completed for this stage, inclusive of Customer Centered Design Workshop as needed. Add text about co-ownership with JSC.": "ex:QualityAttribute_ensure_customer_cent_f10e2586",
  "QualityAttribute:Protein:6:Ensure DPAT review/approval of all changes to clinical protocol that lead to a change in the IPPI/PM study.": "ex:QualityAttribute_ensure_dpat_review_a_62196836",
  "QualityAttribute:Protein:6:Ensure ED Criticality Report is reviewed/updated as needed, and transition to LD Criticality Report if possible.": "ex:QualityAttribute_ensure_ed_criticalit_9fb10d0a",
  "QualityAttribute:Protein:6:Ensure implementation of manufacturing variability strategy into the clinical trials.": "ex:QualityAttribute_ensure_implementatio_4d4d7963",
  "QualityAttribute:Protein:6:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_fbbb4c5d",
  "QualityAttribute:Protein:6:Evaluate and implement JNDA requirements to analytical test methods prior to validation. If applicable, trigger discussion with JPKK.": "ex:QualityAttribute_evaluate_and_impleme_6d945d51",
  "QualityAttribute:Protein:6:Finalize stability strategy on room temperature storage for patient use, including a decision about whether 30C can be supported based on a review of the formulation development data (if required in the TPP).": "ex:QualityAttribute_finalize_stability_s_d5630b15",
  "QualityAttribute:Protein:6:Forced degradation study plan completed and approved. Close structure - function knowledge gaps and update control strategy as necessary.": "ex:QualityAttribute_forced_degradation_s_3bada4ee",
  "QualityAttribute:Protein:6:Initiate General Safety and Performance Requirements (GSPR) Checklist (review and update as needed)": "ex:QualityAttribute_initiate_general_saf_624b1797",
  "QualityAttribute:Protein:6:Initiate planning for EOP2 meeting. (CMC RA will bridge between GRT and CMC team).": "ex:QualityAttribute_initiate_planning_fo_449530d1",
  "QualityAttribute:Protein:6:Initiate the Extractables risk assessment (and testing if needed) of New Category I materials if Ph3 and PPQ are at the same site. Develop mitigation plans for high risk materials. \u00a0Identify alternative materials if needed.": "ex:QualityAttribute_initiate_the_extract_1ad0d36e",
  "QualityAttribute:Protein:6:JJ packaging design protocol (review and update as needed)": "ex:QualityAttribute_jj_packaging_design_0c30894d",
  "QualityAttribute:Protein:6:JSC FTE & Capital TT costs established for CAR (API/DP/Device); CAR approved.": "ex:QualityAttribute_jsc_fte_capital_tt_c_de786abd",
  "QualityAttribute:Protein:6:Manufacturing Strategy and Design Plan (review and update as needed)": "ex:QualityAttribute_manufacturing_strate_6deda0f2",
  "QualityAttribute:Protein:6:Manufacturing strategy to introduce routine process variability approved.": "ex:QualityAttribute_manufacturing_strate_5d2599c1",
  "QualityAttribute:Protein:6:PF2P activities (Upstream, Downstream, DP) initiated at Ph 3/ Commercial manufacturing sites.": "ex:QualityAttribute_pf2p_activities_upst_5ca77a90",
  "QualityAttribute:Protein:6:Pack TLI \u2013 secondary packaging concept(s) reviewed & agreed across functions (regulatory, commercial, SCDL, PA CoE, GBP, PCD, VCL, HFS)\nPack TLI + VCL \u2013 Need assessed to source long lead time packaging equipment": "ex:QualityAttribute_pack_tli_secondary_p_8c7c5792",
  "QualityAttribute:Protein:6:Passive shipping systems qualified, if applicable.": "ex:QualityAttribute_passive_shipping_sys_0bf9986f",
  "QualityAttribute:Protein:6:Ph 3 Formulation, raw material, and primary packaging lock achieved based on sufficient stability data (DPD manf'd and tested) at real-time storage conditions, as well as CCIT, material compatibility, and procurement considerations": "ex:QualityAttribute_ph_3_formulation_raw_d240c008",
  "QualityAttribute:Protein:6:Ph3 Container Closure System Development Checklist or Report completed.": "ex:QualityAttribute_ph3_container_closur_d8659622",
  "QualityAttribute:Protein:6:Ph3 DP mfg. equipment qualified (IOQ) & ready.": "ex:QualityAttribute_ph3_dp_mfg_equipment_34660fd8",
  "QualityAttribute:Protein:6:Ph3 Downstream DPFD approved.": "ex:QualityAttribute_ph3_downstream_dpfd_68386acd",
  "QualityAttribute:Protein:6:Ph3 Eng run executed (DP process and DP characterization), if applicable": "ex:QualityAttribute_ph3_eng_run_executed_cfb51aff",
  "QualityAttribute:Protein:6:Ph3 Intermediate (if applicable), DS and DP JOS approved.": "ex:QualityAttribute_ph3_intermediate_if_41bd7465",
  "QualityAttribute:Protein:6:Ph3 JoS approved (IPC as applicable)": "ex:QualityAttribute_ph3_jos_approved_ipc_45247c90",
  "QualityAttribute:Protein:6:Ph3 Primary Component Specifications completed.": "ex:QualityAttribute_ph3_primary_componen_1dbc9015",
  "QualityAttribute:Protein:6:Ph3 QC  Bioassay cell banks produced if not completed eat an earlier stage gate": "ex:QualityAttribute_ph3_qc_bioassay_cell_5c7b04bc",
  "QualityAttribute:Protein:6:Ph3 Shipping routes verified/mock shipments complete for DS, DP, and samples.": "ex:QualityAttribute_ph3_shipping_routes_1da02e35",
  "QualityAttribute:Protein:6:Ph3 Upstream DPFDs approved.": "ex:QualityAttribute_ph3_upstream_dpfds_a_683eb7b8",
  "QualityAttribute:Protein:6:Ph3 downstream process characterization, and sampling plan protocol approved.": "ex:QualityAttribute_ph3_downstream_proce_c9bbc57e",
  "QualityAttribute:Protein:6:Ph3 non-compendial raw material methods developed and qualified  with approved reports.": "ex:QualityAttribute_ph3_non_compendial_r_8b1c3bd3",
  "QualityAttribute:Protein:6:Ph3 upstream DS mfg. equipment qualified (IOQ) & ready.": "ex:QualityAttribute_ph3_upstream_ds_mfg_6bffd7f5",
  "QualityAttribute:Protein:6:Ph3 upstream process characterization, and sampling plan protocol approved (includes cell culture media characterization / testing plan for metals variability, if required).": "ex:QualityAttribute_ph3_upstream_process_47573bc7",
  "QualityAttribute:Protein:6:Phase 3 DP material commercial specifications (excipients, primary packaging, etc.) completed.": "ex:QualityAttribute_phase_3_dp_material_49681f87",
  "QualityAttribute:Protein:6:Placebo & active comparator blinding assessment with Clinical team documented (if applicable).": "ex:QualityAttribute_placebo_active_compa_9d5cb684",
  "QualityAttribute:Protein:6:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_fdb434b5",
  "QualityAttribute:Protein:6:Process-related impurity risk assessment approved and shared with AD": "ex:QualityAttribute_process_related_impu_3e1d0ad2",
  "QualityAttribute:Protein:6:Product characterization method development  completed.": "ex:QualityAttribute_product_characteriza_cf03b19f",
  "QualityAttribute:Protein:6:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_57ebd4e8",
  "QualityAttribute:Protein:6:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_090ca89f",
  "QualityAttribute:Protein:6:Protocol approved for generation of EEPCB, and biologics research Cell and Developability Sciences notified to enable Ph3 (pivotal) genetic characterization stability testing.  Initiate importation code generation for cell bank shipment into United States, if applicable.": "ex:QualityAttribute_protocol_approved_fo_d88f3591",
  "QualityAttribute:Protein:6:Protocol approved for generation of EEPCB, and cell and developability sciences notified to enable Ph3 genetic characterization testing.": "ex:QualityAttribute_protocol_approved_fo_a01bc821",
  "QualityAttribute:Protein:6:Refresh forecast and capacity planning for API and DP via initial New Product Segmentation (NPS) and Forecast Integration Session (FIS) - Socialization, if needed": "ex:QualityAttribute_refresh_forecast_and_3dd7dc0a",
  "QualityAttribute:Protein:6:Review DS & DP shipment (simulated transportation supportive) study report (on Primary Containers). Ph3 downstream DS mfg. equipment qualified (IOQ) & ready.": "ex:QualityAttribute_review_ds_dp_shipmen_03f66eb5",
  "QualityAttribute:Protein:6:Review DS and DP documents, including robustness study report, process characterization plan/protocols/reports, sampling plan, DPFD, small-scale model, SAFT report, EEPCB protocol, process variability plan.": "ex:QualityAttribute_review_ds_and_dp_doc_d000192b",
  "QualityAttribute:Protein:6:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_4a62d883",
  "QualityAttribute:Protein:6:Review current plans and data to determine if development buy-ups are needed.": "ex:QualityAttribute_review_current_plans_61d9c8e6",
  "QualityAttribute:Protein:6:SMQ process complete and DS/DP raw materials Late Development Qualified/Commercial Qualified prior to Ph3 DS/DP release.": "ex:QualityAttribute_smq_process_complete_2251f4d8",
  "QualityAttribute:Protein:6:Site(s) Integrated project plans prepared (upstream, downstream, DP) - Project specific integrated KEM.": "ex:QualityAttribute_site_s_integrated_pr_600d08af",
  "QualityAttribute:Protein:6:Stability strategy finalized for intermediate, DS, DP and Combination Product and earlier stage data reviewed and verified.": "ex:QualityAttribute_stability_strategy_f_20cbeef4",
  "QualityAttribute:Protein:6:Stage 6A/6B CMC Team presentation completed.": "ex:QualityAttribute_stage_6a_6b_cmc_team_b478ed35",
  "QualityAttribute:Protein:6:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_2013fe85",
  "QualityAttribute:Protein:6:TTP approved, including defined Ph3 DP mfg. process (w/ process characterization and enhanced sampling plans) and strategy to introduce process variability/hold times/etc.": "ex:QualityAttribute_ttp_approved_includi_edab98e7",
  "QualityAttribute:Protein:6:USP/DSP small scale model protocols drafted.": "ex:QualityAttribute_usp_dsp_small_scale_52f7b5ff",
  "QualityAttribute:Protein:6:Update  Criticality Analysis (CQA and CTQ for device, if applicable). Verify and confirm a clear link between established CQAs and the Justification of Specifications.": "ex:QualityAttribute_update_criticality_a_84fffe41",
  "QualityAttribute:Protein:6:Update  Criticality Analysis (CQA, CPPS and CMAs).": "ex:QualityAttribute_update_criticality_a_8cce3b40",
  "QualityAttribute:Protein:6:Update CMC Risk register including risk of manufacturing ProVal batches at risk before POC data is known.": "ex:QualityAttribute_update_cmc_risk_regi_a9765e8f",
  "QualityAttribute:Protein:6:Update PRA, complete all sections": "ex:QualityAttribute_update_pra_complete_6d0ebadf",
  "QualityAttribute:Protein:6:Update drug product expiry memo to support temperature excursions.": "ex:QualityAttribute_update_drug_product_1d5cffb3",
  "QualityAttribute:Protein:6:Update \u00a0Criticality assessment (CQA, CPPs, CMAs).": "ex:QualityAttribute_update_criticality_a_c1911bb0",
  "QualityAttribute:Protein:6:Updated  Criticality assessment (CQA reassessment and identification of Ph 3 PD mfg. CPPs + CMAs).": "ex:QualityAttribute_updated_criticality_87944ed5",
  "QualityAttribute:Protein:6:Upstream PF2P activities completed at Ph 3 manufacturing site.": "ex:QualityAttribute_upstream_pf2p_activi_5a0d5144",
  "QualityAttribute:Protein:6:Upstream reports approved for robustness studies (as defined in Stage Gate 4 Ph2b/Ph3 devt plan).": "ex:QualityAttribute_upstream_reports_app_6d9f0645",
  "QualityAttribute:Protein:6:Verify no change is expected  in analytical methods between Phase 3 and Process Validation (PPQ).": "ex:QualityAttribute_verify_no_change_is_92f3ecf9",
  "QualityAttribute:Protein:6:Verify process characterization test sampling plans  and evaluate impurity method validation requirements according to the process-related  impurity risk assessment report  for commercial manufacturing process report from API (include nitrosamines as applicable).": "ex:QualityAttribute_verify_process_chara_8f928614",
  "QualityAttribute:Protein:7:Additional downstream process robustness studies initiated (if required).": "ex:QualityAttribute_additional_downstrea_c8f57475",
  "QualityAttribute:Protein:7:Additional upstream process robustness studies initiated (if required).": "ex:QualityAttribute_additional_upstream_ef76064a",
  "QualityAttribute:Protein:7:Alignment with Medical Affairs on potential demands": "ex:QualityAttribute_alignment_with_medic_4350db86",
  "QualityAttribute:Protein:7:Any new DS and DP analytical method development and co-qualification/transfer completed.": "ex:QualityAttribute_any_new_ds_and_dp_an_714d7f62",
  "QualityAttribute:Protein:7:CPDP Development and Verification Stage": "ex:QualityAttribute_cpdp_development_and_c1a9e360",
  "QualityAttribute:Protein:7:Collaborate with JSC Quality  to finalize PPQ/commercial stability protocol strategy and check stability container to be used for  PPQ DS specified in stability protocol and  the equivalency between stability container and DS bottles used in production is documented in a technical document.": "ex:QualityAttribute_collaborate_with_jsc_da972be1",
  "QualityAttribute:Protein:7:Collaborate with JSC quality to ensure that Stability strategy (e.g. number of batches, timepoints, tests) for PPQ and commercial  manufacturing agreed with PQM Stability CoE for all protein modalities.": "ex:QualityAttribute_collaborate_with_jsc_180a0b28",
  "QualityAttribute:Protein:7:Complete  co-validation plans and start to  prepare co-validation protocols with JSC  Quality labs for release and stability methods for PPQ.": "ex:QualityAttribute_complete_co_validati_053d5fcf",
  "QualityAttribute:Protein:7:Complete Request Intake Form for Product Quality Complaint New Product Introduction for Clinical": "ex:QualityAttribute_complete_request_int_52607a1c",
  "QualityAttribute:Protein:7:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.  Complete HF studies, if needed. (For non-combination products.\u00a0 See Comment in Stage 3)": "ex:QualityAttribute_complete_or_revisit_ae049554",
  "QualityAttribute:Protein:7:Confirm that PPQ/commercial stability protocols are finalized by the Product Quality Specialist in PQM and ensure that the stability container to be used for DS PPQ/commercial material is defined by the CMC team and equivalency between stability container and DS bottles used in production has been documented": "ex:QualityAttribute_confirm_that_ppq_com_bb241231",
  "QualityAttribute:Protein:7:Confirm that Product Quality Specialist in PQM  is involved in a timely manner to ensure that Stability strategy (e.g. number of batches, timepoints, tests) for PPQ and commercial manufacturing agreed with PQM Stability CoE for all protein modalities": "ex:QualityAttribute_confirm_that_product_56fa6e58",
  "QualityAttribute:Protein:7:Confirm that sampling plans have been set up such that (non-clinical) needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) and analytical needs are met.": "ex:QualityAttribute_confirm_that_samplin_1cff5e1c",
  "QualityAttribute:Protein:7:Coordinate aggregated clinical/non-clinical demand in support of Ph3 mfg. and provide to the JSC organization.": "ex:QualityAttribute_coordinate_aggregate_1bf84685",
  "QualityAttribute:Protein:7:DP ProVal master plan drafted / approved.": "ex:QualityAttribute_dp_proval_master_pla_a8af92d9",
  "QualityAttribute:Protein:7:DP formulation robustness DOE study initiated.": "ex:QualityAttribute_dp_formulation_robus_bf03133d",
  "QualityAttribute:Protein:7:DPD PF2P Stage 4 activities completed.": "ex:QualityAttribute_dpd_pf2p_stage_4_act_b83735cd",
  "QualityAttribute:Protein:7:DS Downstream PF2P Stage 4 activities completed.": "ex:QualityAttribute_ds_downstream_pf2p_s_ce174473",
  "QualityAttribute:Protein:7:DS ProVal master plan approved.": "ex:QualityAttribute_ds_proval_master_pla_38dcbdcd",
  "QualityAttribute:Protein:7:DS Upstream PF2P Stage 4 activities completed (person in plant).": "ex:QualityAttribute_ds_upstream_pf2p_sta_5faa540c",
  "QualityAttribute:Protein:7:DS and DP release testing and COA completed by release lab.": "ex:QualityAttribute_ds_and_dp_release_te_29fdfc07",
  "QualityAttribute:Protein:7:DS virus and microbiology methods approved at QC and/or contract test sites.": "ex:QualityAttribute_ds_virus_and_microbi_82fc1330",
  "QualityAttribute:Protein:7:Deliver Ph3 packaged kits to clinical sites to meet FPI": "ex:QualityAttribute_deliver_ph3_packaged_e557a3ea",
  "QualityAttribute:Protein:7:Design Output Specifications (as appropriate)": "ex:QualityAttribute_design_output_specif_c13285cc",
  "QualityAttribute:Protein:7:Design Validation Plan (Initiate)": "ex:QualityAttribute_design_validation_pl_16042d9c",
  "QualityAttribute:Protein:7:Design Verification Protocols and Reports": "ex:QualityAttribute_design_verification_c02fa95c",
  "QualityAttribute:Protein:7:Design and Development Plan  (Update)": "ex:QualityAttribute_design_and_developme_5f55949a",
  "QualityAttribute:Protein:7:Developed scenarios in support of strategic planning (as required).": "ex:QualityAttribute_developed_scenarios_0e6eeba5",
  "QualityAttribute:Protein:7:Development & Verification Stage Design Review": "ex:QualityAttribute_development_verifica_3d0ea5b8",
  "QualityAttribute:Protein:7:Device Design Verification Plan  (Update)": "ex:QualityAttribute_device_design_verifi_71f3267a",
  "QualityAttribute:Protein:7:Device Master Record (DMR)": "ex:QualityAttribute_device_master_record_3c955fc6",
  "QualityAttribute:Protein:7:Device Risk Management  (Update) -  CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_73e81c61",
  "QualityAttribute:Protein:7:Device Risk Management  (Update) -  Product Risk Assessment (Update)": "ex:QualityAttribute_device_risk_manageme_2d14bad3",
  "QualityAttribute:Protein:7:Device Risk Management  (Update) - Device Control Strategy (Device) (Initiate)": "ex:QualityAttribute_device_risk_manageme_d44dad34",
  "QualityAttribute:Protein:7:Device Risk Management  (Update) - Risk Management Plan/Report (Update)": "ex:QualityAttribute_device_risk_manageme_16b0d786",
  "QualityAttribute:Protein:7:Device Risk Management  (Update) - dFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_f36a8e19",
  "QualityAttribute:Protein:7:Device Risk Management  (Update) - uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_52ac58de",
  "QualityAttribute:Protein:7:Distribution Testing Procedure -Technical Report Adoption or Develop Test Protocol (as needed)": "ex:QualityAttribute_distribution_testing_0043d43f",
  "QualityAttribute:Protein:7:Downstream small-scale model qualification reports approved.": "ex:QualityAttribute_downstream_small_sca_53599771",
  "QualityAttribute:Protein:7:EHS Requirement: Review DGTC reqs. Into Ph3 1st, 2nd and 3rd packaging solution": "ex:QualityAttribute_ehs_requirement_revi_1d76530e",
  "QualityAttribute:Protein:7:EHS requirements: update DP SDS": "ex:QualityAttribute_ehs_requirements_upd_fa6db6e9",
  "QualityAttribute:Protein:7:End of Phase 2/Pre-Phase 3 meeting completed with HA and feedback incorporated into Ph3 CMC strategy": "ex:QualityAttribute_end_of_phase_2_pre_p_9f79f689",
  "QualityAttribute:Protein:7:End of Phase 2/Pre-Phase 3 meeting package submitted  to HA": "ex:QualityAttribute_end_of_phase_2_pre_p_427f923e",
  "QualityAttribute:Protein:7:End of Phase 2/Pre-Phase 3/Scientific Advice meeting package completed": "ex:QualityAttribute_end_of_phase_2_pre_p_8b6849e4",
  "QualityAttribute:Protein:7:Ensure Completion of  IPC, release and stability method co-validations or transfers prior to PPQ": "ex:QualityAttribute_ensure_completion_of_aefd784a",
  "QualityAttribute:Protein:7:Ensure DPAT review/approval of all changes to clinical protocol that lead to a change to the IPPI/PM study.": "ex:QualityAttribute_ensure_dpat_review_a_4a44629e",
  "QualityAttribute:Protein:7:Ensure ED Criticality Report is reviewed/updated as needed, and transition to LD Criticality Report if possible.": "ex:QualityAttribute_ensure_ed_criticalit_8c7a7ed3",
  "QualityAttribute:Protein:7:Ensure completion of Customer Centered Design deliverables for this stage, if applicable. Add text regarding co-ownership with JSC.": "ex:QualityAttribute_ensure_completion_of_9212d996",
  "QualityAttribute:Protein:7:Ensure completion of assessment of Device Abuse/Misuse and mitigation, if applicable.": "ex:QualityAttribute_ensure_completion_of_232ae5a9",
  "QualityAttribute:Protein:7:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_9920664f",
  "QualityAttribute:Protein:7:Ensure that QTPP is finalized to prepare for process validation activities. If QTPP is not finalized, it should be captured as a risk.": "ex:QualityAttribute_ensure_that_qtpp_is_995a785a",
  "QualityAttribute:Protein:7:Execute selection, qualification and release testing specifications/methods gap mitigation for DS (including MCB, WCB) and DP Raw Materials and Product Contact Polymeric Materials for PPQ manufacture including specifications and analytical methods.": "ex:QualityAttribute_execute_selection_qu_a020a22b",
  "QualityAttribute:Protein:7:Finalize plans for transfer of execution of PPQ and commercial  release and stability methods to JSC Quality and obtain agreement.": "ex:QualityAttribute_finalize_plans_for_t_0f90fb2f",
  "QualityAttribute:Protein:7:First Ph3 clinical DS and DP release (CoA, CoC & QP).": "ex:QualityAttribute_first_ph3_clinical_d_b94b6fd2",
  "QualityAttribute:Protein:7:Five product samples representative of those to be tested in the HF validation study ready for submission to FDA": "ex:QualityAttribute_five_product_samples_21258f75",
  "QualityAttribute:Protein:7:Formulation/process dev history report updated/initiated.": "ex:QualityAttribute_formulation_process_11f08962",
  "QualityAttribute:Protein:7:Human Factors Validation Study - HFS Execution Summary report": "ex:QualityAttribute_human_factors_valida_8857739d",
  "QualityAttribute:Protein:7:Human Factors Validation Study - HFS Protocol": "ex:QualityAttribute_human_factors_valida_b26724d7",
  "QualityAttribute:Protein:7:IFU - Development & IFU Draft (as needed)": "ex:QualityAttribute_ifu_development_ifu_a1100899",
  "QualityAttribute:Protein:7:IND/IMPD review (Manufacturing & Packaging locations, Stability plan, as needed) and delivery of submission labels": "ex:QualityAttribute_ind_impd_review_manu_9388b8c8",
  "QualityAttribute:Protein:7:JJ packaging design protocol (review and update as needed)": "ex:QualityAttribute_jj_packaging_design_f7f03092",
  "QualityAttribute:Protein:7:Labeling - Design & Content Development (as needed)": "ex:QualityAttribute_labeling_design_cont_4f196483",
  "QualityAttribute:Protein:7:Manufacturing and Design Transfer Plan (review and update as needed)": "ex:QualityAttribute_manufacturing_and_de_b5c5e43e",
  "QualityAttribute:Protein:7:PF2P activities completed.": "ex:QualityAttribute_pf2p_activities_comp_f85e350f",
  "QualityAttribute:Protein:7:Participate in Criticality Analysis (CQA)  and add product specific information as available.   Increased  (p)CMA  identification, increased (p)CPP knowledge.": "ex:QualityAttribute_participate_in_criti_cc5cbf1d",
  "QualityAttribute:Protein:7:Ph2/3 comparability study strategy reviewed at BCC.": "ex:QualityAttribute_ph2_3_comparability_63f95daf",
  "QualityAttribute:Protein:7:Ph3 Analytical sections of IND/IMPD submission completed.": "ex:QualityAttribute_ph3_analytical_secti_9e560f46",
  "QualityAttribute:Protein:7:Ph3 CMC dossier prepared & management approval completed": "ex:QualityAttribute_ph3_cmc_dossier_prep_dac32b99",
  "QualityAttribute:Protein:7:Ph3 DP CMC sections of IND/IMPD submission completed.": "ex:QualityAttribute_ph3_dp_cmc_sections_651a97b2",
  "QualityAttribute:Protein:7:Ph3 Downstream CMC sections of IND/IMPD submission completed.": "ex:QualityAttribute_ph3_downstream_cmc_s_98fd604c",
  "QualityAttribute:Protein:7:Ph3 Downstream TTR & CSRs approved.": "ex:QualityAttribute_ph3_downstream_ttr_c_3afa790c",
  "QualityAttribute:Protein:7:Ph3 Eng run and/or CTM DP mfg. process TTR approved (if required).": "ex:QualityAttribute_ph3_eng_run_and_or_c_2db8400e",
  "QualityAttribute:Protein:7:Ph3 Mfg CMC sections of IND/IMPD submission reviewed and approved within JSC.": "ex:QualityAttribute_ph3_mfg_cmc_sections_7213c7bc",
  "QualityAttribute:Protein:7:Ph3 Product and Device Specifications/JoS approved.": "ex:QualityAttribute_ph3_product_and_devi_ec70c45d",
  "QualityAttribute:Protein:7:Ph3 Upstream CMC sections of IND/IMPD submission completed.": "ex:QualityAttribute_ph3_upstream_cmc_sec_97e925b0",
  "QualityAttribute:Protein:7:Ph3 Upstream TTR & CSRs approved.": "ex:QualityAttribute_ph3_upstream_ttr_csr_f5d04fd7",
  "QualityAttribute:Protein:7:Ph3 clinical DS and DP batch(es) manufacturing successfully executed (at least 1 batch).": "ex:QualityAttribute_ph3_clinical_ds_and_fcc1f6a6",
  "QualityAttribute:Protein:7:Ph3 clinical device mfg. & assembly successfully executed (if applicable).": "ex:QualityAttribute_ph3_clinical_device_b937a246",
  "QualityAttribute:Protein:7:Ph3 downstream batches released & process reports approved.": "ex:QualityAttribute_ph3_downstream_batch_80aa4557",
  "QualityAttribute:Protein:7:Ph3 intermediate DS and DP temperature cycling completed and stability statement approved.": "ex:QualityAttribute_ph3_intermediate_ds_e14c1a17",
  "QualityAttribute:Protein:7:Ph3 pharmacy manual studies completed & documented.  IPPI approved.": "ex:QualityAttribute_ph3_pharmacy_manual_36b40a7f",
  "QualityAttribute:Protein:7:Ph3 supplies manufactured, released, and delivered to clinical sites to meet FPI.": "ex:QualityAttribute_ph3_supplies_manufac_9f0ef479",
  "QualityAttribute:Protein:7:Ph3 upstream batches released & process characterization reports approved.": "ex:QualityAttribute_ph3_upstream_batches_ebe9ae0d",
  "QualityAttribute:Protein:7:Ph3 upstream, downstream and DP process samples shipped to test sites.": "ex:QualityAttribute_ph3_upstream_downstr_9a6e008e",
  "QualityAttribute:Protein:7:Phase 3 pharmacy manual testing completed.": "ex:QualityAttribute_phase_3_pharmacy_man_2e05f591",
  "QualityAttribute:Protein:7:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_1ea71d09",
  "QualityAttribute:Protein:7:Prepare JSC QC Labs for execution of method co-validations and transfer of execution ownership": "ex:QualityAttribute_prepare_jsc_qc_labs_198e2d90",
  "QualityAttribute:Protein:7:Primary/ Working  Reference standard Specification document aligned with the current DS specification and drafted.": "ex:QualityAttribute_primary_working_refe_1a6ab749",
  "QualityAttribute:Protein:7:Process Validation Strategy, key deliverables, and timing established.": "ex:QualityAttribute_process_validation_s_ab46ae25",
  "QualityAttribute:Protein:7:Process characterization testing of Ph 3 intermediate, DS and DP batches completed & data made available to study director.": "ex:QualityAttribute_process_characteriza_2389e3d3",
  "QualityAttribute:Protein:7:Product Design Rationale Report (if applicable)": "ex:QualityAttribute_product_design_ratio_356a93c8",
  "QualityAttribute:Protein:7:Product Strategy Roadmap (PSR) refreshed.": "ex:QualityAttribute_product_strategy_roa_4e2846b8",
  "QualityAttribute:Protein:7:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_a1134d77",
  "QualityAttribute:Protein:7:Project plan updated and reviewed with CMC Team.": "ex:QualityAttribute_project_plan_updated_e9da3ad8",
  "QualityAttribute:Protein:7:Protocol for generation of EEPCB executed (included in sampling plan), EEPCB shipped to Cell Banking, Cell and Developability Sciences notified to enable Ph3 (pivotal) genetic characterization stability testing; genetic characterization completed and reports generated.": "ex:QualityAttribute_protocol_for_generat_b5575683",
  "QualityAttribute:Protein:7:Provide a high level summary of any late development IP discussions. Discuss any novel original ideas and innovations and progress made toward completing a patent application.": "ex:QualityAttribute_provide_a_high_level_36c14b1e",
  "QualityAttribute:Protein:7:QA review of Ph3 CMC dossier.": "ex:QualityAttribute_qa_review_of_ph3_cmc_b6be322d",
  "QualityAttribute:Protein:7:Refresh forecast and capacity planning for API and DP via initial New Product Segmentation (NPS) and Forecast Integration Session (FIS) - Socialization, if needed": "ex:QualityAttribute_refresh_forecast_and_646f3e11",
  "QualityAttribute:Protein:7:Regulated Substances Plan (review and update as needed)": "ex:QualityAttribute_regulated_substances_d08ff08c",
  "QualityAttribute:Protein:7:Regulated Substances Report and Supplier Regulated Substances Declarations": "ex:QualityAttribute_regulated_substances_8258d96f",
  "QualityAttribute:Protein:7:Review PRA, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_pra_update_if_a63dd4fa",
  "QualityAttribute:Protein:7:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_3f7d10e7",
  "QualityAttribute:Protein:7:Review current plans and data to determine if development buy-ups are needed.": "ex:QualityAttribute_review_current_plans_989df459",
  "QualityAttribute:Protein:7:Review of Human Factors Validation Study for submission to FDA": "ex:QualityAttribute_review_of_human_fact_14b55bb3",
  "QualityAttribute:Protein:7:Review process characterization report, small-scale model qualification report, process robustness study plan, TTR & CSRs, ProVal master plan (for both upstream and downstream).": "ex:QualityAttribute_review_process_chara_4b9c891b",
  "QualityAttribute:Protein:7:Review the polysorbate control strategy  critical questions and identify any risks  and mitigation plans prior to PPQ.": "ex:QualityAttribute_review_the_polysorba_9e37a2cc",
  "QualityAttribute:Protein:7:Secondary Package \u2013 Process Design (as needed)": "ex:QualityAttribute_secondary_package_pr_515d4e5f",
  "QualityAttribute:Protein:7:Stability Plan": "ex:QualityAttribute_stability_plan_f3096a40",
  "QualityAttribute:Protein:7:Stage 7 CMC Council presentation review completed.": "ex:QualityAttribute_stage_7_cmc_council_efd6f598",
  "QualityAttribute:Protein:7:Submit approved HF validation study protocol": "ex:QualityAttribute_submit_approved_hf_v_b6d0efb2",
  "QualityAttribute:Protein:7:Submit product samples to FDA upon request": "ex:QualityAttribute_submit_product_sampl_19da37e5",
  "QualityAttribute:Protein:7:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_dd40e58c",
  "QualityAttribute:Protein:7:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_8a0afd4e",
  "QualityAttribute:Protein:7:Update Clinical and Regulatory Plans (if applicable)": "ex:QualityAttribute_update_clinical_and_94529e99",
  "QualityAttribute:Protein:7:Update Criticality Analysis (CQA, CPP, CMA) as applicable.": "ex:QualityAttribute_update_criticality_a_5d3e2523",
  "QualityAttribute:Protein:7:Update Criticality Analysis (CQA, CPPs, CMAs), as applicable": "ex:QualityAttribute_update_criticality_a_978217ed",
  "QualityAttribute:Protein:7:Update DHF": "ex:QualityAttribute_update_dhf_e57cee13",
  "QualityAttribute:Protein:7:Update Device Stability Plan": "ex:QualityAttribute_update_device_stabil_9f111b75",
  "QualityAttribute:Protein:7:Update General Safety and Performance Requirements (GSPR) Checklist (review and update as needed)": "ex:QualityAttribute_update_general_safet_e05c32f6",
  "QualityAttribute:Protein:7:Update strategic forecast and capacity planning for API and DP via NPS/FIS.": "ex:QualityAttribute_update_strategic_for_50eb108f",
  "QualityAttribute:Protein:7:Updated COGS and GP for launch and steady state (Prior to Full Development Decision).": "ex:QualityAttribute_updated_cogs_and_gp_a9e7a6d7",
  "QualityAttribute:Protein:7:Upstream small-scale model qualification report approved.": "ex:QualityAttribute_upstream_small_scale_a1f604c0",
  "QualityAttribute:Protein:7:VCL \u2013 secondary packaging source site selection completed\nPack TLI \u2013 commercial structural packaging design reviewed & agreed\nPack TLI \u2013 General packaging process and equipment requirements defined\nVCL/site \u2013 Packaging equipment (upgrades) budget approved": "ex:QualityAttribute_vcl_secondary_packag_8a496cb8",
  "QualityAttribute:Protein:7:Validate  titer methods  prior to PPQ": "ex:QualityAttribute_validate_titer_metho_cf3d1342",
  "QualityAttribute:Protein:8:Additional downstream process robustness studies report approved (if required).": "ex:QualityAttribute_additional_downstrea_360771e3",
  "QualityAttribute:Protein:8:Additional upstream process robustness studies report approved (if required).": "ex:QualityAttribute_additional_upstream_e10ef31d",
  "QualityAttribute:Protein:8:Alignment with Medical Affairs on potential demands": "ex:QualityAttribute_alignment_with_medic_66e1b31e",
  "QualityAttribute:Protein:8:All IPC,  DS and DP, release/stability test methods approved for PPQ.": "ex:QualityAttribute_all_ipc_ds_and_dp_re_5d8c8e74",
  "QualityAttribute:Protein:8:All PF2P activities completed for commercial process.": "ex:QualityAttribute_all_pf2p_activities_3c55985c",
  "QualityAttribute:Protein:8:All polymeric risk scoring initiated and completed by end of PPQ. Initiate Extractables study if required.": "ex:QualityAttribute_all_polymeric_risk_s_486fc590",
  "QualityAttribute:Protein:8:Allocate  and screen material for bioassay  to support generation of working reference material.": "ex:QualityAttribute_allocate_and_screen_6c18bb07",
  "QualityAttribute:Protein:8:Apply previous lessons learned to the ProVal Strategy if applicable.": "ex:QualityAttribute_apply_previous_lesso_b41efb82",
  "QualityAttribute:Protein:8:Approve Criticality Analysis.": "ex:QualityAttribute_approve_criticality_327add7c",
  "QualityAttribute:Protein:8:Assess regulatory strategy and planned availability of any required ProVal dossier deliverables (e.g. protocols, validation summary reports) to ensure consistency with current HA guidance/feedback and/or changes in Industry Standards": "ex:QualityAttribute_assess_regulatory_st_323c6060",
  "QualityAttribute:Protein:8:Assign a Commercial SI to participate in the analytical subteam": "ex:QualityAttribute_assign_a_commercial_d427f70a",
  "QualityAttribute:Protein:8:CPDP Design & Process Validation": "ex:QualityAttribute_cpdp_design_process_57ee5931",
  "QualityAttribute:Protein:8:Characterization of excipients, heavy metals and silicones (process/product impurities) for clinical batches  completed.": "ex:QualityAttribute_characterization_of_235427fc",
  "QualityAttribute:Protein:8:Co-validations / method transfers  completed with JSC and reports approved.": "ex:QualityAttribute_co_validations_metho_eae3273a",
  "QualityAttribute:Protein:8:Commercial Container Closure System Development Report updated as needed.": "ex:QualityAttribute_commercial_container_a2853ec3",
  "QualityAttribute:Protein:8:Commercial Primary Component Specifications updated as needed.": "ex:QualityAttribute_commercial_primary_c_e6bfe5db",
  "QualityAttribute:Protein:8:Commercial financial product flow system set-up.": "ex:QualityAttribute_commercial_financial_f3756a01",
  "QualityAttribute:Protein:8:Commercial secondary packaging strategy initiated.": "ex:QualityAttribute_commercial_secondary_f0bb5bd1",
  "QualityAttribute:Protein:8:Commercial shipping routes identified for DS, DP & Finished Product (for DPD shipper validation).": "ex:QualityAttribute_commercial_shipping_951816c5",
  "QualityAttribute:Protein:8:Complete  initial process FMEA (COMBO Product Requirement)": "ex:QualityAttribute_complete_initial_pro_83cc1acc",
  "QualityAttribute:Protein:8:Complete Request Intake Form for Product Quality Complaint New Product Introduction for Clinical as part of the general Product Quality Complaint Process": "ex:QualityAttribute_complete_request_int_f4e0f86d",
  "QualityAttribute:Protein:8:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.  Complete HF studies, if needed. (For non-combination products.\u00a0 See Comment in Stage 3)": "ex:QualityAttribute_complete_or_revisit_bd9bfa6d",
  "QualityAttribute:Protein:8:Complete protocols/documentation supporting inclusion of raw materials variation and characterization in DS and DP Process Validation Strategy (media, buffers, resins, chemicals, excipients and polymeric product contact materials).": "ex:QualityAttribute_complete_protocols_d_e6cc7e67",
  "QualityAttribute:Protein:8:Complete selection, qualification and release testing specifications/methods gap mitigations for raw materials for DS and DP for PPQ manufacture.": "ex:QualityAttribute_complete_selection_q_1e87a6f1",
  "QualityAttribute:Protein:8:Confirm that sampling plans have been set up such that needs and BTDS/PSTS/TD sample needs (i.e. reference materials, development activities) analytical needs,  and regulatory needs (i.e., samples for local health authority testing requirements) are met .": "ex:QualityAttribute_confirm_that_samplin_2f9a3a6e",
  "QualityAttribute:Protein:8:Confirm with API that  Ph3 process impurity testing completed (include nitrosamines as applicable).": "ex:QualityAttribute_confirm_with_api_tha_c837f19e",
  "QualityAttribute:Protein:8:Coordinate aggregated clinical/non-clinical demand in support of Ph3 mfg. and provide to the JSC organization .": "ex:QualityAttribute_coordinate_aggregate_92e23c90",
  "QualityAttribute:Protein:8:DP process development and robustness studies data reviewed at level 1 governance.": "ex:QualityAttribute_dp_process_developme_b6884f8b",
  "QualityAttribute:Protein:8:DP process validation protocol approved (8B).": "ex:QualityAttribute_dp_process_validatio_30afb566",
  "QualityAttribute:Protein:8:DS & DP expiry extension completed (if required).": "ex:QualityAttribute_ds_dp_expiry_extensi_e7532f4d",
  "QualityAttribute:Protein:8:DS and DP Process Validation Batch Records and SOP's approved.": "ex:QualityAttribute_ds_and_dp_process_va_8f23ac9f",
  "QualityAttribute:Protein:8:DS and DP commercial min & max batch sizes determined.": "ex:QualityAttribute_ds_and_dp_commercial_e8ff46d7",
  "QualityAttribute:Protein:8:DS small scale model data reviewed at Functional Level 1 governance.": "ex:QualityAttribute_ds_small_scale_model_9b530cb8",
  "QualityAttribute:Protein:8:DS upstream & downstream process control, pooling, hold-time, and characterization functional area review completed (8A).": "ex:QualityAttribute_ds_upstream_downstre_1b6538fc",
  "QualityAttribute:Protein:8:Design Control - Design Validation  (CPDP Deliverables)": "ex:QualityAttribute_design_control_desig_e351b577",
  "QualityAttribute:Protein:8:Design Control - Design Validation Protocol": "ex:QualityAttribute_design_control_desig_892e1d7f",
  "QualityAttribute:Protein:8:Design Control - Design Validation Protocol/Execution": "ex:QualityAttribute_design_control_desig_6a8309cf",
  "QualityAttribute:Protein:8:Design Control - Design Validation Report": "ex:QualityAttribute_design_control_desig_ec9cebae",
  "QualityAttribute:Protein:8:Design Control - Design Validation Summary Report": "ex:QualityAttribute_design_control_desig_4775af26",
  "QualityAttribute:Protein:8:Design Control - Software Validation Report (If Applicable)": "ex:QualityAttribute_design_control_softw_ff712423",
  "QualityAttribute:Protein:8:Design Output  (CPDP Deliverables) - DHF  (Update if required)": "ex:QualityAttribute_design_output_cpdp_d_8f2bd440",
  "QualityAttribute:Protein:8:Design Output  (CPDP Deliverables) - DMR  (Update if required)": "ex:QualityAttribute_design_output_cpdp_d_47c576da",
  "QualityAttribute:Protein:8:Developed scenarios in support of strategic planning (as required), strategic impact analysis (critical path, risk, budget variances).": "ex:QualityAttribute_developed_scenarios_88b8c90d",
  "QualityAttribute:Protein:8:Device  incoming, in-process and release/stability test methods approved for PPQ.": "ex:QualityAttribute_device_incoming_in_p_f412688a",
  "QualityAttribute:Protein:8:Device Risk Management  (Update) - CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_e37b7756",
  "QualityAttribute:Protein:8:Device Risk Management  (Update) - Device Control Strategy (Review and Update)": "ex:QualityAttribute_device_risk_manageme_afadbdc3",
  "QualityAttribute:Protein:8:Device Risk Management  (Update) - Product Risk Assessment (Update)": "ex:QualityAttribute_device_risk_manageme_5c02b2dc",
  "QualityAttribute:Protein:8:Device Risk Management  (Update) - Risk Management Plan (Update)": "ex:QualityAttribute_device_risk_manageme_50fde51a",
  "QualityAttribute:Protein:8:Device Risk Management  (Update) - Risk Management Report (Update)": "ex:QualityAttribute_device_risk_manageme_519865ac",
  "QualityAttribute:Protein:8:Device Risk Management  (Update) - dFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_c4e9cc58",
  "QualityAttribute:Protein:8:Device Risk Management  (Update) - pFMEA (Initiate)": "ex:QualityAttribute_device_risk_manageme_809ccc1c",
  "QualityAttribute:Protein:8:Device Risk Management  (Update) - uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_90877a6d",
  "QualityAttribute:Protein:8:Document list (including process characterization reports, robustness study reports, process validation protocol and reports) compiled for process development section of BLA and PAI readiness.": "ex:QualityAttribute_document_list_includ_4b17a313",
  "QualityAttribute:Protein:8:Downstream process validation protocol approved (8A).": "ex:QualityAttribute_downstream_process_v_80fc885d",
  "QualityAttribute:Protein:8:EHS Requirement: complete design for sustainability document, develop label for DP": "ex:QualityAttribute_ehs_requirement_comp_2778827e",
  "QualityAttribute:Protein:8:EHS Requirement: determine if OEL for DS is needed, update DS SDS, develop label for drug substance, REACH notification approved  - as applicable\u00a0 (see EHS tab for contacts).": "ex:QualityAttribute_ehs_requirement_dete_a300c7a1",
  "QualityAttribute:Protein:8:Ensure CMC team members identified in functional review matrices review the following draft Reports if applicable (DS Process Validation Plan; DP Process Validation Plan; DS/DP updated Criticality Analysis; DS & DP Comparability Report(s); Pharmaceutical Development Report(s). Needs further discussion within Portfolio Management.": "ex:QualityAttribute_ensure_cmc_team_memb_081102b5",
  "QualityAttribute:Protein:8:Ensure Customer Centered Design deliverables are completed for this stage. (CMCL Co-owner)": "ex:QualityAttribute_ensure_customer_cent_fc35b3c1",
  "QualityAttribute:Protein:8:Ensure Customer Centered Design deliverables are completed for this stage. (VCL co-owns this deliverable)": "ex:QualityAttribute_ensure_customer_cent_2724c608",
  "QualityAttribute:Protein:8:Ensure DPAT review/approval of all changes to clinical protocol that lead to a change to the IPPI/PM study.": "ex:QualityAttribute_ensure_dpat_review_a_11b29c9c",
  "QualityAttribute:Protein:8:Ensure LD Criticality Report and DS/DP control strategy assessment reports are completed.": "ex:QualityAttribute_ensure_ld_criticalit_60e98644",
  "QualityAttribute:Protein:8:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_9b568713",
  "QualityAttribute:Protein:8:Ensure that Stability protocols for PPQ and commercial  manufacturing prepared by PQM Product Quality Specialist for all protein modalities.": "ex:QualityAttribute_ensure_that_stabilit_1ff229d7",
  "QualityAttribute:Protein:8:Ensure that Stability strategy (e.g. number of batches, timepoints, tests) for PPQ and commercial  manufacturing prepared by PQM Stability CoE for all protein modalities.": "ex:QualityAttribute_ensure_that_stabilit_5241f915",
  "QualityAttribute:Protein:8:Ensure that an overview of pre-license studies done by DPDS (e.g. F/T, temp cycling, photostability studies)  is provided to JSC  Quality. Include proven temp range in the shelf life memo with a reference to study report": "ex:QualityAttribute_ensure_that_an_overv_ca80e5f3",
  "QualityAttribute:Protein:8:Ensure that data recording/reporting strategy finalized in test methods and rolled out to the laboratories and PQM stability CoE.": "ex:QualityAttribute_ensure_that_data_rec_fd26ab30",
  "QualityAttribute:Protein:8:Ensure that resin re-use matrices are identified by API and methods co-validated/qualified with JSC QC.": "ex:QualityAttribute_ensure_that_resin_re_078a4f1d",
  "QualityAttribute:Protein:8:Facilitate After Action Review and PF2P sessions.": "ex:QualityAttribute_facilitate_after_act_b300c48a",
  "QualityAttribute:Protein:8:Final equipment and process changes implemented (based on After Action Review from clinical production).": "ex:QualityAttribute_final_equipment_and_7e9b55f0",
  "QualityAttribute:Protein:8:Finalize Criticality Analysis (CQA, CPP's, CMA's and control strategy).": "ex:QualityAttribute_finalize_criticality_f4ecbc9a",
  "QualityAttribute:Protein:8:Finalize Criticality Analysis (CQA, CPP's, CMAs and control strategy).": "ex:QualityAttribute_finalize_criticality_85abbe9e",
  "QualityAttribute:Protein:8:Functional area review of DS and DP process control, pooling, hold-time, and characterization.": "ex:QualityAttribute_functional_area_revi_28629f65",
  "QualityAttribute:Protein:8:Generate strategy for characterization tests to be included into Process Validation DPC (if applicable) DS and DP specifcation documents.": "ex:QualityAttribute_generate_strategy_fo_1c8904b9",
  "QualityAttribute:Protein:8:Initiate forced degradation, variant characterization, and other S.3.1 characterization studies.": "ex:QualityAttribute_initiate_forced_degr_67c262b3",
  "QualityAttribute:Protein:8:JJ Packaging Design protocol (review and update if needed)": "ex:QualityAttribute_jj_packaging_design_08c480ab",
  "QualityAttribute:Protein:8:Marketing Application  dossier strategy and development timeline completed.  Review the current MAA/BLA review process, timeline and plan (BLA/MAA kick off meeting) with extended team and functional areas": "ex:QualityAttribute_marketing_applicatio_43d2381e",
  "QualityAttribute:Protein:8:Packaging equipment design review completed": "ex:QualityAttribute_packaging_equipment_5b53f388",
  "QualityAttribute:Protein:8:Packaging process FMEA done and control plan defined": "ex:QualityAttribute_packaging_process_fm_e6f8cb2b",
  "QualityAttribute:Protein:8:Participate in After Action Review from Ph3 batches and document in risk register.": "ex:QualityAttribute_participate_in_after_3af35e15",
  "QualityAttribute:Protein:8:Participate in Criticality Analysis (CQA, CPPs, CMA's, control strategy, CPV 3a plan/protocol).": "ex:QualityAttribute_participate_in_criti_55b2b3c1",
  "QualityAttribute:Protein:8:Passive shipping systems qualified, if applicable.": "ex:QualityAttribute_passive_shipping_sys_6d4a20f2",
  "QualityAttribute:Protein:8:Pediatric CMC assessment (assess potential for pediatric formulation development) completed.": "ex:QualityAttribute_pediatric_cmc_assess_d7a870b5",
  "QualityAttribute:Protein:8:Ph3 DS / DP product characterization testing completed.": "ex:QualityAttribute_ph3_ds_dp_product_ch_6c2c4839",
  "QualityAttribute:Protein:8:Ph3 clinical supply manufactured and allocated to meet CDT approved clinical demands (if applicable).": "ex:QualityAttribute_ph3_clinical_supply_76de30be",
  "QualityAttribute:Protein:8:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_957dddd5",
  "QualityAttribute:Protein:8:Primary and working reference material specification and qualification SOPs approved.": "ex:QualityAttribute_primary_and_working_0deccb18",
  "QualityAttribute:Protein:8:Product characterization  test methods approved  prior to PPQ/commercial testing": "ex:QualityAttribute_product_characteriza_cb71fd32",
  "QualityAttribute:Protein:8:Product specific Intermediate, DS and DP method validation/co-validation/transfer protocols approved for PPQ": "ex:QualityAttribute_product_specific_int_16a247bf",
  "QualityAttribute:Protein:8:Project plan updated and reviewed with CMC Team: prioritize, track team milestones & deliverables, proactive management of KEM aligned to CMC SG\u2019s.": "ex:QualityAttribute_project_plan_updated_64719280",
  "QualityAttribute:Protein:8:Protocol approved for generation of EEPCB, and Cell and Developability Sciences notified to enable ProVal genetic characterization testing.  Initiate importation code generation for cell bank shipment into United States, if applicable.": "ex:QualityAttribute_protocol_approved_fo_77736657",
  "QualityAttribute:Protein:8:Review Clinical Batch release/stability data .  Update Criticality Analysis (CQA for intermediate DS, DP  and CTQ for device and control strategy) and specifications as appropriate.": "ex:QualityAttribute_review_clinical_batc_af6e3aab",
  "QualityAttribute:Protein:8:Review DP  formulation robustness DOE study (available data on range finding).": "ex:QualityAttribute_review_dp_formulatio_7c550aa5",
  "QualityAttribute:Protein:8:Review DS and DP documents, including process robustness study report, small-scale model dev report, process validation protocol, genetic stability validation protocol, small scale model data functional and tech review, CQA and CPP report/memos, process validation strategy.": "ex:QualityAttribute_review_ds_and_dp_doc_b3a6fa14",
  "QualityAttribute:Protein:8:Review PRA, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_pra_update_if_383163f0",
  "QualityAttribute:Protein:8:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_bc27fba6",
  "QualityAttribute:Protein:8:Review the polysorbate control strategy  critical questions and ensure all previously identified risks are mitigated for PPQ": "ex:QualityAttribute_review_the_polysorba_5fafc0d1",
  "QualityAttribute:Protein:8:Sampling plan reviewed for DS/DP process validation characterization.": "ex:QualityAttribute_sampling_plan_review_bbfaa90d",
  "QualityAttribute:Protein:8:Stage 8A/8B CMC Team presentation review completed.": "ex:QualityAttribute_stage_8a_8b_cmc_team_f924c90d",
  "QualityAttribute:Protein:8:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_e9d2256e",
  "QualityAttribute:Protein:8:Support JSC in scenarios commercial sourcing strategic planning  (as required), strategic impact analysis (critical path, risk, budget variances).": "ex:QualityAttribute_support_jsc_in_scena_7605edce",
  "QualityAttribute:Protein:8:Support risk management activities: includes risk identification, mitigation, monitor & control; risk register utilization.": "ex:QualityAttribute_support_risk_managem_cf04eb2c",
  "QualityAttribute:Protein:8:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_8351da04",
  "QualityAttribute:Protein:8:Update General Performance and Safety (GSPR) Checklist": "ex:QualityAttribute_update_general_perfo_4b599c96",
  "QualityAttribute:Protein:8:Update Process impurity risk assessment": "ex:QualityAttribute_update_process_impur_9e37ccc5",
  "QualityAttribute:Protein:8:Update Regulated Substances Plan (if required)": "ex:QualityAttribute_update_regulated_sub_23a69ef2",
  "QualityAttribute:Protein:8:Update of Regulated Substances Report and Supplier Regulated Substances Declarations (if required)": "ex:QualityAttribute_update_of_regulated_0abe83ef",
  "QualityAttribute:Protein:8:Upstream process validation protocol approved (8A).": "ex:QualityAttribute_upstream_process_val_5f14dcc7",
  "QualityAttribute:Protein:9:API Upstream and Downstream criticality analysis and control strategy review by 9A.": "ex:QualityAttribute_api_upstream_and_dow_068ae85a",
  "QualityAttribute:Protein:9:Alignment with Medical Affairs on potential demands": "ex:QualityAttribute_alignment_with_medic_bd56ff6d",
  "QualityAttribute:Protein:9:Analytical pre-BLA meeting content & management review completed (if applicable).": "ex:QualityAttribute_analytical_pre_bla_m_7b9939a5",
  "QualityAttribute:Protein:9:Applicable CTD draft analytical sections started.": "ex:QualityAttribute_applicable_ctd_draft_e767b465",
  "QualityAttribute:Protein:9:Approve Brand Protection Product Risk Assessment VAT for Brand Protection": "ex:QualityAttribute_approve_brand_protec_6eba1674",
  "QualityAttribute:Protein:9:CPDP Design & Process Validation": "ex:QualityAttribute_cpdp_design_process_89114351",
  "QualityAttribute:Protein:9:CTD draft upstream and downstream sections started.": "ex:QualityAttribute_ctd_draft_upstream_a_8c4f42a0",
  "QualityAttribute:Protein:9:Calculate Thermal Density of Temperature Shipping Systems (as needed)": "ex:QualityAttribute_calculate_thermal_de_9faa7ef8",
  "QualityAttribute:Protein:9:Cleaning validation completed.": "ex:QualityAttribute_cleaning_validation_806dfe28",
  "QualityAttribute:Protein:9:Clinical Submission": "ex:QualityAttribute_clinical_submission_05c8b51f",
  "QualityAttribute:Protein:9:Commercial Secondary Packaging Source locked.": "ex:QualityAttribute_commercial_secondary_edfeacd0",
  "QualityAttribute:Protein:9:Commercialization Readiness Checklist": "ex:QualityAttribute_commercialization_re_63f59a6c",
  "QualityAttribute:Protein:9:Complete EU Excipient Risk Assessment (DP-independent by end of PPQ and DP-dependent as part of BLA preparation).": "ex:QualityAttribute_complete_eu_excipien_61e70eeb",
  "QualityAttribute:Protein:9:Complete ICH Q3D Elemental Impurities Risk Assessment on DP.": "ex:QualityAttribute_complete_ich_q3d_ele_b94e7c52",
  "QualityAttribute:Protein:9:Complete Product characterization studies (degradation pathways etc.).": "ex:QualityAttribute_complete_product_cha_bfa61412",
  "QualityAttribute:Protein:9:Complete Request Intake Form for Product Quality Complaint New Product Introduction for Clinical as part of the general Product Quality Complaint Process": "ex:QualityAttribute_complete_request_int_187f6f02",
  "QualityAttribute:Protein:9:Complete analysis and documentation of raw material-related elements of Process Validation (media, buffers, resins, chemicals, excipients and polymeric product contact materials).": "ex:QualityAttribute_complete_analysis_an_534313ac",
  "QualityAttribute:Protein:9:Complete any additional process impurity method qualification/validations as needed.": "ex:QualityAttribute_complete_any_additio_9a947ac4",
  "QualityAttribute:Protein:9:Complete applicable  PRM and WRM qualification testing in JSC QC  and provide results to DPDS AD.": "ex:QualityAttribute_complete_applicable_16b1fb9b",
  "QualityAttribute:Protein:9:Complete in vivo studies for glycoform clearance and degradation as needed.": "ex:QualityAttribute_complete_in_vivo_stu_a691e938",
  "QualityAttribute:Protein:9:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.  Complete HF studies, if needed. (For non-combination products.\u00a0 See Comment in Stage 3)": "ex:QualityAttribute_complete_or_revisit_7112eecc",
  "QualityAttribute:Protein:9:Complete raw material-related source documents for CTD for media, buffers, resins, excipients and polymeric product contact materials.": "ex:QualityAttribute_complete_raw_materia_63a7be61",
  "QualityAttribute:Protein:9:Complete transfer of execution of PPQ and commercial  release and stability methods to JSC QC (i.e ownership of secondary transfers). Includes device methods.": "ex:QualityAttribute_complete_transfer_of_4aaf6bc5",
  "QualityAttribute:Protein:9:Contact Procurement to establish a contract with the Notified Body and execute contract 2 months before submission of technical package for review.": "ex:QualityAttribute_contact_procurement_e85f6f82",
  "QualityAttribute:Protein:9:Continue preparation of S.3.1 Elucidation of Structure.": "ex:QualityAttribute_continue_preparation_45502557",
  "QualityAttribute:Protein:9:Control Plan": "ex:QualityAttribute_control_plan_6e957235",
  "QualityAttribute:Protein:9:Control Strategy": "ex:QualityAttribute_control_strategy_52fd7f7b",
  "QualityAttribute:Protein:9:Coordinate aggregated clinical/non-clinical demand in support of Ph3 mfg. and provide to the JSC organization": "ex:QualityAttribute_coordinate_aggregate_aac090d3",
  "QualityAttribute:Protein:9:Create and complete the technical dossier for review and opinion by NB, and assemble  package for submission to NB": "ex:QualityAttribute_create_and_complete_ccf32f52",
  "QualityAttribute:Protein:9:DP & Device criticality analysis and control strategy review completed (9B).": "ex:QualityAttribute_dp_device_criticalit_4917967d",
  "QualityAttribute:Protein:9:DP and Device pre-BLA meeting content & management review completed (if applicable).": "ex:QualityAttribute_dp_and_device_pre_bl_d26780bb",
  "QualityAttribute:Protein:9:DP development history and other CTD source documents completed.": "ex:QualityAttribute_dp_development_histo_5544f9c4",
  "QualityAttribute:Protein:9:DP process validation data review completed (9B).": "ex:QualityAttribute_dp_process_validatio_525c78f6",
  "QualityAttribute:Protein:9:DS & DP shipment (simulated transportation supportive) study report approved.": "ex:QualityAttribute_ds_dp_shipment_simul_05036a12",
  "QualityAttribute:Protein:9:DS and DP ProVal batches released.": "ex:QualityAttribute_ds_and_dp_proval_bat_2c31f840",
  "QualityAttribute:Protein:9:DS intermediate, DS and DP comprehensive analytical data review by functional area completed including stability data.": "ex:QualityAttribute_ds_intermediate_ds_a_49b8f0b9",
  "QualityAttribute:Protein:9:DS upstream and downstream process validation data & small-scale module validation review by Level 1 governance completed (9A).": "ex:QualityAttribute_ds_upstream_and_down_e73e8c6e",
  "QualityAttribute:Protein:9:DS: at-risk launch inventory build approved and production initiated (if needed).": "ex:QualityAttribute_ds_at_risk_launch_in_f705a0ec",
  "QualityAttribute:Protein:9:Design Control - Design and Development Plan  (Update)": "ex:QualityAttribute_design_control_desig_08d961df",
  "QualityAttribute:Protein:9:Design History File (Update)": "ex:QualityAttribute_design_history_file_713f2838",
  "QualityAttribute:Protein:9:Design Validation Protocols, Reports & Summary Report": "ex:QualityAttribute_design_validation_pr_1008eb16",
  "QualityAttribute:Protein:9:Design Validation and Process Validation Stage Design Review": "ex:QualityAttribute_design_validation_an_6ef83241",
  "QualityAttribute:Protein:9:Developed scenarios in support of strategic planning (as required), strategic impact analysis (critical path, risk, budget variances).": "ex:QualityAttribute_developed_scenarios_fa6a0e10",
  "QualityAttribute:Protein:9:Device Master Record (DMR) (Update)": "ex:QualityAttribute_device_master_record_1d858e43",
  "QualityAttribute:Protein:9:Device Risk Management  (Update) - CTQ Flow Down (Update)": "ex:QualityAttribute_device_risk_manageme_dcb9fdbc",
  "QualityAttribute:Protein:9:Device Risk Management  (Update) - Device Control Strategy (Review and Update)": "ex:QualityAttribute_device_risk_manageme_fc77ef2f",
  "QualityAttribute:Protein:9:Device Risk Management  (Update) - Product Risk Assessment (Update)": "ex:QualityAttribute_device_risk_manageme_2832a942",
  "QualityAttribute:Protein:9:Device Risk Management  (Update) - Risk Management Plan/Report (Update)": "ex:QualityAttribute_device_risk_manageme_b502301a",
  "QualityAttribute:Protein:9:Device Risk Management  (Update) - dFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_f1d34dbf",
  "QualityAttribute:Protein:9:Device Risk Management  (Update) - pFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_293a9c0e",
  "QualityAttribute:Protein:9:Device Risk Management  (Update) - uFMEA (Update)": "ex:QualityAttribute_device_risk_manageme_81bfefa0",
  "QualityAttribute:Protein:9:Distribution Assessment team created after packaging sourcing decision": "ex:QualityAttribute_distribution_assessm_acfcdcd6",
  "QualityAttribute:Protein:9:Distribution Testing Procedure \u2013 Approve Test Protocol & Distribution Test Results (as needed)": "ex:QualityAttribute_distribution_testing_c0879efc",
  "QualityAttribute:Protein:9:Draft / Approve CPP / Criticality reports": "ex:QualityAttribute_draft_approve_cpp_cr_4fff46b6",
  "QualityAttribute:Protein:9:Draft and obtain AD endorsement of initial commercial specifications for intermediate, DS, DP. Final proposal will come following availability of 3-6 mo stability data on Proval batches (evaluate deliverable for accelerated programs).": "ex:QualityAttribute_draft_and_obtain_ad_a8104be2",
  "QualityAttribute:Protein:9:EEPCB generation executed; genetic characterization completed by Cell and Developability Sciences and reports approved": "ex:QualityAttribute_eepcb_generation_exe_469380c4",
  "QualityAttribute:Protein:9:EHS Requirement: REACH registration approved, develop industrial hygiene (IH) sampling and method  - as applicable\u00a0 (see EHS tab for contacts).": "ex:QualityAttribute_ehs_requirement_reac_c6045f1d",
  "QualityAttribute:Protein:9:EHS Requirement: Update DP SDS to align with approved IFU/product label": "ex:QualityAttribute_ehs_requirement_upda_ef9c5a64",
  "QualityAttribute:Protein:9:Ensure CMC team members identified in functional review matrices review the following draft Reports: DS & DP specification and JOS; DS & DP Criticality Reports. Needs further discussion within Portfolio Management.": "ex:QualityAttribute_ensure_cmc_team_memb_c4163942",
  "QualityAttribute:Protein:9:Ensure Customer Centered Design deliverables are completed for this stage (combo products), inclusive of Customer Centered Design Workshop as needed.": "ex:QualityAttribute_ensure_customer_cent_ac1a3088",
  "QualityAttribute:Protein:9:Ensure Customer Centered Design deliverables are completed for this stage. (CMCL Co-owner)": "ex:QualityAttribute_ensure_customer_cent_c7435d75",
  "QualityAttribute:Protein:9:Ensure LD Criticality Report is updated (if applicable).": "ex:QualityAttribute_ensure_ld_criticalit_c731501b",
  "QualityAttribute:Protein:9:Ensure Primary and Working reference standard qualification and characterization testing completed.": "ex:QualityAttribute_ensure_primary_and_w_637245d1",
  "QualityAttribute:Protein:9:Ensure overall CSC FTE and OOP budget compound and study level in place": "ex:QualityAttribute_ensure_overall_csc_f_a1a4a239",
  "QualityAttribute:Protein:9:Executed In-Use Reliability Testing Report": "ex:QualityAttribute_executed_in_use_reli_d5acbded",
  "QualityAttribute:Protein:9:Facilitate After Action Review and PF2P sessions.": "ex:QualityAttribute_facilitate_after_act_a7bb336f",
  "QualityAttribute:Protein:9:Final Design Verification and Summary Report": "ex:QualityAttribute_final_design_verific_0e4789be",
  "QualityAttribute:Protein:9:Final Labeling/IFU (Update) Deliver Label Working Group (LWG) approved IFU (as needed)": "ex:QualityAttribute_final_labeling_ifu_u_c871dacd",
  "QualityAttribute:Protein:9:For EU MDR identify economic operators and update Quality Agreements (if applicable)": "ex:QualityAttribute_for_eu_mdr_identify_5ebfdb09",
  "QualityAttribute:Protein:9:Functional area review of DS and DP reports, including process validation data and small-scale model validation, criticality analysis, and development history.": "ex:QualityAttribute_functional_area_revi_006d22c9",
  "QualityAttribute:Protein:9:Generate strategy for characterization tests to be included in the commercial lab specs, based on review of data from char tests during PPQ campaigns": "ex:QualityAttribute_generate_strategy_fo_e5df0e2f",
  "QualityAttribute:Protein:9:High level Commercial Launch Strategy initiated.": "ex:QualityAttribute_high_level_commercia_f40194b9",
  "QualityAttribute:Protein:9:Human Factors Plan (Update)": "ex:QualityAttribute_human_factors_plan_u_0d107a11",
  "QualityAttribute:Protein:9:Human Factors Summary Report": "ex:QualityAttribute_human_factors_summar_1a94603c",
  "QualityAttribute:Protein:9:IFU - DDO Submission & HA Approval (as needed)": "ex:QualityAttribute_ifu_ddo_submission_h_f513fe01",
  "QualityAttribute:Protein:9:Identify Notified Body for EU device review, initiate conversations with Notified Body (SG9A)": "ex:QualityAttribute_identify_notified_bo_02a20413",
  "QualityAttribute:Protein:9:Initiate long term leachable study to support BLA/Marketing Application using process validation batches.": "ex:QualityAttribute_initiate_long_term_l_33a08ae8",
  "QualityAttribute:Protein:9:JJ Packaging Design Protocol (review and updated when needed)": "ex:QualityAttribute_jj_packaging_design_5036ef64",
  "QualityAttribute:Protein:9:JSC QC complete transfer of execution of PPQ and commercial release and stability methods from DPDS AD.": "ex:QualityAttribute_jsc_qc_complete_tran_dd9732c8",
  "QualityAttribute:Protein:9:Maintain sample archive/permanent retention program for all Clinical and ProVal batches.": "ex:QualityAttribute_maintain_sample_arch_ef99806f",
  "QualityAttribute:Protein:9:Marketing Application development in progress and complete dossier strategy for content for derivative dossiers": "ex:QualityAttribute_marketing_applicatio_740d6721",
  "QualityAttribute:Protein:9:Nitrosamine risk assessment documented and control strategy defined (with API, AD, Material Sciences, PC&D and PQM)": "ex:QualityAttribute_nitrosamine_risk_ass_d46df4cd",
  "QualityAttribute:Protein:9:PAI readiness plans established.": "ex:QualityAttribute_pai_readiness_plans_00130b9f",
  "QualityAttribute:Protein:9:Packaging physical distribution testing completed": "ex:QualityAttribute_packaging_physical_d_bbdd0d65",
  "QualityAttribute:Protein:9:Packaging thermal protection (outbound DC) defined": "ex:QualityAttribute_packaging_thermal_pr_92f19e4a",
  "QualityAttribute:Protein:9:Post Market Product Management Plan (if applicable)": "ex:QualityAttribute_post_market_product_c53e4e99",
  "QualityAttribute:Protein:9:Post Market Safety Reporting including MARL (if applicable)": "ex:QualityAttribute_post_market_safety_r_a076e66d",
  "QualityAttribute:Protein:9:Pre-Approval Inspection Readiness - Checklist execution Summary/Remediation Report": "ex:QualityAttribute_pre_approval_inspect_35e31bde",
  "QualityAttribute:Protein:9:Pre-Approval Inspection Readiness - PAI Readiness Checklist (Device/Combo)": "ex:QualityAttribute_pre_approval_inspect_d47c4d74",
  "QualityAttribute:Protein:9:Pre-Submission meeting package submitted to HA's/meetings completed (if applicable).": "ex:QualityAttribute_pre_submission_meeti_b66039c4",
  "QualityAttribute:Protein:9:Pre-submission package prepared and approved for HA meeting if applicable": "ex:QualityAttribute_pre_submission_packa_0ab3646a",
  "QualityAttribute:Protein:9:ProVal  process characterization (upstream, downstream & DP) data provided to study director.": "ex:QualityAttribute_proval_process_chara_7095ea2f",
  "QualityAttribute:Protein:9:ProVal DS and DP batches manufactured.": "ex:QualityAttribute_proval_ds_and_dp_bat_d569169e",
  "QualityAttribute:Protein:9:ProVal characterization, release and stability samples sent to testing labs (as required).": "ex:QualityAttribute_proval_characterizat_be905a2e",
  "QualityAttribute:Protein:9:ProVal device batches manufactured.": "ex:QualityAttribute_proval_device_batche_5c7ca42d",
  "QualityAttribute:Protein:9:Process Performance Qualification Protocols and  Reports": "ex:QualityAttribute_process_performance_6e61765b",
  "QualityAttribute:Protein:9:Product Strategy Roadmap (PSR) refreshed.": "ex:QualityAttribute_product_strategy_roa_db2e203a",
  "QualityAttribute:Protein:9:Project FTE and OOP demand estimates completed and updated in Planning System.": "ex:QualityAttribute_project_fte_and_oop_35a9b1ad",
  "QualityAttribute:Protein:9:Project plan updated and reviewed with CMC Team: prioritize, track team milestones & deliverables, proactive management of KEM aligned to CMC SG\u2019s.": "ex:QualityAttribute_project_plan_updated_083b4711",
  "QualityAttribute:Protein:9:Provide a detailed description of the completed IP review of novel ideas and innovations during late phase development.  Request approval of patent and publication strategy.": "ex:QualityAttribute_provide_a_detailed_d_ed46b7fb",
  "QualityAttribute:Protein:9:Qualification Report of Insulated Shipping Container for Temperature Sensitive Products (as needed)": "ex:QualityAttribute_qualification_report_632fedb7",
  "QualityAttribute:Protein:9:Regulatory Submission": "ex:QualityAttribute_regulatory_submissio_61483817",
  "QualityAttribute:Protein:9:Review PRA, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_pra_update_if_aa9916af",
  "QualityAttribute:Protein:9:Review PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_prm_plan_repo_18b5f334",
  "QualityAttribute:Protein:9:Review cold-chain and DS/DP shipping strategy (for primary containers).": "ex:QualityAttribute_review_cold_chain_an_5ab86dd4",
  "QualityAttribute:Protein:9:Review current plans and data to determine if development buy-ups are needed.": "ex:QualityAttribute_review_current_plans_c5454b0f",
  "QualityAttribute:Protein:9:Review data and make final recommendation (temperature and time duration) for room temperature storage for patient use (if required in the TPP).": "ex:QualityAttribute_review_data_and_make_d739e18d",
  "QualityAttribute:Protein:9:Secondary Package \u2013 Process Qualification (as needed)": "ex:QualityAttribute_secondary_package_pr_4965b0ce",
  "QualityAttribute:Protein:9:Shipping Process Validation Report \u2013 Cold Chain (as needed)": "ex:QualityAttribute_shipping_process_val_36234e38",
  "QualityAttribute:Protein:9:Stage 9A/9B/9C Council presentation review completed.": "ex:QualityAttribute_stage_9a_9b_9c_counc_c9bcb766",
  "QualityAttribute:Protein:9:Submit the technical dossier for review and opinion by the Notified Body (at least 6 months before MAA submission).": "ex:QualityAttribute_submit_the_technical_bbaf215a",
  "QualityAttribute:Protein:9:Support CMC TL and CMC team to meet all deliverables through planning coordination.": "ex:QualityAttribute_support_cmc_tl_and_c_41c775fc",
  "QualityAttribute:Protein:9:Support risk management activities: includes risk identification, mitigation, monitor & control; risk register utilization.": "ex:QualityAttribute_support_risk_managem_2ac4ba01",
  "QualityAttribute:Protein:9:Traceability Matrix Template (Finalize)": "ex:QualityAttribute_traceability_matrix_909092e5",
  "QualityAttribute:Protein:9:Update CMC Risk Register.": "ex:QualityAttribute_update_cmc_risk_regi_005e516e",
  "QualityAttribute:Protein:9:Update General Safety and Performance Requirements (GSPR) Checklist (if required)": "ex:QualityAttribute_update_general_safet_06b58ab1",
  "QualityAttribute:Protein:9:Update Regulatory Plan": "ex:QualityAttribute_update_regulatory_pl_6cd0c570",
  "QualityAttribute:Protein:9:Update SWOT Assessment (if needed).": "ex:QualityAttribute_update_swot_assessme_dd5c22c1",
  "QualityAttribute:Protein:9:Update of Regulated Substances Plan (if required)": "ex:QualityAttribute_update_of_regulated_1e0d1c19",
  "QualityAttribute:Protein:9:Update of Regulated Substances Report and Supplier Regulated Substances Declarations (if required)": "ex:QualityAttribute_update_of_regulated_89c538fa",
  "QualityAttribute:Protein:9:Update to Design Transfer Plan and Design Transfer Report": "ex:QualityAttribute_update_to_design_tra_1ab8d964",
  "QualityAttribute:Protein:9:Updated strategic forecast and capacity planning for API and DP via NPS/FIS.": "ex:QualityAttribute_updated_strategic_fo_c6c3144a",
  "QualityAttribute:Protein:9:Upstream and downstream development history & other CTD source documents completed.": "ex:QualityAttribute_upstream_and_downstr_b7219645",
  "QualityAttribute:Protein:9:Upstream and downstream pre-BLA meeting CMC content & management review completed (if applicable).": "ex:QualityAttribute_upstream_and_downstr_75e0e1a8",
  "QualityAttribute:SM:10:API batch overview report": "ex:QualityAttribute_api_batch_overview_r_f09f3267",
  "QualityAttribute:SM:10:API comparability report bw API PPQ batches, registration batches  and Phase 3 process [P&MS / AD]": "ex:QualityAttribute_api_comparability_re_8ca8116d",
  "QualityAttribute:SM:10:API process/materials design space at full scale confirmed based on short-term variation": "ex:QualityAttribute_api_process_material_b1536ede",
  "QualityAttribute:SM:10:API solid state characterized at release and stability including polymorphic purity [P&MS, AD]": "ex:QualityAttribute_api_solid_state_char_7735b42c",
  "QualityAttribute:SM:10:Action plan ready for API validation campaign outstanding issues": "ex:QualityAttribute_action_plan_ready_fo_682933f1",
  "QualityAttribute:SM:10:Advanced control strategy defined for filing (Advanced = anything beyond release based on off-line (after the fact) testing)": "ex:QualityAttribute_advanced_control_str_c01a15fa",
  "QualityAttribute:SM:10:Align continued process verification (CPV) strategy": "ex:QualityAttribute_align_continued_proc_8275efdf",
  "QualityAttribute:SM:10:Align funding for any post launch optimization (JSC or R&D) as outcome of Product Strategy": "ex:QualityAttribute_align_funding_for_an_9caf313d",
  "QualityAttribute:SM:10:Assess the preparation, together with the CMC team, of a  white paper for any risks and issues  identified": "ex:QualityAttribute_assess_the_preparati_6c805cff",
  "QualityAttribute:SM:10:Batch Information Report (required for dossier)": "ex:QualityAttribute_batch_information_re_49234dee",
  "QualityAttribute:SM:10:Blinding strategy confirmed, based on clinical development plan (placebo need & timing; options for blinding eg overencapsulation, matching (coated) placebo formulation, packaging design, etc)": "ex:QualityAttribute_blinding_strategy_co_52c7c21d",
  "QualityAttribute:SM:10:Bridging strategy: Strategy for post approval changes : what studies for what type of changes": "ex:QualityAttribute_bridging_strategy_st_3589fa66",
  "QualityAttribute:SM:10:Build good Rationales:\n*Source documents for final BCS classification\n*Completed validation of the PBBM model in case of use of the model in the regulatory submission\n*Justification of dissolution specs document with reference to CBA (critical to bioavailability attributes), totality of clinical data, IVIVC/IVIVR and/or hBA studies span of the pivotal clinical batches": "ex:QualityAttribute_build_good_rationale_48bb98f9",
  "QualityAttribute:SM:10:CMC-TPP comm locked (incl. aspects not impacting stability()SM without device)": "ex:QualityAttribute_cmc_tpp_comm_locked_65584663",
  "QualityAttribute:SM:10:CPDP Commercialization Stage / Design Control: \n*Design and Development Plan  (Update)\n*Device Master Record (DMR) (Update)\n*Design History File (Update)": "ex:QualityAttribute_cpdp_commercializati_293fa273",
  "QualityAttribute:SM:10:CPDP Commercialization Stage / Device Risk Management  (Update):\n*Risk Management Plan (Update)\n*Product Risk Assessment/Hazard ID (Update)\n*uFMEA (Update)\n*CTQ Flow Down (Update)\n*Device Control Strategy (Review and Update)\n*dFMEA (Update)\n*pFMEA (Update)\n*Risk Management Report (Update)": "ex:QualityAttribute_cpdp_commercializati_1ac55989",
  "QualityAttribute:SM:10:Collect country specific requirements in Country Level Regulatory Requirements (CLRR), well in advance, with priority given based on the GFLS e.g. Japan and China.  Ensure only regulatory methods (not in-house methods) are filed at the global and local level.  Assess the need for a pre-submission consistency check.": "ex:QualityAttribute_collect_country_spec_371f6d17",
  "QualityAttribute:SM:10:Comm. API, intermediates, raw materials CQAs lock confirmed": "ex:QualityAttribute_comm_api_intermediat_aa4e5830",
  "QualityAttribute:SM:10:Commercial Container Closure System Summary Report": "ex:QualityAttribute_commercial_container_b2b6a348",
  "QualityAttribute:SM:10:Commitment stability protocol completed": "ex:QualityAttribute_commitment_stability_7a6c811f",
  "QualityAttribute:SM:10:Complete bulk holding studies; align holding periods to plant planning needs.": "ex:QualityAttribute_complete_bulk_holdin_b86f31f1",
  "QualityAttribute:SM:10:Complete commercial design rationale document": "ex:QualityAttribute_complete_commercial_203aec02",
  "QualityAttribute:SM:10:Complete distribution risk assessment (transport studies and API/DP/FG shipping lane qualification); finalize/align transportation channel /shipping routes and shipping protection": "ex:QualityAttribute_complete_distributio_9af81020",
  "QualityAttribute:SM:10:Complete intermediate bulk holding studies; align holding periods to plant planning needs.": "ex:QualityAttribute_complete_intermediat_6daad9d1",
  "QualityAttribute:SM:10:Continued Process Verification Plan to confirm design space based on long-term variation (for parenterals)": "ex:QualityAttribute_continued_process_ve_a9fae46f",
  "QualityAttribute:SM:10:Continued development program in case of accelerated filing/knowledge gaps": "ex:QualityAttribute_continued_developmen_8306f2d7",
  "QualityAttribute:SM:10:Control strategy for comm. full scale process": "ex:QualityAttribute_control_strategy_for_f3b49429",
  "QualityAttribute:SM:10:Control strategy for commercial full scale process available (incl nitrosamines if applicable)": "ex:QualityAttribute_control_strategy_for_8b273c68",
  "QualityAttribute:SM:10:Country specific requirements for filing, e.g. sufficient reference materials available, specifications, ANVISA requirements, chromatograms": "ex:QualityAttribute_country_specific_req_1fceab13",
  "QualityAttribute:SM:10:Create Supply Chain File": "ex:QualityAttribute_create_supply_chain_c2819de0",
  "QualityAttribute:SM:10:Create use-related risk analysis (URRA), if needed.": "ex:QualityAttribute_create_use_related_r_062997c0",
  "QualityAttribute:SM:10:Cross functional Risk register completed and mitigation plan developed, also highlighting the gaps and any mitigations with respect to key deliverables": "ex:QualityAttribute_cross_functional_ris_d091d74a",
  "QualityAttribute:SM:10:Customer Centered Design deliverables completed for this stage. (incorporating any country specific requirements i.e. Japan as necessary)": "ex:QualityAttribute_customer_centered_de_a7fd537e",
  "QualityAttribute:SM:10:DP batch overview report": "ex:QualityAttribute_dp_batch_overview_re_f90fba2a",
  "QualityAttribute:SM:10:DP sections in NDA/MAA completed and checked (3.2.P.1, 3.2.P.2, 3.2.P.3)": "ex:QualityAttribute_dp_sections_in_nda_m_f1810a26",
  "QualityAttribute:SM:10:DP solid state characterized at release and stability including polymorphic purity using sensitive methods [P&MS, AD]": "ex:QualityAttribute_dp_solid_state_chara_fbf7b9e7",
  "QualityAttribute:SM:10:Dissolution method development report": "ex:QualityAttribute_dissolution_method_d_49438c2a",
  "QualityAttribute:SM:10:EHS Requirement:  Facilitate completion of ERA and include in filings": "ex:QualityAttribute_ehs_requirement_faci_c38468c7",
  "QualityAttribute:SM:10:EHS Requirement: EH&S compliance assessment conducted; Update MSDS for DS": "ex:QualityAttribute_ehs_requirement_eh_s_0c1f06b2",
  "QualityAttribute:SM:10:EHS Requirement: IH sampling method confirmed.": "ex:QualityAttribute_ehs_requirement_ih_s_e004107d",
  "QualityAttribute:SM:10:Ensure Launch supplies for pre-approval programs (ATU, NPP, EAP) are in place": "ex:QualityAttribute_ensure_launch_suppli_bab55ad2",
  "QualityAttribute:SM:10:Execute VCRM Product Risk Assessment and establish VCRM Plan": "ex:QualityAttribute_execute_vcrm_product_138959e4",
  "QualityAttribute:SM:10:Final IP assessment done": "ex:QualityAttribute_final_ip_assessment_8380f0e4",
  "QualityAttribute:SM:10:Final IP assessment on product and process": "ex:QualityAttribute_final_ip_assessment_8cd6f3cb",
  "QualityAttribute:SM:10:Final draft file reviewed": "ex:QualityAttribute_final_draft_file_rev_0c7c2e7b",
  "QualityAttribute:SM:10:Final specifications and justification documents": "ex:QualityAttribute_final_specifications_c10384b6",
  "QualityAttribute:SM:10:Finalize / lock Commercial secondary and tertiary packaging design (mock-ups US/EU, printed components, artwork for registration samples)": "ex:QualityAttribute_finalize_lock_commer_52fa109c",
  "QualityAttribute:SM:10:Finalize commercial specifications for filing, incorporate regional requirements. These may include:\n*incoming inspection specifications for device components/raw materials, including shelf life\n*release specification for combination product, including shelf life\n*primary container (unfilled and filled) specifications that are related to device function\n*identify critical process parameters (component, subassembly, final assembly, etc) and range": "ex:QualityAttribute_finalize_commercial_118156a7",
  "QualityAttribute:SM:10:Finalize launch strategy (i.e. GFLS - Global Filing and Launch Sequence)": "ex:QualityAttribute_finalize_launch_stra_104df5e2",
  "QualityAttribute:SM:10:Finalize on-time launch deliverables (operational forecast is in systems, batch release flow is in place)": "ex:QualityAttribute_finalize_on_time_lau_fb48741b",
  "QualityAttribute:SM:10:Finalize\u00a0end-to-end Control strategy": "ex:QualityAttribute_finalize_end_to_end_eaee9fe5",
  "QualityAttribute:SM:10:Formulation Development report  with design space available": "ex:QualityAttribute_formulation_developm_7709e1da",
  "QualityAttribute:SM:10:Functional area review of DS and DP data/reports (characterization, process validation -if applicable, criticality analysis, development history); aligned with CMCT.": "ex:QualityAttribute_functional_area_revi_2ee7d4a3",
  "QualityAttribute:SM:10:Identify any SLOB risk and update via S&OP process (i.e. DSRM) as applicable": "ex:QualityAttribute_identify_any_slob_ri_c381e4bf",
  "QualityAttribute:SM:10:If necessary, update CTD dossiers and facilitate updates to source documents as a result of HA meeting outcome or general feedback.": "ex:QualityAttribute_if_necessary_update_1367d40a",
  "QualityAttribute:SM:10:If requried, complete Design Verification protocl and report (based on PPQ batches)": "ex:QualityAttribute_if_requried_complete_2ad4e695",
  "QualityAttribute:SM:10:In-use, excursion and bulk stability report": "ex:QualityAttribute_in_use_excursion_and_d0f3f396",
  "QualityAttribute:SM:10:Include commercial information into storage statement": "ex:QualityAttribute_include_commercial_i_5136563f",
  "QualityAttribute:SM:10:Initiate the launch change control": "ex:QualityAttribute_initiate_the_launch_a979ab16",
  "QualityAttribute:SM:10:Knowledge gaps identified and remediation plan proposed": "ex:QualityAttribute_knowledge_gaps_ident_d7d3973b",
  "QualityAttribute:SM:10:LCM Plan to close knowledge gaps available for review": "ex:QualityAttribute_lcm_plan_to_close_kn_cdd58ffb",
  "QualityAttribute:SM:10:Life cycle management strategy": "ex:QualityAttribute_life_cycle_managemen_1e3ecd1a",
  "QualityAttribute:SM:10:Method comparison report (as needed)": "ex:QualityAttribute_method_comparison_re_53f83342",
  "QualityAttribute:SM:10:Method transfers to primary test sites complete": "ex:QualityAttribute_method_transfers_to_e330e4d2",
  "QualityAttribute:SM:10:Nitrosamine risk assessment report approved": "ex:QualityAttribute_nitrosamine_risk_ass_ceee3abb",
  "QualityAttribute:SM:10:Overview of knowledge and knowledge gaps about criticality, causality, scientific mechanism of CPP's and CMA's and documented in the process characterization/development reports": "ex:QualityAttribute_overview_of_knowledg_304b07b0",
  "QualityAttribute:SM:10:PAI Assessment completion (per site)": "ex:QualityAttribute_pai_assessment_compl_296793bf",
  "QualityAttribute:SM:10:PPQ Report prepared and approved in line with new FDA Guidance on Process Validation (if required for submission)": "ex:QualityAttribute_ppq_report_prepared_068621c5",
  "QualityAttribute:SM:10:PPQ Report prepared and approved in line with new FDA Guidance on Process Validation, if required for submission (e.g. non-standard processes, parenterals)": "ex:QualityAttribute_ppq_report_prepared_d87572d6",
  "QualityAttribute:SM:10:Passive shipping systems qualified, if applicable (Commercial Supply Chain through first internal DC)": "ex:QualityAttribute_passive_shipping_sys_a0d1dd17",
  "QualityAttribute:SM:10:Plan, prepare and execute and follow-up HA meetings to present topics for seeking advice on,  including QbD elements in the NDA/MAA": "ex:QualityAttribute_plan_prepare_and_exe_22ef32f3",
  "QualityAttribute:SM:10:Prepare CMC section File": "ex:QualityAttribute_prepare_cmc_section_8dc2f9fd",
  "QualityAttribute:SM:10:Proactively and informally track Product Performance Dashboard metrics": "ex:QualityAttribute_proactively_and_info_ccc561f9",
  "QualityAttribute:SM:10:Proactively and informally track Robustness Index Dashboard metrics": "ex:QualityAttribute_proactively_and_info_f76c01e3",
  "QualityAttribute:SM:10:Process Development report  with Critical Process Parameters, Critical Material attributes, and design space available": "ex:QualityAttribute_process_development_d8931cf6",
  "QualityAttribute:SM:10:Product Lifecycle Dashboard reviewed": "ex:QualityAttribute_product_lifecycle_da_455fc32a",
  "QualityAttribute:SM:10:Project timelines, scope and resources updated in line with current assumptions": "ex:QualityAttribute_project_timelines_sc_3d4d592f",
  "QualityAttribute:SM:10:Quality Agreements  / Site qualification completed for commercial use for RSM, GMP INT,  API  & DP manufacturing (if new/additional supplier)": "ex:QualityAttribute_quality_agreements_s_26977c9f",
  "QualityAttribute:SM:10:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) for PPQ/commercial when applicable:\n*Supplier and Contractor Audit\n*Device Quality Agreement (Final Assembly)\n*Device Quality Agreement (Device component, device itself and Purchasing Contro/ for Combo Products)\n*Device Testing Quality Agreement (Lab to Lab)  \n*Third Party Design Control Audit Report (If Applicable)": "ex:QualityAttribute_readiness_for_the_co_2e4a8ffe",
  "QualityAttribute:SM:10:Real-time in-process test (PAT) on factors showing substantial variation and impact on CQA's  incorporated where relevant in control strategy": "ex:QualityAttribute_real_time_in_process_63107025",
  "QualityAttribute:SM:10:Real-time in-process test on factors showing substantial variation and impact on CQA's  incorporated where relevant in control strategy": "ex:QualityAttribute_real_time_in_process_498b7123",
  "QualityAttribute:SM:10:Reassess selected CQAs, CPPs, CMAs as scope for Product Performance Dashboard and confirm via Level 1 review": "ex:QualityAttribute_reassess_selected_cq_0611eaeb",
  "QualityAttribute:SM:10:Reassess selected CQAs, CPPs, CMAs as scope for Product Performance Dashboard and confirm with RD FA": "ex:QualityAttribute_reassess_selected_cq_efbc17dc",
  "QualityAttribute:SM:10:Reassess selected CQAs, CPPs, CMAs as scope for Robustness Index Dashboard and confirm via Level 1 review": "ex:QualityAttribute_reassess_selected_cq_7d24e5d8",
  "QualityAttribute:SM:10:Refresh COGS / GP, if needed in preparation for commercial launch": "ex:QualityAttribute_refresh_cogs_gp_if_n_b251bb7c",
  "QualityAttribute:SM:10:Registration stability report": "ex:QualityAttribute_registration_stabili_125d1e2b",
  "QualityAttribute:SM:10:Regulated Substances\n*Update Regulated Substances Plan and Report (if applicable)\n*Update Supplier Regulated Substances Declarations (if applicable)": "ex:QualityAttribute_regulated_substances_1c796acf",
  "QualityAttribute:SM:10:Remediation plan for any outstanding issue from the process validation campaign": "ex:QualityAttribute_remediation_plan_for_fbc875dc",
  "QualityAttribute:SM:10:Residual risk assessment + mitigation plan updated; residual risk status confirmed as low": "ex:QualityAttribute_residual_risk_assess_ebcff15d",
  "QualityAttribute:SM:10:Review and approve CTD dossiers": "ex:QualityAttribute_review_and_approve_c_43fcf46e",
  "QualityAttribute:SM:10:Review of PPQ campaigns:\n*treading and mitigation of manufacturing issues\n*Identify any new/unique manufacturing/testing requirements and update manufacturing requirement documents for commercial when appropirate\n*Evaluate impact of these learnings and implement required activities for commercial manufacturing process": "ex:QualityAttribute_review_of_ppq_campai_622c4ec2",
  "QualityAttribute:SM:10:Review system readiness for post-market safety reporting (PMSR) (Combo product requirement)": "ex:QualityAttribute_review_system_readin_89ad812a",
  "QualityAttribute:SM:10:Review/align CMC sections of Common Technical Document": "ex:QualityAttribute_review_align_cmc_sec_575e4f13",
  "QualityAttribute:SM:10:Shipping:\n*Calculate thermal density of temperature shipping systems (as needed)\n*Qualification report of insulated shipping container for temperature sensitive products\n*Shipping process validation report - cold chain (as needed)": "ex:QualityAttribute_shipping_calculate_t_fa16f418",
  "QualityAttribute:SM:10:Site compliance and PAI readiness evaluated (include regulatory compliance both at global and site level).": "ex:QualityAttribute_site_compliance_and_7e0f9a60",
  "QualityAttribute:SM:10:Source documents and white papers completed and approved": "ex:QualityAttribute_source_documents_and_3ad99c28",
  "QualityAttribute:SM:10:Source documents/White papers completed and approved and action plans in place to address gaps": "ex:QualityAttribute_source_documents_whi_2d165cd6",
  "QualityAttribute:SM:10:Stage gate approval form": "ex:QualityAttribute_stage_gate_approval_120c55f4",
  "QualityAttribute:SM:10:Sufficient stability data points (up to 12 months) completed for registration batch": "ex:QualityAttribute_sufficient_stability_818312ac",
  "QualityAttribute:SM:10:Supplier qualification for SM/RM starting materials/raw materials for INT and API and excipients and packaging materials for DP for commercial  use completed, if new material/supplier combination": "ex:QualityAttribute_supplier_qualificati_477788fe",
  "QualityAttribute:SM:10:Update CTQ flowdown for the following:\n*Molding\n*Subassembly\n*Final assembly\n*Packaging": "ex:QualityAttribute_update_ctq_flowdown_67041d65",
  "QualityAttribute:SM:10:Update FMEAs (u, p, d) (including verification and effectiveness) (COMBO Product Requirement / drug-only product with a complex administration interface)": "ex:QualityAttribute_update_fmeas_u_p_d_i_79720cc2",
  "QualityAttribute:SM:10:Update IFU/training based on learnings from HF studies, Design Verification, and Design Validation activities.": "ex:QualityAttribute_update_ifu_training_75338cd7",
  "QualityAttribute:SM:10:Update PQV Data Governance Sharepoint (if needed)": "ex:QualityAttribute_update_pqv_data_gove_53093d26",
  "QualityAttribute:SM:10:Update PRA applicable to product category (including verification and effectiveness) and verify if additional risk has to be considered/added.\nUpdate PRM Plan/Report (including Product Risk Benefit Analysis), update if additional risk management activities are completed/known": "ex:QualityAttribute_update_pra_applicabl_f756d895",
  "QualityAttribute:SM:10:Update Supplier Product Risk Assessment (SPRA) and Material Tracker for inclusion in the VCRM Product Risk Assessment and VCRM Plan.  This is also an input to the Integrated Launch Readiness heatmap (SG#11).": "ex:QualityAttribute_update_supplier_prod_da2acd7c",
  "QualityAttribute:SM:11:API Life Cycle Plan available": "ex:QualityAttribute_api_life_cycle_plan_45d88eee",
  "QualityAttribute:SM:11:Approve Drug Product  &  Packaging PPQ reports": "ex:QualityAttribute_approve_drug_product_6c51a16a",
  "QualityAttribute:SM:11:Approve Packaging at risk memo if production at risk is needed.": "ex:QualityAttribute_approve_packaging_at_699769fd",
  "QualityAttribute:SM:11:Blinding strategy confirmed, based on clinical development plan (placebo need & timing; options for blinding eg overencapsulation, matching (coated) placebo formulation, packaging design, etc": "ex:QualityAttribute_blinding_strategy_co_e1908a02",
  "QualityAttribute:SM:11:CMC responses to HA's completed": "ex:QualityAttribute_cmc_responses_to_ha_5cdeebfd",
  "QualityAttribute:SM:11:CPDP Commercialization Stage /Design Control: \n*Design and Development Plan  (Update)\n*Manufacturing Strategy and Design Transfer Plan (finalize)\n*Device Master Record (DMR) (Update)\n*Design History File (Update)": "ex:QualityAttribute_cpdp_commercializati_a829244b",
  "QualityAttribute:SM:11:Check, examine and if applicable,  file patents related to combo product": "ex:QualityAttribute_check_examine_and_if_8b75313c",
  "QualityAttribute:SM:11:Combined with \"Remediation plans agreed upon, in place and included in LCM plan (remediation plans refer to CA & CS related improvements.\"": "ex:QualityAttribute_combined_with_remedi_37ff7c55",
  "QualityAttribute:SM:11:Complete PAI follow-up actions": "ex:QualityAttribute_complete_pai_follow_d8b30c05",
  "QualityAttribute:SM:11:Completion of key actions of continued development program in case of accelerated filing/knowledge gaps": "ex:QualityAttribute_completion_of_key_ac_2d991dd9",
  "QualityAttribute:SM:11:Continued Process Verification Plan /matrix to confirm and maintain the state of control": "ex:QualityAttribute_continued_process_ve_7065fade",
  "QualityAttribute:SM:11:Continued Process Verification Plan to confirm and maintain the state of control if required": "ex:QualityAttribute_continued_process_ve_78b97193",
  "QualityAttribute:SM:11:Continued Process Verification Plan to confirm design space based on full mfg variation approved if required": "ex:QualityAttribute_continued_process_ve_bcc3c663",
  "QualityAttribute:SM:11:Cross Functional Lessons Learned": "ex:QualityAttribute_cross_functional_les_be00f65b",
  "QualityAttribute:SM:11:Cross functional Risk register completed and mitigation plan developed, also highlighting the gaps and any mitigations with respect to key deliverables": "ex:QualityAttribute_cross_functional_ris_5d02e15a",
  "QualityAttribute:SM:11:DP Life Cycle Mgmt Plan updated, approved and work initiated": "ex:QualityAttribute_dp_life_cycle_mgmt_p_12605785",
  "QualityAttribute:SM:11:Deliver the Integrated Launch Readiness (ILR) Heatmap and coordinate with the Global Commercial Leader to complete the \"Product/SC Readiness\" portion of the GCSO \"Launch Preparations Dashboard\".": "ex:QualityAttribute_deliver_the_integrat_23832490",
  "QualityAttribute:SM:11:Development and validation of secondary packaging completed": "ex:QualityAttribute_development_and_vali_1fe8aff5",
  "QualityAttribute:SM:11:Device LCM development work initiated": "ex:QualityAttribute_device_lcm_developme_8d466d31",
  "QualityAttribute:SM:11:Device Risk Management  (Update):\n*Product Risk Assessment/Hazard ID (Update)\n*uFMEA (Update)\n*CTQ Flow Down (Update)\n*Device Control Strategy (Review and Update)\n*dFMEA (Update)\n*pFMEA (Update)\n*Risk Management Report (Update)": "ex:QualityAttribute_device_risk_manageme_4677ad72",
  "QualityAttribute:SM:11:EHS Requirement: Update Process safety testing": "ex:QualityAttribute_ehs_requirement_upda_28f25e27",
  "QualityAttribute:SM:11:Ensure Site business systems set-up is complete and all sites are ready for launch": "ex:QualityAttribute_ensure_site_business_532e8922",
  "QualityAttribute:SM:11:Ensure functional launch plans are in place, launch meetings with Local Operating Companies started, importation activities/licenses planned, launch quantities agreed, launch supplies manufactured and delivered to DC.": "ex:QualityAttribute_ensure_functional_la_1079f1b2",
  "QualityAttribute:SM:11:Finalize Supply Chain File / Product Pulse Database": "ex:QualityAttribute_finalize_supply_chai_22d81605",
  "QualityAttribute:SM:11:Finalize commercial specifications for filing, incorporate regional requirements. These may include:\n*incoming inspection specifications for device components/raw materials, including shelf life\n*release specification for combination product, including shelf life\n*primary container (unfilled and filled) specifications that are related to device function": "ex:QualityAttribute_finalize_commercial_13088342",
  "QualityAttribute:SM:11:Global Product Distribution Chain implemented": "ex:QualityAttribute_global_product_distr_9e622aea",
  "QualityAttribute:SM:11:If required, update CTQ flowdown for the following:\n*Molding\n*Subassembly\n*Final assembly\n*Packaging": "ex:QualityAttribute_if_required_update_c_fc7c7840",
  "QualityAttribute:SM:11:Initiate preparation of Product Fact Book for training CQ": "ex:QualityAttribute_initiate_preparation_edc5da4f",
  "QualityAttribute:SM:11:LCM Plan to close knowledge gaps and to address business needs approved": "ex:QualityAttribute_lcm_plan_to_close_kn_65aa3298",
  "QualityAttribute:SM:11:LCM Plan to close process knowledge gaps and to address business needs approved": "ex:QualityAttribute_lcm_plan_to_close_pr_0e70ea38",
  "QualityAttribute:SM:11:LCM Plan to close product knowledge gaps and to address business needs approved": "ex:QualityAttribute_lcm_plan_to_close_pr_45f20d3e",
  "QualityAttribute:SM:11:Launch readiness checklist complete": "ex:QualityAttribute_launch_readiness_che_b62c6d69",
  "QualityAttribute:SM:11:Lessons learned report available": "ex:QualityAttribute_lessons_learned_repo_cd88916b",
  "QualityAttribute:SM:11:Marketed Stability Plan in place for all markets": "ex:QualityAttribute_marketed_stability_p_62630e71",
  "QualityAttribute:SM:11:PPQ report prepared and approved (if not prepared and approved already for submission)": "ex:QualityAttribute_ppq_report_prepared_35c693ef",
  "QualityAttribute:SM:11:Perform and align BPAL status update for Integrated Launch Readiness (ILR) heatmap and Council endorsement.": "ex:QualityAttribute_perform_and_align_bp_26943674",
  "QualityAttribute:SM:11:Perform and align BPAL status update in preparation for Integrated Launch Readiness (ILR) heatmap and Council endorsement": "ex:QualityAttribute_perform_and_align_bp_c9ccf04c",
  "QualityAttribute:SM:11:Plan in place for transfer of analytics to secondary release laboratories": "ex:QualityAttribute_plan_in_place_for_tr_a35c33c9",
  "QualityAttribute:SM:11:Prepare responses to HA questions.": "ex:QualityAttribute_prepare_responses_to_1358a41f",
  "QualityAttribute:SM:11:Product Lifecycle Dashboard reviewed": "ex:QualityAttribute_product_lifecycle_da_3dd4e9fa",
  "QualityAttribute:SM:11:Project timelines, scope and resources updated in line with current assumptions": "ex:QualityAttribute_project_timelines_sc_960e0cf0",
  "QualityAttribute:SM:11:Provide COGS and GP, documenting assumptions, for update of the Integrated Launch Readiness heatmap.": "ex:QualityAttribute_provide_cogs_and_gp_ea12372f",
  "QualityAttribute:SM:11:Provide JSC relevant CTD regulatory responses": "ex:QualityAttribute_provide_jsc_relevant_0484f602",
  "QualityAttribute:SM:11:Provide data for CPV 3a protocol": "ex:QualityAttribute_provide_data_for_cpv_ca580faf",
  "QualityAttribute:SM:11:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) for commercial when applicable:\n*Supplier and Contractor Audit\n*Device Quality Agreement (Manufacturing)\n*Device Quality Agreement (Device component, device itself and Purchasing Control/ for Combo Products)\n*Device Testing Quality Agreement (Lab to Lab)   \n*Third Party Design Control Audit Report (If Applicable)": "ex:QualityAttribute_readiness_for_the_co_0c603869",
  "QualityAttribute:SM:11:Regulated Substances\n*Update Regulated Substances Plan and Report (if applicable)\n*Update Supplier Regulated Substances Declarations (if applicable)": "ex:QualityAttribute_regulated_substances_a833d893",
  "QualityAttribute:SM:11:Remediation Plans agreed upon for any outstanding issue from the PPQ campaign, in place and included in LCM Plan (remediation plans refer to CA & CS related improvements)": "ex:QualityAttribute_remediation_plans_ag_7129f137",
  "QualityAttribute:SM:11:Remediation Plans agreed upon, in place and included in LCM Plan (remediation plans refer to CA & CS related improvements)": "ex:QualityAttribute_remediation_plans_ag_479f7d7c",
  "QualityAttribute:SM:11:Remediation plan for any outstanding issue from the process validation compaign": "ex:QualityAttribute_remediation_plan_for_b5f3adf9",
  "QualityAttribute:SM:11:Report status of global regulatory submissions, HA questions, post-approval commitments": "ex:QualityAttribute_report_status_of_glo_46846030",
  "QualityAttribute:SM:11:Responses on NDA/MAA to HA completed": "ex:QualityAttribute_responses_on_nda_maa_38d3de13",
  "QualityAttribute:SM:11:Responses to PAI questions": "ex:QualityAttribute_responses_to_pai_que_f4104305",
  "QualityAttribute:SM:11:Review FMEAs (u, p, d), update if additional/changed risk management activities (COMBO Product Requirement  / drug-only product with a complex administration interface)": "ex:QualityAttribute_review_fmeas_u_p_d_u_07ab108c",
  "QualityAttribute:SM:11:Review and if required, update\u00a0end-to-end Control strategy": "ex:QualityAttribute_review_and_if_requir_9543f8ef",
  "QualityAttribute:SM:11:Stage gate approval form": "ex:QualityAttribute_stage_gate_approval_f88e1395",
  "QualityAttribute:SM:11:Supply agreements approved and in-place with all CMOs": "ex:QualityAttribute_supply_agreements_ap_26ddfd3c",
  "QualityAttribute:SM:11:Support PAI checklist for API analytical activities": "ex:QualityAttribute_support_pai_checklis_0bdfc7a0",
  "QualityAttribute:SM:11:Support PAI checklist for DP analytical activities": "ex:QualityAttribute_support_pai_checklis_bd0f1619",
  "QualityAttribute:SM:11:Support PAI of mfg site": "ex:QualityAttribute_support_pai_of_mfg_s_274108f9",
  "QualityAttribute:SM:11:Support Prior Approval Inspection (PAI) at the site(s)": "ex:QualityAttribute_support_prior_approv_aa67602e",
  "QualityAttribute:SM:11:Update CMC Risk Register; low residual risk confirmed.": "ex:QualityAttribute_update_cmc_risk_regi_1c0f6dac",
  "QualityAttribute:SM:11:Update Knowledge Management database with Product Fact Book (SCDL)": "ex:QualityAttribute_update_knowledge_man_c422e550",
  "QualityAttribute:SM:11:Update PQV Data Governance Sharepoint (commercial)": "ex:QualityAttribute_update_pqv_data_gove_f2717911",
  "QualityAttribute:SM:11:Update PRA applicable to product category (including verification and effectiveness) and verify if additional risk has to be considered/added.\nUpdate PRM Plan/Report (including Product Risk Benefit Analysis), update if additional risk management activities are completed/known": "ex:QualityAttribute_update_pra_applicabl_3793a55c",
  "QualityAttribute:SM:11:Update any process design aspect and related document if requested by authority": "ex:QualityAttribute_update_any_process_d_3a1e8f2b",
  "QualityAttribute:SM:11:Update any product design aspect and related document if requested by authority": "ex:QualityAttribute_update_any_product_d_4917bac3",
  "QualityAttribute:SM:11:Update forecast and capacity planning; Ensure regional operational forecasts have been translated into manufacturing forecasts, risks identified /mitigation strategy in place": "ex:QualityAttribute_update_forecast_and_a25cb7e3",
  "QualityAttribute:SM:11:VCRM MAP updated; Resiliencey Strategy Finalized": "ex:QualityAttribute_vcrm_map_updated_res_6e210ad1",
  "QualityAttribute:SM:11:Verify all TPP attributes are defined and complete and aligned cross-functionally in preparation for launch": "ex:QualityAttribute_verify_all_tpp_attri_f814f312",
  "QualityAttribute:SM:11:Work with LWG, update combination product label (carton, device, blister,etc) based on learnings from HF studies, Design Verification, and Design Validation activities.": "ex:QualityAttribute_work_with_lwg_update_14c1f0e4",
  "QualityAttribute:SM:12:API process robustness assessed through stabilization metric": "ex:QualityAttribute_api_process_robustne_a66bcbb8",
  "QualityAttribute:SM:12:Additional development work/regulatory commitment assigned": "ex:QualityAttribute_additional_developme_a1d5129b",
  "QualityAttribute:SM:12:Assess commercial laboratory  specifications and identify opportunities to reduce INH specifications in alignment with TOO Product Performance Assessment.": "ex:QualityAttribute_assess_commercial_la_9cdd7998",
  "QualityAttribute:SM:12:Assess commercial laboratory  specifications and identify opportunities to reduce in-house (INH) specifications in alignment with Transfer of Ownership (TOO) Product Performance Assessment.": "ex:QualityAttribute_assess_commercial_la_5d142680",
  "QualityAttribute:SM:12:Blinding strategy confirmed, based on clinical development plan (placebo need & timing; options for blinding eg overencapsulation, matching (coated) placebo formulation, packaging design,...)": "ex:QualityAttribute_blinding_strategy_co_2805edfd",
  "QualityAttribute:SM:12:CMC Product Risk Register transfer from CMC to JSC": "ex:QualityAttribute_cmc_product_risk_reg_492cfcc3",
  "QualityAttribute:SM:12:CPDP Commercialization Stage /Design Control: \n*Design and Development Plan  (Update)\n*Review & Update Traceability Matrix (if applicable)\n*Device Master Record (DMR) (Update)\n*Design History File (Update)\n*CMC Memo for Design Control Stage 4 Review": "ex:QualityAttribute_cpdp_commercializati_de4a614d",
  "QualityAttribute:SM:12:CPV 3a report available": "ex:QualityAttribute_cpv_3a_report_availa_e8005095",
  "QualityAttribute:SM:12:CPV 3a report, if available": "ex:QualityAttribute_cpv_3a_report_if_ava_673728a2",
  "QualityAttribute:SM:12:Clinical  Primary Component Specifications (ph4), if applicable": "ex:QualityAttribute_clinical_primary_com_8a76833f",
  "QualityAttribute:SM:12:Clinical Container Closure System Suitability Assessment (ph4), if applicable": "ex:QualityAttribute_clinical_container_c_0145be6c",
  "QualityAttribute:SM:12:Close out of the R&D IDP": "ex:QualityAttribute_close_out_of_the_r_d_bc57a33c",
  "QualityAttribute:SM:12:Collect lessons learned from FDA/EMA/CDE/and other Health Agencies' assessment for continuous improvement.": "ex:QualityAttribute_collect_lessons_lear_cb12b974",
  "QualityAttribute:SM:12:Commercialization Stage Design Review; Stage gate approval form": "ex:QualityAttribute_commercialization_st_9d492af3",
  "QualityAttribute:SM:12:Complete Lessons learned": "ex:QualityAttribute_complete_lessons_lea_61b7fbad",
  "QualityAttribute:SM:12:Complete TOO Product Performance Assessment (product specific quantitative process and performance) to be reviewed at Robust Design Focus Area touchpoint 3.  Align transfer of ownership; team agreement that process is robust and product is stable to transfer ownership (including CPV 3a report, if available).": "ex:QualityAttribute_complete_too_product_6663f48d",
  "QualityAttribute:SM:12:Completion of continued development program in case of accelerated filing/knowledge gaps": "ex:QualityAttribute_completion_of_contin_abd1a2b7",
  "QualityAttribute:SM:12:Confirm control strategy is ensuring state of control": "ex:QualityAttribute_confirm_control_stra_0025d6c7",
  "QualityAttribute:SM:12:Consolidate lessons learned": "ex:QualityAttribute_consolidate_lessons_edabb08a",
  "QualityAttribute:SM:12:Continual verification of models and design space": "ex:QualityAttribute_continual_verificati_7e239704",
  "QualityAttribute:SM:12:Continued Process Verification Plan to confirm design space based on long-term variation in execution and transferred if required": "ex:QualityAttribute_continued_process_ve_cc251a8d",
  "QualityAttribute:SM:12:Control strategy information and justification transferred": "ex:QualityAttribute_control_strategy_inf_298c8e2b",
  "QualityAttribute:SM:12:DP & Excipients Life Cycle Mgmt Plan (SPRA and Tracker) updated": "ex:QualityAttribute_dp_excipients_life_c_33c111c7",
  "QualityAttribute:SM:12:Design space information and justification transferred": "ex:QualityAttribute_design_space_informa_f38149cb",
  "QualityAttribute:SM:12:Device Risk Management (Update):\n*Risk Management Plan (Update)\n*Product Risk Assessment/Hazard ID (Update)\n*uFMEA (Update)\n*CTQ Flow Down (Update)\n*Device Control Strategy (Review and Update)\n*dFMEA (Update)\n*pFMEA (Update)\n*Risk Management Report (Update)": "ex:QualityAttribute_device_risk_manageme_739419f4",
  "QualityAttribute:SM:12:EHS Requirement: Final API OEL confirmed": "ex:QualityAttribute_ehs_requirement_fina_525b8266",
  "QualityAttribute:SM:12:Evaluate AD assesment of commercial laboratory  specifications (identification of opportunities to reduce in-house (INH) specifications in alignment with Transfer of Ownership (TOO) Product Performance Assessment.": "ex:QualityAttribute_evaluate_ad_assesmen_2beb1f32",
  "QualityAttribute:SM:12:Execute Launches, report metrics": "ex:QualityAttribute_execute_launches_rep_e1b9a4f4",
  "QualityAttribute:SM:12:Funding for any post launch optimization (JSC or R&D) as outcome of Product Strategy secured": "ex:QualityAttribute_funding_for_any_post_f7c5b66d",
  "QualityAttribute:SM:12:Generate CPV (continuous process verification) report": "ex:QualityAttribute_generate_cpv_continu_26014597",
  "QualityAttribute:SM:12:If there is a significant body of API data available by TOO, complete CPV 3a report to confirm design space and state of control.": "ex:QualityAttribute_if_there_is_a_signif_281ebff3",
  "QualityAttribute:SM:12:LCM Plan for drug product and process  to close knowledge gaps in execution and transfer.": "ex:QualityAttribute_lcm_plan_for_drug_pr_4834de11",
  "QualityAttribute:SM:12:LCM Plan to close knowledge gaps and to address business needs in execution and transferred": "ex:QualityAttribute_lcm_plan_to_close_kn_a748fd3d",
  "QualityAttribute:SM:12:Maintenance of Control strategy based on full mfg experience and newly acquired knowledge": "ex:QualityAttribute_maintenance_of_contr_8120055b",
  "QualityAttribute:SM:12:Maintenance of Design Space based on full mfg experience and newly acquired knowledge incl. models and operational limits": "ex:QualityAttribute_maintenance_of_desig_def45944",
  "QualityAttribute:SM:12:Material Change Qualification Report,if applicable": "ex:QualityAttribute_material_change_qual_3b8afcff",
  "QualityAttribute:SM:12:PPQS (Proactive Product Quality Scan) available": "ex:QualityAttribute_ppqs_proactive_produ_55460aa1",
  "QualityAttribute:SM:12:Process design, selection and justification transferred": "ex:QualityAttribute_process_design_selec_0c551668",
  "QualityAttribute:SM:12:Process design, selection, justification, and process understanding transferred": "ex:QualityAttribute_process_design_selec_a27cad0a",
  "QualityAttribute:SM:12:Process understanding transferred": "ex:QualityAttribute_process_understandin_2cddebd1",
  "QualityAttribute:SM:12:Product design, selection and justification transferred": "ex:QualityAttribute_product_design_selec_15ce5e60",
  "QualityAttribute:SM:12:Product design, selection and justification transferred. Product knowledge transferred as assessed via TOO Product Performance Assessment (RDFA touchpoint #3).": "ex:QualityAttribute_product_design_selec_2b88a502",
  "QualityAttribute:SM:12:Product knowledge transferred": "ex:QualityAttribute_product_knowledge_tr_dfb8977f",
  "QualityAttribute:SM:12:Quality Risk Assessment incl. Criticality Analysis updated": "ex:QualityAttribute_quality_risk_assessm_e8d9c5f3",
  "QualityAttribute:SM:12:Quality Risk Assessment incl. Criticality Analysis updated if needed": "ex:QualityAttribute_quality_risk_assessm_7a2b179f",
  "QualityAttribute:SM:12:Real time stability data for release profile. Update justification of specs or revisit QC release specs if necessary to remain within specs over shelf-life": "ex:QualityAttribute_real_time_stability_6ccf98bb",
  "QualityAttribute:SM:12:Regulated Substances\n*Update Regulated Substances Plan and Report (if applicable)\n*Update Supplier Regulated Substances Declarations (if applicable)": "ex:QualityAttribute_regulated_substances_663b80c9",
  "QualityAttribute:SM:12:Review and if required, update end-to-end Control strategy": "ex:QualityAttribute_review_and_if_requir_86fa4587",
  "QualityAttribute:SM:12:Review of commercial manufacturing campaigns:\n*treading and mitigation of manufacturing issues\n*Identify any new/unique manufacturing/testing requirements and update manufacturing requirement documents for commercial when appropirate\n*Evaluate impact of these learnings and implement required activities for commercial manufacturing process": "ex:QualityAttribute_review_of_commercial_57e7fb97",
  "QualityAttribute:SM:12:Review/update PMSR and TEC file (Combo product requirement)": "ex:QualityAttribute_review_update_pmsr_a_de996455",
  "QualityAttribute:SM:12:Risk & mitigation plan updated. Low residual risk confirmed": "ex:QualityAttribute_risk_mitigation_plan_c2144eb9",
  "QualityAttribute:SM:12:Robustness Index Dashboard generated according to agreed upon scope and considering HA feedback": "ex:QualityAttribute_robustness_index_das_37d401d7",
  "QualityAttribute:SM:12:Support design and development of new secondary packaging required by different regions": "ex:QualityAttribute_support_design_and_d_06e43509",
  "QualityAttribute:SM:12:Transfer of Ownership information shared  (including Analytical knowledge transfer, i.e. stability statements/shelf life statements, method transfer documentation)": "ex:QualityAttribute_transfer_of_ownershi_5ce4d51b",
  "QualityAttribute:SM:12:Transfer of Ownership information shared (including Analytical knowledge transfer, i.e. stability statements, method transfer documentation)": "ex:QualityAttribute_transfer_of_ownershi_2685471e",
  "QualityAttribute:SM:12:Transfer of ownership for nitrosamine risk assessment": "ex:QualityAttribute_transfer_of_ownershi_7934e4a2",
  "QualityAttribute:SM:12:Trend and analyze complaints from commercial launch and any ongoing clinical studies, identify any LCM/mitigation if required.": "ex:QualityAttribute_trend_and_analyze_co_bad2db6d",
  "QualityAttribute:SM:12:Update Cost of Goods Sold (COGS) and Gross Profit (GP) for steady state.  Summarize COGS progression and opportunities": "ex:QualityAttribute_update_cost_of_goods_754c4078",
  "QualityAttribute:SM:12:Update Knowledge Management database as applicable": "ex:QualityAttribute_update_knowledge_man_8e30ba0c",
  "QualityAttribute:SM:12:Update combination product label (carton, device, bliste,etc) based on final version approved by HA.": "ex:QualityAttribute_update_combination_p_6b15c4f4",
  "QualityAttribute:SM:12:Update post-approval strategy for RTRt as required": "ex:QualityAttribute_update_post_approval_e11dad18",
  "QualityAttribute:SM:3:1st GMP batch produced/ released based on evaluation appropriate QAs": "ex:QualityAttribute_1st_gmp_batch_produc_76a0baf9",
  "QualityAttribute:SM:3:AD contribution to CMC IP strategy.": "ex:QualityAttribute_ad_contribution_to_c_0d6ab2c7",
  "QualityAttribute:SM:3:AD contribution to CMC Intellectual Property (IP) strategy.": "ex:QualityAttribute_ad_contribution_to_c_f2c05bf7",
  "QualityAttribute:SM:3:API Form strategy  for Late development defined in line with formulation strategy Phase 2b>3> commercial : In case form change is foreseen, Form Selection Reportupdated and endorsed by Solid State Expert Team [P&MS / LPC (ERDC) SSWG M2]": "ex:QualityAttribute_api_form_strategy_fo_dc219783",
  "QualityAttribute:SM:3:API release testing of 1st GMP batch + stability statement": "ex:QualityAttribute_api_release_testing_88f2b374",
  "QualityAttribute:SM:3:API salt/form confirmed for Ph2a based on continued efforts to build knowledge and unravel the solid form landscape .    [P&MS]": "ex:QualityAttribute_api_salt_form_confir_9d8c17d5",
  "QualityAttribute:SM:3:API salt/polymorph and particle/powder characterization methods for release and stability (P&MS/AD)": "ex:QualityAttribute_api_salt_polymorph_a_02399210",
  "QualityAttribute:SM:3:API solid state characterized at release and on stability (AD/P&MS)": "ex:QualityAttribute_api_solid_state_char_d4c8ce72",
  "QualityAttribute:SM:3:API specification": "ex:QualityAttribute_api_specification_895838fe",
  "QualityAttribute:SM:3:API stability study 1st GMP batch \u00a0initiated": "ex:QualityAttribute_api_stability_study_bc05f4f3",
  "QualityAttribute:SM:3:Accelerated Physical and chemical stability  studies on DP concepts performed to select preferred Phase 2a concepts (AD/P&MS)": "ex:QualityAttribute_accelerated_physical_ae730aa7",
  "QualityAttribute:SM:3:Acceptable DP quality after contact with equipment train, for example leachables and extractables report from Material Sciences": "ex:QualityAttribute_acceptable_dp_qualit_e21e4abd",
  "QualityAttribute:SM:3:Assessment of IP strategy (FTO, possibility to expand patent estate)": "ex:QualityAttribute_assessment_of_ip_str_e7e50a57",
  "QualityAttribute:SM:3:Assessment of IP strategy (align with API)": "ex:QualityAttribute_assessment_of_ip_str_e0a8194d",
  "QualityAttribute:SM:3:Assessment whether CMC LD will be complex  for API/DP,  time critical  vs. compound asset risk profile": "ex:QualityAttribute_assessment_whether_c_031b37ac",
  "QualityAttribute:SM:3:Bio relevant method (e.g. PBDT) applied on Phase 2a concepts, if applicable": "ex:QualityAttribute_bio_relevant_method_21f6252b",
  "QualityAttribute:SM:3:Biopharmaceutical testing:\n*Biopharmaceutical behaviour (ADME) of Phase1 product and Ph2a concept understood [Biopharm team]\n*Animal PK study on Phase 2a concepts considered if not BCS-1 or not IR and if deeded appropriate [Biopharm team]\n*If Phase2a is  conventional solid formulation and if not yet known, consider the effect of API PSD  if not BCS-1  : PBBM model (sensitivity analysis) / animal PK (if relevant) [Biopharm team]": "ex:QualityAttribute_biopharmaceutical_te_d304c07d",
  "QualityAttribute:SM:3:Blinding strategy (ph 1>2a>2b) outlined based on clinical development plan (placebo need & timing; options for blinding; eg overencapsulation, matching (coated) placebo formulation, packaging design,etc)": "ex:QualityAttribute_blinding_strategy_ph_4c9982d5",
  "QualityAttribute:SM:3:Bridging strategy: Bridging strategy defined between phase 1(b) - 2a -2b if different formulation[Biopharm team]": "ex:QualityAttribute_bridging_strategy_br_58089c61",
  "QualityAttribute:SM:3:CDCP (Clinical Design Control Process) for Phase 1 completed:\n*CDCP Development Plan\n*Clinical Device Traceability Matrix\n*Clinical Device Risk Management": "ex:QualityAttribute_cdcp_clinical_design_b827abaa",
  "QualityAttribute:SM:3:CPDP (Combination Prodiuct Development Process)  Portfolio Management & Concept Feasibility Stage for phase3/commercial (optional):\n *Gather information for feasibility report\n *Identify phase 3 and/or commercial device options": "ex:QualityAttribute_cpdp_combination_pro_76eea57a",
  "QualityAttribute:SM:3:China container DMF compliance and any other country specific requirements": "ex:QualityAttribute_china_container_dmf_c4d9d71b",
  "QualityAttribute:SM:3:Clinical CMC-TPP defined for Phase 2a product ( [CMC-L]": "ex:QualityAttribute_clinical_cmc_tpp_def_26718e49",
  "QualityAttribute:SM:3:Clinical Container Closure System Suitability Assessment (Ph1)": "ex:QualityAttribute_clinical_container_c_1801356d",
  "QualityAttribute:SM:3:Clinical primary Component Specifications (Ph1)": "ex:QualityAttribute_clinical_primary_com_04be1e7a",
  "QualityAttribute:SM:3:Complete activities required for Phase 3/Commercial device selection if applicable:\n*bench test/stress test\n*user preference studies\n*key stakeholders' input\n*Phase 1 clinical study results": "ex:QualityAttribute_complete_activities_c13f0a4d",
  "QualityAttribute:SM:3:Complete for Phase 1:\n*Define critical and essential technical and usability performance requirements to support Phase 1 studies\n*Define test strategy. If required develop methods to verify technical and usability requirements are met\n*Collect data (from supplier and/or Janssen's own testing) to verify design requirements are met\n*If required, conduct combination product stability test suitable for phase 1, generate reports\n*If required, create IFU\n*Select packaging design \n*Define and provide traning to site staff/patients\n*Set up device PQC handling process including where complaints will be investigated. Work with clinical QC to set up/update appropriate complaint categories and conclusions\n* Identify hazards, hazardous siutations,  failure modes for combination product": "ex:QualityAttribute_complete_for_phase_1_6a12eb05",
  "QualityAttribute:SM:3:Complete initial Product Risk Assessment (PRA) for the relevant product category .(Only sections related to hazard analysis and initial risk evaluation are required).\n\nUse existing generic PRM/PRA whenever possible.": "ex:QualityAttribute_complete_initial_pro_05ab8f45",
  "QualityAttribute:SM:3:Complexity Assessment Form/decision completed or revisited with team.  uFMEA for clinical product completed, if needed.": "ex:QualityAttribute_complexity_assessmen_c2af161d",
  "QualityAttribute:SM:3:Country specify requirements in Country Level Regulatory Requirements (CLRR) database": "ex:QualityAttribute_country_specify_requ_7683e130",
  "QualityAttribute:SM:3:Create Quality Reaction Scheme (QRS) and Quality Synthesis Description (QSYN) prior to FIH filing": "ex:QualityAttribute_create_quality_react_57496740",
  "QualityAttribute:SM:3:Create/Review/Update Phase 1 and 2 specification and process parameters  These may include:\n*Incoming inspection specifications for device components/raw materials, including shelf life\n*Release specification for combination product, including shelf life\n*Primary container (unfilled and filled) specifications that are related to device function\n *Identify presumed critical process parameters (component, subassembly, final assembly, etc) and range": "ex:QualityAttribute_create_review_update_37e92cf2",
  "QualityAttribute:SM:3:Create/update acceptance criteria and sample size for incoming and release tests based on risk assessement for Phase 1 and 2 when appropriate": "ex:QualityAttribute_create_update_accept_1065c9eb",
  "QualityAttribute:SM:3:Critical questions updated in accordance with Lean ED principles": "ex:QualityAttribute_critical_questions_u_cf315d15",
  "QualityAttribute:SM:3:Cross functional Risk register completed and mitigation plan developed, also highlighting the gaps and any mitigations with respect to key deliverables": "ex:QualityAttribute_cross_functional_ris_936972e8",
  "QualityAttribute:SM:3:Cross-functional project plan updated in line with PhIIa strategy": "ex:QualityAttribute_cross_functional_pro_ec4734c3",
  "QualityAttribute:SM:3:DP characterization plan incl solid state at Tzero and on stability (AD/P&MS)": "ex:QualityAttribute_dp_characterization_8de61aeb",
  "QualityAttribute:SM:3:DP release testing and stability initiated for Ph1 DP and stability statement documented": "ex:QualityAttribute_dp_release_testing_a_cc3a3408",
  "QualityAttribute:SM:3:DP specification": "ex:QualityAttribute_dp_specification_a9e0dcf0",
  "QualityAttribute:SM:3:Develop cross-functional plan and resource estimates for scenarios (if necessary)": "ex:QualityAttribute_develop_cross_functi_774051de",
  "QualityAttribute:SM:3:EHS Requirement: Author DS SDS; Confirm PBOEL HHC": "ex:QualityAttribute_ehs_requirement_auth_3e6a860e",
  "QualityAttribute:SM:3:Engineering study for Phase 1b/2 design (stress testing, accelerated aging) (optional)": "ex:QualityAttribute_engineering_study_fo_49f61a66",
  "QualityAttribute:SM:3:Ensure providers are qualified and required documents provided to PQI and introduce all Investigational Medical Products (IMP), including all third party  products if applicable, in PQV database or sharepoint.": "ex:QualityAttribute_ensure_providers_are_acd36932",
  "QualityAttribute:SM:3:Excipients used are within established safety limits\u00a0Formula and/or Excipient safety report [P&MS]": "ex:QualityAttribute_excipients_used_are_4e1fd24c",
  "QualityAttribute:SM:3:FDS report v2": "ex:QualityAttribute_fds_report_v2_85fc6d10",
  "QualityAttribute:SM:3:FiH PK profile understood :\n*Review of FIH data completed [Biopharm team]\n*FiH SAD /MAD  PK profiles and first-pass metabolism understood, dose-linearity evaluated  and PBBM simulations verified and refined with clinical data. Is the  rate/extent of absorption in line with anticipated PK/PD or do we need to change?  [Biopharm team]\n*Potential for food effect evaluated for BCS-2/3/4: in-vitro testing for BCS2/4\n*Biopharm critical questions and Biopharm strategy for Phase 2a updated  [Biopharm team]\n*High level Biopharm strategy defined for late development in line with the possible LD  formulation strategy scenarios for Phase 2b>3>commercial [Biopharm team]": "ex:QualityAttribute_fih_pk_profile_under_fd4958d0",
  "QualityAttribute:SM:3:Fit-for-purpose mfg process suitable for Ph2a volumes (preferably in line with design std's/decision tree). [DPD]": "ex:QualityAttribute_fit_for_purpose_mfg_361b7b97",
  "QualityAttribute:SM:3:Formulation concepts evaluated for Phase 2a (preferably in line with design std's/decision tree). Fit-for-purpose formulation yet in line with CDT strategy  for the compound [DPD]": "ex:QualityAttribute_formulation_concepts_67e1c733",
  "QualityAttribute:SM:3:Formulation strategy (ph 1>2a>2b) updated based on FIH results  [Biopharm team]": "ex:QualityAttribute_formulation_strategy_d4802716",
  "QualityAttribute:SM:3:IPPI completed prior to FIH (if applicable)": "ex:QualityAttribute_ippi_completed_prior_2921fd78",
  "QualityAttribute:SM:3:Identify critical analytical attributes and ensure process to collect and monitor timely": "ex:QualityAttribute_identify_critical_an_ba1be0a9",
  "QualityAttribute:SM:3:If required complete Combination product designation evaluation form (TV-eFRM-07474) for Phase 2": "ex:QualityAttribute_if_required_complete_78680b2f",
  "QualityAttribute:SM:3:Implement suitable manfuaturing controls for Phase 1b/2 combination product processes:\n* Incoming and release tests\n* in process control/inspection": "ex:QualityAttribute_implement_suitable_m_f2f19fed",
  "QualityAttribute:SM:3:Impurities and degradants assessed according to the Global Impurity Management Policy (repeated as new DP formulations are implemented or when new impurities/degradants are detected).[AD]": "ex:QualityAttribute_impurities_and_degra_a6b4f2fb",
  "QualityAttribute:SM:3:Impurity Mgmt report 1 approved and in line with the Global Impurity Management Policy (incl. Impurities qualified, nitrosamine assessment and documented in Tox memo) incl NRER v1 (nitrosmaine risk evaluation report v1)": "ex:QualityAttribute_impurity_mgmt_report_1af587e2",
  "QualityAttribute:SM:3:In vitro ( Dissolution) / in silico studies:\n*Physiology based dissolution method ( evtlly customized  in setup/ parameters to increase in-vivo relevance ) performed on  Phase 2a concepts appropriate according to BCS [AD Disso Sci]\n*Where useful, PBBM applied to guide drug product development  [P&MS]": "ex:QualityAttribute_in_vitro_dissolution_b5913e97",
  "QualityAttribute:SM:3:In-vivo relevance: Evaluated whether (customized) Physiology based dissolution screening method and PBBM  had relevance to the obtained in-vivo data [Biopharm team]": "ex:QualityAttribute_in_vivo_relevance_ev_078c2093",
  "QualityAttribute:SM:3:Including LD KEM, critical path activities, buy-ups, and when to start (at risk)": "ex:QualityAttribute_including_ld_kem_cri_42c9ddca",
  "QualityAttribute:SM:3:Inclusion of preferred packaging materials and administration sets (e.g. IV sets, dispensers, NG tubes) and defined in the TPP": "ex:QualityAttribute_inclusion_of_preferr_a5f5ca17",
  "QualityAttribute:SM:3:Initiate Clinical Design Control Process (CDCP) as appropriate (for Combo products)": "ex:QualityAttribute_initiate_clinical_de_efbea14a",
  "QualityAttribute:SM:3:Initiate technical transfer protocol, finalize technical transfer report in case of Extemporaneous Preparations.": "ex:QualityAttribute_initiate_technical_t_d3841f3e",
  "QualityAttribute:SM:3:Kick-Off Customer Centered Design Process, inclusive of Customer Centered Design Workshop as needed; align on the Compound Overview & Timeline; Prioritize Deliverables (incorporating country specific requirements i.e Japan as necessary)": "ex:QualityAttribute_kick_off_customer_ce_d42046e3",
  "QualityAttribute:SM:3:LD  strategy [Ph2b>Ph3>Commercial] based upon LD TA strategy, first LD TPP,  technical direction forward.": "ex:QualityAttribute_ld_strategy_ph2b_ph3_153b60c2",
  "QualityAttribute:SM:3:Lessons Learned, if program is not proceeding to full development": "ex:QualityAttribute_lessons_learned_if_p_e009c2eb",
  "QualityAttribute:SM:3:List of excipients with suppliers used in formulation available to support Supplier Qualification for clinical (P&MS + procurement), spec in place and supplier qualified for clinical Ph2a": "ex:QualityAttribute_list_of_excipients_w_9473faed",
  "QualityAttribute:SM:3:Mainly empirical control strategy with extra controls where needed": "ex:QualityAttribute_mainly_empirical_con_96a94274",
  "QualityAttribute:SM:3:Materials with supplier used in synthesis (from GMP SM onwards) phase appropriate qualified": "ex:QualityAttribute_materials_with_suppl_848674bd",
  "QualityAttribute:SM:3:Method development & qualification": "ex:QualityAttribute_method_development_q_8c1528a7",
  "QualityAttribute:SM:3:Method development & qualification (AD/P&MS)": "ex:QualityAttribute_method_development_q_edcf2d5d",
  "QualityAttribute:SM:3:Microbial Risk Assessment for Extemporaneous Preparations completed and available for Quality review (if appropriate)": "ex:QualityAttribute_microbial_risk_asses_be6aaf03",
  "QualityAttribute:SM:3:PMQ testing (Pharmacy Manual Qualification) completed prior to FIH (if applicable)": "ex:QualityAttribute_pmq_testing_pharmacy_f684e68c",
  "QualityAttribute:SM:3:Packaging identified for Phase 2a (fit-for-purpose, preferable standard pack).": "ex:QualityAttribute_packaging_identified_a35e5dc3",
  "QualityAttribute:SM:3:Pediatric CMC Assessment (assess potential for ped formulation development)  (see separate list for pediatric stage gate deliverables to achieve at SG4 like pediatric CMC TPP )": "ex:QualityAttribute_pediatric_cmc_assess_2a94cf4f",
  "QualityAttribute:SM:3:Ph1b IND/CTA completed": "ex:QualityAttribute_ph1b_ind_cta_complet_c836905f",
  "QualityAttribute:SM:3:Ph2b DP concepts well characterized including solid state [DPD/P&MS/AD]. Failure modes (incl. in vivo failure) explored,  understood, and preferentially designed out. Relevant solid state forms defined (P&MS).  Source document (DPIR) for DP sections of CTA section verified and approved.": "ex:QualityAttribute_ph2b_dp_concepts_wel_5478dd4d",
  "QualityAttribute:SM:3:Pharmacopiea compliance : requirements of USP/EP/ChP considered": "ex:QualityAttribute_pharmacopiea_complia_30698c66",
  "QualityAttribute:SM:3:Phase 2a Bridging strategy  defined and how to bridge to later stages": "ex:QualityAttribute_phase_2a_bridging_st_b0f2af98",
  "QualityAttribute:SM:3:Phase 2a Development strategy in place": "ex:QualityAttribute_phase_2a_development_9d37a4d4",
  "QualityAttribute:SM:3:PhysChem characterization of product including solid state/PK/Stability/Mfg'ability/IP documented in reports  [P&MS/AD/DPD/API SM/Biopharm team]": "ex:QualityAttribute_physchem_characteriz_1fc3c46e",
  "QualityAttribute:SM:3:Plan, prepare, and execute HA meetings (US EoP-2, EU scientific advise) to present, discuss, and agree on key regulatory strategies (e.g. QbD elements, starting materials, API/DP primary stability protocols, etc).": "ex:QualityAttribute_plan_prepare_and_exe_3330be0b",
  "QualityAttribute:SM:3:Proof of Structure (POS)": "ex:QualityAttribute_proof_of_structure_p_f7f1d71c",
  "QualityAttribute:SM:3:Quality Agreements / Site qualification for clinical use for GMP INT, API and DP": "ex:QualityAttribute_quality_agreements_s_f1917404",
  "QualityAttribute:SM:3:Raw materials Specifications {P&MS]": "ex:QualityAttribute_raw_materials_specif_82f7eaf5",
  "QualityAttribute:SM:3:Re-assessment of development and clinical mfg siting (Ph2) (internal / external) with attention to CMO readiness in terms of knowledge and capability\u00a0[PPDS/CSC/ESI]": "ex:QualityAttribute_re_assessment_of_dev_86e05ce1",
  "QualityAttribute:SM:3:Re-assessment of development and clinical mfg siting (Ph2) (internal / external) with attention to CMO readiness in terms of knowledge and capability\u00a0[PPDS/CSC/ESI]. (Note: If new CMO identified, team is extended)": "ex:QualityAttribute_re_assessment_of_dev_ad028d4f",
  "QualityAttribute:SM:3:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) for Phase 1b/2 when applicable:\n*Supplier and Contractor Audit\n*Device Quality Agreement (Manufacturing)\n*Device Quality Agreement (Device component, device itself and Purchasing Contro/ for Combo Products)\n*Device Testing Quality Agreement (Lab to Lab)  \n* Third Party Design Control Audit Report (If Applicable)": "ex:QualityAttribute_readiness_for_the_co_fbcdf572",
  "QualityAttribute:SM:3:Reference standard qualified for identification, assay and impurities": "ex:QualityAttribute_reference_standard_q_0ee29b49",
  "QualityAttribute:SM:3:Resource estimates (FTE and OOP) calculated for PhIIa development and approved by CMC team": "ex:QualityAttribute_resource_estimates_f_df76f05d",
  "QualityAttribute:SM:3:Review of FiH clinical data completed": "ex:QualityAttribute_review_of_fih_clinic_4e38f7ab",
  "QualityAttribute:SM:3:Review of Phase 1 manufacturing campaigns completed:\n*Trending and mitigation of manufacuting issues\n*Identify and implement required activities for subsequent clinical phases and commercial design": "ex:QualityAttribute_review_of_phase_1_ma_7aa885a1",
  "QualityAttribute:SM:3:Review of Phase 1 product/mfg campaigns completed (i.e CoA's CTM batches/Ph1 reports/Master Batch Record/lessons learned for Ph2)": "ex:QualityAttribute_review_of_phase_1_pr_3c484c5f",
  "QualityAttribute:SM:3:Review of Phase 1 trials completed:\n*Trending and mitigation of device clinical complaints (device design and usability related)\n*Identify any new/unique user requirements (i.e., PK, usability, etc) for clinical phases and commercial design\n*Identify and implement required design change and/or mitigation activities for subsequent clinical phases and commercial design\n*Update clinical product risk assessment": "ex:QualityAttribute_review_of_phase_1_tr_6f0e65a2",
  "QualityAttribute:SM:3:RiPBS report with Shelf life prediction for selected clinical formulation": "ex:QualityAttribute_ripbs_report_with_sh_6e735ce1",
  "QualityAttribute:SM:3:Risk assessment for residual elemental impurities for DS to be included to ensure proper screening in initiated from Ph I": "ex:QualityAttribute_risk_assessment_for_b28f1362",
  "QualityAttribute:SM:3:Select Phase 2 device if applicable": "ex:QualityAttribute_select_phase_2_devic_26b1d10c",
  "QualityAttribute:SM:3:Select and implement suitable (Fit-for-Purpose) manufacturing process for Phase 1b.  If required, identify Fit-for-Purpose mfg process suitable for Ph2 volumes. This may include and are not limited to:\n*Device component manufacturing\n*Subassembly\n*Final assembly\n*Packaging": "ex:QualityAttribute_select_and_implement_b12dd9e4",
  "QualityAttribute:SM:3:Source documents for API sections of CTA submission verified and approved (Refer to TV-SOP-21562)": "ex:QualityAttribute_source_documents_for_a9c71ba8",
  "QualityAttribute:SM:3:Standard well understood excipients/suppliers if feasible [P&MS]": "ex:QualityAttribute_standard_well_unders_5087de73",
  "QualityAttribute:SM:3:Suitability of excipients evaluated and compliance to regulatory strategy summarized in Excipient Safety Report [P&MS]": "ex:QualityAttribute_suitability_of_excip_1727b9a4",
  "QualityAttribute:SM:3:Supplier Material Qualification completed for starting materials and raw materials for API and excipients and packaging materials for DP for clinical use: AIM record": "ex:QualityAttribute_supplier_material_qu_98ea50f1",
  "QualityAttribute:SM:3:Synthesis development plan for 2nd GMP batch available": "ex:QualityAttribute_synthesis_developmen_accbd482",
  "QualityAttribute:SM:3:Target settings and workable range defined  for presumed critical process parameters (Ph2a DP){DPD]": "ex:QualityAttribute_target_settings_and_ec46a8b4",
  "QualityAttribute:SM:3:Trigger for 2nd GMP batch developed": "ex:QualityAttribute_trigger_for_2nd_gmp_2e324e83",
  "QualityAttribute:SM:3:Update Cleaning Validation Limit\u00a0[DPD SI/CSC]": "ex:QualityAttribute_update_cleaning_vali_2c2f39f5",
  "QualityAttribute:SM:3:Weak points of molecule defined and translated into development/spec strategy": "ex:QualityAttribute_weak_points_of_molec_99a6ca15",
  "QualityAttribute:SM:3:critical analytical attributes identified and ensure process to collect and monitor timely": "ex:QualityAttribute_critical_analytical_35d7f74b",
  "QualityAttribute:SM:3:weak points of formulation defined and translated into development/spec strategy": "ex:QualityAttribute_weak_points_of_formu_39327b28",
  "QualityAttribute:SM:4:\"Product Compliance Focus Area\" consulted and Nitrosamine strategy aligned for API.": "ex:QualityAttribute_product_compliance_f_94e12105",
  "QualityAttribute:SM:4:\"Product Compliance Focus Area\" consulted and Nitrosamine strategy aligned for DP.": "ex:QualityAttribute_product_compliance_f_f8f40f07",
  "QualityAttribute:SM:4:API cost simulation & sensitivity analysis based on anticipated sales price and sales forecast from Marketing and compared with JSC-VCL delivered cost target": "ex:QualityAttribute_api_cost_simulation_2ed56159",
  "QualityAttribute:SM:4:API form (salt/polymorph) locked for late development (except for ASD formulations) based on continuous efforts to understand the polymorphic landscape . API form selection report needs to be updated to document final form selection and endorsed by Solid State Expert Team even when no form switch is required.  [P&MS] M3.": "ex:QualityAttribute_api_form_salt_polymo_49cd7716",
  "QualityAttribute:SM:4:API late development specifications proposal": "ex:QualityAttribute_api_late_development_5af7b0ee",
  "QualityAttribute:SM:4:API test methods developed fit-for-purpose and qualified": "ex:QualityAttribute_api_test_methods_dev_545d0721",
  "QualityAttribute:SM:4:API test parameters - strategy assessment according to Final Development Requirements  incl. PAT": "ex:QualityAttribute_api_test_parameters_9b5710cb",
  "QualityAttribute:SM:4:Accelerated Physical and chemical stability  studies on DP concepts performed to select preferred  one (AD/P&MS)": "ex:QualityAttribute_accelerated_physical_5f814c14",
  "QualityAttribute:SM:4:Advance control strategy (i.e. PAT) developed/assessed [DPD/AD/Engineering/JSC]": "ex:QualityAttribute_advance_control_stra_360b4d7c",
  "QualityAttribute:SM:4:Assess Regulatory feasibility of QbD: consider \u00a0nature of API synthesis \u00a0and DP formulation type, development work already performed (API/DP) and development strategy, current regulatory environment to enable \u00a0decision to adopt a full QbD, hybrid or traditional approach": "ex:QualityAttribute_assess_regulatory_fe_180b93e0",
  "QualityAttribute:SM:4:Assess clinical and commercial sourcing strategy.  Determine the impact to the commercial supply chain in case launch would have to be from the clinical site.": "ex:QualityAttribute_assess_clinical_and_57c4cba1",
  "QualityAttribute:SM:4:Assessment whether Nitrosamine risk factors are present in the  DP  formulation /process and optimization plan, and reviewed by Compliance Focus Area [P&MS]": "ex:QualityAttribute_assessment_whether_n_69a234fb",
  "QualityAttribute:SM:4:Assessment whether Nitrosamine risk factors are present in the API and optimization plan": "ex:QualityAttribute_assessment_whether_n_4937b7ab",
  "QualityAttribute:SM:4:BCS Classification: Final solubility data on locked API form reported in BCS classification report [P&MS]": "ex:QualityAttribute_bcs_classification_f_8be00d53",
  "QualityAttribute:SM:4:Batch overview of relevant formulations": "ex:QualityAttribute_batch_overview_of_re_5c3ec40a",
  "QualityAttribute:SM:4:Biopharmaceutical testing:\n*Consider animal PK study on Phase 2b concepts if not BCS-1 and not IR": "ex:QualityAttribute_biopharmaceutical_te_07ffe3d7",
  "QualityAttribute:SM:4:Blinding strategy re-evaluated based on clinical development plan (placebo need & timing; options for blinding eg overencapsulation, matching (coated) placebo formulation, packaging design, etc)": "ex:QualityAttribute_blinding_strategy_re_9310b4a3",
  "QualityAttribute:SM:4:Bridging strategy & clinical relevance strategy as part of the biopharm strategy:\n*Bridging Strategy Phase 2a-Phase2b-Phase3-Commercial formulation/process/mfg site if different formula or major process change and no biowaiver. Consider possibility to adapt Sourcing Strategy  depending upon the complexity of proving BE  [e.g. CR, Inhalation, patches, ...]  [CMC-L/Biopharm team/DPD]\n*High level strategy for clinical relevant specs if already a final formulation is selected .  IVIVC strategy in case of Controlled Release [Biopharm team]": "ex:QualityAttribute_bridging_strategy_cl_8033c131",
  "QualityAttribute:SM:4:CPDP Protolfio Management & Concept Feasibility Stage:\n*Combination Product Feasibility Report\n*Create User Description and User Requirement Document for phase 3/Commercial design based on Phase 1, HF studies, TPP (if available) and other learnings": "ex:QualityAttribute_cpdp_protolfio_manag_a19f3c2a",
  "QualityAttribute:SM:4:Characterization methods , incl sensitive polymorphic purity methods developed for release and stability (P&MS together with AD) and risk assessment for DS and DP nitrosamines": "ex:QualityAttribute_characterization_met_abf897d7",
  "QualityAttribute:SM:4:China DMF compliance": "ex:QualityAttribute_china_dmf_compliance_d375fe45",
  "QualityAttribute:SM:4:Clinical CMC TPP for Phase 2b defined; Draft CMC TPP available for pivotal trials & commercial including final target PK profile": "ex:QualityAttribute_clinical_cmc_tpp_for_14123a61",
  "QualityAttribute:SM:4:Clinical Container Closure System Suitability Assessment (Ph2)": "ex:QualityAttribute_clinical_container_c_e6456135",
  "QualityAttribute:SM:4:Clinical primary Component Specifications (Ph2)": "ex:QualityAttribute_clinical_primary_com_4b438322",
  "QualityAttribute:SM:4:Close to final mfg process techniques according to decision tree [TV-TRG-08773] based upon Reliable Technology with good manufacturability": "ex:QualityAttribute_close_to_final_mfg_p_16ae4ca8",
  "QualityAttribute:SM:4:Communicate BPAL aspiration targets for drug substance, drug product and align with CMCT.": "ex:QualityAttribute_communicate_bpal_asp_73093d23",
  "QualityAttribute:SM:4:Compatability testing (DP and equipment train) complete and acceptable": "ex:QualityAttribute_compatability_testin_1f6994e1",
  "QualityAttribute:SM:4:Complete Excipient compatibility evaluation": "ex:QualityAttribute_complete_excipient_c_d00eee90",
  "QualityAttribute:SM:4:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for clinical product, as needed.": "ex:QualityAttribute_complete_or_revisit_9fe13695",
  "QualityAttribute:SM:4:Complete/update for Phase 2 device if applicable:\n*Define/update critical and essential technical and usability performance requirements to support phase 2 studies\n* Define/upate test strategy. If required develop methods to verify technical and usability requirements are met\n*If required, conduct combination product stability test suitable for phase 2\n*Collect data (from supplier and/or Janssen's own testing) to verify design requirements are met\n*Create/Update IFU\n*Select package design\n*Define and provide traning to site staff/patients": "ex:QualityAttribute_complete_update_for_426dbf9b",
  "QualityAttribute:SM:4:Country specify requirement in CLRR database": "ex:QualityAttribute_country_specify_requ_dd0b8016",
  "QualityAttribute:SM:4:Criticality analysis draft in-place, possible CQA's/pCQA's defined. CA of the DP must be reviewed/approved before release of the Ph2b and Ph3 batches (CQA identification is described in TV-TRG-06961)": "ex:QualityAttribute_criticality_analysis_9387f5c1",
  "QualityAttribute:SM:4:Cross functional Risk register completed and mitigation plan developed, also highlighting the gaps and any mitigations with respect to key deliverables.": "ex:QualityAttribute_cross_functional_ris_016d0265",
  "QualityAttribute:SM:4:DP Solid state strategy for late development defined and reviewed by Solid State Focus Area [P&MS]": "ex:QualityAttribute_dp_solid_state_strat_ec8f1a8b",
  "QualityAttribute:SM:4:DP characterization at release and stability including solid state (AD/P&MS)": "ex:QualityAttribute_dp_characterization_26efdbba",
  "QualityAttribute:SM:4:DP specifications defined for clinical filings": "ex:QualityAttribute_dp_specifications_de_e2c2c85c",
  "QualityAttribute:SM:4:DP stability protocol and studies initiated (if formulation/packaging/methods changed)": "ex:QualityAttribute_dp_stability_protoco_5652b9d1",
  "QualityAttribute:SM:4:DP stability storage statements updated": "ex:QualityAttribute_dp_stability_storage_190e7369",
  "QualityAttribute:SM:4:DP test methods developed fit-for-purpose and qualified": "ex:QualityAttribute_dp_test_methods_deve_8bbd0076",
  "QualityAttribute:SM:4:Deliver preliminary BOM (List of materials with supplier used in synthesis (from GMP SM onwards) to support Qualification for clinical (RM,SM and/or API): API-SI to ASL + QI)": "ex:QualityAttribute_deliver_preliminary_df656840",
  "QualityAttribute:SM:4:Dissolution studies: \n*Physiology based dissolution  method on Phase 2b concepts, appropriate according to BCS class\n*If not yet known, effect of API PSD (non-BCS1) and excipient attributes  which might be well involved in the drug release mechanism [DPD/AD/P&MS]": "ex:QualityAttribute_dissolution_studies_840c9c71",
  "QualityAttribute:SM:4:Draft Criticality Analysis according to ssCA TV-SOP-35966": "ex:QualityAttribute_draft_criticality_an_84bc15e7",
  "QualityAttribute:SM:4:Draft Full Development Strategy available": "ex:QualityAttribute_draft_full_developme_ad4e6e7e",
  "QualityAttribute:SM:4:Draft formulation Development Report describing the development history available (including formulation strategy and material and product characterization plan, see TV-TRG-06295)": "ex:QualityAttribute_draft_formulation_de_25ab0455",
  "QualityAttribute:SM:4:EHS Requirement: Update EH&S assessment  and initiate Chemical Compliance (REACH & Substance of Concern) roundtable and occupational tox testing strategy. Initiate EH&S Process Risk analysis, safety check document.": "ex:QualityAttribute_ehs_requirement_upda_81bc3fc4",
  "QualityAttribute:SM:4:Evaluate existing and if required update/create acceptance criteria and sample size for incoming and release tests based on risk assessement for Phase 2": "ex:QualityAttribute_evaluate_existing_an_7fb79212",
  "QualityAttribute:SM:4:Excipient: suitability evaluation and alignment with regulatory strategy (EP, USP, C-JP, CP), SWOT assessment, method development initiated and specification in place and suppliers qualified for clinical   (P&MS/PCD)": "ex:QualityAttribute_excipient_suitabilit_dffc1b37",
  "QualityAttribute:SM:4:Excipients used are within established safety limits. [P&MS] Formula and/or Excipient safety report": "ex:QualityAttribute_excipients_used_are_b84abfcb",
  "QualityAttribute:SM:4:FDS report v3": "ex:QualityAttribute_fds_report_v3_7a6692ed",
  "QualityAttribute:SM:4:Failure modes for API solid state defined, understood and designed out to the extent possible (P&MS/CTU)) M3.": "ex:QualityAttribute_failure_modes_for_ap_877779c8",
  "QualityAttribute:SM:4:First version of Best Process assessment done: proposed comm. synthesis route locked and supported by appropriate experimentation, Proof of concept batch, and science": "ex:QualityAttribute_first_version_of_bes_02854432",
  "QualityAttribute:SM:4:Fit-for-purpose packaging, preferably standard": "ex:QualityAttribute_fit_for_purpose_pack_f47da793",
  "QualityAttribute:SM:4:Formal CMC-Council endorsement to deviate from default CM-strategy (if applicable)": "ex:QualityAttribute_formal_cmc_council_e_51555ff3",
  "QualityAttribute:SM:4:Formulation Design & selection:\n*Biopharm strategy for late development incl sequence of  in vitro and in vivo  studies to come to product with targeted PK profile.\n*Designed for final PK profile, from mechanistic understanding of PK /PD relationship.\n*In case Phase 2b is the pivotal clinical trial then preferentially final formulation at start of the pivotal clinical trials to avoid critical path BE studies.\n* PBBM model established to guide formulation development if appropriate and possible [Biopharm team]\n*Reliable by Design : formulation with inherent in-vivo robustness (e.g. low variability, no dose dumping), stable for drug release profile, mfg\u2019able, minimal biopharmaceutical liabilities\n* Design for biowaiver if BCS 1/3": "ex:QualityAttribute_formulation_design_s_0776158f",
  "QualityAttribute:SM:4:High level E2E CM-strategy & draft plan & clinical control strategy plan (EO-SG4 vs SG5 - FD-plan) (CM-Council), inc. sourcing strategy, API-needs/plan/budget impact, strategic capacity risks, throughput strategy, runtime strategy,... (SG5 > \"detailed\" FD-plan in SG5), including plan to include PPQ data in MAA (CM regarded as new technology)": "ex:QualityAttribute_high_level_e2e_cm_st_8ea262fa",
  "QualityAttribute:SM:4:Identify and implement suitable manfuaturing controls for Phase 2:\n*Incoming and release tests\n*in-process control/inspection": "ex:QualityAttribute_identify_and_impleme_18d98d58",
  "QualityAttribute:SM:4:Identify impurities that require tox evaluation/qualification.": "ex:QualityAttribute_identify_impurities_3d9a0616",
  "QualityAttribute:SM:4:If Ph2b is a pivotal study SG#6 deliverables must be considered.": "ex:QualityAttribute_if_ph2b_is_a_pivotal_3e6f08f0",
  "QualityAttribute:SM:4:If required, complete CDCP (Clinical Design Control Process) for Phase 2:\n*CDCP Development Plan\n*Clinical Device Traceability Matrix\n*Clinical Device Risk Management (PRA)\n*Clinical Device Design Review\n*Clinical Device Development DHF": "ex:QualityAttribute_if_required_complete_d0fcf912",
  "QualityAttribute:SM:4:In-vivo relevance:\n*Evaluated whether Physiology based dissolution method and clinical QC method sofar had relevance to the obtained PK data. Use this to design a clinically relevant QC dissolution method if possible [AD/Biopharm team]": "ex:QualityAttribute_in_vivo_relevance_ev_3d9d68a3",
  "QualityAttribute:SM:4:Investigate options for IP protection [DPD]": "ex:QualityAttribute_investigate_options_a4f167d6",
  "QualityAttribute:SM:4:Kick-off Customer Centric Design Team and ensure critical elements are incorporated into Ph2b *Bridging data (phase 2a to phase 2b) and bridging strategy (phase 2b to phase 3). IVIVC strategy if applicable.": "ex:QualityAttribute_kick_off_customer_ce_94650dcd",
  "QualityAttribute:SM:4:Map out options for Registration/Commercial Production - These may include but are not limited to:\n*Device component manufacturing\n*Subassembly\n*Final assembly\n*Packaging": "ex:QualityAttribute_map_out_options_for_5c1e61dc",
  "QualityAttribute:SM:4:Mfg process suitable for Phase 3 volumes identified": "ex:QualityAttribute_mfg_process_suitable_5a9986b9",
  "QualityAttribute:SM:4:Multi generation full development plan created : product /process design over different clinical phases, commercial": "ex:QualityAttribute_multi_generation_ful_5b1ea56b",
  "QualityAttribute:SM:4:Overview of impurity profile of relevant batches": "ex:QualityAttribute_overview_of_impurity_4bf3fb3d",
  "QualityAttribute:SM:4:Paper based assessment of potential use of advanced monitoring tools (NIR) for testing & additional process knowledge at Lab (F2M only)": "ex:QualityAttribute_paper_based_assessme_572d6e48",
  "QualityAttribute:SM:4:Passive shipping systems qualified, if applicable (ph2b only - internal supply chain)": "ex:QualityAttribute_passive_shipping_sys_7eac0a09",
  "QualityAttribute:SM:4:Pediatric CMC Assessment (assess potential for ped formulation development) see separate list of deliverables for pediatric development": "ex:QualityAttribute_pediatric_cmc_assess_842eadc4",
  "QualityAttribute:SM:4:Perform salt and/or cocrystal screen in view of IP [P&MS] M3.": "ex:QualityAttribute_perform_salt_and_or_d685b802",
  "QualityAttribute:SM:4:Ph2 IND/CTA completed": "ex:QualityAttribute_ph2_ind_cta_complete_5c0a2068",
  "QualityAttribute:SM:4:Ph2b DP concept selected based on matrix table criteria according to Formulation Design Initiative guidelines (eg manufacturability, stability, PK, phys-chem characterization, chemical and solid-state excipient compatibility,  IP)": "ex:QualityAttribute_ph2b_dp_concept_sele_01f92e20",
  "QualityAttribute:SM:4:Ph2b DP reliable design close to Ph3/ Commercial (preferably platform) based upon Reliable Delivery Technology (platform: prior knowledge//enabling: appropriate experiments & science)": "ex:QualityAttribute_ph2b_dp_reliable_des_b22af401",
  "QualityAttribute:SM:4:Ph2b DP selection rationale documented in Formulation Decision Matrix v2 according to Formulation Design Initiative (FDI) guidelines.": "ex:QualityAttribute_ph2b_dp_selection_ra_992f97b2",
  "QualityAttribute:SM:4:Pharmacopiea compliance : consider the requirement of USP/EP/ChP": "ex:QualityAttribute_pharmacopiea_complia_916bc930",
  "QualityAttribute:SM:4:Phase 3/Commercial Device:\n*Select device\n*Collect user group and user environment information\n*Define/update critical and essential technical and usability and performance requirements": "ex:QualityAttribute_phase_3_commercial_d_af6dbeb6",
  "QualityAttribute:SM:4:Platform excipients /suppliers if possible. Non std excipients/suppliers if justified.  If enabling : High -Throughput screening of Formulation/Excipients  options [P&MS]": "ex:QualityAttribute_platform_excipients_5f75f22b",
  "QualityAttribute:SM:4:Polymorphism landscape well understood and the relevant (pseudo)polymorphic forms defined.  (P&MS) M3.": "ex:QualityAttribute_polymorphism_landsca_d50909a2",
  "QualityAttribute:SM:4:Preliminary Ph2b/Ph3/commercial manufacturing technology fit and manufacturing network assessment completed (API and DP)": "ex:QualityAttribute_preliminary_ph2b_ph3_f6e411b9",
  "QualityAttribute:SM:4:Preliminary control strategy for API": "ex:QualityAttribute_preliminary_control_be9677cc",
  "QualityAttribute:SM:4:Process & Mfg technology strategy developed and assessed.": "ex:QualityAttribute_process_mfg_technolo_daf0443c",
  "QualityAttribute:SM:4:Process control & product release strategy developed/assessed": "ex:QualityAttribute_process_control_prod_dbc992f7",
  "QualityAttribute:SM:4:Project timelines, scope and resources updated in line with current assumptions": "ex:QualityAttribute_project_timelines_sc_c525912f",
  "QualityAttribute:SM:4:Provide input to the SPRA and Material Readiness Tracker in collaboration with JSC and PQM.": "ex:QualityAttribute_provide_input_to_the_bcfd7a99",
  "QualityAttribute:SM:4:QA for commercial API initiated at CMC level and where needed impacting synthesis decision.": "ex:QualityAttribute_qa_for_commercial_ap_dacffdb2",
  "QualityAttribute:SM:4:Quality Agreements / Site qualification for clinical use for GMP INT, API and DP sites, if new supplier": "ex:QualityAttribute_quality_agreements_s_d938a4c2",
  "QualityAttribute:SM:4:Re-assessment siting decision for development & clin, mfg.": "ex:QualityAttribute_re_assessment_siting_caef90cd",
  "QualityAttribute:SM:4:Regulatory starting materials proposed for commercial": "ex:QualityAttribute_regulatory_starting_e042691b",
  "QualityAttribute:SM:4:Regulatory strategy document, which will include regulatory risk assessment and mitigation strategy and the EHS/Compliance/Regulatory requirement for compound handling, planned HA meetings,\u00a0outcomes of any HA meetings documented, overview of any Q&A from HA in Phase 1": "ex:QualityAttribute_regulatory_strategy_96ff0f1c",
  "QualityAttribute:SM:4:Release testing Excipients (P&MS)": "ex:QualityAttribute_release_testing_exci_ef9124b3",
  "QualityAttribute:SM:4:Retest/Storage statement updated": "ex:QualityAttribute_retest_storage_state_f9ff3007",
  "QualityAttribute:SM:4:Review and if required update specification and process windows for Phase 2. These may include:\n*incoming inspection specifications for device components/raw materials, including shelf life\n*release specification for combination product, including shelf life\n*primary container (unfilled and filled) specifications that are related to device function\n*identify critical process parameters (component, subassembly, final assembly, etc) and range": "ex:QualityAttribute_review_and_if_requir_9a283454",
  "QualityAttribute:SM:4:Review existing PRA applicable to product category and verify if additional risk has to be considered/added.\n\nReview PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_existing_pra_ff5e8ea3",
  "QualityAttribute:SM:4:RiPBS report with Shelf life prediction for selected clinical formulation (supports development package; not for filing)": "ex:QualityAttribute_ripbs_report_with_sh_ca62310d",
  "QualityAttribute:SM:4:Select and implement suitable (Fit-for-Purpose) manufacturing process for Phase 2 If required": "ex:QualityAttribute_select_and_implement_8a05a613",
  "QualityAttribute:SM:4:Sensitive polymorphic purity methods developed/qualified? to check , optimize DP concept and process (P&MS)": "ex:QualityAttribute_sensitive_polymorphi_e2892425",
  "QualityAttribute:SM:4:Specification strategy developed/assessed": "ex:QualityAttribute_specification_strate_1dcaedd1",
  "QualityAttribute:SM:4:Stability protocol and stability initiated (if synthesis/method changed)": "ex:QualityAttribute_stability_protocol_a_aaa968d1",
  "QualityAttribute:SM:4:Study Plan for process parameters and material attributes (DPD/QuantScience)": "ex:QualityAttribute_study_plan_for_proce_bbec58a2",
  "QualityAttribute:SM:4:Supplier Material Qualification completed for starting materials and raw materials for API and excipients and packaging materials for DP for clinical use, if new material/supplier combination": "ex:QualityAttribute_supplier_material_qu_d6661209",
  "QualityAttribute:SM:4:Target and tentative range API PSD for desired PK profile and mfg considerations defined [DPD/P&MS/API SM/AD]": "ex:QualityAttribute_target_and_tentative_52406892",
  "QualityAttribute:SM:4:Update PQV Data Governance Sharepoint (if needed)": "ex:QualityAttribute_update_pqv_data_gove_a071473b",
  "QualityAttribute:SM:5:API Solid state strategy for late development updated [P&MS / Solid state Working Group]": "ex:QualityAttribute_api_solid_state_stra_74bf8db3",
  "QualityAttribute:SM:5:API Sourcing current SWOT initiated, based on current BOM": "ex:QualityAttribute_api_sourcing_current_21bf13a3",
  "QualityAttribute:SM:5:API and DP batches with sufficiently broad variation (PAR boundaries) for in vivo performance assessment considered as to justify proposed comm. specification setting (e.g. impurity profile, particle size, dissolution)": "ex:QualityAttribute_api_and_dp_batches_w_71a1b612",
  "QualityAttribute:SM:5:API batches with sufficiently broad variation (to become API PAR boundaries) for in vivo performance assessment considered  (= clinically relevant comm. specifications, e.g. impurity profile, particle size)": "ex:QualityAttribute_api_batches_with_suf_d3189cdc",
  "QualityAttribute:SM:5:API solid state characterized at release and stability. [AD/P&MS]": "ex:QualityAttribute_api_solid_state_char_39686afa",
  "QualityAttribute:SM:5:API sparing strategies for development, scale-up and tech transfer": "ex:QualityAttribute_api_sparing_strategi_4a8b265e",
  "QualityAttribute:SM:5:API test methods developed fit-for-purpose and qualified incl for solid state (AD/P&MS)": "ex:QualityAttribute_api_test_methods_dev_5307cecc",
  "QualityAttribute:SM:5:Acceptable DP quality after contact with equipment train": "ex:QualityAttribute_acceptable_dp_qualit_a09729b3",
  "QualityAttribute:SM:5:Acceptable safety\u00a0for high risk\u00a0product contact materials": "ex:QualityAttribute_acceptable_safety_fo_8f7a4afa",
  "QualityAttribute:SM:5:All excipients and raw materials are confirmed acceptable in the mfg region from manufacturing SHE-perspective (REACH)": "ex:QualityAttribute_all_excipients_and_r_287346b0",
  "QualityAttribute:SM:5:Are the weak points of formulation defined and is this translation into development/spec strategy up to date and accurate": "ex:QualityAttribute_are_the_weak_points_ba7a8549",
  "QualityAttribute:SM:5:Are the weak points of molecule defined and is this translation into development/spec strategy up to date and accurate": "ex:QualityAttribute_are_the_weak_points_2d4e1344",
  "QualityAttribute:SM:5:Biopharm strategy (assuming final dose is known) for late development updated": "ex:QualityAttribute_biopharm_strategy_as_888b0570",
  "QualityAttribute:SM:5:Biopharmaceutical testing:\n*If Phase2b is a solid /suspension : multivariate effect o critical to bioavailability attributes (CBAs) API PSD, CMAs, CPPs) understood if not BCS-1. API PSD recommendation.\n*If possible, have started to explore non-BE PK boundaries via variation of CBAs (for validation of safety space strategy/PBBM)\n*Phase 2b product bridged with Phase 2a (approach BCS class driven)\n*Preferentially final PK profile obtained as per PK target: AUC, Tmax, Cmax, half life, peak/trough levels\n*Understood PK and PD profile. Refined PBBM model. Verified hypotheses": "ex:QualityAttribute_biopharmaceutical_te_f1f45f0d",
  "QualityAttribute:SM:5:Blinding strategy confirmed, based on clinical development plan (placebo need & timing; options for blinding eg overencapsulation, matching (coated) placebo formulation, packaging design, etc)": "ex:QualityAttribute_blinding_strategy_co_e57c6046",
  "QualityAttribute:SM:5:Bridging strategy: \n*Bridging Strategy Phase2b-Phase3-Commercial  formulation/process/mfg site if different  formula or major process change and no biowaiver. Consider possibility to adapt Sourcing Strategy  depending upon the complexity of proving BE  [e.g. CR, Inhalation, patches, ...] [DPD/Biopharm team/Disso team]\n*bridging strategy (if required) and Clinically Relevant Control strategy approved by Biopharmaceutics focus area": "ex:QualityAttribute_bridging_strategy_br_9fbda6b4",
  "QualityAttribute:SM:5:Budget & resources": "ex:QualityAttribute_budget_resources_1693474b",
  "QualityAttribute:SM:5:CPDP Project Definition & Planning Stage for Phase 3/Commercial:\n*Combination product designation evaluation form\n*Design and Development Plan  (Initiate)\n*User Requirement (Initiate)\n*Technial Design Requirement  (Initiate)\n*Human Factor Study Plan  (Initiate)\n*Device Design Verification Plan  (Initiate)\n*Regulated Substance Plan (Initiate)\n*Manufacturing Strategy and Design Transfer Plan (Initiate)\n*Clinical Plan (Initiate)\n*Stability Plan (Initiate)\n*Design History File (Initiate)\n*Device Risk Management  (Initiate)\n*Risk Management Plan (Initiate)\n*Product Risk Assessment/ Hazard ID (Initiate)\n*uFMEA (Initiate)\n*CTQ Flow Down(Initiate)\n*Regulatory Strategy\n*General Safety and Performance Requirements (GSPR) Checklist (initiate)": "ex:QualityAttribute_cpdp_project_definit_ebfe7827",
  "QualityAttribute:SM:5:CQA's for Ph2b API further evaluated (sliding scale criticality analysis)\n\nUpdate Criticality Analysis. The ssCA must be reviewed and approved before the production of the intermediate and DS batch(es).": "ex:QualityAttribute_cqa_s_for_ph2b_api_f_50e13be0",
  "QualityAttribute:SM:5:CQAs /pCQAs defined and documented": "ex:QualityAttribute_cqas_pcqas_defined_a_0c48836f",
  "QualityAttribute:SM:5:Check, examine and if applicable, file patents related to combo product/device": "ex:QualityAttribute_check_examine_and_if_7949f706",
  "QualityAttribute:SM:5:China DMF compliance": "ex:QualityAttribute_china_dmf_compliance_189279de",
  "QualityAttribute:SM:5:Commercial Concept Development Summary": "ex:QualityAttribute_commercial_concept_d_72fcc7ff",
  "QualityAttribute:SM:5:Commercial DP specification strategy proposed.": "ex:QualityAttribute_commercial_dp_specif_cca4b8cb",
  "QualityAttribute:SM:5:Complete Deliver checklist and align strategy with Deliver.": "ex:QualityAttribute_complete_deliver_che_bb45042a",
  "QualityAttribute:SM:5:Complete Product Strategy Roadmap and schedule endorsement at Product Strategy Council.": "ex:QualityAttribute_complete_product_str_0bc2debc",
  "QualityAttribute:SM:5:Complete VCRM product typing": "ex:QualityAttribute_complete_vcrm_produc_658a7f1e",
  "QualityAttribute:SM:5:Complete first Forecast Integration Session (FIS), performed annually thereafter.": "ex:QualityAttribute_complete_first_forec_ba783e4a",
  "QualityAttribute:SM:5:Complete initial User FMEA (COMBO Product Requirement / drug-only product with a complex administration interface)": "ex:QualityAttribute_complete_initial_use_a3397bb5",
  "QualityAttribute:SM:5:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create uFMEA for commercial product, if needed.": "ex:QualityAttribute_complete_or_revisit_0d76a4c8",
  "QualityAttribute:SM:5:Confirm regulatory feasibility of QbD and define preliminary high level QbD regulatory strategy: \u00a0Confirm QbD approach (Full QbD, hybrid or traditional approach). Define and agree on regulatory QbD expectations: e.g. data to support \u00a0mfg process, control strategy and clinically relevant specifications/design space, stability \u00a0profile.": "ex:QualityAttribute_confirm_regulatory_f_6888b70b",
  "QualityAttribute:SM:5:Cost of goods evaluation available from TLI/VCL": "ex:QualityAttribute_cost_of_goods_evalua_cc7bc79b",
  "QualityAttribute:SM:5:Criticality analysis for Phase 2b completed and cross-functionally endorsed and approved prior to batch release.": "ex:QualityAttribute_criticality_analysis_221bf18f",
  "QualityAttribute:SM:5:Cross functional Risk register completed and mitigation plan developed, also highlighting the gaps and any mitigations with respect to key deliverables": "ex:QualityAttribute_cross_functional_ris_d84282b4",
  "QualityAttribute:SM:5:Cross functionally aligned full development strategy and BPAL strategy, incl. consolidated multi generation development plan available for final Council review.": "ex:QualityAttribute_cross_functionally_a_69050bef",
  "QualityAttribute:SM:5:Cross functionally aligned full scale process development strategy incl. plan to multivariately identify CPPs and CMAs.": "ex:QualityAttribute_cross_functionally_a_c6ff24ab",
  "QualityAttribute:SM:5:Cross-functional project plan updated in line with PhIIb/PhIII strategy": "ex:QualityAttribute_cross_functional_pro_8f8211d5",
  "QualityAttribute:SM:5:Customer Centered Design deliverables completed for this stage, including of a Customer Centered Design Workshop as needed (incorporating country specific requirements i.e. Japan as necessary)": "ex:QualityAttribute_customer_centered_de_4b18d46d",
  "QualityAttribute:SM:5:DP Solid state strategy for late development defined [P&MS]": "ex:QualityAttribute_dp_solid_state_strat_6e87d25d",
  "QualityAttribute:SM:5:DP solid state characterized at release and stability.  [AD/ P&MS]": "ex:QualityAttribute_dp_solid_state_chara_5a3de06e",
  "QualityAttribute:SM:5:DP test methods developed fit-for-purpose and qualified including for solid state. (AD/P&MS)": "ex:QualityAttribute_dp_test_methods_deve_fdc29e8d",
  "QualityAttribute:SM:5:Deliver an aligned Integrated Launch Readiness (ILR) Heatmap and \"Product/SC Readiness\" portion of the GCSO \"Launch Preparations Dashboard\".": "ex:QualityAttribute_deliver_an_aligned_i_b4c0128a",
  "QualityAttribute:SM:5:Deliver current BOM (includes all materials next to SM, INT, API) to AS + QI": "ex:QualityAttribute_deliver_current_bom_6b5ab25b",
  "QualityAttribute:SM:5:Develop cross-functional plan and resource estimates for scenarios (if necessary)": "ex:QualityAttribute_develop_cross_functi_87cc1d7d",
  "QualityAttribute:SM:5:Draft Control strategy for Ph3/Commercial API available": "ex:QualityAttribute_draft_control_strate_178270d0",
  "QualityAttribute:SM:5:Draft Product Improvement Approach if appropriate": "ex:QualityAttribute_draft_product_improv_07cf2184",
  "QualityAttribute:SM:5:EHS Requirement: Initiate additional Hazard Safety testing based on risk assessment; initiate Env risk assessment (ERA); waste handling/disposal; SDS  for intermediates": "ex:QualityAttribute_ehs_requirement_init_5763ea3e",
  "QualityAttribute:SM:5:EHS Requirement: Integrate DGTC (Dangerous Goods Transportation Compliance) requirements into Ph2 1st, 2nd, 3rd packaging solution [CSC]": "ex:QualityAttribute_ehs_requirement_inte_626299b4",
  "QualityAttribute:SM:5:Empirical control strategy, if needed with extra controls, and reviewed by RDFA#1": "ex:QualityAttribute_empirical_control_st_3873ac20",
  "QualityAttribute:SM:5:Ensure customer centric design team has been kicked-off": "ex:QualityAttribute_ensure_customer_cent_aebd8053",
  "QualityAttribute:SM:5:Excipient strategy (Supplier qualification plan for commercial, Material characterization plan, specification in place) and alignment with Sourcing [MatSci], Supplier qualified  for any new excipient for clinical": "ex:QualityAttribute_excipient_strategy_s_be6d1d03",
  "QualityAttribute:SM:5:Excipients used are within established safety limits. Formula and/or Excipient safety report": "ex:QualityAttribute_excipients_used_are_53801754",
  "QualityAttribute:SM:5:Excipients: Risk assessment for residual elemental impurities and solvents  (P&MS)": "ex:QualityAttribute_excipients_risk_asse_50cb4f0d",
  "QualityAttribute:SM:5:Experiment with advanced control tools in support of future process control or RTR testing (in line with proposed control strategy) [DPD/AD]": "ex:QualityAttribute_experiment_with_adva_e05d6081",
  "QualityAttribute:SM:5:Experiment with advanced control tools in support of future process control or RTR testing if applicable [API Dev/AD]": "ex:QualityAttribute_experiment_with_adva_bdd3ff65",
  "QualityAttribute:SM:5:Experimentation plan available to understand multivariate CPP/CMA impact on CQAs, acceptable ranges, interactions and normal variation using CA (DPD/QuantScience)": "ex:QualityAttribute_experimentation_plan_09d61ffa",
  "QualityAttribute:SM:5:Experimentation plans set up in consultation with statisticians to meet future  Robustness Index Dashboard requirements": "ex:QualityAttribute_experimentation_plan_887dd3d7",
  "QualityAttribute:SM:5:Experimentation plans set up in consultation with statisticians to meet future Robustness Index Dashboard requirements (needed for transfer of ownership)": "ex:QualityAttribute_experimentation_plan_036425b1",
  "QualityAttribute:SM:5:Finalize options for Registration/Commercial Production. Thes may include and are not limited to:\n*Device component manufacturing\n*Subassembly\n*Final assembly\n*Packaging": "ex:QualityAttribute_finalize_options_for_c1ace34a",
  "QualityAttribute:SM:5:Forecast Ph2b/3 developed": "ex:QualityAttribute_forecast_ph2b_3_deve_6b1f1cf9",
  "QualityAttribute:SM:5:Formulation development strategy for  Phase 3/Commercial.": "ex:QualityAttribute_formulation_developm_95dddb77",
  "QualityAttribute:SM:5:Further assessment IP: opportunities identified for formulation, drug delivery, and packaging, targeting extended  patent exclusivity and long term marketing advantages over competitors.": "ex:QualityAttribute_further_assessment_i_8c858209",
  "QualityAttribute:SM:5:GMP PAT methods developed in line with proposed control strategy": "ex:QualityAttribute_gmp_pat_methods_deve_b3c1fc35",
  "QualityAttribute:SM:5:If applicable/Expected: E2E alignment (DPDS/JSC) on potential compound specific equipment requirements/upgrades & CAPEX related, have first draft PF2P available": "ex:QualityAttribute_if_applicable_expect_764bc46e",
  "QualityAttribute:SM:5:Impact API properties studied  (BA, downstream mfg'ability,...) and documented": "ex:QualityAttribute_impact_api_propertie_3df6746c",
  "QualityAttribute:SM:5:Implement suitable manfuaturing controls for Phase 3:\n*Incoming and release tests\n*in process control/inspection": "ex:QualityAttribute_implement_suitable_m_77d13af8",
  "QualityAttribute:SM:5:Impurities and degradants assessed according to the Global Impurity Management Policy (repeated as new DP formulations are implemented or when new impurities/degradants are detected).": "ex:QualityAttribute_impurities_and_degra_86f0b4e0",
  "QualityAttribute:SM:5:Impurity Mgmt report 2 approved and in line with the Global Impurity Management Policy (incl. Impurities qualified and documented in Tox memo, as well as nitrosamine risk assessment).": "ex:QualityAttribute_impurity_mgmt_report_ff3ecf6d",
  "QualityAttribute:SM:5:In-vivo relevance:\n*Clinically relevant controls strategy updated\n*Preliminary evaluation of the Relevance of the QC dissolution method given the different animal PK and human BA studies on different formulation concepts/variants , API PSD, variability of excipients involved in the release mechanism,\u2026\n*API and DP batches with sufficiently broad variation (= future PAR boundaries) for in vivo performance assessment considered as to justify proposed comm. specification setting (e.g. impurity profile, particle size, dissolution) (include batches with non-BE PK profiles if available)\n*Additional clinical PK BA/BE studies anticipated to support the Clinically relevant dissolution specs/controls and/or bridging strategies?": "ex:QualityAttribute_in_vivo_relevance_cl_c92df64a",
  "QualityAttribute:SM:5:Inclusion of granularity and more detailed CMC info in TPP": "ex:QualityAttribute_inclusion_of_granula_676cce88",
  "QualityAttribute:SM:5:Initiate Supplier Product Risk Assessment (SPRA) and Material Tracker for preparation of Integrated Launch Readiness heatmap.": "ex:QualityAttribute_initiate_supplier_pr_6da16a55",
  "QualityAttribute:SM:5:Investigate options for IP protection [DPD]": "ex:QualityAttribute_investigate_options_245457ac",
  "QualityAttribute:SM:5:LD mfg budget and resource plan available": "ex:QualityAttribute_ld_mfg_budget_and_re_3031482e",
  "QualityAttribute:SM:5:Late Development and Commercial API specification strategy proposed  & strategy aligned towards data collection": "ex:QualityAttribute_late_development_and_b4a7e066",
  "QualityAttribute:SM:5:Late Development stability strategy for process and product understanding (intermediates, edge of failure considerations)": "ex:QualityAttribute_late_development_sta_2239bd7d",
  "QualityAttribute:SM:5:Lessons Learned": "ex:QualityAttribute_lessons_learned_2bb76c94",
  "QualityAttribute:SM:5:Material supplier selection completed and documented": "ex:QualityAttribute_material_supplier_se_ae694ed1",
  "QualityAttribute:SM:5:Multivariate Impact composition on critical process parameters and (p)CQA's, major ingredient properties (API & excipients) incl. excipient compatibility understood and documented (QbD, robust design) [DPD/P&MS / /Disso team]": "ex:QualityAttribute_multivariate_impact_e85b0185",
  "QualityAttribute:SM:5:Need/functionality each excipient demonstrated/documented in Formulation Decision Matrix according to FDI guidelines. Strategy for proving functionality-related characteristics (FRC) defined.": "ex:QualityAttribute_need_functionality_e_dccfd24c",
  "QualityAttribute:SM:5:Nitrosamine risk assessment for DP (P&MS)": "ex:QualityAttribute_nitrosamine_risk_ass_05747cd1",
  "QualityAttribute:SM:5:Pediatric CMC Assessment (assess potential for ped formulation development)": "ex:QualityAttribute_pediatric_cmc_assess_ea2f2c14",
  "QualityAttribute:SM:5:Perform and align BPAL status update for Integrated Launch Readiness (ILR) heatmap and Council endorsement.": "ex:QualityAttribute_perform_and_align_bp_7b0b847b",
  "QualityAttribute:SM:5:Perform and align BPAL targets for RDFA#1, Integrated Launch Readiness (ILR) heatmap, and Council endorsement.": "ex:QualityAttribute_perform_and_align_bp_b42a5707",
  "QualityAttribute:SM:5:Ph2b IND/CTA ready for submission": "ex:QualityAttribute_ph2b_ind_cta_ready_f_3fd06e7b",
  "QualityAttribute:SM:5:Ph2b concept further developed via stress testing to reliable and stable formula acc to BP minimizing tablet appearance nonconformance (e.g. Japan), decision tree and matrix table and major failure modes known and designed out": "ex:QualityAttribute_ph2b_concept_further_460d7941",
  "QualityAttribute:SM:5:Ph2b concept further developed via stress testing to reliable and stable process: major failure modes known and designed out": "ex:QualityAttribute_ph2b_concept_further_784d2dda",
  "QualityAttribute:SM:5:Ph2b/3 supply plan in place": "ex:QualityAttribute_ph2b_3_supply_plan_i_b1167c22",
  "QualityAttribute:SM:5:Ph2b/3 synthesis strategy and supply plan in place": "ex:QualityAttribute_ph2b_3_synthesis_str_be50d13f",
  "QualityAttribute:SM:5:Pharmacopiea compliance : consider the requirement of USP/EP/ChP": "ex:QualityAttribute_pharmacopiea_complia_861525e3",
  "QualityAttribute:SM:5:Phase 3/Commercial Device:\n*Conduct formative human factor and bench studies to refine/optimize design and IFU\n*Review and update User Description, User Requirement, Technical Design Requirement documents  based on Phase 2, HF studies, TPP (if available) and other learnings\n*Complete defining/updating critical and essential technical and usability and performance requirements\n*Identify CTQ (Critical to Quality)s and stability indicating TDRs (Technical Design Requirements)\n*Define/update test strategy. \n*Develop and qualify methods to verify technical requirements are met.\n*Define combination product stability strategy suitable for phase 3\n*Create IFU\n* Identify hazards, hazardous situations, failure modes and likelihoods\n*Engineering study (stress testing, accelerated aging) (optional)\n*Select phase 3 packaging design": "ex:QualityAttribute_phase_3_commercial_d_2b4bdd01",
  "QualityAttribute:SM:5:Plan for excipients comm. spec's/methods [DPD/P&MS]": "ex:QualityAttribute_plan_for_excipients_935081d7",
  "QualityAttribute:SM:5:Plan, prepare, and execute HA meetings (US EoP-2, EU scientific advise) to present, discuss, and agree on key regulatory strategies (e.g. QbD elements, starting materials, API/DP primary stabilty protocols, etc).": "ex:QualityAttribute_plan_prepare_and_exe_90e172ef",
  "QualityAttribute:SM:5:Preliminary study plan available to identify CPP's/CMA's based on DOE's and risk mgmt tools.": "ex:QualityAttribute_preliminary_study_pl_110f23d3",
  "QualityAttribute:SM:5:Process control strategy, product release (including PAT/RTR) approach aligned": "ex:QualityAttribute_process_control_stra_09c93be8",
  "QualityAttribute:SM:5:Project Definition & Planning Stage Design Review": "ex:QualityAttribute_project_definition_p_8237d36c",
  "QualityAttribute:SM:5:Provide COGS and GP, documenting assumptions, for preparation of the Integrated Launch Readiness heatmap.": "ex:QualityAttribute_provide_cogs_and_gp_ec95761b",
  "QualityAttribute:SM:5:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) for Phase 3:\n*Supplier and Contractor Audit\n*Device Quality Agreement (Final Assembly)\n*Device Quality Agreement (Device component, device itself and Purchasing Contro/ for Combo Products)\n*Device Testing Quality Agreement (Lab to Lab) \n*Third Party Design Control Audit Report (If Applicable)\n*Review and update acceptance criteria and sample size based on risk assessment for Phase 3": "ex:QualityAttribute_readiness_for_the_co_fe3d6f86",
  "QualityAttribute:SM:5:Regulatory Strategy documented  and in line with full development strategy": "ex:QualityAttribute_regulatory_strategy_3feffc5e",
  "QualityAttribute:SM:5:Resource estimates (FTE and OOP) calculated for PhIIb/PhIII development": "ex:QualityAttribute_resource_estimates_f_0789988e",
  "QualityAttribute:SM:5:Review and refine phase 3/commercial specifications. These may include:\n* incoming inspection specifications for device components/raw materials, including shelf life\n*release specification for combination product, including shelf life\n*primary container (unfilled and filled) specifications that are related to device function\n* identify critical process parameters (component, subassembly, final assembly, etc) and range": "ex:QualityAttribute_review_and_refine_ph_3232c786",
  "QualityAttribute:SM:5:Review existing PRA applicable to product category and verify if additional risk has to be considered/added\nReview PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_existing_pra_4f8be3ce",
  "QualityAttribute:SM:5:RiBPS and/or Accelerated chemical/ Physical stability  studies performed to understand failure modes, delineate the T/RH safe space , predict shelf life   [AD/ P&MS]": "ex:QualityAttribute_ribps_and_or_acceler_46c28872",
  "QualityAttribute:SM:5:Risk assessment for Extractable&Leachable completed [P&MS]": "ex:QualityAttribute_risk_assessment_for_edf71c14",
  "QualityAttribute:SM:5:SQ to start COC based on current BOM": "ex:QualityAttribute_sq_to_start_coc_base_c8d1607b",
  "QualityAttribute:SM:5:Siting decision development & clinical manufacturing re-assessed (internal / external) with attention to CMO readiness in terms of knowledge and capability.": "ex:QualityAttribute_siting_decision_deve_a456694a",
  "QualityAttribute:SM:5:Solvent recovery, waste handling & disposal requirements evaluated, in line with BPAL - sustainability ambition setting": "ex:QualityAttribute_solvent_recovery_was_acea8ce5",
  "QualityAttribute:SM:5:Specification strategy (statistically sound and clin. relevant spec's).": "ex:QualityAttribute_specification_strate_43a8369f",
  "QualityAttribute:SM:5:Stability protocol & stability initiated (if formulation/methods changed)": "ex:QualityAttribute_stability_protocol_s_e5265c1b",
  "QualityAttribute:SM:5:Stability protocol & stability initiated (if synthesis/methods changed)": "ex:QualityAttribute_stability_protocol_s_05182ab5",
  "QualityAttribute:SM:5:Stability storage statements updated if appropriate": "ex:QualityAttribute_stability_storage_st_e60870fe",
  "QualityAttribute:SM:5:Stage Gate approval form for SG#5.": "ex:QualityAttribute_stage_gate_approval_529035f5",
  "QualityAttribute:SM:5:Supplier Material Qualification completed  for GMP INT, API and DP sites, including Quality Agreements / Site qualification for clinical use": "ex:QualityAttribute_supplier_material_qu_556c519f",
  "QualityAttribute:SM:5:Supplier Material Qualification completed for starting materials and raw materials for API and excipients and packaging materials for DP for clinical use, if new material/supplier combination.": "ex:QualityAttribute_supplier_material_qu_7cb0dd06",
  "QualityAttribute:SM:5:Synthesis related freedom to operate exercise performed and documented": "ex:QualityAttribute_synthesis_related_fr_4f4efdbe",
  "QualityAttribute:SM:5:Target settings and workable range defined and documented  for critical process parameters (Ph2b DP)": "ex:QualityAttribute_target_settings_and_331c54a6",
  "QualityAttribute:SM:5:Target values defined and documented for API CQA's including solid state and particle/powder properties  (e.g. morphology,particle size, SSA, density ,...)[AD/P&MS ]": "ex:QualityAttribute_target_values_define_4a71c0fd",
  "QualityAttribute:SM:5:Third Party Supplier Design Control Audit Report (If applicable)": "ex:QualityAttribute_third_party_supplier_c0adbde8",
  "QualityAttribute:SM:5:Update PQV Data Governance Sharepoint (if needed)": "ex:QualityAttribute_update_pqv_data_gove_c3e57315",
  "QualityAttribute:SM:5:Verify all stage appropriate TPP attributes are defined and aligned cross-functionally for pivotal trials & commercial including final target PK profile": "ex:QualityAttribute_verify_all_stage_app_47dd8283",
  "QualityAttribute:SM:5:Verify all stage appropriate TPP attributes are defined and aligned cross-functionally.": "ex:QualityAttribute_verify_all_stage_app_d67d5e97",
  "QualityAttribute:SM:5:Well characterized Ph 2b DP incl. solid state  [AD/ P&MS]": "ex:QualityAttribute_well_characterized_p_0e946018",
  "QualityAttribute:SM:6:1st version of full development CA and control strategy approved before 1st release of phase 2b supplies": "ex:QualityAttribute_1st_version_of_full_30eec0ad",
  "QualityAttribute:SM:6:API and DP batches with sufficiently broad variation for in vivo performance assessment considered as to justify proposed comm. specification setting (e.g. impurity profile, particle size, dissolution)": "ex:QualityAttribute_api_and_dp_batches_w_455952e4",
  "QualityAttribute:SM:6:API batches with sufficiently broad variation considered for in vivo performance assessment (clinically relevant comm. specifications, e.g. impurity profile, particle size)": "ex:QualityAttribute_api_batches_with_suf_d9169bfe",
  "QualityAttribute:SM:6:API material tracker updated, based on current BOM": "ex:QualityAttribute_api_material_tracker_a660edb5",
  "QualityAttribute:SM:6:API solid state characterized at release and stability .  [AD/ P&MS]": "ex:QualityAttribute_api_solid_state_char_488465ef",
  "QualityAttribute:SM:6:API solid state control strategy [CTU/ AD/ P&MS": "ex:QualityAttribute_api_solid_state_cont_b0187078",
  "QualityAttribute:SM:6:API, SM, INT, RM test methods developed fit-for-purpose and qualified including solid state (only if part of the specs) for API (AD/P&MS)": "ex:QualityAttribute_api_sm_int_rm_test_m_e9415bb6",
  "QualityAttribute:SM:6:API/SDP boundary evaluation": "ex:QualityAttribute_api_sdp_boundary_eva_626289e7",
  "QualityAttribute:SM:6:Acceptable DP quality after contact with equipment train": "ex:QualityAttribute_acceptable_dp_qualit_45606db0",
  "QualityAttribute:SM:6:Advanced control strategies (PAT)  explored in support of process DOEs. Strategy defined and chemometric models in place to monitor PhIII campaigns. Experiment with advanced control tools in support of future process control or RTR testing [DPD/AD]": "ex:QualityAttribute_advanced_control_str_9b6a35e7",
  "QualityAttribute:SM:6:Biopharm assessment batch to CM": "ex:QualityAttribute_biopharm_assessment_7466fcbf",
  "QualityAttribute:SM:6:Biopharmaceutical testing:\n*Animal PK study on Phase 3 concepts and formulas considered if not BCS-1 or not Immediate release (if appropriate)\n*Phase 3 formula bridged with Phase 2b via comparative hBA study , when needed. Consider to include formulation /process variants to evaluate in-vivo effect and to help development of clinically relevant dissolution method (include batches with non-BE PK profiles if available)\n*Fully understood PK profile. Hypotheses verified. Refined PBBM model.": "ex:QualityAttribute_biopharmaceutical_te_e9796f94",
  "QualityAttribute:SM:6:Blinding strategy confirmed, based on clinical development plan (placebo need & timing; options for blinding eg overencapsulation, matching (coated) placebo formulation, packaging design, etc)": "ex:QualityAttribute_blinding_strategy_co_0e2aca20",
  "QualityAttribute:SM:6:Bridging package phase 2b to phase 3 and bridging to commercial formulation/process": "ex:QualityAttribute_bridging_package_pha_934f9ecb",
  "QualityAttribute:SM:6:Bridging strategy:\n*BE strategy Phase3-Registration Batches-Commercial-   Next generation if no biowaiver\n*Forecast, batch size and supply plan for Ph3 developed": "ex:QualityAttribute_bridging_strategy_be_91532e10",
  "QualityAttribute:SM:6:Build  link product/process/materials with in-vivo:\n*Mechanistic understanding from the CA-driven DoEs what formulation factors / product attributes/process parameters/material attributes (= critical to bioavailability attributes or CBAs) and their interaction  might influence drug release profile, and possibly the PK performance. Therefore, a battery of in-vitro dissolution methods (also physiology based disso methods) been performed  on DoE samples to derive which samples are most worthwhile to test further in vivo.\n*Strategy/Plan issued for clinically relevant QC dissolution method, spec,  and design space development. Review CBAs/CMAs/CPPs affecting QC disso and also the larger formulation variables (concepts screened before Phase III lock) for in vivo relevance assessment. Consider in vitro characterization, animal PK, human PK, PK modeling for support clinically relevant specs. Include relevant aged sample or similar change in release profile if there is a stability trend.\n*If the plan is to develop an IVIVC, the formulas for slower/faster release profiles are identified\n*QC dissolution method for Phase 3 refined based upon discrimination (DoEs) and current knowledge of biorelevance ( concepts /qualities already tested before in animal PK / human PK)": "ex:QualityAttribute_build_link_product_p_08780907",
  "QualityAttribute:SM:6:CMC-TPP locked (except aspects not impacting stability) for pivotal/comm product (SM without device)": "ex:QualityAttribute_cmc_tpp_locked_excep_d3e34c29",
  "QualityAttribute:SM:6:CPDP Development & Verification Stage review": "ex:QualityAttribute_cpdp_development_ver_341e1bdd",
  "QualityAttribute:SM:6:CPP and CMA proposed based on prior knowledge, screening DOE's and risk mgmt tools (API Dev/QuantScience)": "ex:QualityAttribute_cpp_and_cma_proposed_1f796146",
  "QualityAttribute:SM:6:Causal relationship established between proces parameters/material attributes and CQA/mfg-ability factors for intermediate scale via prior knowledge and experimentation and reflected in CA": "ex:QualityAttribute_causal_relationship_feb8240a",
  "QualityAttribute:SM:6:Challenge polymorphism screen to reconfirm API solid state  as final form  on API of final synthesis, purity, in broad range of solvents with focus on the process relevant ones. Phase diagramfor selected API form in crystallization solvent system.   (P&MS/CTU)": "ex:QualityAttribute_challenge_polymorphi_d0191521",
  "QualityAttribute:SM:6:Characterization and suitability study of potential commercial primary packs completed/documented. Fit-for-purpose packaging for clinical, preferably standard.": "ex:QualityAttribute_characterization_and_6c5c8d00",
  "QualityAttribute:SM:6:Check sourcing strategy and line similarity R&D/commercial as part of decision making process to move forward with CM development": "ex:QualityAttribute_check_sourcing_strat_fb6c3580",
  "QualityAttribute:SM:6:China container DMF compliance and any other country specific requirements": "ex:QualityAttribute_china_container_dmf_5b032734",
  "QualityAttribute:SM:6:Cleaning methods available": "ex:QualityAttribute_cleaning_methods_ava_14853603",
  "QualityAttribute:SM:6:Clinical Container Closure System Suitability Assessment (Ph3)": "ex:QualityAttribute_clinical_container_c_df1388ba",
  "QualityAttribute:SM:6:Clinical primary Component Specifications (Ph3)": "ex:QualityAttribute_clinical_primary_com_1b186056",
  "QualityAttribute:SM:6:Close to final CQAs /pCQAs defined in Criticality Analysis (CA).  First version of full development CA and control strategy approved before first release of phase 2b supplies.": "ex:QualityAttribute_close_to_final_cqas_587c7eb1",
  "QualityAttribute:SM:6:Comm. API CQA's defined/documented and correlated with CMC TPP": "ex:QualityAttribute_comm_api_cqa_s_defin_db9bc9d6",
  "QualityAttribute:SM:6:Complete Stage Gate Approval Form": "ex:QualityAttribute_complete_stage_gate_69945b91",
  "QualityAttribute:SM:6:Complete formulation design intiative matrix and include optimization DP design and composition  (Robustness/Characterization/Appearance e.g. Japan) including for solid state.": "ex:QualityAttribute_complete_formulation_86ddf40c",
  "QualityAttribute:SM:6:Complete initial Design FMEA (COMBO Product Requirement)": "ex:QualityAttribute_complete_initial_des_748d6f46",
  "QualityAttribute:SM:6:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.": "ex:QualityAttribute_complete_or_revisit_ec848267",
  "QualityAttribute:SM:6:Confirm Late Development stability strategy for process and product understanding (intermediates, edge of failure considerations, commercial packaging screening)": "ex:QualityAttribute_confirm_late_develop_d8582bb2",
  "QualityAttribute:SM:6:Confirm Phase 3 & Late Development stability strategy and execution for process and product understanding (intermediates, edge of failure considerations)": "ex:QualityAttribute_confirm_phase_3_late_c25c84f9",
  "QualityAttribute:SM:6:Control strategy for Ph3 product reflects current P&P understanding": "ex:QualityAttribute_control_strategy_for_e5c0de58",
  "QualityAttribute:SM:6:Country requirements for novel excipients and restrictions (e.g. China DMF, titanium dioxide, etc)": "ex:QualityAttribute_country_requirements_3ac5b4e3",
  "QualityAttribute:SM:6:Criticality analysis complete prior to the release of Phase 2b and Phase 3 batches": "ex:QualityAttribute_criticality_analysis_7986d7d8",
  "QualityAttribute:SM:6:Cross functional Risk register completed and mitigation plan developed, also highlighting the gaps and any mitigations with respect to key deliverables": "ex:QualityAttribute_cross_functional_ris_2e665ff7",
  "QualityAttribute:SM:6:Customer Centered Design deliverables completed for this stage, including of a Customer Centered Design Workshop as needed (incorporating country specific requirements i.e. Japan as necessary)": "ex:QualityAttribute_customer_centered_de_a4f07dba",
  "QualityAttribute:SM:6:DOE/Edge of Failure study reports for key Phase 3 manufacturing steps/measurements": "ex:QualityAttribute_doe_edge_of_failure_52e8e853",
  "QualityAttribute:SM:6:DP design locked and documented in TPP/DP-IR except for features not impacting registration stability": "ex:QualityAttribute_dp_design_locked_and_558d8009",
  "QualityAttribute:SM:6:DP solid state characterized at release and stability. [AD/P&MS]": "ex:QualityAttribute_dp_solid_state_chara_aee102a5",
  "QualityAttribute:SM:6:DP solid state control strategy [P&MS]": "ex:QualityAttribute_dp_solid_state_contr_0cc26c1a",
  "QualityAttribute:SM:6:DP test methods developed fit-for-purpose and qualified": "ex:QualityAttribute_dp_test_methods_deve_14e00a86",
  "QualityAttribute:SM:6:Define strategy for RTRt": "ex:QualityAttribute_define_strategy_for_8412406e",
  "QualityAttribute:SM:6:Design Control:\n*Design and Development Plan and other plans (update)\n*Manufacturing Strategy and Design Transfer Plan (update)\n*Design Output Specification\n*Initiate Design Transfer Checklist (s) for phase 3\n*CMC memo for Design Control Design Review": "ex:QualityAttribute_design_control_desig_5bd924f7",
  "QualityAttribute:SM:6:Design Input Stage Design Review": "ex:QualityAttribute_design_input_stage_d_3de02ea3",
  "QualityAttribute:SM:6:Develop and qualify test methods for Phase 3/Commercial Design Verification": "ex:QualityAttribute_develop_and_qualify_9efb9b1b",
  "QualityAttribute:SM:6:Device Risk Management  (Update)\n*Risk Management Plan (Update)\n*Product Risk Assessment/Hazard ID (Update)\n*uFMEA (Update)\n*CTQ Flow Down (Update)\n*dFMEA (Initiate)": "ex:QualityAttribute_device_risk_manageme_fcd607ca",
  "QualityAttribute:SM:6:Dissolution studies: Phase 3 concepts evaluated with Physiology based dissolution screening method appropriate according to BCS": "ex:QualityAttribute_dissolution_studies_559f32b2",
  "QualityAttribute:SM:6:DoE on material attributes is planned or completed/documented": "ex:QualityAttribute_doe_on_material_attr_7b3a1645",
  "QualityAttribute:SM:6:EHS Requirement: Process Risk Analysis in line with expected upscaling; Supplier EHS assessment; Determine OEL for DS": "ex:QualityAttribute_ehs_requirement_proc_1db2b4e1",
  "QualityAttribute:SM:6:Endorse commercial sourcing decision for API , Drug Product, Device, Primary Packaging, Quality Release and Stabilty Laboratories through Network Sourcing Council": "ex:QualityAttribute_endorse_commercial_s_4089c2df",
  "QualityAttribute:SM:6:Ensure CDT/GFLS alignment re EMAX filing strategy impacting CMC timelines (including China process validation requirements). Focus on Japan when no MRA/MOU applies": "ex:QualityAttribute_ensure_cdt_gfls_alig_40015c5a",
  "QualityAttribute:SM:6:Ensure manufacturing site readiness in support of Clinical Ph3.": "ex:QualityAttribute_ensure_manufacturing_fd783dae",
  "QualityAttribute:SM:6:Excipient: Material qualification ongoing (incl material robustness, supplier comparability), , SWOT completed, material characterization ongoing, will be documented in in TMQR (Technical Material Qualification Report). Clinical spec implemented .  (P&MS)": "ex:QualityAttribute_excipient_material_q_db95b800",
  "QualityAttribute:SM:6:Excipients used are within established safety limits\u00a0Formula and/or Excipient safety report": "ex:QualityAttribute_excipients_used_are_7e6fc4d3",
  "QualityAttribute:SM:6:Excipients, primary packs, devices characterized/documented": "ex:QualityAttribute_excipients_primary_p_4169b17a",
  "QualityAttribute:SM:6:Execute agreed upon studies (in vitro or in vivo or in silico studies) for justification of specifications": "ex:QualityAttribute_execute_agreed_upon_17cd7061",
  "QualityAttribute:SM:6:Execute agreed upon studies for justification of specifications": "ex:QualityAttribute_execute_agreed_upon_aae90288",
  "QualityAttribute:SM:6:Experiment with PAT tools in support of future process control or Real Time Release (RTR) testing [API Dev/AD]": "ex:QualityAttribute_experiment_with_pat_f6d15d24",
  "QualityAttribute:SM:6:Experimentation plan (for example a Tech Transfer plan) available for process scale-up towards comm. scale taking advantage from existing scale-up models to minimize effort": "ex:QualityAttribute_experimentation_plan_3610879c",
  "QualityAttribute:SM:6:Extractables&Leachables-test report completed for Category 1 materials (incl mitigation)": "ex:QualityAttribute_extractables_leachab_5c6098c0",
  "QualityAttribute:SM:6:Facilitate cross-functional (SMPD, CDT, include JPKK) discussion on global debossment strategy": "ex:QualityAttribute_facilitate_cross_fun_52e39d42",
  "QualityAttribute:SM:6:Final API crystallization step locked/documented in line with locked API characteristics": "ex:QualityAttribute_final_api_crystalliz_e93ac1a6",
  "QualityAttribute:SM:6:Final excipient grades, suppliers selected/documented": "ex:QualityAttribute_final_excipient_grad_a8de47ba",
  "QualityAttribute:SM:6:Final mfg technique/process selected and documented in CA acc. to decision tree. Justification for deviation documented.": "ex:QualityAttribute_final_mfg_technique_c03ecb3a",
  "QualityAttribute:SM:6:Final robust in-use procedure (IFU) completed/documented and qualified": "ex:QualityAttribute_final_robust_in_use_d6b59d0d",
  "QualityAttribute:SM:6:Finalize phase 3/commercial specifications. These may include:\n*incoming inspection specifications for device components/raw materials, including shelf life\n*release specification for combination product, including shelf life\n*primary container (unfilled and filled) specifications that are related to device function\n*identify critical process parameters (component, subassembly, final assembly, etc) and range": "ex:QualityAttribute_finalize_phase_3_com_fd84a13e",
  "QualityAttribute:SM:6:First insight into CPP, CMA and environment normal variation + impact on API quality, manufacturability and stability": "ex:QualityAttribute_first_insight_into_c_bc09c5bf",
  "QualityAttribute:SM:6:First insight into CPP/CMA interactions using prior knowledge and DOE's": "ex:QualityAttribute_first_insight_into_c_4efc0e76",
  "QualityAttribute:SM:6:First insight on causality and scientific mechanism how CPP/CMA affect API quality including solid state, manufacturability and stability, and documented in the process characterization/development reports": "ex:QualityAttribute_first_insight_on_cau_2a83a2da",
  "QualityAttribute:SM:6:Fit-for-purpose RTD -based control strategy": "ex:QualityAttribute_fit_for_purpose_rtd_ffda5f1e",
  "QualityAttribute:SM:6:For ASD projects, final form of API must now be locked.  Form selction report must be updated and endorsed by Solid State Expert Team. [P&MS]": "ex:QualityAttribute_for_asd_projects_fin_a1e986cc",
  "QualityAttribute:SM:6:Formulation Design & Selection:\n*Final formulation / processing platform at start of the pivotal clinical trials to avoid risky and critical path BE studies\n*Final concept is selected based upon BA, stab (chem, phys, release profile ), manufacturability, manufacturing platform & technology \n*reliability/agility, customer centric design\n*Optimized  stability trend for release profile\n*According to QTPP and Formulation Design Initiative Matrix Criteria": "ex:QualityAttribute_formulation_design_s_ab9501e3",
  "QualityAttribute:SM:6:Formulation development report draft with at minimum: summary of formulation history and plan in place for robustness towards concentration, robustness towards excipient grades and suppliers (FRC: functionality related characteristics) and robustness towards material attribute variation (pCMAs)": "ex:QualityAttribute_formulation_developm_d3fd7d89",
  "QualityAttribute:SM:6:GMP PAT methods developed in line with proposed control strategy": "ex:QualityAttribute_gmp_pat_methods_deve_18690ff1",
  "QualityAttribute:SM:6:If TT is needed for PhIII, at least 1 successful demo batch produced with Phase III equipment/scale with full characterization and stability data generated.": "ex:QualityAttribute_if_tt_is_needed_for_441eb03d",
  "QualityAttribute:SM:6:If changes occur within final process, is change process and potential impacts well considered, and are appropriate studies front loaded to de-risk. Also is comparability/clinical considerations well considered": "ex:QualityAttribute_if_changes_occur_wit_4fa60fd7",
  "QualityAttribute:SM:6:If changes occur within final process, is change process and potential impacts well considered, and are appropriate studies front loaded to derisk. Also is comparability/clinical considerations well considered": "ex:QualityAttribute_if_changes_occur_wit_caa472b5",
  "QualityAttribute:SM:6:Implementation of PAT tools for process monitoring and/or control strategy": "ex:QualityAttribute_implementation_of_pa_36ce6ab5",
  "QualityAttribute:SM:6:Impurities and degradants assessed according to the Global Impurity Management Policy (repeated as new DP formulations are implemented or when new impurities/degradants are detected)": "ex:QualityAttribute_impurities_and_degra_66cf6f06",
  "QualityAttribute:SM:6:Impurity Mgmt report 3 approved and in line with the Global Impurity Management Policy (incl. Impurities qualified and documented in Tox memo, as well as nitrosamine risk assessment).": "ex:QualityAttribute_impurity_mgmt_report_9103a5e8",
  "QualityAttribute:SM:6:Impurity profile known": "ex:QualityAttribute_impurity_profile_kno_91c7aca4",
  "QualityAttribute:SM:6:Integrated CM line performance evaluation": "ex:QualityAttribute_integrated_cm_line_p_a1dc5e1e",
  "QualityAttribute:SM:6:Investigation Starting material suppliers, routes and impurities initiated": "ex:QualityAttribute_investigation_starti_fd0be8c9",
  "QualityAttribute:SM:6:Key outcomes of any HA meetings completed": "ex:QualityAttribute_key_outcomes_of_any_fcc93d9c",
  "QualityAttribute:SM:6:Mechanistic understanding provided and documented in support of PP/MA-CQA/mfg-ability factor causal relationships for intermediate scale": "ex:QualityAttribute_mechanistic_understa_a3733941",
  "QualityAttribute:SM:6:Mfg equipment of same design/operating principles as future commercial site": "ex:QualityAttribute_mfg_equipment_of_sam_7c280332",
  "QualityAttribute:SM:6:Mfg process suitable for Phase 3 volumes installed and qualified. If required, select manfuacturing processes for Registration/Commercial Production. Thes may include and are not limited to:\n*Device component manufacturing\n*Subassembly\n*Final assembly\n*Packaging": "ex:QualityAttribute_mfg_process_suitable_735d6ddc",
  "QualityAttribute:SM:6:Nitrosamine risk level confirmed for API in \"Product Compliance Focus Area\" on nitrosamines (P&MS). Decision if API confirmatory testing will be required.": "ex:QualityAttribute_nitrosamine_risk_lev_85ae6526",
  "QualityAttribute:SM:6:Nitrosamine risk level confirmed for DP in \"Product Compliance Focus Area\" on nitrosamines (P&MS). Decision if DP confirmatory testing will be required.": "ex:QualityAttribute_nitrosamine_risk_lev_3b11419b",
  "QualityAttribute:SM:6:Offline performance evaluation of individual unit operations": "ex:QualityAttribute_offline_performance_c056ae76",
  "QualityAttribute:SM:6:On track to executing API and DP batches with sufficiently broad variation (PAR boundaries) for in vivo performance assessment considered to support future commercial specification setting and develop a plan if not available (e.g. impurity profile, particle size, dissolution)": "ex:QualityAttribute_on_track_to_executin_89e43d76",
  "QualityAttribute:SM:6:On track to executing of required API batches with sufficiently broad variation (to become API PAR boundaries) for in vivo performance assessment considered to support future commercial specification setting\u00a0and develop a plan if not available (= clinically relevant comm. specifications, e.g. impurity profile, particle size)": "ex:QualityAttribute_on_track_to_executin_c4e278a3",
  "QualityAttribute:SM:6:Optimized, final API properties locked, justified, documented and approved.": "ex:QualityAttribute_optimized_final_api_1ec2bea8",
  "QualityAttribute:SM:6:Overview of any Q&A from HA in Phase 1 and Phase 2 IND/CTA": "ex:QualityAttribute_overview_of_any_q_a_b9b5d704",
  "QualityAttribute:SM:6:PAT method development/validation fit for purpose and follow up of development and clinical batches with PAT": "ex:QualityAttribute_pat_method_developme_1d5da186",
  "QualityAttribute:SM:6:Passive shipping systems qualified, if applicable (ph3 only - internal supply chain)": "ex:QualityAttribute_passive_shipping_sys_3287ed99",
  "QualityAttribute:SM:6:Pharmacopiea compliance : consider the requirement of USP/EP/ChP": "ex:QualityAttribute_pharmacopiea_complia_4404dd47",
  "QualityAttribute:SM:6:Phase 3/Commercial:\n*Review and update User Description, User Requirement, Technical Design Requirement documents  based on Phase 2, HF studies, and other learnings\n*Update IFU\n*Identify hazard, hazardous siutation,  failure modes and likelihood for phase 3 and commercial devices\n*Review of Phase 2 mfg campaigns\n*Trending and mitigation of manufacturing issues\n*Identify any new/unique manufacturing requirements and update manufacturing equipment requirement documents when appropirate\n*Evaluate impact of these learnings and identify required activities for phase 3 and commercial manufacturing process": "ex:QualityAttribute_phase_3_commercial_r_93cd3e6e",
  "QualityAttribute:SM:6:Plan, prepare and execute HA meetings (US EoP-2, EU Scientific Advice) to present, discuss and agree on key regulatory strategies (e.g. QbD elements, starting materials, API/DP primary stabiltiy protocols, etc)": "ex:QualityAttribute_plan_prepare_and_exe_9cb3fb93",
  "QualityAttribute:SM:6:Prepare for Ph3 IND/CTA": "ex:QualityAttribute_prepare_for_ph3_ind_836f071a",
  "QualityAttribute:SM:6:Process Optimum defined and target ranges identified for Ph3 (= at intermediate scale?)": "ex:QualityAttribute_process_optimum_defi_f6c2bb91",
  "QualityAttribute:SM:6:Process boundary evaluation": "ex:QualityAttribute_process_boundary_eva_33fe75fa",
  "QualityAttribute:SM:6:Process fit to plant (PF2P) completed in support of Commercial Sourcing decision.": "ex:QualityAttribute_process_fit_to_plant_e9003f1d",
  "QualityAttribute:SM:6:Project timelines, scope and resources updated in line with current assumptions": "ex:QualityAttribute_project_timelines_sc_0a4b1f40",
  "QualityAttribute:SM:6:Propose global product debossment  / scoring development plan to Customer Centric Design (CCD) Team": "ex:QualityAttribute_propose_global_produ_ffaa7fea",
  "QualityAttribute:SM:6:Qualify suitable manfuaturing controls for Phase 3:\n* Incoming and release tests   \n* in process control/inspection": "ex:QualityAttribute_qualify_suitable_man_688fdbef",
  "QualityAttribute:SM:6:Quality Agreements / Site qualification completed for clinical use for GMP INT, API and DP sites manufacturing, if new supplier": "ex:QualityAttribute_quality_agreements_s_a8a7d188",
  "QualityAttribute:SM:6:Quality Agreements / Site qualification for GMP INT, API and DP sites manufacturing for commercial use initiated": "ex:QualityAttribute_quality_agreements_s_ee451fd4",
  "QualityAttribute:SM:6:Rationale PH III Starting Materials completed/documented": "ex:QualityAttribute_rationale_ph_iii_sta_55c8df76",
  "QualityAttribute:SM:6:Re-assess preliminary high level QbD regulatory strategy :  Define elements of QbD to be included in NDA/MAA and assess risk/benefit": "ex:QualityAttribute_re_assess_preliminar_4c58e1b1",
  "QualityAttribute:SM:6:Regulatory strategy document including regulatory risk assessment and mitigation strategy": "ex:QualityAttribute_regulatory_strategy_1fc806b6",
  "QualityAttribute:SM:6:Review existing PRA applicable to product category and verify if additional risk has to be considered/added.\nReview PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_existing_pra_9b36f7b5",
  "QualityAttribute:SM:6:Review of Phase 2 trials completed:\n*Trending and mitigation of device clinical complaints (device and usability related)\n*Identify any new/unique user requirements (i.e., PK, usability, etc) for later clinical phases and commercial design\n*Identify and implement required design change and/or mitigation activities for subsequent clinical phases and commercial design\n*Update clinical risk assessment": "ex:QualityAttribute_review_of_phase_2_tr_b5c8af52",
  "QualityAttribute:SM:6:Review the submission plan endorsed by CDT, including GFLS country list and timeline. \u00a0Consult GFLS Playbook and CLRR database for country-specific requirements, including manufacturing sites & timing for stability batches and temperature zone, DP configurations for stability and pharmacy manual studies, PPQ strategy, and incorporate the requirements in the late stage CMC strategy definition and Phase 3 manufacturing resource plan.": "ex:QualityAttribute_review_the_submissio_8665ff0f",
  "QualityAttribute:SM:6:Review the submission plan endorsed by CDT, including GFLS country list and timeline. \u00a0Consult GFLS Playbook and CLRR database for country-specific requirements, including manufacturing sites & timing for stability batches and temperature zone, DP configurations for stability and pharmacy manual studies, PPQ strategy, and incorporate the requirements in the late stage CMC strategy definition and Phase 3 manufacturing resource plan.\"": "ex:QualityAttribute_review_the_submissio_c788a20e",
  "QualityAttribute:SM:6:RiBPS and/or Accelerated chemical/Physical stability  studies performed to understand failure modes, delineate the T/RH safe space, predict shelf life   and to suggest best packaging configurations  [AD/P&MS]": "ex:QualityAttribute_ribps_and_or_acceler_d9d9caa7",
  "QualityAttribute:SM:6:Risk assessment (CA) at CQA, CPP and CMA level close to completed": "ex:QualityAttribute_risk_assessment_ca_a_ea9a024d",
  "QualityAttribute:SM:6:SQ to start COC based on current BOM": "ex:QualityAttribute_sq_to_start_coc_base_d6aecd21",
  "QualityAttribute:SM:6:Seek regulatory feedback on acceptability of proposed debossing with regional RA colleagues wherever a pre-registration or registration of debossing characters is mandatory (example: Korea and Japan)": "ex:QualityAttribute_seek_regulatory_feed_6448a3a3",
  "QualityAttribute:SM:6:Specifications for Phase 3 excipients implemented": "ex:QualityAttribute_specifications_for_p_485b2eaa",
  "QualityAttribute:SM:6:Stability storage statements updated if appropriate": "ex:QualityAttribute_stability_storage_st_6772a031",
  "QualityAttribute:SM:6:Start feasibility study for surrogate model for Disso": "ex:QualityAttribute_start_feasibility_st_2453bfb9",
  "QualityAttribute:SM:6:Supplier Material Qualification completed for starting materials/raw materials for INT and API and excipients and packaging materials for  DP for clinical use, if new material/supplier combination": "ex:QualityAttribute_supplier_material_qu_0ff8cbbb",
  "QualityAttribute:SM:6:Supplier Material qualification for  starting materials/raw materials for INT, API and excipients and packaging materials  for DP for commercial  use\n (SM/RM, INT, API) initiated (CoC initiated by SQ)": "ex:QualityAttribute_supplier_material_qu_a36650e4",
  "QualityAttribute:SM:6:Supply plan": "ex:QualityAttribute_supply_plan_c1309482",
  "QualityAttribute:SM:6:TT strategy and site readiness plan initiated": "ex:QualityAttribute_tt_strategy_and_site_f449e828",
  "QualityAttribute:SM:6:Tech reports for formulation and process development in place": "ex:QualityAttribute_tech_reports_for_for_e1f03407",
  "QualityAttribute:SM:6:The TT strategy has been agreed upon with JSC. Fit-to-plant assessment completed and remediation plan available. Strategy and scale -up plan laid down in a Tech Transfer plan.": "ex:QualityAttribute_the_tt_strategy_has_e0490642",
  "QualityAttribute:SM:6:Update (if required) current BOM (includes all materials next to SM, INT, API) to AS + QI": "ex:QualityAttribute_update_if_required_c_6e210761",
  "QualityAttribute:SM:6:Update PQV Data Governance Sharepoint (if needed)": "ex:QualityAttribute_update_pqv_data_gove_3eb18066",
  "QualityAttribute:SM:6:Update Regulated Substance (RS) plan and RS Report": "ex:QualityAttribute_update_regulated_sub_ae205918",
  "QualityAttribute:SM:6:Update all test acceptance criteria and sample size based on risk assessement for Phase 3": "ex:QualityAttribute_update_all_test_acce_4fb054ec",
  "QualityAttribute:SM:6:Update specification for late development Ph 2B/Ph3 DP taking into account the current thinking on commercial DP specification strategy (defined parameters for late stage development)": "ex:QualityAttribute_update_specification_0d96bdac",
  "QualityAttribute:SM:6:Update specification for late development Ph2b/3 API taking into account current thinking on commercial API specification strategy (defined parameters for late stage development)": "ex:QualityAttribute_update_specification_7fd2c562",
  "QualityAttribute:SM:6:When appropriate, CPP/CMA variable space explored at intermediate scale for each impacted CQA (release/stability) or manufacturability factor via DoE.": "ex:QualityAttribute_when_appropriate_cpp_733e28e2",
  "QualityAttribute:SM:6:With the customer centric design (CCD) team, align worst case debossment strategy for development.": "ex:QualityAttribute_with_the_customer_ce_7d758b47",
  "QualityAttribute:SM:7:API and DP batches with sufficiently broad variation for in vivo performance assessment considered as to justify proposed comm. specification setting (e.g. impurity profile, particle size, dissolution)": "ex:QualityAttribute_api_and_dp_batches_w_ede0ad96",
  "QualityAttribute:SM:7:API batches with sufficiently broad variation considered for in vivo performance assessment (= clinically relevant comm. specifications, e.g. impurity profile, particle size)": "ex:QualityAttribute_api_batches_with_suf_c09340bd",
  "QualityAttribute:SM:7:API solid state characterized at release and stability including polymorphic purity (AD / P&MS )": "ex:QualityAttribute_api_solid_state_char_65969ac0",
  "QualityAttribute:SM:7:API solid state control strategy  Phase 3 - Commercial known and documented [AD/P&MS]": "ex:QualityAttribute_api_solid_state_cont_c9a6883c",
  "QualityAttribute:SM:7:Align registration, stability and PPQ strategy with CMCL/CMCT (e.g. equipment, batch sizes, manufacturing/packaging locations, dual sources of materials or components, etc)": "ex:QualityAttribute_align_registration_s_17a1f1cc",
  "QualityAttribute:SM:7:Analytical Strategy for Registration campaign for methods, specifications and stability (e.g. consideration development, consideration for final comm. spec's, JOS, boundary batches and edge of failure, Gage R&R, validation & transfer.": "ex:QualityAttribute_analytical_strategy_fa816a63",
  "QualityAttribute:SM:7:Approved CA report for GMP batch ph3": "ex:QualityAttribute_approved_ca_report_f_fccb377c",
  "QualityAttribute:SM:7:Are the weak points of formulation defined and suitably translated into control strategies with appropriate knowledge?": "ex:QualityAttribute_are_the_weak_points_aa60dd2b",
  "QualityAttribute:SM:7:Are the weak points of molecule/formulation defined and suitably translated into control strategies with appropriate knowledge": "ex:QualityAttribute_are_the_weak_points_f5ba5d60",
  "QualityAttribute:SM:7:Blinding strategy confirmed, based on clinical development plan (placebo need & timing; options for blinding eg overencapsulation, matching (coated) placebo formulation, packaging design, etc)": "ex:QualityAttribute_blinding_strategy_co_f546ae3d",
  "QualityAttribute:SM:7:Brand protection/vulnerability assessment complete.": "ex:QualityAttribute_brand_protection_vul_e065e2b4",
  "QualityAttribute:SM:7:Bridging strategy: BE strategy endorsed for Phase3-Registration Batches-Commercial-Next generation if no biowaiver [Biopharm team/AD, DPD]": "ex:QualityAttribute_bridging_strategy_be_ed792624",
  "QualityAttribute:SM:7:Budget & resources": "ex:QualityAttribute_budget_resources_028e6c51",
  "QualityAttribute:SM:7:Build  link product/process/materials with in-vivo: Strategy endorsed for clinically relevant QC dissolution method, spec, and design space development incl. agreement on type of relBA studies [Biopharm team/AD, DPD]": "ex:QualityAttribute_build_link_product_p_acc08957",
  "QualityAttribute:SM:7:CPDP Development & Verification Stage / Device Risk Management  (Update):\n*Risk Management Plan (Update)\n*Product Risk Assessment/Hazard ID (Update)\n*uFMEA (Update)\n*CTQ Flow Down (Update)\n*Device Control Strategy (Device) (Initiate)\n*dFMEA (Update)\n*Risk Management Report (Update)": "ex:QualityAttribute_cpdp_development_ver_b276855f",
  "QualityAttribute:SM:7:CPDP Development & Verification Stage /Design Control:\n*Design and Development Plan  (Update)\n*Device Design Verification Plan  (Update)\n*Develop Labeling/IFU\n*Product Design Rationale Report for Phase 3, if applicable\n*Design Verification Protocols and Reports for Phase 3\n*Update Clinical and Regulatory Plans\n*Update Device Stability Plan\n*Summary of Human Factors Activities\n*Design Validation Plan for commercial (Initiate)\n*Device Master Record (complete for phase 3 and Initiate for commercial)\n*Manufacturing Strategy and Design Transfer Plan (update)\n*Design History File (Update)\n*CMC Memo for Design Control Stage 2": "ex:QualityAttribute_cpdp_development_ver_9e947a32",
  "QualityAttribute:SM:7:CPP, CMA (incl. multiple suppliers) and environment normal variation and impact on API quality, manufacturability and stability at pilot scale known": "ex:QualityAttribute_cpp_cma_incl_multipl_92a2398b",
  "QualityAttribute:SM:7:CPP/CMA defined at pilot scale based on prior knowledge, DOE's and risk mgmt tools": "ex:QualityAttribute_cpp_cma_defined_at_p_acf739e2",
  "QualityAttribute:SM:7:Causality and scientific mechanism how CPP/CMA affect API quality, manufacturability and stability at pilot scale known, and documented in the process characterization/development report": "ex:QualityAttribute_causality_and_scient_c3b89bd3",
  "QualityAttribute:SM:7:China container DMF compliance and any other country specific requirements": "ex:QualityAttribute_china_container_dmf_8d2133fd",
  "QualityAttribute:SM:7:Complete investment at risk memo for PPQ batches (if required).": "ex:QualityAttribute_complete_investment_673b972d",
  "QualityAttribute:SM:7:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.  Complete HF studies, if needed.": "ex:QualityAttribute_complete_or_revisit_45132912",
  "QualityAttribute:SM:7:Control strategy for Ph3 product reflects prior knowledge and current P&P understanding": "ex:QualityAttribute_control_strategy_for_b7c26d45",
  "QualityAttribute:SM:7:Control strategy for comm. API pilot scale process based on prior knowledge, current P&P understanding and current state of CA": "ex:QualityAttribute_control_strategy_for_83827b42",
  "QualityAttribute:SM:7:Cross functional Risk register completed and mitigation plan developed, also highlighting the gaps and any mitigations with respect to key deliverables": "ex:QualityAttribute_cross_functional_ris_a4d5b3f0",
  "QualityAttribute:SM:7:Cross-functional project plan updated  in line with Registration, Transfer & Launch strategy": "ex:QualityAttribute_cross_functional_pro_11b2d7c2",
  "QualityAttribute:SM:7:Current BOM update and COC: refer to SG 6 actions": "ex:QualityAttribute_current_bom_update_a_cb2d46ea",
  "QualityAttribute:SM:7:Customer Centered Design deliverables completed for this stage. (incorporating any country specific requirements i.e. Japan as necessary)": "ex:QualityAttribute_customer_centered_de_b57f96f7",
  "QualityAttribute:SM:7:DP solid state characterized at release and stability including polymorphic purity using sensitive methods [P&MS/AD]": "ex:QualityAttribute_dp_solid_state_chara_bb201559",
  "QualityAttribute:SM:7:DP solid state control strategy  Phase 3--> commercial known and documented [AD/P&MS]": "ex:QualityAttribute_dp_solid_state_contr_3f7c00b7",
  "QualityAttribute:SM:7:DP test methods developed fit-for-purpose and qualified": "ex:QualityAttribute_dp_test_methods_deve_d682ffae",
  "QualityAttribute:SM:7:Deliver an updated aligned Integrated Launch Readiness (ILR) Heatmap and \"Product/SC Readiness\" portion of the GCSO \"Launch Preparations Dashboard\".": "ex:QualityAttribute_deliver_an_updated_a_16989806",
  "QualityAttribute:SM:7:Develop cross-functional plan and resource estimates for scenarios (if necessary)": "ex:QualityAttribute_develop_cross_functi_1dff670b",
  "QualityAttribute:SM:7:Develop/Update and qualify test methods for Registration batches:\n*Incoming and release tests  \n*in process control/inspection": "ex:QualityAttribute_develop_update_and_q_0f616cb6",
  "QualityAttribute:SM:7:Development & Verification Stage Design Review for phase 3": "ex:QualityAttribute_development_verifica_6c98f4ec",
  "QualityAttribute:SM:7:EHS Requirement: Complete EHS process safety studies initiated previously.": "ex:QualityAttribute_ehs_requirement_comp_8c25eb76",
  "QualityAttribute:SM:7:EHS Requirement: Initiate Env Tox study. Initiate environmental fate and effect studies.": "ex:QualityAttribute_ehs_requirement_init_c5b5ea70",
  "QualityAttribute:SM:7:EHS Requirement: Integrate DGTC (Dangerous Goods Transportation Compliance) requirements into Ph3 1st, 2nd and 3rd packaging solution [CSC]": "ex:QualityAttribute_ehs_requirement_inte_98560be3",
  "QualityAttribute:SM:7:EHS Requirement: Integrate Dangerous Goods Transportation Compliance (DGTC) requirements into commercial primary, secondary, tertiary packaging strategy": "ex:QualityAttribute_ehs_requirement_inte_a5869e7e",
  "QualityAttribute:SM:7:Engineering study for commercial design completed (stress testing, accelerated aging) (optional)": "ex:QualityAttribute_engineering_study_fo_3ea7d1a4",
  "QualityAttribute:SM:7:Establish stability startegy  for registration and PPQ batches  and prepare the responsibility hand-over to PQM. Carla: in line with API, I would propose a similar sentence: Analytical Strategy for Registration campaign for methods, specifications and stability (e.g. consideration development, consideration for final comm. spec's, JOS, boundary batches and edge of failure, Gage R&R, validation & transfer.": "ex:QualityAttribute_establish_stability_81237e29",
  "QualityAttribute:SM:7:Evaluate multiple suppliers building blocks and raw materials at pp scale": "ex:QualityAttribute_evaluate_multiple_su_a3dacea6",
  "QualityAttribute:SM:7:Excipient: Supplier qualification, Material qualification on-going, SWOT completed, material characterization on-going [P&MS/DPD]": "ex:QualityAttribute_excipient_supplier_q_b9d5d54e",
  "QualityAttribute:SM:7:Excipients: evaluation of material properties by planning boundary batch mfg": "ex:QualityAttribute_excipients_evaluatio_f1ad6774",
  "QualityAttribute:SM:7:Execute agreed upon studies (boundary batch/edge of failure studies) for justification of specifications": "ex:QualityAttribute_execute_agreed_upon_a139f330",
  "QualityAttribute:SM:7:Execute agreed upon studies for justification of specification": "ex:QualityAttribute_execute_agreed_upon_d2e8982d",
  "QualityAttribute:SM:7:Execute agreed upon studies for justification of specifications": "ex:QualityAttribute_execute_agreed_upon_fe418b8d",
  "QualityAttribute:SM:7:Execute experimentation plan (incl. scale-up models) to evaluate/confirm CPP/CMA design space at representative scale": "ex:QualityAttribute_execute_experimentat_b8ee5fb7",
  "QualityAttribute:SM:7:Execute experimentation plan (incl. scale-up models) to evaluate/confirm CPP/CMA-CQA/Mfg-ability factors with as a result causal relationships at representative scale": "ex:QualityAttribute_execute_experimentat_2aad0ace",
  "QualityAttribute:SM:7:Finalize commercial specifications for registration batches. These may include:\n*incoming inspection specifications for device components/raw materials, including shelf life\n*release specification for combination product, including shelf life\n*primary container (unfilled and filled) specifications that are related to device function\n*identify critical process parameters (component, subassembly, final assembly, etc) and range": "ex:QualityAttribute_finalize_commercial_c67dd635",
  "QualityAttribute:SM:7:For Phase 3:\n*Define and provide training to site staff/patients\n*Set up device PQC handling process including where complaints will be investigated. Work with clinical QC to set up/update appropriate complaint categories and conclusions\n*complete design verification (device bench testing) with sufficient stability results": "ex:QualityAttribute_for_phase_3_define_a_b22bb532",
  "QualityAttribute:SM:7:Full Development Strategy confirmed and plans documented and approved": "ex:QualityAttribute_full_development_str_613ebac7",
  "QualityAttribute:SM:7:Gap analysis on knowledge completed and remediation plan developed": "ex:QualityAttribute_gap_analysis_on_know_e1f91012",
  "QualityAttribute:SM:7:Gap analysis on process knowledge completed and remediation plan available": "ex:QualityAttribute_gap_analysis_on_proc_f9aeef21",
  "QualityAttribute:SM:7:Gap analysis on process knowledge completed and remediation plan developed": "ex:QualityAttribute_gap_analysis_on_proc_c8b51b24",
  "QualityAttribute:SM:7:Gap analysis on product knowledge completed and remediation plan available": "ex:QualityAttribute_gap_analysis_on_prod_440e6720",
  "QualityAttribute:SM:7:Global packaging strategy aligned with GCSO; secondary & tertiary packaging defined and  aligned through CMC and VCT": "ex:QualityAttribute_global_packaging_str_b4b91f6e",
  "QualityAttribute:SM:7:Impurity profile characterized (ID + quantified + tox qualified)(supplier variation included)": "ex:QualityAttribute_impurity_profile_cha_89d1b57b",
  "QualityAttribute:SM:7:Install process equipment required for registration batches and continue to refine and update CTQ flow down for the following processes:\n*Molding\n*Subassembly\n*Final assembly\n*Packaging": "ex:QualityAttribute_install_process_equi_21ee95f6",
  "QualityAttribute:SM:7:Investigate options for IP protection [DPD]": "ex:QualityAttribute_investigate_options_18da56a3",
  "QualityAttribute:SM:7:List of critical process parameters /material attributes in line with current Criticality Analysis": "ex:QualityAttribute_list_of_critical_pro_24df38b9",
  "QualityAttribute:SM:7:Multi generation plan": "ex:QualityAttribute_multi_generation_pla_091050cf",
  "QualityAttribute:SM:7:PK bridging strategy developed for  Phase 3 \u00e0 registration batches \u00e0 commercial\u00e0 post approval / next generation": "ex:QualityAttribute_pk_bridging_strategy_78d6a4a5",
  "QualityAttribute:SM:7:PMI calculation of the process (in house steps) using ACS GCIPR guidance": "ex:QualityAttribute_pmi_calculation_of_t_cf0bc4cc",
  "QualityAttribute:SM:7:Perform BPAL status check in preparation for Integrated Launch Readiness (ILR) heatmap and Council endorsement.": "ex:QualityAttribute_perform_bpal_status_ec32bff4",
  "QualityAttribute:SM:7:Perform and align BPAL status update in preparation for Integrated Launch Readiness (ILR) heatmap and Council endorsement.": "ex:QualityAttribute_perform_and_align_bp_54710a34",
  "QualityAttribute:SM:7:Ph3 DP supply plan available": "ex:QualityAttribute_ph3_dp_supply_plan_a_b7e03257",
  "QualityAttribute:SM:7:Ph3 IND/CTA filing completed": "ex:QualityAttribute_ph3_ind_cta_filing_c_2bcb71f5",
  "QualityAttribute:SM:7:Ph3 Stability protocol & stability initiated (if formulation/methods changed)": "ex:QualityAttribute_ph3_stability_protoc_3cea0d7c",
  "QualityAttribute:SM:7:Ph3 Stability protocol & stability initiated (if synthesis/methods changed)": "ex:QualityAttribute_ph3_stability_protoc_0bd830be",
  "QualityAttribute:SM:7:Pharmacopiea compaliance : consider the requirement of USP/EP/ChP": "ex:QualityAttribute_pharmacopiea_compali_aca8e5a7",
  "QualityAttribute:SM:7:Plan for evaluation of excipients comm. spec's/methods [P&MS/DPD]": "ex:QualityAttribute_plan_for_evaluation_2219b415",
  "QualityAttribute:SM:7:Process Fit to Plant (PF2P) Remediation Plan": "ex:QualityAttribute_process_fit_to_plant_102db268",
  "QualityAttribute:SM:7:Process control strategy in line with BPAL strategy (assess partial RTRT/use of GMP-PAT on Ph3)": "ex:QualityAttribute_process_control_stra_ef3b04c1",
  "QualityAttribute:SM:7:Process optimum defined at pilot scale": "ex:QualityAttribute_process_optimum_defi_912094bf",
  "QualityAttribute:SM:7:Process validation strategy (PPQ) based on current CA and available experimental data": "ex:QualityAttribute_process_validation_s_3644f284",
  "QualityAttribute:SM:7:Process validation strategy (PPQ) based on current CA and available experimental data (number of batches, batch size, equipment train, API/SM/IM sources, etc)": "ex:QualityAttribute_process_validation_s_23960528",
  "QualityAttribute:SM:7:Process/material mechanistic understanding captured in Criticality Analysis": "ex:QualityAttribute_process_material_mec_aab40cd2",
  "QualityAttribute:SM:7:Product knowledge captured in Criticality Analysis": "ex:QualityAttribute_product_knowledge_ca_c5191e2f",
  "QualityAttribute:SM:7:Quality Agreements / Site qualification completed for clinical use for GMP INT, API and DP sites manufacturing, if new supplier": "ex:QualityAttribute_quality_agreements_s_c97e7ee0",
  "QualityAttribute:SM:7:Quality Agreements / Site qualification for commercial use for GMP INT, API and DP sites manufacturing on-going": "ex:QualityAttribute_quality_agreements_s_0f336266",
  "QualityAttribute:SM:7:Readiness for the Combo Product and/or labs (Initial Purchasing Controls) for registration/commercial when applicable:\n*Supplier and Contractor Audit\n*Device Quality Agreement (Final assembly)\n*Device Quality Agreement (Device component, device itself and Purchasing Control/ for Combo Products)\n*Device Testing Quality Agreement (Lab to Lab)  \n*Third Party Design Control Audit Report (If Applicable)": "ex:QualityAttribute_readiness_for_the_co_9f73235e",
  "QualityAttribute:SM:7:Real-time in-process test on factors showing substantial variation and impact on CQA's  incorporated where relevant in control strategy": "ex:QualityAttribute_real_time_in_process_aaaa4005",
  "QualityAttribute:SM:7:Regulatory strategy document, including QbD elements for the MAA/NDA,  and including regulatory risk assessment and mitigation strategy, planned HA meetings (e.g. emphasis on agreement for starting materials, proposed QC dissolution method, other key issues requiring input prior to registration), key outcomes of any HA meetings completed, global submission strategy (from GRT), overview of any Q&A from HA in Phase 1 and Phase 2 IND/CTA (updated from Stage 6)": "ex:QualityAttribute_regulatory_strategy_ad526d18",
  "QualityAttribute:SM:7:Regulatory strategy in line with FD strategy": "ex:QualityAttribute_regulatory_strategy_08c52987",
  "QualityAttribute:SM:7:Resource estimates (FTE and OOP) calculated for Registration, Transfer & Launch": "ex:QualityAttribute_resource_estimates_f_c2a7646c",
  "QualityAttribute:SM:7:Review and update Device Supplier Quality Agreement and audit status": "ex:QualityAttribute_review_and_update_de_c957270b",
  "QualityAttribute:SM:7:Review and update User Description, User Requirement, Technical Design Requirement documents for phase 3/Commercial design based on Phase 2, HF studies, and other learnings": "ex:QualityAttribute_review_and_update_us_ffeab254",
  "QualityAttribute:SM:7:Review existing PRA applicable to product category and verify if additional risk has to be considered/added.\nReview PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_existing_pra_033378b5",
  "QualityAttribute:SM:7:Review of Human Factors Validation Study protocol for submission to FDA, as applicable": "ex:QualityAttribute_review_of_human_fact_12e49fa4",
  "QualityAttribute:SM:7:Select commercial packaging design": "ex:QualityAttribute_select_commercial_pa_991c9af1",
  "QualityAttribute:SM:7:Specification strategy (clin. relevant spec's)": "ex:QualityAttribute_specification_strate_6114825d",
  "QualityAttribute:SM:7:Specify Country Level Regulatory Requirements (CLRR)": "ex:QualityAttribute_specify_country_leve_e4c14b8c",
  "QualityAttribute:SM:7:Spiking experimentation initiated; actual & potential impurities synthesized": "ex:QualityAttribute_spiking_experimentat_ec8612c9",
  "QualityAttribute:SM:7:Stability storage statements updated if appropriate": "ex:QualityAttribute_stability_storage_st_6ad546cf",
  "QualityAttribute:SM:7:Stage Gate Approval Form": "ex:QualityAttribute_stage_gate_approval_97fd6c5d",
  "QualityAttribute:SM:7:Strategy and plan for development of design space  including for solid state": "ex:QualityAttribute_strategy_and_plan_fo_253b0efb",
  "QualityAttribute:SM:7:Strategy and plan for development of final comm. product in line with BPAL strategy": "ex:QualityAttribute_strategy_and_plan_fo_b653563d",
  "QualityAttribute:SM:7:Strategy for further development of the  control strategy  including for solid state [API/ AD/P&MS]": "ex:QualityAttribute_strategy_for_further_2fc05c32",
  "QualityAttribute:SM:7:Supplier Material Qualification completed for for starting materials/raw materials for INT in API and excipients and packaging materials for DP for clinical use, if new material/supplier combination": "ex:QualityAttribute_supplier_material_qu_7acd3b35",
  "QualityAttribute:SM:7:Supplier qualification for commercial for starting materials/raw materials for INT and API and excipients and packaging materials for DP for commercial use  ongoing (CoC amended, if needed) for both SM & Combo products": "ex:QualityAttribute_supplier_qualificati_e1fa95e0",
  "QualityAttribute:SM:7:Suppliers raw/starting materials thoroughly qualified (robustness/capability/reliability)": "ex:QualityAttribute_suppliers_raw_starti_98c9a659",
  "QualityAttribute:SM:7:Support API-SM in experimentation with PAT tools in support of future process control or Real Time Release (RTR) testing": "ex:QualityAttribute_support_api_sm_in_ex_2e0bc6e5",
  "QualityAttribute:SM:7:TT strategy and site readiness plan available": "ex:QualityAttribute_tt_strategy_and_site_2147f4fa",
  "QualityAttribute:SM:7:Test methods developed fit-for-purpose and qualified including API, starting materials/raw materials/intermediates": "ex:QualityAttribute_test_methods_develop_5fb91729",
  "QualityAttribute:SM:7:To support potential HA interactions (EoP2), complete CMC Team review of the following DRAFT key dossier-centric reports (or of required information related to these reports): API Specification Report, DP Specification Report, Starting Material Justification Report, Dissolution Method Development Report, and Formulation Development Report.": "ex:QualityAttribute_to_support_potential_036b3424",
  "QualityAttribute:SM:7:Update COGS and GP, documenting assumptions, for preparation of the Integrated Launch Readiness heatmap.": "ex:QualityAttribute_update_cogs_and_gp_d_8957a060",
  "QualityAttribute:SM:7:Update PQV Data Governance Sharepoint (if needed)": "ex:QualityAttribute_update_pqv_data_gove_71074506",
  "QualityAttribute:SM:7:Update Regulated Substance (RS) plan and RS Report": "ex:QualityAttribute_update_regulated_sub_9267fe04",
  "QualityAttribute:SM:7:Update Supplier Product Risk Assessment (SPRA) and Material Tracker for preparation of Integrated Launch Readiness heatmap.": "ex:QualityAttribute_update_supplier_prod_78f88184",
  "QualityAttribute:SM:7:Update specification for Ph3 API taking into account current thinking on commercial API specification strategy (defined parameters for late stage development) including starting materials/raw materials/intermediates": "ex:QualityAttribute_update_specification_68cac308",
  "QualityAttribute:SM:7:Update specification for Ph3 DP taking into account current thinking on commercial DP specification strategy (defined parameters for late stage development)": "ex:QualityAttribute_update_specification_aeb3d2b3",
  "QualityAttribute:SM:7:Updated criticality analysis report confirmed and approved prior to release of  GMP batch ph3": "ex:QualityAttribute_updated_criticality_ba5083d1",
  "QualityAttribute:SM:7:Validation strategy": "ex:QualityAttribute_validation_strategy_e665a4c4",
  "QualityAttribute:SM:7:Verify all stage appropriate TPP attributes are defined and aligned cross-functionally (including food and beverage study).": "ex:QualityAttribute_verify_all_stage_app_0d1cbd40",
  "QualityAttribute:SM:8:*Passive shipping systems qualified, if applicable, and PPQ batches are to be used for commercial purposes (Registration/PPQ Pkg MTl-internal supply chain)\n*Calculate thermal density of temperature shipping systems (as needed)\n*Qualification report of insulated shipping container for temp sensitive products (as needed)\n*Shipping process validation report - cold chain (as needed)\n*Distribution testing protocol and report": "ex:QualityAttribute_passive_shipping_sys_637a934a",
  "QualityAttribute:SM:8:AD contributions to CMC \u201cIP wall of defence\u201d and to the \u201cLCM IP strategy\u201d.": "ex:QualityAttribute_ad_contributions_to_99cbe574",
  "QualityAttribute:SM:8:AD contributions to CMC \u201cIP wall of defense\u201d and to the \u201cLCM IP strategy\u201d.": "ex:QualityAttribute_ad_contributions_to_d562d3b3",
  "QualityAttribute:SM:8:API CQA's issued  for registration.": "ex:QualityAttribute_api_cqa_s_issued_for_00b1b16e",
  "QualityAttribute:SM:8:API and DP batches available with sufficiently broad variation for in vivo performance assessment considered as to justify proposed comm. specification setting (e.g. impurity profile, particle size, dissolution)": "ex:QualityAttribute_api_and_dp_batches_a_8a5ae70f",
  "QualityAttribute:SM:8:API batches available with sufficiently broad variation considered for in vivo performance assessment (= clinically relevant comm. specifications, e.g. impurity profile, particle size)": "ex:QualityAttribute_api_batches_availabl_919cc72f",
  "QualityAttribute:SM:8:API batches with sufficiently broad variation considered for in vivo performance assessment (= clinically relevant comm. specifications, e.g. impurity profile, particle size)": "ex:QualityAttribute_api_batches_with_suf_25baee4b",
  "QualityAttribute:SM:8:API characteristics confirmed and documented": "ex:QualityAttribute_api_characteristics_8b63baf6",
  "QualityAttribute:SM:8:API comparability report bw final process and Phase 3 process [P&MS/AD]": "ex:QualityAttribute_api_comparability_re_bfbc5435",
  "QualityAttribute:SM:8:API form and underlying studies re-confirmed as actual for API process, purity, DP, and DP process, storage, and in-use.": "ex:QualityAttribute_api_form_and_underly_c4b0622c",
  "QualityAttribute:SM:8:API reg. batch mfg plan available": "ex:QualityAttribute_api_reg_batch_mfg_pl_5c8f5f95",
  "QualityAttribute:SM:8:API registration stability initiated (protocol)": "ex:QualityAttribute_api_registration_sta_bb6a93e4",
  "QualityAttribute:SM:8:API robustness reports (and/or Proactively and informally track Robustness Index dashboard metrics)": "ex:QualityAttribute_api_robustness_repor_f1b07d3b",
  "QualityAttribute:SM:8:API solid state characterized at release and stability including polymorphic purity": "ex:QualityAttribute_api_solid_state_char_91f3bfab",
  "QualityAttribute:SM:8:Already mentionned in \"Quality Agreements / Site qualification completed for commercial use for RSM, GMP INT,  API  & DP manufacturing\".": "ex:QualityAttribute_already_mentionned_i_42341afc",
  "QualityAttribute:SM:8:Analytical Strategy for Registration campaign for methods, specifications and stability aligned and endorsed at the Stability Focus Area.": "ex:QualityAttribute_analytical_strategy_0b63c6e7",
  "QualityAttribute:SM:8:Appropriate PAT tools and methods in place in support of control strategy (process control or RTR testing)": "ex:QualityAttribute_appropriate_pat_tool_c6390c1d",
  "QualityAttribute:SM:8:Appropriate PAT tools and methods in place, eventually in combination with control model, insupport of control strategy (process control or RTR testing": "ex:QualityAttribute_appropriate_pat_tool_fac0b739",
  "QualityAttribute:SM:8:Are the weak points of molecule/formulation defined and suitably translated into control strategies with appropriate knowledge": "ex:QualityAttribute_are_the_weak_points_9d256382",
  "QualityAttribute:SM:8:Assess the strategy for implementing the commercial line throughput as of DP registration batches": "ex:QualityAttribute_assess_the_strategy_66e4e0a1",
  "QualityAttribute:SM:8:Batch evaluation with material batches from multiple sources": "ex:QualityAttribute_batch_evaluation_wit_50538336",
  "QualityAttribute:SM:8:Best Process aspects aligned with JSC (steerco meeting)": "ex:QualityAttribute_best_process_aspects_e424f77d",
  "QualityAttribute:SM:8:Biopharmaceutical testing:\n*Commercial formula Bioequivalent with Phase 3 if the commercial formulation isn't the same as the Ph 3; either by a BE study , either by  in-vitro dissolution studies, including SUPAC,  biorelevant media ,  if  in-vitro approach is accepted by the agencies (eoPH2 or pre-NDA meeting)\n*Relative hBA Studies finalized for development of clinically relevant QC dissolution method, shelf-life spec , and design space": "ex:QualityAttribute_biopharmaceutical_te_1d8860b7",
  "QualityAttribute:SM:8:Blinding strategy confirmed, based on clinical development plan (placebo need & timing; options for blinding eg overencapsulation, matching (coated) placebo formulation, packaging design,etc)": "ex:QualityAttribute_blinding_strategy_co_b53a5d02",
  "QualityAttribute:SM:8:Boundary study across unit operations planned.": "ex:QualityAttribute_boundary_study_acros_8f15e09b",
  "QualityAttribute:SM:8:Bridging strategy phase 3/registration batches/ commercial site/ post approval": "ex:QualityAttribute_bridging_strategy_ph_ce3f403a",
  "QualityAttribute:SM:8:Bridging strategy: BE strategy between Phase3/Registration Batches and Commercial-Next generation if no biowaiver": "ex:QualityAttribute_bridging_strategy_be_222c8713",
  "QualityAttribute:SM:8:Build  link product/process/materials with in-vivo:\n*Mechanistic understanding on what drives the release profile.\n*Final PBBM model for IR formulas /Final IVIVC model for CR formulations\n*Final Clinically relevant QC dissolution method defined after testing the method candidates on hBA samples (best correlation with in-vivo). Suitability of Dissolution QC method discussed with health care agencies including regarding PBBM model use, CBA approach etc . *Rationale for QC dissolution method based upon guidelines and discriminatory properties towards in-vivo relevant changes in product, process, materials. Documentation done in Disso Method Development Report (including surrogate model strategy for CM-applications)\n*Test all pivotal clinical batches and DoE design space batches with final QC method and findings reflected in CA\n*Based upon the rhBA define which variability is allowed in resupply of the Phase 3 batches": "ex:QualityAttribute_build_link_product_p_390062f4",
  "QualityAttribute:SM:8:Bulk/intermediate handling/storage  containers qualified": "ex:QualityAttribute_bulk_intermediate_ha_3f41274b",
  "QualityAttribute:SM:8:CPDP Process & Design Validation Stage / Design Control:\n*Design Transfer Checklist (s) for registration batches\n*Manufacturing Strategy and Design Transfer Plan (update)\n*Product Design Rationale Report for Commercial Design, if applicable\n*Registration batch tech transfer report\n*Design Verification Protocols and Reports for Commercial Design, if applicable  \n*Complaint Handling Plan (initiate)\n*Initiate Design Transfer Checklist (s) for registration batches": "ex:QualityAttribute_cpdp_process_design_07d11e7a",
  "QualityAttribute:SM:8:CQAs, CPPs, CMAs selected as scope for Product Performance Dashboard and confirmed by RD FA": "ex:QualityAttribute_cqas_cpps_cmas_selec_e54cf971",
  "QualityAttribute:SM:8:CQAs, CPPs, CMAs selected as scope for Product Performance Dashboard and confirmed via Level 1 review": "ex:QualityAttribute_cqas_cpps_cmas_selec_e4b70937",
  "QualityAttribute:SM:8:CQAs, CPPs, CMAs selected as scope for Robustness Index Dashboard and confirmed by RD FA. (TP#2 RD FA)": "ex:QualityAttribute_cqas_cpps_cmas_selec_77e63f56",
  "QualityAttribute:SM:8:Certified reference standards for relevant API forms when polymorphic purity is CQA.": "ex:QualityAttribute_certified_reference_091b4eb5",
  "QualityAttribute:SM:8:Cold chain worked out if applicable": "ex:QualityAttribute_cold_chain_worked_ou_869c530f",
  "QualityAttribute:SM:8:Comm. API process described in preparation of API registration batches": "ex:QualityAttribute_comm_api_process_des_5cbf232e",
  "QualityAttribute:SM:8:Commercial Container Closure System Suitability Development Report": "ex:QualityAttribute_commercial_container_c62d408a",
  "QualityAttribute:SM:8:Commercial Primary Component Specifications": "ex:QualityAttribute_commercial_primary_c_95fb329b",
  "QualityAttribute:SM:8:Commercial process selection documented in Tech Transfer Plan (TTP)": "ex:QualityAttribute_commercial_process_s_03218e09",
  "QualityAttribute:SM:8:Commercial product selection documented in Tech Transfer Plan (TTP)": "ex:QualityAttribute_commercial_product_s_05e50ea8",
  "QualityAttribute:SM:8:Complete CMC Team review of the following DRAFT key dossier-centric reports to support MA dossier authoring: API Justification of Specification Report (when release data from registration batches are available), DP Justification of Specification Report (when release data from registration batches are available), Starting Material Justification Report, Dissolution Method Development Report, Synthesis Criticality Analysis Report, DP Criticality Analysis Report, Formulation Development Report, and 3.2.P.2.3 Dossier Section Outline.": "ex:QualityAttribute_complete_cmc_team_re_1478377f",
  "QualityAttribute:SM:8:Complete Launch Inventory/Capacity FPO deliverables (supply chain modeled, launch volume defined, inventory/safety stock defined...)": "ex:QualityAttribute_complete_launch_inve_cae772ca",
  "QualityAttribute:SM:8:Complete Printed Packaging Components FPO deliverables (branding guideline, mock up US/EU, Artwork for Reg samples)": "ex:QualityAttribute_complete_printed_pac_ac093338",
  "QualityAttribute:SM:8:Complete initial Process FMEA (COMBO Product Requirement)": "ex:QualityAttribute_complete_initial_pro_a48f60ee",
  "QualityAttribute:SM:8:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.  Complete HF studies, if needed.": "ex:QualityAttribute_complete_or_revisit_43a9df2c",
  "QualityAttribute:SM:8:Confirm final global debossment & commercial image strategy": "ex:QualityAttribute_confirm_final_global_38ce60d7",
  "QualityAttribute:SM:8:Confirm global commercial image and debossment strategy with GRL/Regional regulatory leads, and all appropriate stakeholders": "ex:QualityAttribute_confirm_global_comme_f05d11f5",
  "QualityAttribute:SM:8:Control strategy for registration batch purpose based on prior knowledge, current P&P understanding and current state of CA, including control strategy to guarantee for solid state at release and over retest period": "ex:QualityAttribute_control_strategy_for_9a22c1fd",
  "QualityAttribute:SM:8:Criticality Analysis report approved prior to start of API registration batches.": "ex:QualityAttribute_criticality_analysis_ed0f3206",
  "QualityAttribute:SM:8:Cross functional Risk register completed and mitigation plan developed, also highlighting the gaps and any mitigations with respect to key deliverables.": "ex:QualityAttribute_cross_functional_ris_7ccab7bb",
  "QualityAttribute:SM:8:Current BOM update and COC: refer to SG 6 actions": "ex:QualityAttribute_current_bom_update_a_4ed74b6d",
  "QualityAttribute:SM:8:Customer Centered Design deliverables completed for this stage.": "ex:QualityAttribute_customer_centered_de_6783895b",
  "QualityAttribute:SM:8:DOE/Edge of Failure study reports for key registration manufacturing steps/measurements": "ex:QualityAttribute_doe_edge_of_failure_5e63133a",
  "QualityAttribute:SM:8:DP method validation report (if appropriate)": "ex:QualityAttribute_dp_method_validation_8902ff7e",
  "QualityAttribute:SM:8:DP nitrosamine confirmatory testing on registration stability initiated if required": "ex:QualityAttribute_dp_nitrosamine_confi_0ee4d14a",
  "QualityAttribute:SM:8:DP registration stability  (protocol)[Consider country specific regulatory requirements in registration stability; ensure protocol includes sufficient samples, etc, for products where a shelf life beyond 36 months may be pursued]": "ex:QualityAttribute_dp_registration_stab_2acc446b",
  "QualityAttribute:SM:8:DP solid state characterized at release and stability including polymorphic purity using sensitive methods": "ex:QualityAttribute_dp_solid_state_chara_5969c9c6",
  "QualityAttribute:SM:8:DP stability (protocol) for in use, shipping, cyclic and bulk studies": "ex:QualityAttribute_dp_stability_protoco_93242c6a",
  "QualityAttribute:SM:8:Demonstrate that the debossed product meets all development and regulatory specifications": "ex:QualityAttribute_demonstrate_that_the_929668f1",
  "QualityAttribute:SM:8:Design for Sustainability completed in line with BPAL.": "ex:QualityAttribute_design_for_sustainab_f8ae0c10",
  "QualityAttribute:SM:8:Device Risk Management  (Update):\n*Risk Management Plan (Update)\n*Product Risk Assessment/Hazard ID (Update)\n*uFMEA (Update)\n*CTQ Flow Down (Update)\n*Device Control Strategy (Review and Update)\n*dFMEA (Update)\n*pFMEA (Initiate)\n*Risk Management Report (Update)": "ex:QualityAttribute_device_risk_manageme_fe51f3d2",
  "QualityAttribute:SM:8:E&L-test report completed for Category 2 materials (incl mitigation)": "ex:QualityAttribute_e_l_test_report_comp_cd428983",
  "QualityAttribute:SM:8:EHS Requirement: Author DP SDS (after formulation lock) and align with label": "ex:QualityAttribute_ehs_requirement_auth_6a92d260",
  "QualityAttribute:SM:8:EHS Requirement: PbOEL and cleaning methods for intermediates known. Finalize OEL for API.": "ex:QualityAttribute_ehs_requirement_pboe_31bc0ba7",
  "QualityAttribute:SM:8:Elemental impurity final evaluation initiated as part of API CQA": "ex:QualityAttribute_elemental_impurity_f_57dd78e6",
  "QualityAttribute:SM:8:Establish end to end registration control strategy based on available pFMEA and experiments/datasets, including:\n*Sampling strategy and acceptance criteria": "ex:QualityAttribute_establish_end_to_end_58b3e3ed",
  "QualityAttribute:SM:8:Evaluate whether the registration batches will be representative of the proposed commercial production, and propose the appropriate bridging strategy, if needed": "ex:QualityAttribute_evaluate_whether_the_70df82da",
  "QualityAttribute:SM:8:Exc/Pack: SWOT completed incl. BCP and risk mitigation plan [P&MS /Pack& Dev]": "ex:QualityAttribute_exc_pack_swot_comple_7e8b4af0",
  "QualityAttribute:SM:8:Excipient spec/method ready and release aligned with Regulatory Strategy (Select: EU, US, JPN, China)": "ex:QualityAttribute_excipient_spec_metho_786631cc",
  "QualityAttribute:SM:8:Execute agreed upon studies (e.g. edge of failure and boundary batch studies) for justification of specifications": "ex:QualityAttribute_execute_agreed_upon_92deb1e3",
  "QualityAttribute:SM:8:Execute agreed upon studies for justification of specification": "ex:QualityAttribute_execute_agreed_upon_0cb551b4",
  "QualityAttribute:SM:8:Execute agreed upon studies for justification of specifications": "ex:QualityAttribute_execute_agreed_upon_81683425",
  "QualityAttribute:SM:8:Experimentation plans set up in consultation with Quantitative Science statisticians to meet future Robustness Index Dashboard requirements": "ex:QualityAttribute_experimentation_plan_c52b1edd",
  "QualityAttribute:SM:8:Experimentation plans set up in consultation with statisticians to meet future Product Performance Dashboard requirements": "ex:QualityAttribute_experimentation_plan_29d36bb1",
  "QualityAttribute:SM:8:Final API solid state control strategy and solid state analytical methods  [ P&MS/ AD]": "ex:QualityAttribute_final_api_solid_stat_a7169c02",
  "QualityAttribute:SM:8:Final DP CQA's defined/documented in CA": "ex:QualityAttribute_final_dp_cqa_s_defin_96d6d3bd",
  "QualityAttribute:SM:8:Final DP solid state control strategy and solid state analytical methods  [ P&MS/ AD]": "ex:QualityAttribute_final_dp_solid_state_17b0de4c",
  "QualityAttribute:SM:8:Final market image equivalent in performance to phase 3  locked/documented": "ex:QualityAttribute_final_market_image_e_681f3069",
  "QualityAttribute:SM:8:Final product design space completed/documented documented in CA including for desired solid state.": "ex:QualityAttribute_final_product_design_15f31be0",
  "QualityAttribute:SM:8:Final \u00a0CMC TPP": "ex:QualityAttribute_final_cmc_tpp_7ac8e6c2",
  "QualityAttribute:SM:8:First good draft of dossier centric reports": "ex:QualityAttribute_first_good_draft_of_80137764",
  "QualityAttribute:SM:8:For registration/commercial, Excipient characterized, spec's justified and approved, supplier qualified, supplier spec alignment": "ex:QualityAttribute_for_registration_com_ea22c20f",
  "QualityAttribute:SM:8:For registration/commercial, Packaging characterized and specifications justified and approved, supplier approved": "ex:QualityAttribute_for_registration_com_b94a3902",
  "QualityAttribute:SM:8:Formulation Development report completed and approved including all technical documents supporting the CA approved": "ex:QualityAttribute_formulation_developm_1a37d418",
  "QualityAttribute:SM:8:Further IP assessment on product and process": "ex:QualityAttribute_further_ip_assessmen_d96fe30b",
  "QualityAttribute:SM:8:Further development for surrogate model for Disso in line with QC method": "ex:QualityAttribute_further_development_38089105",
  "QualityAttribute:SM:8:If changes occur within final process, is change process and potential impacts well considered, and are appropriate studies front loaded to derisk. Also is comparability/clinical considerations well considered": "ex:QualityAttribute_if_changes_occur_wit_04eef6fe",
  "QualityAttribute:SM:8:Impact of CPP's, CMA's and environment normal, short-term variation on API quality, manufacturability and stability confirmed at pilot scale including for solid state": "ex:QualityAttribute_impact_of_cpp_s_cma_5122e86d",
  "QualityAttribute:SM:8:Implement and qualify suitable manufacturing controls for registration campaign:\n*Incoming and release tests  \n*in process control/inspection": "ex:QualityAttribute_implement_and_qualif_9f6f6f32",
  "QualityAttribute:SM:8:Incorporate model-based process control in control strategy in line with BPAL strategy": "ex:QualityAttribute_incorporate_model_ba_36aa4e3a",
  "QualityAttribute:SM:8:Initiate PAI readiness": "ex:QualityAttribute_initiate_pai_readine_c3ec7c0e",
  "QualityAttribute:SM:8:Initiate authoring CTD sections, execute gap assessment.": "ex:QualityAttribute_initiate_authoring_c_27c1534a",
  "QualityAttribute:SM:8:Initiate system and financial flow set-up": "ex:QualityAttribute_initiate_system_and_05cb04f8",
  "QualityAttribute:SM:8:Initiating development studies to support commercial specification strategy e.g. boundary batches, edge of failure studies": "ex:QualityAttribute_initiating_developme_b2ff67fa",
  "QualityAttribute:SM:8:Integrated line performance evaluation @ registration site": "ex:QualityAttribute_integrated_line_perf_cd2c9b70",
  "QualityAttribute:SM:8:Investigate options for IP protection [DPD]": "ex:QualityAttribute_investigate_options_852c149e",
  "QualityAttribute:SM:8:Issue specifications for registration & update comm specification strategy": "ex:QualityAttribute_issue_specifications_487b4bf6",
  "QualityAttribute:SM:8:Issue specifications for registration & update comm specification strategy (e.g. JOS, boundary batches)": "ex:QualityAttribute_issue_specifications_3adfff4f",
  "QualityAttribute:SM:8:Late Development \u2013 DP lock: Initiate Elemental Impurity Risk Assessment (ICH Q3D)": "ex:QualityAttribute_late_development_dp_572f160e",
  "QualityAttribute:SM:8:Locked and validated intended commercial analytical methods for API including solid state when CQA.": "ex:QualityAttribute_locked_and_validated_69ac7ba1",
  "QualityAttribute:SM:8:Locked and validated intended commercial analytical methods for DP and  for solid state when CQA": "ex:QualityAttribute_locked_and_validated_f5fb0c5e",
  "QualityAttribute:SM:8:Material rationale updated including risk mitigation plan in case regulatory starting materials (SM) not accepted.": "ex:QualityAttribute_material_rationale_u_2262a916",
  "QualityAttribute:SM:8:Mfg registration campaign: protocol and report": "ex:QualityAttribute_mfg_registration_cam_2343e2d3",
  "QualityAttribute:SM:8:Mfg site ready for registration batches": "ex:QualityAttribute_mfg_site_ready_for_r_cccf6ba4",
  "QualityAttribute:SM:8:Multivariate boundaries for CPP's, CMA's and environmental conditions incl. campaigning, material ageing and process stress effects at pilot scale": "ex:QualityAttribute_multivariate_boundar_e6e5a54e",
  "QualityAttribute:SM:8:NDA/MAA forced degradation studies": "ex:QualityAttribute_nda_maa_forced_degra_50a8b817",
  "QualityAttribute:SM:8:Optimized, representative mfg process locked and documented preferably in accordance with decision tree process flow and matrix table.": "ex:QualityAttribute_optimized_representa_4aeaff8c",
  "QualityAttribute:SM:8:PAT method development/validation (inc orchestrations) and follow up of transfer and registration batches with PAT if defined in RTRt strategy": "ex:QualityAttribute_pat_method_developme_874521a5",
  "QualityAttribute:SM:8:PMI calculation of the process (in house steps) using ACS GCIPR and DfE meeting, as applicable": "ex:QualityAttribute_pmi_calculation_of_t_f10bd8c5",
  "QualityAttribute:SM:8:Plan for execution registration batches approved": "ex:QualityAttribute_plan_for_execution_r_afb59730",
  "QualityAttribute:SM:8:Prefinal control strategy based upon updated Criticality analysis  report, including guaranteeing solid state at release, across shelf life, and in-use": "ex:QualityAttribute_prefinal_control_str_45bb4427",
  "QualityAttribute:SM:8:Process Design space defined at registration scale": "ex:QualityAttribute_process_design_space_f6470d5a",
  "QualityAttribute:SM:8:Process and Materials Design space defined at representative scale including for solid state. Scale of registration and validation batches defined.": "ex:QualityAttribute_process_and_material_01640c25",
  "QualityAttribute:SM:8:Process characterization at registration scale completed": "ex:QualityAttribute_process_characteriza_9e184d66",
  "QualityAttribute:SM:8:Process optimized in robustness, manufacturability and COGS; Review and align at Robust Design Focus Area (RDFA) #2.": "ex:QualityAttribute_process_optimized_in_53bfcf5a",
  "QualityAttribute:SM:8:Process validation strategy (PPQ) available based on current CA and available experimental data (number of batches, batch size, equipment train, API/SM/IM sources, etc)": "ex:QualityAttribute_process_validation_s_e7b8e5d9",
  "QualityAttribute:SM:8:Process validation strategy (PPQ) based on available CA and experiments/datasets": "ex:QualityAttribute_process_validation_s_3c0c7081",
  "QualityAttribute:SM:8:Product well characterized incl solid state and confirmed to be equivalent to phase 3 (Comparability Report)": "ex:QualityAttribute_product_well_charact_0dee0a2c",
  "QualityAttribute:SM:8:Project timelines, scope and resources updated in line with current assumptions": "ex:QualityAttribute_project_timelines_sc_0bf485e5",
  "QualityAttribute:SM:8:Quality Agreements / Site qualification completed for commercial use for RSM, GMP INT,  API  & DP manufacturing": "ex:QualityAttribute_quality_agreements_s_f3cc9944",
  "QualityAttribute:SM:8:RTD- or PAT-based control strategy representative for commercial in line with BPAL strategy": "ex:QualityAttribute_rtd_or_pat_based_con_fb398420",
  "QualityAttribute:SM:8:Re-assess IP strategy (FTO, possibility to expand patent estate)": "ex:QualityAttribute_re_assess_ip_strateg_9e0587ef",
  "QualityAttribute:SM:8:Real-time in-process test on factors showing substantial variation and impact on CQA's  incorporated where relevant in control strategy": "ex:QualityAttribute_real_time_in_process_9ca13a7d",
  "QualityAttribute:SM:8:Registration batches  similar/equivalent to the Phase 3 clinical batches and its mfg process/critical materials": "ex:QualityAttribute_registration_batches_aa2522f1",
  "QualityAttribute:SM:8:Registration manufacturing process qualified and CTQs finalized; if required commercial manufacturing lines installed for the following:\n*Subassembly\n*Final assembly\n*Packaging": "ex:QualityAttribute_registration_manufac_1b7986b8",
  "QualityAttribute:SM:8:Registration protocols written": "ex:QualityAttribute_registration_protoco_1db60020",
  "QualityAttribute:SM:8:Registration samples to support local submissions: Country specific needs identified.": "ex:QualityAttribute_registration_samples_4e41de14",
  "QualityAttribute:SM:8:Review and update User Description, User Requirement, Technical Design Requirement documents for Commercial design based on Phase 3, HF studies, and other learnings": "ex:QualityAttribute_review_and_update_us_4aadbabe",
  "QualityAttribute:SM:8:Review and update regulatory strategy document, including QbD elements for the MAA/NDA, and including regulatory risk assessment and mitigation strategy, planned HA meetings (e.g., emphasis on agreement for starting materials, proposed commercial QC dissolution method, other key issues requiring input prior to registration), key outcomes of any HA meetings completed, global submission strategy (from GRT), overview of any Q&A from HA in Phase 1, Phase 2 and Phase 3 IND/CTA": "ex:QualityAttribute_review_and_update_re_54dc4f55",
  "QualityAttribute:SM:8:Review existing PRA applicable to product category and verify if additional risk has to be considered/added.\nReview PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_existing_pra_50c037d1",
  "QualityAttribute:SM:8:Review of Phase 3 trials (completed/ongoing):\n*trending and mitigation of device clinical complaints (device and usability related)\n*Identify any new/unique user requirements (i.e., PK, usability, etc) and update User Description and User Requirement documents when appropriate\n*Evaluate impact of these learnings and identify required activities for phase 3 and commercial design": "ex:QualityAttribute_review_of_phase_3_tr_0aec05cf",
  "QualityAttribute:SM:8:Review of completed phase 3 mfg campaigns:\n*trending and mitigation of manufacturing issues\n*Identify any new/unique manufacturing requirements and update manufacturing equipment requirement documents for registration/commercial when appropirate\n*Evaluate impact of these learnings and identify required activities for registration/commercial manufacturing process": "ex:QualityAttribute_review_of_completed_e28dd37d",
  "QualityAttribute:SM:8:RiBPS and Accelerated Physical and chemical stability  studies performed on final commercial representative product , Packaging simulation to define final packaging configurations.": "ex:QualityAttribute_ribps_and_accelerate_7d5795a9",
  "QualityAttribute:SM:8:Risk Mitigation plans completed in preparation of registration batches": "ex:QualityAttribute_risk_mitigation_plan_bba675e7",
  "QualityAttribute:SM:8:Safety gap analysis conducted": "ex:QualityAttribute_safety_gap_analysis_49dbfde0",
  "QualityAttribute:SM:8:Safety sanity check (R-Check) completed": "ex:QualityAttribute_safety_sanity_check_c0cd6a57",
  "QualityAttribute:SM:8:Scale-up effects evaluated based on previous review Phase 2-3 batches and documented": "ex:QualityAttribute_scale_up_effects_eva_e52e0df2",
  "QualityAttribute:SM:8:Stability storage statement requirements updated if appropriate": "ex:QualityAttribute_stability_storage_st_719402e6",
  "QualityAttribute:SM:8:Stability storage statement updated if appropriate": "ex:QualityAttribute_stability_storage_st_7534443e",
  "QualityAttribute:SM:8:Stage gate approval form": "ex:QualityAttribute_stage_gate_approval_22ca254c",
  "QualityAttribute:SM:8:Start batch information report (BIR)": "ex:QualityAttribute_start_batch_informat_a2385c4a",
  "QualityAttribute:SM:8:Starting materials, raw materials, intermediates and final packaging defined and documented": "ex:QualityAttribute_starting_materials_r_edee4390",
  "QualityAttribute:SM:8:Starting materials/raw materials/intermediates stability initiated (protocol)": "ex:QualityAttribute_starting_materials_r_93e8950c",
  "QualityAttribute:SM:8:Supplier qualification for SM/RM starting materials/raw materials for INT and API and excipients and packaging materials for DP for commercial use completed": "ex:QualityAttribute_supplier_qualificati_906428ff",
  "QualityAttribute:SM:8:TT Plan updated and documented": "ex:QualityAttribute_tt_plan_updated_and_f8b6361f",
  "QualityAttribute:SM:8:TT strategy and site readiness plan available": "ex:QualityAttribute_tt_strategy_and_site_87d4bcf0",
  "QualityAttribute:SM:8:Tech reports in place for formulation and process development": "ex:QualityAttribute_tech_reports_in_plac_18ffac30",
  "QualityAttribute:SM:8:Transfer NDA/MAA methods to applicable sites": "ex:QualityAttribute_transfer_nda_maa_met_155c5c59",
  "QualityAttribute:SM:8:Transfer cleaning methods to applicable sites": "ex:QualityAttribute_transfer_cleaning_me_6591adcc",
  "QualityAttribute:SM:8:Transfer commercial API methods incl cleaning methods to applicable sites": "ex:QualityAttribute_transfer_commercial_c0166b50",
  "QualityAttribute:SM:8:Update PQV Data Governance Sharepoint (if needed)": "ex:QualityAttribute_update_pqv_data_gove_f2bbbb76",
  "QualityAttribute:SM:8:Update Process fit to plant (PF2P) incl. Safety gap analysis conducted by the Manufacturing/Packaging sites.": "ex:QualityAttribute_update_process_fit_t_3b52b4cc",
  "QualityAttribute:SM:8:Update nitrosamine risk assessment if changes were made to the process - NRER v2 available; Review and align at Product Compliance Focus Area.": "ex:QualityAttribute_update_nitrosamine_r_95356444",
  "QualityAttribute:SM:8:Update specifications  for starting materials/raw materials/intermediates if required": "ex:QualityAttribute_update_specification_f624c5aa",
  "QualityAttribute:SM:8:Update strategy for RTRt": "ex:QualityAttribute_update_strategy_for_02725194",
  "QualityAttribute:SM:8:Update the nitrosamine risk assessment including assessment on selected primary packaging and device; Review and align at Product Compliance Focus Area.": "ex:QualityAttribute_update_the_nitrosami_42d159f6",
  "QualityAttribute:SM:8:Update/qualify methods for starting materials/raw materials/intermediates if required": "ex:QualityAttribute_update_qualify_metho_7604d39b",
  "QualityAttribute:SM:8:Updated Criticality analysis interim report : final list of CPPs/CMAs and prefinal control strategy\nCA approved prior to release of DP registration batches.": "ex:QualityAttribute_updated_criticality_c2430fb9",
  "QualityAttribute:SM:8:Verify External Contract Labs sourced through the EMs are qualified through EMs": "ex:QualityAttribute_verify_external_cont_c68eb81e",
  "QualityAttribute:SM:8:Verify Starting Material Suppliers sourced through the EMs are qualified through EMs": "ex:QualityAttribute_verify_starting_mate_da5cc089",
  "QualityAttribute:SM:8:Where relevant and feasible incorporate model-based process control in control strategy": "ex:QualityAttribute_where_relevant_and_f_23e2b0b3",
  "QualityAttribute:SM:8:Widened in-use procedure, yet equivalent in performance to phase 3, completed/documented": "ex:QualityAttribute_widened_in_use_proce_4eb270bb",
  "QualityAttribute:SM:8:update Regulated Substance plan and RS Report (if applicable)": "ex:QualityAttribute_update_regulated_sub_d09168b2",
  "QualityAttribute:SM:9:API CQA's defined/documented": "ex:QualityAttribute_api_cqa_s_defined_do_df3ee497",
  "QualityAttribute:SM:9:API Sourcing final SWOT delivered, based on final BOM": "ex:QualityAttribute_api_sourcing_final_s_daf9d1ef",
  "QualityAttribute:SM:9:API comparability report bw final process and Phase 3 process [P&MS, AD]": "ex:QualityAttribute_api_comparability_re_b23a812f",
  "QualityAttribute:SM:9:API control strategy for PV batches lock/documented including for solid state [API/AD/P&MS]": "ex:QualityAttribute_api_control_strategy_eac3859b",
  "QualityAttribute:SM:9:API process critical steps defined/documented": "ex:QualityAttribute_api_process_critical_8c6e3055",
  "QualityAttribute:SM:9:API solid state characterized at release and stability including polymorphic purity  [AD, P&MS]": "ex:QualityAttribute_api_solid_state_char_89204093",
  "QualityAttribute:SM:9:API synthesis CA done/documented": "ex:QualityAttribute_api_synthesis_ca_don_8e44b0c3",
  "QualityAttribute:SM:9:Advanced controls (PAT open-loop controls or PAT model-based controls)  where needed or useful. Controls shifted upstream": "ex:QualityAttribute_advanced_controls_pa_2ec60652",
  "QualityAttribute:SM:9:Align funding for any post launch optimization (JSC or R&D).": "ex:QualityAttribute_align_funding_for_an_7421b6d3",
  "QualityAttribute:SM:9:Analytical test methods for SM transferred to suppliers": "ex:QualityAttribute_analytical_test_meth_a2f5c99b",
  "QualityAttribute:SM:9:Approved final control strategy documented and derived from CA, including final control strategy to guarantee for solid state at release, across shelf-life, and in-use [DPD/AD/P&MS]": "ex:QualityAttribute_approved_final_contr_b458c254",
  "QualityAttribute:SM:9:Assessment of characterization data including edge of failure/boundary batches": "ex:QualityAttribute_assessment_of_charac_67cd1db4",
  "QualityAttribute:SM:9:Assessment of release data for specification setting and determine process capabilities in support of PAR/NOR including statistical assessment": "ex:QualityAttribute_assessment_of_releas_45d40527",
  "QualityAttribute:SM:9:Assessment of stability trends including statistical assessment": "ex:QualityAttribute_assessment_of_stabil_22c82de1",
  "QualityAttribute:SM:9:At risk inventory build approved and production planned as applicable.": "ex:QualityAttribute_at_risk_inventory_bu_35786133",
  "QualityAttribute:SM:9:BPAL assessment of formulation and process at PPQ readiness (if PPQ batches vary significantly from DP Registration batches)": "ex:QualityAttribute_bpal_assessment_of_f_db58dd2a",
  "QualityAttribute:SM:9:Biopharmaceutical testing: DP from full scale process /final site equivalent with reg./Ph3 batches through in-vitro and BE study (if in-vitro is not sufficient)": "ex:QualityAttribute_biopharmaceutical_te_2f3cd35a",
  "QualityAttribute:SM:9:Biorelevant assessment of proposed methods, e.g. dissolution, IVIVC": "ex:QualityAttribute_biorelevant_assessme_d84b763d",
  "QualityAttribute:SM:9:Blinding strategy confirmed, based on clinical development plan (placebo need & timing; options for blinding eg overencapsulation, matching (coated) placebo formulation, packaging design,...)": "ex:QualityAttribute_blinding_strategy_co_cd7e63af",
  "QualityAttribute:SM:9:Brand protection features implemented in prim packaging if required (Pack&Device)": "ex:QualityAttribute_brand_protection_fea_b9c90e81",
  "QualityAttribute:SM:9:Build  link product/process/materials with in-vivo (after scale up to final scale):\n*Further refinements to PBBM model and any hypotheses (in line with anticipated use in regulatory submission)\n*Final specs ( disso,  API PSD in drug product\u2026) proposed based upon pivotal clinical batches and from the relative hBA studies, IVIVC model or PBBM model, and statistical evaluation of QC release and stability disso profiles with failure rate determination for potential specification time points\n*Final design space, NOR/and PARs including process / materials control strategy, derived from the conducted in-vivo performance, and clinical relevant dissolution testing and specs\n*Document critical bioavailabilty attributes = API properties, CMA's or CPP's having shown effect on release profile and in vivo (ir)relevance (incl. stats)\n*After scale-up, select optimal CQA specs for filing and justify\n*Define the risk of not performing Clinical Relevant Controls related activities": "ex:QualityAttribute_build_link_product_p_a717e037",
  "QualityAttribute:SM:9:Bulk hold time/storage and transportation studies documented (Pack & Device)": "ex:QualityAttribute_bulk_hold_time_stora_4e6e2651",
  "QualityAttribute:SM:9:CMC Memo for Design Control Stage 3": "ex:QualityAttribute_cmc_memo_for_design_430f6f22",
  "QualityAttribute:SM:9:COG's locked (SM)": "ex:QualityAttribute_cog_s_locked_sm_9894f332",
  "QualityAttribute:SM:9:CPP and CMA defined for full scale validation batches based on scalability knowledge": "ex:QualityAttribute_cpp_and_cma_defined_d93ea19d",
  "QualityAttribute:SM:9:Causality and scientific mechanism how CPP/CMA affect DP quality, manufacturability and stability at full scale known and documented in the process characterization/development reports": "ex:QualityAttribute_causality_and_scient_28bda5b0",
  "QualityAttribute:SM:9:Check readiness of control strategy in support of process validation (PPQ) at manufacturing site (e.g. PAT tools installed and qualified)": "ex:QualityAttribute_check_readiness_of_c_149529ea",
  "QualityAttribute:SM:9:Check readiness of control strategy in support of process validation at manufacturing site (e.g. PAT tools installed and qualified)": "ex:QualityAttribute_check_readiness_of_c_cb8468cf",
  "QualityAttribute:SM:9:Cleaning method assessment": "ex:QualityAttribute_cleaning_method_asse_6b40c485",
  "QualityAttribute:SM:9:Comm. API process confirmed in view of full scale validation batches": "ex:QualityAttribute_comm_api_process_con_6cc82533",
  "QualityAttribute:SM:9:Comm. Product equivalent with Ph3 and registration batches": "ex:QualityAttribute_comm_product_equival_32029e18",
  "QualityAttribute:SM:9:Commercial RTD- or PAT-based control strategy": "ex:QualityAttribute_commercial_rtd_or_pa_0151bc72",
  "QualityAttribute:SM:9:Commercial manufacturing process (if different from registration) qualified and CTQ flowdown completed for the following:\n*Molding\n*Subassembly\n*Final assembly\n*Packaging": "ex:QualityAttribute_commercial_manufactu_18d30e7f",
  "QualityAttribute:SM:9:Commercialisation Readiness Checklist": "ex:QualityAttribute_commercialisation_re_2a22c663",
  "QualityAttribute:SM:9:Complete CMC Team review of the following DRAFT key dossier-centric reports to support MA dossier authoring: Synthesis Criticality Analysis Report, DP Criticality Analysis Report, and API PAR Justification Report": "ex:QualityAttribute_complete_cmc_team_re_9dc8250f",
  "QualityAttribute:SM:9:Complete Design Validation (summative human factor) activities using registration batch supplies": "ex:QualityAttribute_complete_design_vali_5bc816d9",
  "QualityAttribute:SM:9:Complete Design Verification (device bench testing) protocl and report (based on registration batches)": "ex:QualityAttribute_complete_design_veri_e07c1a2a",
  "QualityAttribute:SM:9:Complete Elemental Impurity Risk Assessment Report and Summary (together with final specification setting for the DP)": "ex:QualityAttribute_complete_elemental_i_10d960ba",
  "QualityAttribute:SM:9:Complete distribution risk assessment (API/DP/FG shipping lanes); ensure alignment to stabilty data;  finalize/align transportation channel /shipping routes and shipping protection": "ex:QualityAttribute_complete_distributio_3d6bb9fd",
  "QualityAttribute:SM:9:Complete or revisit Complexity Assessment Form with team.  Create or revise (if necessary) complexity assessment decision.  Create or revise uFMEA for commercial product, if needed.  Complete HF studies, if needed.": "ex:QualityAttribute_complete_or_revisit_34427d8d",
  "QualityAttribute:SM:9:Complete registration batch tech transfer report for combination product": "ex:QualityAttribute_complete_registratio_1a0093ad",
  "QualityAttribute:SM:9:Complete temperature excursion studies": "ex:QualityAttribute_complete_temperature_b61f218d",
  "QualityAttribute:SM:9:Contact Procurement to establish a contract with the Notified Body and execute contract 2 months before submission of technical package for review.  Create and submit the technical dossier for review and opinion by the Notified Body.  Note that NBOp is a deliverable for the MAA; plan for 6-8M for preparation, review, and receipt of opinion.": "ex:QualityAttribute_contact_procurement_7db3c0ad",
  "QualityAttribute:SM:9:Continue PAI readiness": "ex:QualityAttribute_continue_pai_readine_2fef329f",
  "QualityAttribute:SM:9:Continue authoring CTD sections, executing gap assessment": "ex:QualityAttribute_continue_authoring_c_786928ac",
  "QualityAttribute:SM:9:Control strategy (set of defined, existing documents) for validation batch purpose based on final CA. Final CA report approved for the execution of validation batches": "ex:QualityAttribute_control_strategy_set_430dded1",
  "QualityAttribute:SM:9:Create and complete the device technical dossier for review and opinion by Notified Body, as applicable": "ex:QualityAttribute_create_and_complete_fc9f26eb",
  "QualityAttribute:SM:9:Cross functional Risk register completed and mitigation plan developed, also highlighting the gaps and any mitigations with respect to key deliverables": "ex:QualityAttribute_cross_functional_ris_3bab6e92",
  "QualityAttribute:SM:9:Customer Centered Design deliverables completed for this stage.": "ex:QualityAttribute_customer_centered_de_a47f8f87",
  "QualityAttribute:SM:9:DOE/Edge of Failure study reports for key commercial manufacturing steps/measurements": "ex:QualityAttribute_doe_edge_of_failure_04b9ff00",
  "QualityAttribute:SM:9:DP composition, design space, characterization and statistical justification  documented in the process characterization report or formulation development report (FDR)": "ex:QualityAttribute_dp_composition_desig_a461be4f",
  "QualityAttribute:SM:9:DP solid state characterized at release and stability including polymorphic purity using sensitive methods": "ex:QualityAttribute_dp_solid_state_chara_365413d7",
  "QualityAttribute:SM:9:Define WW registration Strategy and Sample Requirements": "ex:QualityAttribute_define_ww_registrati_21b44dcb",
  "QualityAttribute:SM:9:Design Control:\n*Design and Development Plan  (Update)\n*Manufacturing Strategy and Design Transfer Plan (update)\n*Human Factors Plan (Update)\n*Complaint Handling Plan (Update)\n*Final Labeling/IFU (Update)\n*Stability/Ageing Studies\n*Design Validation Protocols, Reports & Summary Report\n*Completed Design Transfer Checklist (s)\n*Process Performance Qualification Protocols and  Reports\n*Traceability Matrix Template (Finalize)\n*Final Design Verification Report\n*Human Factors Summary Report\n*In-use Reliability Testing Report \n*Software Validation (if applicable)\n*Device Master Record (DMR) (Update)\n*Design History File (Update)\n*Clinical/Regulatory Submission Support (Initiate)": "ex:QualityAttribute_design_control_desig_1a61fabd",
  "QualityAttribute:SM:9:Design Validation and Process Validation Stage Design Review": "ex:QualityAttribute_design_validation_an_d5c82580",
  "QualityAttribute:SM:9:Development Summary Report available": "ex:QualityAttribute_development_summary_bab6127c",
  "QualityAttribute:SM:9:Device Risk Management  (Update):\n*Risk Management Plan (Update)\n*Product Risk Assessment/Hazard ID (Update)\n*uFMEA (Update)\n*CTQ Flow Down (Update)\n*Device Control Strategy (Review and Update)\n*dFMEA (Update)\n*pFMEA (Update)\n*Risk Management Report (Update)\n*Post market product management plan (if applicable)": "ex:QualityAttribute_device_risk_manageme_8d636707",
  "QualityAttribute:SM:9:Draft Dissolution method development report": "ex:QualityAttribute_draft_dissolution_me_3e0a681d",
  "QualityAttribute:SM:9:Draft NDA/MAA Justification of Specifications document": "ex:QualityAttribute_draft_nda_maa_justif_b1df3bf8",
  "QualityAttribute:SM:9:Draft Specification justification report, including nitrosamine control strategy if applicable. DP confirmatory testing performed if applicable": "ex:QualityAttribute_draft_specification_aaa96966",
  "QualityAttribute:SM:9:Draft specification justification report (incl. scientifically justified specifications)": "ex:QualityAttribute_draft_specification_65102b70",
  "QualityAttribute:SM:9:EHS Requirement: Chemical registration in place and approved in line with launch strategy and final review of substances of concern used in the manufacturing process": "ex:QualityAttribute_ehs_requirement_chem_2fbddf49",
  "QualityAttribute:SM:9:EHS Requirement: initiate IH sampling method for API": "ex:QualityAttribute_ehs_requirement_init_32b5ab48",
  "QualityAttribute:SM:9:Elemental impurities assessment complete (criticality analysis and control strategy final)": "ex:QualityAttribute_elemental_impurities_a65dd354",
  "QualityAttribute:SM:9:End-to-end control strategy reviewed and if required updated": "ex:QualityAttribute_end_to_end_control_s_f0064466",
  "QualityAttribute:SM:9:Ensure Launch supplies for pre-approval programs (ATU, NPP, EAP) are in place": "ex:QualityAttribute_ensure_launch_suppli_566cb199",
  "QualityAttribute:SM:9:Ensure PPQ Readiness: \n*DS/DP Registration campaign at commercial site completed, tested and reported\n*Scale up activities at commercial site completed\n*Final Validation strategy available\n*Commercial manufacturing and control infrastructure installed and qualified \n*Cleaning validation completed or plan in place utilizing PPQ batch campaign": "ex:QualityAttribute_ensure_ppq_readiness_063c4060",
  "QualityAttribute:SM:9:Ensure manufacturing and packaging site readiness, including capital execution": "ex:QualityAttribute_ensure_manufacturing_83ff43a4",
  "QualityAttribute:SM:9:Excipient variability: impact evaluation in terms of product quality, RTD, and PAT": "ex:QualityAttribute_excipient_variabilit_f35a0467",
  "QualityAttribute:SM:9:Final CA report approved before the execution of PPQ batches": "ex:QualityAttribute_final_ca_report_appr_e009a69d",
  "QualityAttribute:SM:9:Final methods for DP validated and transferred to mfg & test sites": "ex:QualityAttribute_final_methods_for_dp_fa58c0e0",
  "QualityAttribute:SM:9:Final methods for SM/INT/API validated and transferred to mfg & test sites": "ex:QualityAttribute_final_methods_for_sm_20bd681b",
  "QualityAttribute:SM:9:Final process design space (CPPs, CMAs) including for solid state approved/documented at comm scale and final site": "ex:QualityAttribute_final_process_design_cad254ed",
  "QualityAttribute:SM:9:Final selection of regulatory/inhouse parameters based on required control strategies based on cross functional risk assessment. Explanation of key test parameters not required": "ex:QualityAttribute_final_selection_of_r_12249634",
  "QualityAttribute:SM:9:Finalize DP NDA/MAA specifications for start of validation campaign (confirmation of commercail specification limits at stage gate 9C)": "ex:QualityAttribute_finalize_dp_nda_maa_3ffbba23",
  "QualityAttribute:SM:9:Finalize SM/INT/API NDA/MAA specifications for start of validation campaign (confirmation of commercial specification limits at stage gate 9C)": "ex:QualityAttribute_finalize_sm_int_api_4cdd84e7",
  "QualityAttribute:SM:9:Finalize current BOM (includes all materials next to SM, INT, API) to AS + QI": "ex:QualityAttribute_finalize_current_bom_a33c1249",
  "QualityAttribute:SM:9:Further Development for surrogate model for Disso and model lock when Disso method is locked if defined in the RTRt strategy": "ex:QualityAttribute_further_development_a6c0aaf5",
  "QualityAttribute:SM:9:GMP-Risk Score attributed for all excipients in material risk assessment report": "ex:QualityAttribute_gmp_risk_score_attri_bb2cd0cd",
  "QualityAttribute:SM:9:Health Authority Communication": "ex:QualityAttribute_health_authority_com_9be12da3",
  "QualityAttribute:SM:9:High level commercial launch strategy initiated; Complete Launch Inventory/Capacity FPO deliverables (launch volume defined, pre-approval demand defined, agreements on safety stock in place)": "ex:QualityAttribute_high_level_commercia_61f019a0",
  "QualityAttribute:SM:9:Identify Notified Body for EU device review, initiate conversations with Notified Body.": "ex:QualityAttribute_identify_notified_bo_4d1a142f",
  "QualityAttribute:SM:9:Identify Notified Body for EU device review, initiate conversations with Notified Body. Contact Procurement to establish a contract with the Notified Body and execute contract 2 months before submission of technical package for review.  Create and submit the technical dossier for review and opinion by the Notified Body.  Note that NBOp is a deliverable for the MAA; plan for 6-8M for preparation, review, and receipt of opinion. [newly added per Device regulatory request Nov 16,2020]": "ex:QualityAttribute_identify_notified_bo_e244354e",
  "QualityAttribute:SM:9:Impact of CPP's, CMA's and environment normal, short-term variation on API quality, manufacturability and stability confirmed at full scale": "ex:QualityAttribute_impact_of_cpp_s_cma_7f19c9ed",
  "QualityAttribute:SM:9:Impact of CPP's, CMA's and environment normal, short-term variation on DP quality, manufacturability and stability at representative scale documented including for solid state": "ex:QualityAttribute_impact_of_cpp_s_cma_ce3e8af6",
  "QualityAttribute:SM:9:Implement suitable manufacturing controls for PPQ/commercial campaign:\n*Incoming and release tests\n*in process control/inspection": "ex:QualityAttribute_implement_suitable_m_66da08c0",
  "QualityAttribute:SM:9:Impurity Mgmt report 4 approved and in line with the Global Impurity Mgmt Policy (incl. impurities qualified and documented in Tox memo, as well as the nitrosamine risk assessment and NRER available)": "ex:QualityAttribute_impurity_mgmt_report_80041909",
  "QualityAttribute:SM:9:Initiate stability protocol on validation (PPQ) batches": "ex:QualityAttribute_initiate_stability_p_821833b0",
  "QualityAttribute:SM:9:Initiate storage statement for SM, INt as applicable": "ex:QualityAttribute_initiate_storage_sta_2f23149e",
  "QualityAttribute:SM:9:Investigate options for IP protection [DPD]": "ex:QualityAttribute_investigate_options_7b5a7463",
  "QualityAttribute:SM:9:Material selection documented. Material supplier selection, qualification and justification documented in Supplier/Material Qualification Report (commonly referred to as the Material Qualification Report [MQR])": "ex:QualityAttribute_material_selection_d_1eca5e86",
  "QualityAttribute:SM:9:Material specifications, characterization and statistical justification, if applicable, documented": "ex:QualityAttribute_material_specificati_85cf3eab",
  "QualityAttribute:SM:9:Method comparison report (if appropriate)": "ex:QualityAttribute_method_comparison_re_d9441104",
  "QualityAttribute:SM:9:Mfg process incl. all unit operations and related equipment characterized at full scale & locked/documented, preferably in line with decision tree and matrix table  (DPD)": "ex:QualityAttribute_mfg_process_incl_all_01e533cb",
  "QualityAttribute:SM:9:Multivariate boundaries for CPPs, CMAs, and environmental conditions including campaigning, material aging, and process effects at pilot scale": "ex:QualityAttribute_multivariate_boundar_22b1a837",
  "QualityAttribute:SM:9:Optimal operating settings and multivariate boundaries for CPP's and CMA's confirmed for full scale validation batches": "ex:QualityAttribute_optimal_operating_se_03b8416c",
  "QualityAttribute:SM:9:Optimal operating settings defined and documented (optimization DOEs)": "ex:QualityAttribute_optimal_operating_se_6bb2aae9",
  "QualityAttribute:SM:9:PMI calculation of the final process (in house steps) using ACS GCIPR guidance": "ex:QualityAttribute_pmi_calculation_of_t_c6d9b451",
  "QualityAttribute:SM:9:PPQ (stage 2) protocol ready and in line with respective Health Authority guidance. PPQ sampling plan ready, based on the approved pre-PPQ statistical reports.": "ex:QualityAttribute_ppq_stage_2_protocol_95db22e9",
  "QualityAttribute:SM:9:PPQreadiness checklist completed": "ex:QualityAttribute_ppqreadiness_checkli_8d910e50",
  "QualityAttribute:SM:9:Proactively and informally track Robustness Index Dashboard metrics": "ex:QualityAttribute_proactively_and_info_9fd0c6d9",
  "QualityAttribute:SM:9:Process Design space defined at commercial scale": "ex:QualityAttribute_process_design_space_53165111",
  "QualityAttribute:SM:9:Process/Materials design space at full scale defined": "ex:QualityAttribute_process_materials_de_9741159b",
  "QualityAttribute:SM:9:Project timelines, scope and resources updated in line with current assumptions": "ex:QualityAttribute_project_timelines_sc_7631df16",
  "QualityAttribute:SM:9:Proven Acceptable Ranges defined/documented and robustness experiments (DOE) finalized including for solid state": "ex:QualityAttribute_proven_acceptable_ra_9f50a641",
  "QualityAttribute:SM:9:QbD method deliverables available, e.g. Gage R&R, analytical inter-lab variability": "ex:QualityAttribute_qbd_method_deliverab_e68ff02e",
  "QualityAttribute:SM:9:Quality Agreements  / Site qualification completed for commercial use for RSM, GMP INT,  API  & DP manufacturing (if new/additional supplier)": "ex:QualityAttribute_quality_agreements_s_e7ef1fac",
  "QualityAttribute:SM:9:Real-time in-process test on factors showing substantial variation and impact on CQA's  incorporated where relevant in control strategy": "ex:QualityAttribute_real_time_in_process_dc190ba6",
  "QualityAttribute:SM:9:Refresh COGS and GP for launch/steady state updated, incl assumptions documented": "ex:QualityAttribute_refresh_cogs_and_gp_084fec96",
  "QualityAttribute:SM:9:Release and stability testing sites qualified and if applicbale, capable to enter data into J&J eLIMS.": "ex:QualityAttribute_release_and_stabilit_993fee02",
  "QualityAttribute:SM:9:Review and update regulatory strategy document, including QbD elements for the MAA/NDA, and including regulatory risk assessment and mitigation strategy, planned HA meetings (e.g., emphasis on agreement for starting materials, proposed commercial QC dissolution method, other key issues requiring input prior to registration), key outcomes of any HA meetings completed, global submission strategy (from GRT), overview of any Q&A from HA in Phase 1, Phase 2 and Phase 3 IND/CTA": "ex:QualityAttribute_review_and_update_re_d6f5d415",
  "QualityAttribute:SM:9:Review existing PRA applicable to product category and verify if additional risk has to be considered/added.\nReview PRM Plan/Report, update if additional risk management activities are completed/known": "ex:QualityAttribute_review_existing_pra_a91940b8",
  "QualityAttribute:SM:9:Review final proposal for SM, INT, API and DP commercial specifications for filing taking the following deliverables into account;": "ex:QualityAttribute_review_final_proposa_6e7244db",
  "QualityAttribute:SM:9:Review final release and shelf life specifications and related documented evidence (justification, supporting data, white papers, stability data, statistical analysis, tox qualification, risk assessment)": "ex:QualityAttribute_review_final_release_abac0ae8",
  "QualityAttribute:SM:9:Review of registration campaigns:\n*Treading and mitigation of manufacturing issues\n*Identify any new/unique manufacturing/testing requirements and update manufacturing requirement documents for commercial when appropriate\n*Evaluate impact of these learnings and implement required activities for commercial manufacturing process": "ex:QualityAttribute_review_of_registrati_7c2157ea",
  "QualityAttribute:SM:9:Review statistical rationale during PPQ (for Combo products)": "ex:QualityAttribute_review_statistical_r_97ad1fdb",
  "QualityAttribute:SM:9:Risk analysis and mitigation plan updated in CMC risk register": "ex:QualityAttribute_risk_analysis_and_mi_4b1c02ce",
  "QualityAttribute:SM:9:Risk mitigation plans completed in preparation of validation batches": "ex:QualityAttribute_risk_mitigation_plan_89d26f6d",
  "QualityAttribute:SM:9:Runtime strategy aligned (regulatory)": "ex:QualityAttribute_runtime_strategy_ali_2bfd0fd7",
  "QualityAttribute:SM:9:SQ: COC closed before release PPQ batches": "ex:QualityAttribute_sq_coc_closed_before_82b373cd",
  "QualityAttribute:SM:9:Samples ready for QC testing prior to filing China NDA \u2013 dependent on when process is validated": "ex:QualityAttribute_samples_ready_for_qc_64ac112a",
  "QualityAttribute:SM:9:Scale factors documented in the process characterization report": "ex:QualityAttribute_scale_factors_docume_1e6777d9",
  "QualityAttribute:SM:9:Scale factors known and documented": "ex:QualityAttribute_scale_factors_known_4500e943",
  "QualityAttribute:SM:9:Scale-up to commercial throughput @ commercial site with final API:\n*Offline performance evaluation of individual unit operations\n*Integrated line performance evaluation\n*Process DoE": "ex:QualityAttribute_scale_up_to_commerci_8b71e7d5",
  "QualityAttribute:SM:9:Spiking experiments finished": "ex:QualityAttribute_spiking_experiments_618b16b0",
  "QualityAttribute:SM:9:Stage gate approval form": "ex:QualityAttribute_stage_gate_approval_25d11d85",
  "QualityAttribute:SM:9:Statistically justified spec's confirmed for validation": "ex:QualityAttribute_statistically_justif_dbdecba4",
  "QualityAttribute:SM:9:Supplier qualification for  starting materials/raw materials for INT and API and excipients and packaging materials for DP for commercial use completed, if new material/supplier combination": "ex:QualityAttribute_supplier_qualificati_87e46929",
  "QualityAttribute:SM:9:Toxicological Qualification": "ex:QualityAttribute_toxicological_qualif_63c1a4da",
  "QualityAttribute:SM:9:Up to date batch overview available": "ex:QualityAttribute_up_to_date_batch_ove_6e6c1782",
  "QualityAttribute:SM:9:Update IFU/training based on learnings from HF studies, Design Verification, and Design Validation activities.": "ex:QualityAttribute_update_ifu_training_15cc9480",
  "QualityAttribute:SM:9:Update PAT methods/validation and follow up of DOE and validation batches with PAT if defined in RTRt strategy": "ex:QualityAttribute_update_pat_methods_v_0fd6dd85",
  "QualityAttribute:SM:9:Update Regulated Substance plan and RS Report (if applicable)": "ex:QualityAttribute_update_regulated_sub_9b59b921",
  "QualityAttribute:SM:9:Update process validation strategy (PPQ) based on available pFMEA and experiments/datasets, including: PPQ sampling strategy and acceptance criteria.": "ex:QualityAttribute_update_process_valid_38779536",
  "QualityAttribute:SM:9:Update stability storage requirements (if appropriate)": "ex:QualityAttribute_update_stability_sto_8314f4f9",
  "QualityAttribute:SM:9:Update strategy for RTRt and implement according to plan": "ex:QualityAttribute_update_strategy_for_d58b3fbd",
  "QualityAttribute:SM:9:Update/Finalize commercial specifications. These may include:\n*incoming inspection specifications for device components/raw materials, including shelf life\n*release specification for combination product, including shelf life\n*primary container (unfilled and filled) specifications that are related to device function\n*identify critical process parameters (component, subassembly, final assembly, etc) and range\n*update General Safety and Performance Requirements (GSPR) Checklist": "ex:QualityAttribute_update_finalize_comm_a716ab11",
  "QualityAttribute:SM:9:Validation protocol (PPQ) completed [in line with FDA Guidance on process validation if required]": "ex:QualityAttribute_validation_protocol_6b82b8de",
  "QualityAttribute:SM:9:Verify initial Deliver Strategy as aligned in the Stage Gate 5 checklist is still applicable.": "ex:QualityAttribute_verify_initial_deliv_3762c036",
  "QualityAttribute:SM:9:White Papers (if needed)": "ex:QualityAttribute_white_papers_if_need_fb34e66a",
  "QualityAttribute:SM:Pediatric:Age-appropriateness of proposed formulation strategy assessed": "ex:QualityAttribute_age_appropriateness_d49261a9",
  "QualityAttribute:SM:Pediatric:Analytical control strategy appropriate for pediatric population": "ex:QualityAttribute_analytical_control_s_ced3a98a",
  "QualityAttribute:SM:Pediatric:Assessment of need for modified API (e.g. particle size) or altnerate salt": "ex:QualityAttribute_assessment_of_need_f_91b960df",
  "QualityAttribute:SM:Pediatric:CMC RA strategy for pediatric formulation(s)": "ex:QualityAttribute_cmc_ra_strategy_for_23e4c87b",
  "QualityAttribute:SM:Pediatric:CMC Section for Pediatric Investigational Plan": "ex:QualityAttribute_cmc_section_for_pedi_fe42ce60",
  "QualityAttribute:SM:Pediatric:CMC TPP \"Pediatric\" Draft (standalone document, separate from TPP for adult indication/formulation)": "ex:QualityAttribute_cmc_tpp_pediatric_dr_bf4dd35e",
  "QualityAttribute:SM:Pediatric:Draft CMC section of PIP": "ex:QualityAttribute_draft_cmc_section_of_c600897f",
  "QualityAttribute:SM:Pediatric:Draft timelines for first pediatric study and submission of pediatric product (from CDT PM)": "ex:QualityAttribute_draft_timelines_for_912cb511",
  "QualityAttribute:SM:Pediatric:Excipient strategy for age group(s), e.g. safety, tox qualification": "ex:QualityAttribute_excipient_strategy_f_52b56003",
  "QualityAttribute:SM:Pediatric:High-level resource estimate (FTE and OOP)": "ex:QualityAttribute_high_level_resource_32096fb4",
  "QualityAttribute:SM:Pediatric:High-level timelines/CMC Key Event Map; understanding of time window available to PDMS for development": "ex:QualityAttribute_high_level_timelines_6df446bf",
  "QualityAttribute:SM:Pediatric:Pediatric CMC Development Strategy (age-groups defined by CDT; age-appropriate formulation strategy)": "ex:QualityAttribute_pediatric_cmc_develo_089f8cd7",
  "QualityAttribute:SM:Pediatric:Pediatric Formulation Strategy including dosing aids and devices": "ex:QualityAttribute_pediatric_formulatio_f7b8c364",
  "QualityAttribute:SM:Pediatric:Product Risk Assessment (Drug Only Products, Device, and Combination Products) (Update): Intended Use, RM Plan, Hazard IDs, QRBA, Summary \nCriticality Analysis (Review & Update, if required) (API & Drug Product)\nControl Strategy (Review & Update, if required) (API, Drug Product)\nInput Post Market Surveillance from Internal & External Sources (if applicable)": "ex:QualityAttribute_product_risk_assessm_258e082f",
  "QualityAttribute:Value Stream:Stage Gate:Deliverable": "ex:QualityAttribute_deliverable_fbbab2bd",
  "Specification:CGT:0": "ex:Specification_04bc37b7",
  "Specification:CGT:1": "ex:Specification_e560a2f4",
  "Specification:CGT:10": "ex:Specification_6489f510",
  "Specification:CGT:11": "ex:Specification_8494829a",
  "Specification:CGT:12": "ex:Specification_084d5a92",
  "Specification:CGT:2": "ex:Specification_83227e66",
  "Specification:CGT:3": "ex:Specification_151ad448",
  "Specification:CGT:4": "ex:Specification_cb8345b0",
  "Specification:CGT:5": "ex:Specification_51f9eeba",
  "Specification:CGT:6": "ex:Specification_4f59f716",
  "Specification:CGT:7": "ex:Specification_61167cee",
  "Specification:CGT:8": "ex:Specification_063b9a51",
  "Specification:CGT:9": "ex:Specification_e759bc20",
  "Specification:Protein:0": "ex:Specification_77930a35",
  "Specification:Protein:1": "ex:Specification_dc350fd3",
  "Specification:Protein:10": "ex:Specification_a8e7bbcb",
  "Specification:Protein:11": "ex:Specification_ecc845af",
  "Specification:Protein:12": "ex:Specification_dda6e847",
  "Specification:Protein:2": "ex:Specification_a9f54758",
  "Specification:Protein:3": "ex:Specification_803d514a",
  "Specification:Protein:4": "ex:Specification_5ba45775",
  "Specification:Protein:5": "ex:Specification_97f044b6",
  "Specification:Protein:6": "ex:Specification_9ebf0892",
  "Specification:Protein:7": "ex:Specification_a540e3de",
  "Specification:Protein:8": "ex:Specification_d18d1a66",
  "Specification:Protein:9": "ex:Specification_8c2dcd5c",
  "Specification:SM:10": "ex:Specification_6beef1e1",
  "Specification:SM:11": "ex:Specification_b433aa7e",
  "Specification:SM:12": "ex:Specification_9c5f4d7b",
  "Specification:SM:3": "ex:Specification_381e54b0",
  "Specification:SM:4": "ex:Specification_7c6bccdf",
  "Specification:SM:5": "ex:Specification_41a851b2",
  "Specification:SM:6": "ex:Specification_eeb1fa10",
  "Specification:SM:7": "ex:Specification_0fffd296",
  "Specification:SM:8": "ex:Specification_dc06c0a4",
  "Specification:SM:9": "ex:Specification_00659f80",
  "Specification:SM:Pediatric": "ex:Specification_db5e112a",
  "Specification:Value Stream:Stage Gate": "ex:Specification_cf4397ae",
  "Stage:CGT:0": "ex:Stage_cgt_0_0f81e3fb",
  "Stage:CGT:1": "ex:Stage_cgt_1_8db56df1",
  "Stage:CGT:10": "ex:Stage_cgt_10_a74dd6db",
  "Stage:CGT:11": "ex:Stage_cgt_11_dda61444",
  "Stage:CGT:12": "ex:Stage_cgt_12_278a67ef",
  "Stage:CGT:2": "ex:Stage_cgt_2_445807e7",
  "Stage:CGT:3": "ex:Stage_cgt_3_62ee4b27",
  "Stage:CGT:4": "ex:Stage_cgt_4_d6e99c8d",
  "Stage:CGT:5": "ex:Stage_cgt_5_a87610ab",
  "Stage:CGT:6": "ex:Stage_cgt_6_7701b000",
  "Stage:CGT:7": "ex:Stage_cgt_7_d0834fae",
  "Stage:CGT:8": "ex:Stage_cgt_8_12d65ad7",
  "Stage:CGT:9": "ex:Stage_cgt_9_2d9c5004",
  "Stage:Protein:0": "ex:Stage_protein_0_16d7ff38",
  "Stage:Protein:1": "ex:Stage_protein_1_e4cecd40",
  "Stage:Protein:10": "ex:Stage_protein_10_607f5f71",
  "Stage:Protein:11": "ex:Stage_protein_11_966a758c",
  "Stage:Protein:12": "ex:Stage_protein_12_08cb3cf8",
  "Stage:Protein:2": "ex:Stage_protein_2_c06697b8",
  "Stage:Protein:3": "ex:Stage_protein_3_c4144c3d",
  "Stage:Protein:4": "ex:Stage_protein_4_bb2d3719",
  "Stage:Protein:5": "ex:Stage_protein_5_6b479628",
  "Stage:Protein:6": "ex:Stage_protein_6_8e238269",
  "Stage:Protein:7": "ex:Stage_protein_7_b3c31156",
  "Stage:Protein:8": "ex:Stage_protein_8_e6b3af37",
  "Stage:Protein:9": "ex:Stage_protein_9_a4954337",
  "Stage:SM:10": "ex:Stage_sm_10_e2cf4cd7",
  "Stage:SM:11": "ex:Stage_sm_11_3e804031",
  "Stage:SM:12": "ex:Stage_sm_12_50f8af46",
  "Stage:SM:3": "ex:Stage_sm_3_fd056f6c",
  "Stage:SM:4": "ex:Stage_sm_4_9d08c8d3",
  "Stage:SM:5": "ex:Stage_sm_5_0a1e4e74",
  "Stage:SM:6": "ex:Stage_sm_6_0aa7a2de",
  "Stage:SM:7": "ex:Stage_sm_7_ace03783",
  "Stage:SM:8": "ex:Stage_sm_8_0715f68f",
  "Stage:SM:9": "ex:Stage_sm_9_c091155b",
  "Stage:SM:Pediatric": "ex:Stage_sm_pediatric_47bafbd4",
  "StageGate:CGT:0": "ex:StageGate_18da05d4",
  "StageGate:CGT:1": "ex:StageGate_e798198c",
  "StageGate:CGT:10": "ex:StageGate_bd2a72a1",
  "StageGate:CGT:11": "ex:StageGate_b9249616",
  "StageGate:CGT:12": "ex:StageGate_6256cbe0",
  "StageGate:CGT:2": "ex:StageGate_4ca65263",
  "StageGate:CGT:3": "ex:StageGate_0672a9d3",
  "StageGate:CGT:4": "ex:StageGate_036c720a",
  "StageGate:CGT:5": "ex:StageGate_6f1b5cce",
  "StageGate:CGT:6": "ex:StageGate_2e07cde1",
  "StageGate:CGT:7": "ex:StageGate_a0aa6c4f",
  "StageGate:CGT:8": "ex:StageGate_941a2e6e",
  "StageGate:CGT:9": "ex:StageGate_a58a2100",
  "StageGate:Protein:0": "ex:StageGate_e8686e7f",
  "StageGate:Protein:1": "ex:StageGate_04cd6140",
  "StageGate:Protein:10": "ex:StageGate_1c44e349",
  "StageGate:Protein:11": "ex:StageGate_a2019bc8",
  "StageGate:Protein:12": "ex:StageGate_cd7ae684",
  "StageGate:Protein:2": "ex:StageGate_689d0f05",
  "StageGate:Protein:3": "ex:StageGate_a50692c2",
  "StageGate:Protein:4": "ex:StageGate_69c9cba0",
  "StageGate:Protein:5": "ex:StageGate_ce306a98",
  "StageGate:Protein:6": "ex:StageGate_f404e2ad",
  "StageGate:Protein:7": "ex:StageGate_499e7391",
  "StageGate:Protein:8": "ex:StageGate_93072eca",
  "StageGate:Protein:9": "ex:StageGate_9bd749be",
  "StageGate:SM:10": "ex:StageGate_48afdd93",
  "StageGate:SM:11": "ex:StageGate_c775a14a",
  "StageGate:SM:12": "ex:StageGate_cf1036d0",
  "StageGate:SM:3": "ex:StageGate_c50fe0fc",
  "StageGate:SM:4": "ex:StageGate_7db0624b",
  "StageGate:SM:5": "ex:StageGate_dfe43eeb",
  "StageGate:SM:6": "ex:StageGate_47829ac2",
  "StageGate:SM:7": "ex:StageGate_eca215a5",
  "StageGate:SM:8": "ex:StageGate_6ef7d0cb",
  "StageGate:SM:9": "ex:StageGate_58e632a4",
  "StageGate:SM:Pediatric": "ex:StageGate_3f1d9728",
  "StagePlan:CGT:0": "ex:StagePlan_0cf51769",
  "StagePlan:CGT:1": "ex:StagePlan_6dfc5009",
  "StagePlan:CGT:10": "ex:StagePlan_2c569519",
  "StagePlan:CGT:11": "ex:StagePlan_3165f88e",
  "StagePlan:CGT:12": "ex:StagePlan_f91654f8",
  "StagePlan:CGT:2": "ex:StagePlan_52cb2fb3",
  "StagePlan:CGT:3": "ex:StagePlan_394619db",
  "StagePlan:CGT:4": "ex:StagePlan_b7d8eaf2",
  "StagePlan:CGT:5": "ex:StagePlan_c38224aa",
  "StagePlan:CGT:6": "ex:StagePlan_b3b36380",
  "StagePlan:CGT:7": "ex:StagePlan_a91c5dee",
  "StagePlan:CGT:8": "ex:StagePlan_2a594b46",
  "StagePlan:CGT:9": "ex:StagePlan_fb471dac",
  "StagePlan:Protein:0": "ex:StagePlan_1a13c241",
  "StagePlan:Protein:1": "ex:StagePlan_c1be0fdd",
  "StagePlan:Protein:10": "ex:StagePlan_c6fc2ad6",
  "StagePlan:Protein:11": "ex:StagePlan_5be86094",
  "StagePlan:Protein:12": "ex:StagePlan_ce679d1f",
  "StagePlan:Protein:2": "ex:StagePlan_73654f20",
  "StagePlan:Protein:3": "ex:StagePlan_188a4c4f",
  "StagePlan:Protein:4": "ex:StagePlan_c07d786c",
  "StagePlan:Protein:5": "ex:StagePlan_3338e664",
  "StagePlan:Protein:6": "ex:StagePlan_2853b822",
  "StagePlan:Protein:7": "ex:StagePlan_6133b935",
  "StagePlan:Protein:8": "ex:StagePlan_e08c10ad",
  "StagePlan:Protein:9": "ex:StagePlan_1296fc33",
  "StagePlan:SM:10": "ex:StagePlan_5006fd13",
  "StagePlan:SM:11": "ex:StagePlan_95168d65",
  "StagePlan:SM:12": "ex:StagePlan_1ff9afdd",
  "StagePlan:SM:3": "ex:StagePlan_b2e3040d",
  "StagePlan:SM:4": "ex:StagePlan_ce0d50dd",
  "StagePlan:SM:5": "ex:StagePlan_ff788992",
  "StagePlan:SM:6": "ex:StagePlan_07d462eb",
  "StagePlan:SM:7": "ex:StagePlan_a2d089a2",
  "StagePlan:SM:8": "ex:StagePlan_fd61467b",
  "StagePlan:SM:9": "ex:StagePlan_f0815b3c",
  "StagePlan:SM:Pediatric": "ex:StagePlan_cf16aa8e"
}